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ABSTRACT 
In this thesis I analysed population-based data on 22955 infants enrolled in a neonatal 
vitamin A supplementation trial in rural Ghana to investigate whether low birth weight 
(LBW: born weighing <2.50kg) was a risk factor for under-vaccination. I also investigated 
whether under-vaccination among LBW infants was occurring within a broader context of 
poorer health outcomes such as increased mortality, illness and health facility admissions 
and lower care-seeking. I additionally investigated how using routine contacts with health 
services (opportunities for vaccination) could be used to improve their vaccination. 
Compared to non-LBW (NLBW) infants, LBW infants were less likely to be vaccinated in 
both the neonatal and postneonatal period. The smaller the baby at delivery the less likely 
they were to be vaccinated (p-trend <0.0001). By the end of the neonatal period, 
moderately LBW (MLBW) infants (1.50-1.99kg) were 1.6 times (adjusted odds ratio 
(aOR)=1.64; 95%CI:1.30-2.08), and very LBW (VLBW) infants (<1.50kg) were 2.4 times 
(aOR=2.42; 95%CI:1.50-3.88) more likely to be BCG unvaccinated. In the postneonatal 
period, VLBW infants had an almost 40% lower DTP1 vaccination rate at age 10 weeks 
(adjusted rate ratio (aRR)=0.58; 95%CI:0.43-0.77) and 18 weeks (aRR=0.63; 95%CI:0.50-
0.80). MLBW infants had vaccination rates approximately 25% lower at these time points. 
Similar results were observed for DTP3.  
LBW infants had much higher mortality rates in infancy compared to NLBW infants. Infants 
weighing 2.00-2.50kg were >2 times (adjusted hazard ratio (aHR)=2.13; 95%CI:1.76-2.59); 
MLBW infants were >8 times (aHR=8.21; 95%CI:6.26-10.76), and VLBW infants were >25 
times (aHR=25.38; 95%CI:18.36-35.10) more likely to die. The trend of higher mortality with 
lower birth weight was seen in each of the neonatal, early and late infant periods, but the 
magnitude of the association declined over time. There was also some evidence that LBW 
infants had increased illness rates in the neonatal period, and in each of the neonatal and 
early infant periods. An absence of care seeking was found for MLBW infants in the first 
year of life (aOR=1.46; 95%CI:1.18-1.81), and in each of the neonatal (aOR=3.30; 
95%CI:1.98-5.48) and early infant periods (aOR=1.74; 95%CI:1.26-2.39) respectively. No 
association was found in the late infant period (p-interaction=0.0002).  
Among all infants (NLBW and LBW) with opportunities for vaccination, most opportunities 
were missed. There was no association between birth weight and uptake of opportunities.  
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In conclusion LBW infants are under-served by vaccination in Ghana. Given their poorer 
health outcomes, efforts to improve their access to care services, including vaccination are 
warranted. Further research into the barriers and facilitators of vaccination of LBW infants 
is warranted, including qualitative research targeting care givers and vaccine providers.  
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CHAPTER 1: BACKGROUND 
Preamble 
In this chapter, I introduce the topics covered by this PhD, and I present relevant background 
data. Specifically, I describe i) the important role of vaccination in reducing the burden of 
infectious disease-related child mortality in Sub-Saharan Africa, ii) current global policy on 
the importance of identifying groups that are under-served by vaccination, and iii) why low 
birth weight infants may be one such under-served group. I outline the rationale for the 
research, and I define the aims and objectives of the PhD. Finally, I describe the structure of 
the thesis.   
1.1. INFECTIOUS DISEASES AND CHILD MORTALITY IN SUB-SAHARAN 
AFRICA 
In 2015 almost 50% of all deaths worldwide in children aged less than five years (an 
estimated 3 million deaths) occurred in Sub-Saharan Africa (SSA)1. A large burden of these 
deaths occurred in the postneonatal period (4-51 completed weeks of age). In 29 countries 
of SSA, at least 60% of under-five deaths were postneonatal deaths2. In 2015, infectious 
diseases were responsible for approximately half of all deaths among under-fives2. 
Pneumonia and diarrhoea were estimated to be responsible for 18% and 9% of all under-
five deaths respectively2.  
1.2. THE ROLE OF VACCINATION IN REDUCING INFECTIOUS-DISEASE 
RELATED CHILD MORTALITY 
Vaccines have been developed against a number of infectious diseases and the World 
Health Organisation (WHO) estimates that up to 2.5 million deaths among children less 
than five years are prevented each year by vaccination against diphtheria, tetanus, 
pertussis (DTP) and measles3,4. Effective implementation of vaccination programmes can 
have dramatic impacts. For instance, the annual measles mortality rate in under-fives 
declined by almost 15% between 2000 and 2010, almost four times the overall rate of 
decline in under-five mortality5. Nevertheless, in 2013 one in every five children was not 
fully vaccinated by 52 weeks of age, and almost three out of every 10 deaths among 
children aged one to 59 months were estimated to be due to vaccine preventable diseases 
12 
 
(VPDs)6. Due to lower vaccine coverage rates in the region, SSA now accounts for a 
disproportionate burden of vaccine preventable diseases (VPDs). Data from 2008 (to the 
best of my knowledge, the most recently available data), reported that globally 46% of all 
deaths due to VPDs occurred in SSA7. 
1.3. RECOMMENDED SCHEDULE FOR ROUTINE VACCINATION 
WHO makes specific recommendations for the minimum age at initiation and staging of 
routine childhood vaccines (Table 1.1)8,9.   
Table 1.1: Summary of WHO recommendations for the administration of selected vaccines 
included in the routine childhood vaccination schedule8,9.  
Antigen Doses in 
Primary 
Series 
Age of 1st dose Interval between Doses 
Bacille Calmette-
Guerin (BCG) 
1 Neonatal period / as soon 
as possible after birth 
- 
Oral Polio Vaccine 
(OPV)1 
 
3 6 weeks 4 weeks (minimum) (with DTP) 
Diphtheria Tetanus 
Pertussis (DTP)2 
3 6 weeks (min) 4 weeks (minimum) – 8 weeks 
Haemophilus 
influenza type b (Hib) 
3 6 weeks (min) with DTP1, 
24 months (max) 
4 weeks (minimum) (with DTP2 & 3) 
Hepatitis B (HB)3 3 – 4  At birth (<24 hrs) 4 weeks (minimum) (with DTP2 & 3) 
Measles containing 
vaccine (MCV)4 
2 9 or 12 months  
 
4 weeks (minimum) 
Yellow Fever 1 9 – 12 months with 
measles 
- 
Pneumococcal 
(conjugate) 
4 6 weeks (min) with DTP1 4 weeks (minimum) (with DTP2 & 3) 
Rotavirus  2 (Rotarix) 
 
3 (Rota Teq) 
6 weeks (min) with DTP1, 
15 weeks (max) 
Rotarix - 4 weeks (minimum) (with 
DTP2) no later than 32 weeks of age 
Rota Teq -  4 weeks (minimum) – 10 
weeks with DTP2 
1 In countries with a high risk of importation or transmission of polio, an additional OPV dose should be given as soon as 
possible after birth 
2. Last dose of primary series to be completed by 6 months. A booster dose is recommended at between 1 and 6 years of age; 
at least 6 months after last primary dose 
3. Preterm low birth weight (LBW) infants may not respond well to HBV vaccination at birth. Doses given to infants weighing 
<2000g do not count towards primary series. By 1 month of age, preterm infants are likely to respond adequately, regardless 
of gestational age or weight at birth. 
4. First dose should be administered at a minimum age of six months 
 
Recommended schedules are informed by the underlying epidemiology of the target 
organism in the target population and the timing that will generate the maximum immune 
response with the minimum risk of adverse events10,11. Deviation from the schedule may 
result in a sub-optimal immune response at the individual level and at a population level 
may reduce the effectiveness of the overall vaccination programme10,11.  
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1.4. EVALUATION OF ROUTINE VACCINE PROGRAMMES: CURRENT 
APPROACHES AND GAPS IN THE DATA 
Routine monitoring of vaccination programmes is essential to evaluate programme 
performance and effectiveness, to inform modifications to the programme and to guide 
strategies for the containment of VPDs12. Vaccine uptake, defined as the proportion of the 
target population that has been vaccinated, is a key indicator in vaccination programme 
evaluation12.  
1.4.1. Methods of assessing vaccine uptake 
WHO and the United Nations Children’s Emergency Fund (UNICEF) generate estimates of 
uptake for each dose of each vaccine in the recommended schedule using a combination of 
administrative data (routine reports of the number of vaccinations given by service 
providers such as health centres, vaccination teams and private physicians over a given 
time) and data from household surveys12,13. Both data sources are subject to a number of 
well-described limitations12,13. For instance, the validity of administrative data is limited by 
incomplete reporting and inaccurate denominator data, leading sometimes to reported 
uptake rates in excess of one hundred percent. Populations likely to be missed in household 
surveys may also be missed by vaccination teams, and this can lead to overestimates of 
coverage14. Children who die may be under-represented in these surveys, and they may be 
less likely to be vaccinated, consequently selection bias may be a substantial problem in 
populations with high infant mortality14.  For all vaccines except BCG (which uses live births 
as a denominator), the reported estimates refer to uptake at 52 weeks of age and the 
denominator only includes children who live to 52 weeks of age12. Estimates refer to all 
vaccinations given, regardless of whether they adhere to recommendations on the timing 
and staging of vaccination12.  
1.4.2. Gaps in the data 
Although many countries report high uptake rates for individual vaccines at 1 year of age, 
and although overall their vaccination programmes perform very well, almost 19 million 
children still do not receive all of their vaccines every year15. Considerable disparities in 
coverage persist, both between and within countries. Studies of the timely delivery of 
vaccines report that whereas uptake of routinely scheduled vaccines is generally high, a 
substantial proportion of children are vaccinated late16-20. An analysis of demographic and 
health survey (DHS) data for 217706 infants from 45 countries reported median vaccination 
delays of 2.3 weeks (interquartile range (IQR):1.4-4.6) for BCG, 2.4 weeks (1.2-3.3) for DTP1, 
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6.2 weeks (3.5-8.5) for DTP3 and 2.7 weeks (1.7-3.1) for MCV16. An analysis of 1403 infants 
recruited in a community-based cluster survey in southern Tanzania reported that 33% of 
infants were delayed in their vaccination with BCG (vaccinated >1 month after the vaccine 
due date), as were 34% for DTP1, 69% for DTP3 and 46% for first dose MCV21. An analysis of 
a population-based cohort in Ghana reported median delays of 2 to 4 weeks for all vaccines 
except birth oral polio vaccine (OPV), which had a median delay of 5 days22.  
Timely administration of vaccines is important. For infections that are most prevalent in the 
first few months of life, such as those caused by pertussis23, Haemophilus influenzae type b 
(Hib) and Streptococcus pneumoniae19,24, delayed vaccination may prolong the risk of 
infection and may reduce the effectiveness of the vaccination programme, even if the 
uptake at 52 weeks of age is high16,19. Unfortunately, data on the timely administration of 
vaccines are not currently included as an indicator in routine programme evaluations and 
so the increased time at risk for contracting a VPD among those who are delayed in being 
vaccinated is not accounted for. Given this, there is increasing interest in monitoring the 
timeliness of vaccination and in characterising those at greatest risk of vaccination delay25.  
Vaccine uptake estimates are reported for the total population. No estimates on uptake 
among those most at risk of under-vaccination, for instance among low birth weight (LBW) 
infants are routinely available. This is further explained in Section 1.5. 
1.4.3. Assessing the timely delivery of vaccines 
There are a number of different approaches to the assessment of timeliness (Table 1.2). 
These include 1) estimating time to vaccination using survival analysis techniques such as 
Kaplan Meier curves or Cox regression16,17,19,22,26,27,30,31,35,36,42; 2) estimating the number of 
additional days a child was under-vaccinated37 or at risk of a VPD due to delayed 
administration of each vaccine41; 3) estimating the proportions delayed in the receipt of 
their vaccinations (using predefined cut-offs for delayed vaccination)20,21,25,30,34,35,39 and 4) 
estimating age-specific up-to-date vaccination rates28,29,32,33,38,40. Person-time analysis 
techniques, such as Cox and Poisson regression, provide the most accurate measure of 
timely delivery of vaccines as they account for the early censoring of individuals due to 
death or loss to follow up and allow these individuals to be included in the analyses.    
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Table 1.2: Summary of outcomes and analytical methods in published studies that assessed timely vaccination 
Citation, Country Outcome Measures Methods 
Gram et al, 2014 22 
Ghana 
Received vaccination within first year of life 
Vaccination within 1, 2, 4 and 6 weeks of due date 
Received all vaccinations appropriate for a particular age 
Median time to vaccination in weeks 
Kaplan Meier 
Cox regression 
Le Polain de Waroux 
et al, 2013 21 
Tanzania 
Delayed vaccination defined as vaccination at > 1month after the recommended age of vaccination Kaplan Meier  
Log binomial regression 
Babirye et al, 2012 26 
Uganda 
Time to vaccination for BCG (birth to 8 weeks), Polio 0 (birth – 4 weeks), Polio1 / DTP1 (4-2 months), Polio2 / DTP2 
(8 weeks – 4 months), Polio3 / DTP3 (12-6 months) & measles (38 weeks to 12 months) 
Kaplan Meier 
Cox regression 
Akmatov & 
Mikolajczyk 
2011 17 
31 LMICs* 
Delayed vaccination – vaccination > 1month after recommended age 
Up-to-date vaccination for children aged 12-59 months (BCG, DTP & Polio) and 18-59 months (measles). 
Age-specific vaccination coverage. 
Kaplan Meier 
Multilevel logistic 
regression 
Fadnes, 2011 27 
South Africa 
Timely vaccination (vaccination within recommended time-periods (birth to 8 weeks for BCG, birth to 4 weeks for 
birth OPV, 4 weeks to 2 months for DTP1, 8 weeks to 4 months for DTP2, 12 weeks to 6 months for DTP3, 38 
weeks to 12 months for measles)) 
Kaplan Meier 
Cox regression 
Mutua et al, 2011 28 
Kenya 
Full vaccination at 24 months of age 
Up-to-date vaccination (receipt of BCG, OPV 1-3, DTP 1-3 & measles) at 3 and 12 months of age   
Descriptive analysis 
Multivariable logistic 
regression 
Moisi et al, 2010 19 
Kenya 
Vaccine uptake at 2, 4, 6, 10, 14, 18 & 22 weeks of age, & at 9, 10, 11, 12 months of age  
Time to vaccination  
Median & IQR for age at vaccination. 
Kaplan Meier 
Log-rank tests.  
Cox regression 
Sadoh & Eregie, 2009 
20 
Nigeria 
% of children vaccinated a) too early (before recommended age), b) on time (within 2 weeks of due date), c) 
acceptably late (2-4 weeks after due date) and d) delayed (>4 weeks after due date) 
Mean & median age at vaccination 
Mean difference between age at vaccination & recommended ages 
Descriptive analysis 
Clarke & Sanderson, 
2009 16 
45 LMICs 
Age-specific coverage rates 
Median, quartiles and IQRs for delays in days for each vaccine 
Uptake within the first year of life 
Uptake within 1, 2, 4 and 6 weeks of the due date 
Kaplan Meier 
Cox regression 
Continued….. 
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Table 1.2 continued 
Citation, Country Outcome Measures Methods 
Corsi et al, 2009 29 
India 
Up-to-date & age-appropriate vaccination 
Infants were age-appropriately vaccinated if they had received BCG by 1 month of age, BCG & 1 dose of OPV/DTP 
by 2 months, BCG & 2 doses of OPV / DTP by 3 months, BCG & 3 doses of OPV/DTP by 4 to 8 months and BCG, 3 
doses of OPV / DTP & 1 dose of measles by 9 months 
Descriptive analysis 
Akmatov et al, 200830  
Armenia, Kazakhstan, 
Kyrgyzstan, 
Uzbekistan 
% of children aged 12-35 months and 12-59 months who were up-to-date with DTP vaccination. % aged 
>18months up-to-date with measles. 
Time to vaccination 
Delayed vaccination (vaccination 1 month after the recommended age). 
Descriptive analysis of % 
up-to-date 
Kaplan Meier 
Multinomial logistic 
regression 
Santibanez et al, 2006. 
31 
USA 
% of children who received 3 or more doses of DTP by 7 months of age & 1 or more dose of MMR by 19 months of 
age. 
Cumulative vaccination coverage for DTP3, DTP4 & MMR1 by age in months 
Chi-square test. 
Kaplan Meier 
Fiks et al, 2006 32 
USA 
Up-to-date vaccination at 3, 7, 13 and 24 months.  
Determinants of delay (defined as not being up-to-date at 24 months) 
 
Calculation of relative risks 
and attributable risks of 
delay at 24 months.  
Logistic regression  
Cui & Gofin, 200633 
China 
Up-to-date vaccination in children aged 12-23 months at 3, 8 and 12 months of age Descriptive analysis 
Logistic regression 
Hull & MacIntyre, 
2006 34  
Australia 
Age-appropriate vaccination – within 30 days of recommended age 
% vaccinated on time, acceptably early, 1-6 months delay, > 6 months delay, not vaccinated at 24 months. 
Descriptive analysis  
Dayan et al, 200635 
Argentina 
% up-to-date and delayed vaccinated at time of interview.  
Age-specific vaccination coverage 
Determinants of delayed vaccination. Delayed vaccination defined as not receiving vaccine at > 1 month after the 
scheduled age.  
(Excluded invalid vaccination doses) 
Kaplan Meier 
Log-binomial regression 
analysis  
Ndiritu, 2006 36 
Kenya 
Median age at vaccination 
Determinants of time to vaccination 
Kaplan Meier 
Cox regression 
Continued… 
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Table 1.2 continued 
Citation, Country Outcome Measures Methods 
Luman et al, 2005 37 
USA 
Cumulative days under-vaccinated during the first 24 months of life for each of six vaccines and all vaccines 
combined. Under-vaccination defined as vaccination at > 1months after the recommended age. 
- % of children delayed 0 days, 1- 7 days, 8-31 days, 1-2 months, 3-6 months, 7-12 months & > 12 months. 
- No. of late vaccines 
- Risk factors for severe delay in vaccination (defined as under-vaccinated for > 6 months for >= 4 vaccines). 
Descriptive analysis 
Logistic regression 
Strine et al, 2003 38  
USA 
Completion of 4 dose DTP by 24 months of age  
On time receipt of DTP4 between 12 and 18 months of age (< 19 months) 
Logistic regression  
Dombkowski et al, 
2002 25 
USA 
Months of vaccination delay relative to age-appropriate vaccination standard 
Up-to-date DTP4, OPV3 and MMR1 and complete 4:3:1 series 
DTP4 & OPV3 at > =19 months were defined as delayed; MMR at >=16 months.  
Mean rates of vaccination 
delay & chi-square tests of 
association  
Luman et al, 200239 
USA 
Age at receipt of vaccines among children aged 24-35 months 
% vaccinated on-time (receipt within 1 month of recommended age)  
% acceptably early (within 4 days before the minimum acceptable age until the routinely recommended age), late 
(> 1 month after the recommended age but before 24 months of age), unvaccinated by 24 months and too early 
to be valid (> 4 days before the minimum acceptable age) 
Determinants of timely vaccination 
Descriptive analysis 
Logistic regression  
Langkamp et al, 2001 
40 
USA 
 
Age at receipt of each of the first 4 doses of DTP, first 3 doses of polio and first dose of MMR.  
Comparison of the mean age at receipt of each dose of DTP, polio and MMR for VLBW, MLBW and NLBW. 
% of children up to date for all vaccinations at 12, 24 and 36 months. 
Determinants of being up-to-date for all vaccinations at 12, 24 and 36 months 
Descriptive analysis 
Logistic regression  
Kahn et al, 1995 41 
Central African 
Republic 
Additional days at risk for measles (age in days at vaccination minus 270 days) 
Age in months to measles vaccination 
Descriptive analysis 
* LMICs = Low and middle income countries; VLBW=very LBW (weighs <1.50kg at birth); MLBW = moderate LBW (weighs 1.50-1.99kg at birth) 
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Surveys solely investigating uptake at predefined cut-offs to assess timely vaccination are 
less sensitive, as individuals whose follow-up is censored before that time point are 
excluded. As the rate of vaccination in infants who die or who are lost-to-follow-up may be 
different to surviving infants, excluding these infants may lead to over-estimates of the 
timeliness of delivery. 
1.5. IDENTIFYING GROUPS AT RISK OF UNDER-VACCINATION 
There have been many studies to investigate the factors associated with non-vaccination 
and delayed vaccination among children in low and middle income countries (LMICs)19,28,43-
45. The factors include lower socioeconomic status (SES)21,28,46,47, being a member of a 
minority ethnic or religious group 21,28,47, increasing distance to a health facility,19,21,47 being 
born at home28,47, lower maternal education21,28,46,47 and age28, child’s higher birth order28,47, 
increased family size47, wet season19,21, female sex47, positive maternal human 
immunodeficiency virus (HIV) status45 and parental knowledge and understanding of 
vaccination44,47-49. 
Measles vaccine coverage in some countries is 33% lower in rural areas than in urban areas 
and almost 60% lower among the poorest quintile of the population compared to the 
richest4. Migrant populations and those living in urban slums are also known to have lower 
vaccine coverage. All these under-vaccinated population groups are likely to suffer from a 
higher disease burden and so ensuring their access to and uptake of preventative care 
services such as vaccination is essential to address health inequalities, to maximise the 
impact of these interventions, and to facilitate economic development. Furthermore 
engagement of these groups is critical to address disease elimination and eradication 
targets4.  
 
Given this, the latest Global Vaccine Action Plan for 2011 to 2020 has specifically advocated 
for the identification and targeting of groups who are under-served by routine vaccination 
services4. Identifying hard-to-reach groups and groups at risk of under-vaccination, as well 
as the factors associated with under-vaccination, have all been identified as priority 
research areas to improve the delivery of vaccines in developing countries50 .  
 
In countries lacking population-based surveillance systems and robust health information 
systems it can be difficult to identify those sub-groups of the population who are under-
vaccinated. Further work is therefore needed to identify specific risk factors of the under-
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vaccinated which will facilitate their easy identification. Low birth weight may be one such 
risk factor.  
1.6: LOW BIRTH WEIGHT INFANTS 
LBW infants are born weighing less than 2.50 kilograms (kg) at birth irrespective of 
gestational age51,52. LBW is due either to preterm birth (defined as delivery before 37 weeks 
of gestation) or restricted foetal (intrauterine) growth53. Restricted foetal growth can cause 
infants to be small for gestational age (SGA) (defined as a sex-specific birth weight below 
the 10th percentile for gestational age as a reference standard51,52).  
The risk factors for LBW are well described53-56, and include low socioeconomic status, 
primiparity and high parity, low maternal age and co-infection with HIV. Most LBW infants 
(96%) are born in LMICs, where the prevalence is twice that in high income settings56.  
1.6.1. The relationship between birth weight, gestational age, and size for 
gestational age 
In LMICs, accurate data on gestational age (GA) are frequently lacking and so LBW is 
commonly used as a proxy for preterm birth57. Birth weight does not directly correlate to 
gestational age, and so direct comparisons are problematic57. For instance only about 50% 
of infants weighing 2.00-2.50kg are preterm57, and a substantive proportion of non-LBW 
(NLBW) infants are SGA (21% in South Asia and 16% in Africa)52. Nonetheless, a birth weight 
of less than 1.50kg (very low birth weight, VLBW) is considered a specific and sensitive 
marker for preterm delivery58,59. In SSA in 2010, about 24% of all infants were estimated to 
be term and SGA, about 10% were pre-term and appropriate for gestational age (AGA) and 
approximately 2% were both preterm and SGA51. This is compared to an estimated 
prevalence of LBW of 14%51. Not all infants that are SGA or pre-term are LBW. 
1.6.2. Population level assessment of LBW 
Estimates of LBW are subject to a number of well-documented biases56,60-62 associated with 
1) the large proportion of infants missing birth weight data and 2) the measurement, 
recording and recall of birth weight data.  
In LMICs almost 50% of infants are not weighed at birth60. Those infants who are weighed 
are more likely to be born to wealthier women with higher levels of educational attainment 
who deliver in facilities and who are less likely to deliver a LBW infant60,61,63. Furthermore, in 
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surveys, written records of birth weight may be less available for infants who die, as it is 
common practice for parents to discard the child health records of deceased infants. This 
may result in an under-ascertainment of birth weight data for LBW infants who are at 
greater risk of mortality56. This may be exacerbated by a general under-reporting of data on 
infants who die64. In order to adjust for these biases, current estimates of the prevalence of 
low birth weight are now routinely adjusted upwards by an average of 24%56,60,62.  
1.6.3. The consequences of LBW – excess mortality and illness  
The association between birth weight and mortality, and illness during infancy in SSA has 
not been extensively studied. Few studies have generated population-based estimates, 
especially for the postneonatal period, and for VLBW infants, who, based on data from 
high-income settings65,66 are known to be at a particularly increased risk of adverse health 
outcomes.  
I searched Pubmed (up to 13 April 2016) 67 to identify studies on the association between 
both a) birth weight and b) preterm delivery, and the outcomes mortality, illness and care 
seeking in SSA. The search terms are detailed in Annex 1. I restricted the search to those 
aged 0-23 months, to humans, and to articles in English, dating from the last 20 years (since 
01 January 1996). In addition, I searched the reference list of selected articles. The search 
yielded 2141 articles, and upon review of the titles, abstracts and reference lists, I identified 
18 papers on the association between birth weight and mortality, illness and care seeking 
(Table 1.3). I identified nine studies that generated estimates on mortality52,68-75, four on 
mortality and illness76-79, and five on illness only80-84.  
Many of the studies were limited by small sample sizes73,78,81,82, or were restricted to 
specific populations such as HIV exposed infants74,77,79 or infants born to mothers recruited 
from antenatal care (ANC)73,75. Furthermore, direct comparison between studies was 
complicated by the use of different exposure variables. Some studies investigated the 
association with preterm delivery or growth retardation52,71,78, and others investigated the 
association with birth weight70,72,73,75,79.   
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Table 1.3: Overview of studies from SSA investigating the association between preterm* birth, birth weight and illness and mortality in the first 
year of life.  
Citation Study population & setting Exposure Outcome Effect estimates (95%CI) 
Mortality     
Sania et al, 
201468 
Prospective cohort study nested within a 
randomised control trial (RCT). 7225 HIV 
negative pregnant women enrolled at ANC, 
Dar es Salaam, Tanzania between 2001 & 
2004. Their singleton infants followed up 
monthly until 1 year of age 
 
Preterm appropriate for 
gestational age (AGA), term SGA 
& preterm SGA compared to term 
AGA (based on LMP) 
 
LBW compared to NLBW infants 
Adjusted HR1 for 
neonatal, 
postneonatal, & 
infant mortality.   
Neonatal  
Preterm AGA:  2.6 (1.8-3.9) 
Term SGA: 2.3 (1.6-3.3) 
Preterm SGA: 15.1 (8.2-27.7) 
LBW: 7.5 (5.5-10.3) 
Postneonatal Mortality  
Preterm AGA: 2.5 (1.6-3.9) 
Term SGA: 0.9 (0.6-1.6) 
Preterm SGA: 2.6 (0.6-11.9) 
LBW: 3.2 (1.9-5.3) 
Infant Mortality:  
Preterm AGA: 2.6 (1.9-3.5) 
Term SGA: 1.7 (1.3-2.3) 
Preterm SGA: 10.0 (5.8-17.8) 
LBW: 5.8 (4.5-7.6) 
Debelew et al, 
201469 
Community based cohort study of 3463 
newborn infants in rural Ethiopia in 2012 – 
2013. 
 
Maternal report of a) preterm 
delivery (<37 weeks of gestational 
age) compared to term & b) small 
size at birth compared to normal 
size at birth 
Adjusted OR2 for the 
determinants of 
neonatal mortality  
a) 2.09 (1.03-4.22) 
b) 1.95 (1.11-3.42) 
 
Kayode et al, 
201470 
Secondary analysis of 2003 & 2008 DHS 
community based household survey data 
for 6900 women aged 15-49 years 
Ghana 
LBW compared to NLBW infants 
(based on maternal recall of 
infant size)  
Adjusted OR2 for the 
determinants 
neonatal mortality 
2.01 (1.23-3.30) 
Continued… 
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Table 1.3 continued 
Citation Study population & setting Exposure Outcome Effect estimates (95%CI) 
Katz et al, 201352 Pooled analysis of data from 20 population-
based cohorts from LMICs (>2 million 
infants) from 1982-2010 
Preterm vs term 
SGA vs AGA 
LBW vs NLBW 
 
(based on mix of ultrasound, 
clinical assessment and LMP) 
Unadjusted RR3 for 
neonatal & 
postneonatal 
mortality 
African Estimates: 
Neonatal: 
SGA: 1.62 (1.14-2.26) 
Preterm: 7.19 (4.12-12.52) 
34-36 wks: 2.74 (1.42-5.26) 
32-33 wks: 11.02 (3.93-30.89) 
<32 wks: 25.79 (15.07-44.14) 
Term SGA: 2.07 (1.65-2.60) 
Preterm AGA: 8.02 (4.05-15.91) 
Preterm SGA: 11.54 (6.76-19.71) 
Postneonatal:  
SGA: 1.46 (1.09-1.96) 
Preterm: 1.99 (1.49-2.66) 
34-<37 wks: 1.92 (1.62-2.28) 
32-<34 wks: 3.01 (1.77-5.14) 
<32 wks: 3.48 (0.81-14.86) 
Term SGA: 1.61 (1.40-1.84) 
Preterm AGA: 1.89 (1.21-2.97) 
Preterm SGA: 3.65 (2.90-5.48) 
Infant:  
SGA: 1.52 (1.21-1.91) 
Preterm: 2.69 (2.28-3.18) 
34-<37 wks: 1.75 (1.31-2.34) 
32-<34 wks: 2.97 (2.16-4.09) 
<32 wks: 8.94 (5.98-13.37) 
Term SGA: 1.68 (1.52-1.86) 
Preterm AGA: 2.96 (1.89-4.64) 
Preterm SGA: 4.75 (3.09-7.32) 
Continued…  
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Table 1.3 continued 
Citation Study population & setting Exposure Outcome Effect estimates (95%CI) 
Marchant et al, 
201271 
Meta-analysis of data on 4843 births from 
4 cohort studies collected from 1999-2010 
1. Kenya: Community based cohort 
2. Tanzania Mwanza, Tanzania Korogwe & 
Uganda: ANC attendees 
 
Uganda - home births excluded 
 
1. LBW vs NLBW 
2. Preterm vs term 
3. SGA vs AGA 
4. Preterm & weight for GA strata 
compared to term AGA 
NMR4 per 1000 live 
births 
 
Unadjusted neonatal 
mortality OR2  
 
Neonatal mortality OR 
1. LBW: 
Overall: 7.64 (4.80-12.15) 
Tanzania Korogwe: 8.96 (3.88-20.69) 
Tanzania Mwanza: 17.82 (6.86-46.28) 
Kenya: 5.49 (2.12-14.16) 
Uganda: 3.45 (1.27-9.40) 
2. Preterm 
@ 34-36 wks: 6.25 (3.03-12.87) 
@<34 wks: 58.74 (28.41-121.45) 
3. SGA: 2.14 (1.33-3.45) 
4. Preterm & Weight for GA strata 
AGA 34-36wks: 3.18 (0.95-10.71) 
AGA <34 wks: 74.92 (32.68-171.75) 
SGA >= 37 wks: 2.23 (1.22-4.10) 
SGA 34-36 wks: 19.88 (8.33-47.47) 
SGA <34 wks: 56.97 (11.13-291.73) 
Kayode et al, 
201272 
Secondary analysis of population-based 
2003 & 2008 Nigerian DHS data on 28647 
infants 
LBW vs NLBW Adjusted OR2 for 
under-5 mortality 
aOR=1.31 (1.09-1.58) 
Bardaji et al, 
201173 
Cohort study nested within an RCT. 997 
infants born to women recruited from ANC 
at a district hospital in Mozambique, 2003-
2005  
LBW vs NLBW Adjusted infant 
mortality OR2 
aOR=2.82 (1.27-6.28)  
Wei et al, 200474 Cohort study (nested within a 
micronutrient supplementation RCT) of 
823 singleton infants born to HIV infected 
women recruited from ANC in Dar es 
Salaam, Tanzania, who delivered in the 
clinic. Year not stipulated. 
LBW vs NLBW Neonatal mortality 
adjusted HR1 
Neonatal: 5.14 (2.32-11.39) 
Postneonatal:  
Overall: 1.75 (0.94-3.28) 
HIV negative/indeterminate: 3.16 (1.36-7.37) 
Infant: 2.40 (1.45-3.95) 
Continued… 
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Table 1.3 continued 
Citation Study population & setting Exposure Outcome Effect estimates (95%CI) 
Bloland et al, 
199675 
Secondary analysis of data on 3724 
singleton infants born to women recruited 
at ANC between 1987-1989 & enrolled in 
a malaria chemoprophylaxis trial in 
Malawi  
LBW (2.00-2.50kg)  
VLBW (<2.00kg) 
 
Compared to NLBW 
Adjusted HR1 for neonatal, 
postneonatal & infant 
mortality 
Neonatal:  
LBW: 2.3 (1.2-4.2) 
VLBW: 12.7 (7.2-23.0) 
Postneonatal (only univariable estimates 
available, as birth weight was excluded from 
the multivariable model) 
LBW:1.3 (0.9-1.8) 
VLBW: 2.4 (1.3-4.4) 
Infant:  
LBW: 1.4 (1.0-2.0) 
VLBW: 5.0 (3.3-7.7) 
Illness and mortality 
Doherty et al, 
201476 
Secondary analysis of 964 HIV unexposed 
infants enrolled in a community 
breastfeeding RCT in South Africa in 2006 
& 2008. Birth weight recorded from child 
health card 
LBW vs NLBW Adjusted HR1 for severe 
event (hospitalisation or 
death) in the first 6 months 
of life 
2.4 (1.3-4.3) 
Kourtis et al, 
201377 
Secondary analysis of 2369 HIV exposed 
uninfected infants enrolled in a 
breastfeeding antiretroviral & nutrition 
trial, Malawi. Mothers recruited through 
ANC. 2004-2010 
BW of 2.00-2.50kg  
vs NLBW 
Adjusted HR1 for neonatal 
mortality. Unadjusted HR for 
postneonatal mortality, 
pneumonia/serious febrile 
illness (SFI), diarrhoea & 
malaria (based on clinical 
diagnosis) 
Neonatal mortality: 12.30 (3.55-42.40) 
Postneonatal mortality: 0.90 (0.28-2.91) 
Pneumonia/SFI: 1.36 (0.96-1.91) 
Diarrhoea: 1.05 (0.62-1.80) 
Malaria: 1.44 (0.69-3.00) 
Continued… 
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Table 1.3 continued 
Citation Study population & setting Exposure Outcome Effect estimates (95%CI) 
Gladstone et al, 
201178  
Community based stratified cohort study of 
840 infants surviving to 6 weeks of life, 
nested within an RCT of antibiotic 
prophylaxis, 2006. All 247 surviving 
preterm infants in the RCT were included, 
along with 593 randomly selected term 
infants.  
Ultrasound dated GA & self-report of 
illness  
Preterm vs term Adjusted HR1 for 
mortality, visits to 
health facilities & 
admissions between 
6 weeks and 2 years 
of life 
Mortality: 1.79 (1.09-2.95) 
No significant differences in reported 
morbidities or admissions 
 
Kuhn et al, 200579 
 
620 HIV exposed HIV uninfected infants 
from Lusaka, Zambia, who survived the 
immediate neonatal period (to day 4 of 
life); nested within a breastfeeding trial of 
mothers recruited at ANC, 2002  
LBW vs NLBW Adjusted HR1 for 
mortality & 
hospitalisation by 4 
months of age 
 
Mortality: 2.43 (1.05-5.65) 
 
No association between LBW and 
hospitalisation 
Illness     
Briegleb et al, 
201580 
Secondary analysis of data on a population-
based cohort of 31999 infant participants 
of a vitamin A RCT in urban and 
periurban/rural Tanzania, between 2010 
and 2014.  
LBW (2.01-2.50kg, ≤2.00kg) vs 
NLBW 
Preterm (<37 weeks) vs term 
(≥37 weeks) 
SGA vs AGA 
 
Overall and in urban v’s 
periurban/rural settings 
HR1 for all cause 
hospitalisation in the 
first year of life 
Overall: 
LBW:  
≤2.00kg: 2.70 (1.77-4.14) 
2.01-2.50kg: 1.05 (0.87-1.26)  
 
Preterm: 0.80 (0.64-1.00) 
SGA: 1.26 (1.05-1.50) 
 
No variation by urban vs periurban/rural areas 
Le Roux et al, 
201581 
Cohort of 697 infants in peri-urban South 
Africa, 2012-2014. Mothers enrolled at 
ANC 
LBW vs NLBW 
Preterm vs term 
IRR5 for clinically 
diagnosed 
pneumonia in the 
first year of life 
LBW:1.47 (0.95-2.20).  
Preterm: 1.52 (1.04-2.20) 
 
Continued… 
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Table 1.3 continued 
Citation Study population & setting Exposure Outcome Effect estimates (95%CI) 
Kalanda et al, 
200982 
Case control study of hospital born LBW 
infants with fetal anaemia & matched 
hospital born NLBW non-fetal anaemia 
controls, Malawi, between 1993 and 1995. 
Follow-up at the hospital at monthly 
intervals.  
LBW fetal anaemia (35) 
LBW non-fetal anaemia (112) 
NLBW non-fetal anaemia (199) 
IRR5 of a) any illness, 
b) malaria, c) 
respiratory infection 
and d) diarrhoea 
 
Illnesses clinically 
diagnosed 
NLBW NFA:  
a) 5.34 (4.99-5.69) 
b) 1.15 (0.99-1.31) 
c) 1.04 (0.89-1.19) 
d) 0.92 (0.73-1.11) 
LBW FA 
a) 4.67 (3.91-5.68) 
b) 0.83 (0.50-1.16) 
c) 0.82 (0.50-1.16) 
d) 0.76 (0.33-1.19) 
LBW NFA: 
a) 5.81 (5.33-6.34) 
b) 1.26 (1.03-1.49) 
c) 1.17 (0.95-1.39) 
d) 1.00 (0.73-1.29) 
Kristensen and 
Olsen, 200683 
Cohort study of 571 infants in Soweto 
South Africa, followed to one year of age. 
Mothers recruited from 4 ANC clinics. HIV 
prevalence among pregnant women of 17% 
LBW (1.70kg-2.49kg) 
Compared to infants weighing 
2.50kg-3.49kg 
Adjusted RR3 for 
acute respiratory 
infections (ARI)  
0.59 (0.51-1.31) 
 
Continued… 
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Table 1.3 continued 
Citation Study population & setting Exposure Outcome Effect estimates (95%CI) 
Madhi et al, 
200684 
Secondary analysis of 39836 infants 
enrolled in a pneumococcal vaccine RCT, 
South Africa, 1998, and followed up for 5 
years. Outcome ascertained through 
hospital based surveillance 
Preterm birth (<36 weeks GA & 
<32 weeks GA)  
vs term (≥36 weeks)  
 
(based on clinical records of GA) 
RR3 for 
hospitalisation for 
respiratory syncytial 
virus (RSV) lower 
respiratory tract 
infection (LRTI) at 
<6mths, 6-12 mths, 
12-24 mths, ≤5 years 
 
Bronchiolitis and 
pneumonia at <5 
years. 
<32w GA vs term 
<6m: 5.5 (3.6-8.3) 
6-12m: 10.1 (6.1-16.5) 
>12-24m: 8.4 (4.6-15.4) 
<5y: 6.7 (5.0-8.9) 
<5y Bronchiolitis: 4.8 (3.0-7.7) 
<5y Pneumonia: 8.8 (6.1-12.6) 
 
32-35w GA vs term 
<6m: 4.8 (3.7-6.3) 
6-12m: 4.3 (2.7-6.8) 
>12-24m: 2.1 (2.7-6.8) 
<5y: 4.0 (3.2-5.0) 
<5y Bronchiolitis: 3.7 (2.7-5.1) 
<5y Pneumonia: 4.3 (3.2-5.9) 
 
<36w GA vs term 
<6m: 4.9 (3.6-6.3) 
6-12m: 5.8 (4.1-8.3) 
>12-24m: 3.7 (2.3-6.0) 
<5y: 4.7 (3.9-5.7) 
<5y Bronchiolitis: 4.0 (3.0-5.3) 
<5y Pneumonia: 5.2 (4.0-6.7) 
* Preterm<37 weeks’ gestation, unless otherwise stated 
1 = hazard ratio; 2 = odds ratio; 3 = risk ratio; 4 = neonatal mortality rate; 5 = incidence rate ratio 
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1.6.4. Birth weight and mortality 
Of the identified studies, only one (Katz et al)52 used population-based data on gestational 
age and birth weight to generate mortality estimates beyond the neonatal period in 
subgroups of gestational age and size for gestational age. This study, a pooled analysis of 
data from 20 studies in 13 LMICs investigated the association between gestational age and 
mortality. It included data for 36636 infants from eight African studies published between 
1997 and 2008 (two from Burkina Faso, one from South Africa, three from Tanzania, one 
from Uganda, and one from Zimbabwe). Of these eight studies, only three studies followed 
infants beyond six weeks of age, and only two to one year of age. The studies that followed 
infants beyond six weeks of age were all more than ten years old, and two included fewer 
than 2000 infants. 
The pooled analysis of the African data indicated that, although preterm infants were at 
greatest risk of dying in the neonatal period, they remained at risk throughout the 
postneonatal period. Preterm infants were approximately seven times (risk ratio (RR)=7.19; 
95%CI:4.12-12.52), two times (RR=1.99; 95%CI:1.49-2.66) and almost three times (RR=2.69; 
95%CI:2.28-3.18) more likely to die in each of the neonatal, postneonatal and overall infant 
time-periods. SGA babies had a lower increased risk of mortality than preterm infants, but 
this risk persisted throughout the first year of life. SGA infants were roughly 1.5 times more 
likely to die in each of the neonatal (RR=1.62; 95%CI:1.14-2.26), postneonatal (RR=1.46; 
95%CI:1.09-1.96) and infant periods (RR=1.52; 95%CI:1.21-1.91). Infants who were preterm 
SGA (equivalent to VLBW) had higher mortality rates in each time-period, and were 
approximately 12 times (RR=11.54; 95%CI:6.76-19.71), four times (RR=3.65; 95%CI:2.90-
5.48) and five times (RR=4.75; 95%CI: 3.09-7.32) more likely to die in each time-period 
(Table 1.3).  
These estimates are similar to those reported recently by Sania et al68 (Table 1.3); although 
Sania reported higher infant mortality rates for preterm SGA (adjusted hazard ratio 
(aHR)=10.0; 95%CI:5.8-17.8). This recent study was not population-based as it recruited 
women who were seeking antenatal care, and so women and infants who were less likely to 
access care would have been underrepresented possibly leading to an underestimate of the 
association.  
A limitation of both studies was their reliance on last menstrual period (LMP) and clinical 
assessment to determine GA. Approximately 90% of the infants in the study by Katz et al52 
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had their GA determined by clinical assessment and maternal recall of LMP. The study by 
Sania et al68 used LMP. Ultrasound is considered the best method for assessing GA. There 
can be poor concordance between GA assessed by ultrasound and by either LMP or clinical 
assessment85-87. This may have caused misclassification of infants by GA which may have 
impacted on the estimates of the association between GA and mortality.  
Recent estimates of the association between birth weight and postneonatal mortality in the 
general population (as opposed to populations recruited from for instance ANC clinics, such 
as the 2011 study by Bardaji et al73, the 2005 study by Kuhn et al79, and the 1996 study by 
Bloland et al75 (Table 1.3)) are lacking.  Those studies that recruited from the general 
population, such as Kayode et al70,72, and Gladstone et al78 did not generate estimates for 
the postneonatal period. Kayode et al70,72 reported neonatal and under-5 mortality rates 
and Gladstone et al78 reported mortality rates for infants between 6 weeks and 2 years of 
age (Table 1.3). In addition, to my knowledge, no studies have generated population-based 
estimates of the risk of mortality for VLBW for the entire infant period, even though the risk 
of mortality may be highest for these infants. 
1.6.5. Birth weight and illness: evidence from SSA 
Nine studies investigated the association between birth weight and infant illness in SSA 
(Table 1.3). All generated estimates beyond the neonatal period, three used population-
based data, and three had more than 1000 participants. One generated estimates for 
infants weighing ≤2.00kg and one by subgroups of gestational age. Nonetheless, as will be 
explained in the following paragraphs, the results of these studies are conflicting, and 
overall there is a lack of robust evidence of how birth weight affects infant illness, especially 
when the evidence from Africa is compared to data from middle and high-income settings.  
Five of the nine identified studies reported no association between birth weight and illness, 
clinic attendance or health facility admissions (an indicator of severe illness)77-79,82,83.  
In contrast, a secondary analysis of a population-based cohort of 31999 infants enrolled in a 
neonatal vitamin A trial from two sites (one urban and one peri-urban/rural) in Tanzania 
reported an association between both birth weight and preterm birth and hospitalisation. 
This study reported that infants weighing ≤2.00kg were 2.7 times more likely to be 
hospitalised in the first year of life compared to NLBW infants (aHR=2.70; 95%CI:1.77-4.14), 
but there was little evidence of an association for infants weighing 2.01-2.50kg. There was 
weak evidence that preterm infants had lower rates of hospitalisation (aHR=0.80; 
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95%CI:0.64-1.00) and some evidence that infants who were small for gestational age had 
moderately higher hospitalisation rates (aHR=1.26; 95%CI:1.05-1.50). These rates did not 
vary between the two sites. As the data on gestational age were based on maternal report 
of LMP, the estimates associated with preterm delivery and size for gestational age should 
be interpreted with caution as a) over 60% of enrolled infants were missing data on LMP, 
and b) gestational age as estimated by LMP is known to be discordant to that estimated 
using ultrasound, the gold standard method for gestational age assessment88. Furthermore, 
this study only analysed admissions to district hospitals, so infants suffering from severe 
illness were likely to be overrepresented.  
Another secondary analysis of data on 39836 infants enrolled in a pneumococcal vaccine 
trial in an urban South African slum84 reported that, in comparison to term infants, infants 
born at less than 32 weeks’ gestation were 5.5, 10.1, 8.4 and 6.7 times more likely to be 
hospitalised for respiratory syncytial virus at each of <6 months of age, 6 to 12 months of 
age, 12 to 24 months of age and at <5 years of age (Table 1.3). They were five and nine 
times more likely to be hospitalised for bronchiolitis (risk ratio (RR) = 4.8; 95%CI:3.0-7.7) 
and pneumonia (RR=8.8; 95%CI:6.1-12.6) in the first five years of life. Elevated risks for 
these outcomes were also observed for infants of 32 to 35 weeks’ gestation and for infants 
<36 weeks’ gestation.  
An association between preterm delivery and pneumonia was also reported by another 
small South African study of 697 infants born to mothers recruited from ANC81; although 
the evidence of an association with LBW compared to NLBW was weaker (Incidence rate 
ratio (IRR)=1.47; 95%CI:0.95-2.20).  
Further evidence of how LBW and preterm delivery can increase the risk of illness comes 
from studies of hospitalised infants. An analysis of 208 infants with laboratory confirmed 
group B streptococcus (GBS) disease in Soweto, South Africa between 1997 and 199889 
reported that both preterm birth and LBW were risk factors for both early (0-6 days of age) 
and late (7-90 days of age) onset invasive GBS. Preterm delivery was a risk factor for 
mortality from both early onset and late onset GBS, whereas LBW was identified as a risk 
factor for mortality from early onset disease only.  
In summation, overall, the association between birth weight and infant illness has not been 
extensively studied in SSA, and the reported data are inconsistent, with some studies 
showing an association and others not. There is some evidence of an increased association 
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between birth weight and illness, but this mostly relates to severe illness (hospitalisation) 
or the data comes from hospitalised cohorts who are more severely ill.  
1.6.6. Birth weight and illness: evidence from middle and high-income settings 
Two studies from a middle-income setting (Brazil) reported that preterm, growth retarded 
and LBW infants are at increased risk of illness, including diarrhoea, vomiting, pneumonia 
and hospitalisation90,91. The first, a study of 4674 infants with known gestational age, 
recruited in southern Brazil in 198290, reported that in the first two years of life, growth 
retarded infants were more likely to be hospitalised for diarrhoea and pneumonia. Preterm 
infants were more likely to be hospitalised for pneumonia, but there was little evidence of 
an increased risk of hospitalisation for diarrhoea.  A similar association between LBW and 
hospitalisation, diarrhoea and vomiting was found in a smaller study of 393 infants 
recruited in northeast Brazil in 199391, although no association was found with cough or 
fever, and there was no difference in rates of medical consultations.  
The most compelling evidence that LBW is a risk factor for illness beyond the neonatal 
period comes from high-income settings. Data from a population-based record linkage 
study of 719311 live born singleton infants in Western Australia65, reported that for every 
week reduction in gestational age below 39 completed weeks, the risk of infection related 
hospital admissions increased by 12%, and for every 0.50kg decrease in birth weight below 
3.00kg, it increased by 19%. This is higher than the 9% increased risk of infection related 
hospitalisation per 0.50kg reduction in birth weight below 3.00kg reported for a population-
based cohort of over 1.7 million infants from Denmark who were followed to 14 years of 
age66. In the Danish study infants weighing <1.00kg at birth were at increased risk of 
hospitalisation due to acute upper respiratory infection, viral pneumonia, bacterial 
pneumonia, septicaemia, and diarrhoea. The risk peaked in infancy.  
These findings from high-income settings are not directly generalisable to African settings 
due to the overall poorer nutritional status, living conditions (crowding and poor access to 
water and sanitation) and access to health care in Africa, as well as the high burden of 
communicable diseases such as malaria. However, at the very least they suggest that the 
increased risk of illness among LBW infants, including infectious illness, is biologically 
plausible as it exists even in the absence of these risk factors for disease.  
I will discuss the association between birth weight and VPDs in Section 1.7. 
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1.6.7. Birth weight and care seeking 
One factor that may influence health outcomes for LBW infants is health care seeking 
behaviour. It has been reported that care seeking is influenced by perceptions relating to 
the severity of disease92, and perceptions relating to the likelihood of survival of the 
infant93. A lack of care seeking for sick LBW infants may partially explain their increased risk 
of mortality.  
Aside from the studies on the risk of hospitalisation (which is a marker for both care seeking 
and severe illness), few studies have actually investigated care seeking among LBW / 
preterm infants. Gladstone et al78, in the aforementioned stratified cohort study from 
Malawi found no difference in the number of times that health care was accessed at 12, 18 
and 24 months of age between preterm and term infants (p=0.86). One qualitative study 
from Uganda94 reported that in the absence of weighing, mothers had poor recognition of 
LBW (especially among uniparous mothers who deliver at home). Many mothers did not 
recognise that LBW newborns were prone to illness, but they did know that they should 
seek care in the event of the infant falling ill. Other than these studies, I found no studies 
that specifically investigated whether birth weight was a determinant of care seeking in 
Africa.  
Clearly much work needs to be done to better characterise the association between birth 
weight illness and care seeking in Africa.  
1.7. THE IMPORTANCE OF VACCINATION OF LBW INFANTS 
Given LBW infants’ increased risk of mortality, and their possible increased risk of overall 
and infectious disease related morbidity, it is essential that they access all available 
preventative care services, including vaccination. Attendance for vaccination will not only 
protect them against vaccine preventable diseases, but it is a contact with the health 
services, and therefore an opportunity to diagnose illness and where indicated to access 
additional preventative and curative care services. Uptake of routine vaccination services 
may reflect an individual’s overall uptake and access to care services, especially 
preventative care services. For instance, it has been shown that mothers who do not take 
their infants to vaccination services are also less likely to attend other preventative care 
services such as ANC clinics95. Delayed and under-vaccination of LBW infants may reflect a 
broader problem of reduced care seeking for these infants, when compared to NLBW 
infants. 
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Preterm infants may have immature immune systems leading to a lower primary antibody 
response to vaccination for certain vaccines such as the glycoconjugate vaccines (like those 
against Hib)96. Nonetheless, the majority achieve protective concentrations of antibody 
following vaccination97. Vaccination is considered as effective and safe in preterm and LBW 
infants as among term and NLBW infants96,97, therefore with the exception of the HB 
vaccine (Table 1.1)8, LBW infants should receive their vaccines at the same chronological 
age as term and NLBW infants98.    
In addition to a lower primary antibody response, vaccination of preterm infants in the first 
year of life generates antibodies that do not persist as long96. Consequently, the normal 
decline in antibody concentrations following vaccination may be of greater clinical 
significance in LBW infants96,97. It is therefore very important that they adhere to the 
schedule of both initial and booster doses of vaccine, and that they fully complete the 
schedule.  
There are two additional reasons why prompt initiation of vaccination is important for LBW 
infants. Firstly, lower trans-placental maternal antibody transfer among LBW compared to 
NLBW infants99,100 may increase their risk of infections with VPDs prior to vaccination. 
Secondly, although data on the risk of VPDs among LBW infants in SSA is lacking, data from 
high-income countries indicate that LBW and preterm infants are at increased risk of 
hospitalisation and death due to VPDs such as pertussis,101 invasive pneumococcal 
disease24,102,103 and Hib104. These diseases are most prevalent in the first few months of 
life19,24.  Furthermore some of the complications of LBW, such as bronchopulmonary 
dysplasia may increase the susceptibility of LBW infants to the complications of pertussis101.   
Adherence to the full vaccination schedule, particularly to the initiation and timing of 
vaccination, may thus be even more important among LBW infants.  
1.7.1. Guidelines for the vaccination of LBW infants 
A number of organisations in high-income countries98,105,106, and at least one in Africa 
(Kenya)107 have specifically recommended that LBW infants receive their vaccines at the 
same chronological age as NLBW infants. In the WHO’s online catalogue of immunisation 
policy recommendations108, in particular in the section on contraindications to vaccination, 
the only recommendations relating to vaccination of preterm and LBW infants are in 
reference to HB vaccinations, where a modification to the routine schedule is indicated 
(Table 1.1). In previous policy documents, dating from the 1990s, prematurity and small for 
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date infants have been explicitly listed as being indicated for all vaccines109. A similar 
statement is not included in today’s policy documents. 
To my knowledge, there are no other current international guidelines on the vaccination of 
LBW infants, and the only international recommendations for the vaccination of these 
infants come indirectly from guidelines developed by WHO for the care of children in 
hospital in low income settings110. Hospital based care workers are advised to check a 
child’s immunisation status prior to discharge and to administer any due vaccines. They are 
advised to vaccinate all children, including those who are sick or malnourished. They are 
also advised to communicate any outstanding issues, including those relating to 
vaccination, to the first-level health worker who referred the child and to advise the mother 
of the next due date for vaccination. Again, birth weight, size and illness are not listed as 
contra-indications to vaccination. These guidelines are not targeted at vaccine providers, 
only at infants admitted to hospital, thereby excluding the majority of infants.  
A number of published papers111,112 have stated that one country in Africa, Guinea Bissau, 
had a policy of delaying the administration of BCG vaccination to LBW infants. They have 
given no details of this policy, nor have they provided references for the policy. I have not 
been able to access any official government documents relating to this, and so I have not 
been able to verify this.  
1.7.2. Adherence to the vaccination schedule among LBW infants 
Several reports from middle and high-income settings have indicated that adherence to the 
routine schedule is worse among LBW infants compared to NLBW infants40,113-118, that they 
are more likely to be vaccinated later than term infants, especially for first dose OPV and 
DTP115, and that vaccine-specific timely vaccination rates are 3% to 15% lower for LBW116 
than NLBW infants. A study of 112 parents of preterm infants who were attending a 
neonatal follow-up clinic in the USA reported that the majority of parents of LBW infants 
were unaware their infants are supposed to be vaccinated at the same chronological age as 
NLBW infants and the parents believed that the decision to initiate vaccination depends on 
the degree of prematurity of the infant and the infant’s weight119. It has also been reported 
that vaccine providers in the United States are reluctant to vaccinate infants who weigh less 
than 4.50kg at the time of vaccination, or who suffer from underlying conditions such as 
bronchopulmonary dysplasia or apnoea of prematurity120.  
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Few studies have directly investigated uptake or timing of vaccination in LBW infants in SSA. 
In addition to the analyses I have carried out as part of this thesis, I am aware of only one 
other study in Africa that has directly addressed this issue.  
This 2015 study121 from two informal urban settlements in Nairobi, Kenya, used data on 
3602 of 8756 infants enrolled in a health and demographic surveillance system between 
2006 and 2013 to investigate time to BCG vaccination. Vaccination of LBW infants 
(categorised as 2.00-2.49kg and <2.00kg) was compared to that of NLBW infants, between 0 
and 90 days of age, using log normal accelerated failure time parametric modelling. Birth 
weight data was based on what was documented at birth on the child health card. In this 
study, only BCG vaccinated infants surviving to at least 90 days of age, and whose 
vaccination card was seen after 90 days of age, were included. Only BCG vaccinated infants 
were included in the analysis. If LBW infants were less likely to be vaccinated, the effect of 
birth weight on time to vaccination would be underestimated. The prevalence of LBW in 
the sample was very low (6%). A high percentage (96%) of infants were born in health 
facilities, and 67% of those born in health facilities were born in private facilities. This study 
reported that 60% of LBW infants received BCG at >5 weeks of age. Infants weighing 2.00-
2.49kg took 1.4 times longer (time ratio (TR)=1.44; 95%CI:1.15-1.82) to be vaccinated than 
NLBW infants. Those weighing <2.00kg took 9 times longer (TR=8.97; 95%CI:6.01-13.39). 
The authors also reported that infants born in public compared to private facilities were 
vaccinated sooner (TR=0.48; 95%CI:0.44-0.53). The association between birth weight and 
BCG vaccination varied by place of delivery. When compared to NLBW infants, infants 
weighing <2.00kg who were born in private health facilities took much longer to be 
vaccinated than those born in public facilities (adjusted TR (aTR)=14.41; 95%CI:10.06-20.64 
versus aTR=1.79; 95%CI:1.27-2.54), as did infants weighing 2.00-2.49kg (aTR=3.66; 
95%CI:1.78-7.50 for those born in private facilities; aTR=1.18; 95%:0.88-1.59 for those born 
in public facilities). Therefore, in this study, being born in a private health facility appeared 
to be a major driver of the association between LBW and vaccination. The authors stated 
that the WHO BCG vaccination position paper9 recommended vaccinating preterm infants 
at >40 weeks, and that this may underlie the delay observed in their study population. 
However, no such recommendation is made in the position paper. The position paper9 
states that all infants should be vaccinated in the neonatal period, and that the only 
contraindications to BCG vaccination are symptomatic HIV infection and exposure to a 
smear positive pulmonary tuberculosis (TB) patient. 
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A number of additional studies have provided indirect evidence that LBW infants could be 
at risk of under-vaccination. An analysis of 5171 infants attending for BCG vaccination at 
four health centres in urban Nigeria122 indicated that compared to children who were not 
undernourished, undernourished children (two standard deviations below either the 
normal z-scores for weight for age or height/length for age or for body mass index) were 
1.7 times more likely to attend for vaccination at more than two weeks of age (aOR=1.70; 
95%CI:1.45-2.09) and six weeks of age (aOR=1.74; 95%CI:1.45-2.09). This study did not 
explicitly investigate the association with birth weight and BCG vaccination. As LBW is one 
of several contributory factors, along with feeding practices and illness, to 
undernourishment, these results cannot be taken as directly indicative of an association 
with birth weight123. In addition, the authors did not find an association between preterm 
delivery and BCG vaccination.  
A study investigating the effect of early DTP vaccination on mortality in LBW infants in 
Guinea-Bissau reported that compared to LBW infants who were vaccinated with DTP1 at 
two months of age, those LBW infants who were unvaccinated had poorer anthropometric 
status (including mean birth weight, mean weight gain between enrolment and two months 
of age, mean weight at two months of age, mean weight for age z score, mean length at 
two months, mean height for age z score, mean mid-upper arm circumference, mean head 
circumference and mean abdominal circumference)112. Although this study made no 
comparison to NLBW infants, it does suggest an association between severity of LBW and 
vaccination.  
Another study from Guinea Bissau111 of 7138 infants born at hospital between 1989 and 
1999, reported that LBW infants had lower BCG uptake rates until 18 months of age, 
compared to NLBW infants. However, as explained in Section 1.7.1, the authors stated that 
in Guinea Bissau there was a policy of not vaccinating LBW infants at birth, and mothers 
were instead advised to return for BCG vaccination, either when the child had gained 
weight or at the scheduled visit for DTP/OPV vaccination at six weeks of age. Given this 
policy, these results are not generalisable to other African populations where no such policy 
exists. Again these authors cited a WHO policy of delaying BCG vaccination until 40 weeks; 
however as stated in Section 1.7.1, no such recommendation appears to be given in the 
document109.  
A review of unpublished grey literature studies from low income settings identified thirteen 
studies reporting parental reluctance to bring sick, weak or malnourished children for 
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vaccination for reasons of social stigma and fatalism124. In this review, an additional 47 
studies reported false contra-indications (including infant illness and weight) as reasons for 
non-vaccination cited by both vaccine providers and parents124. Infant illness is repeatedly 
cited in the grey literature as a reason for non-vaccination, with health workers in Kenya, 
Nigeria, Pakistan and many other places citing this as a contra-indication to vaccination124. 
In a study of health workers and mothers in Mozambique, 40% of mothers and many health 
workers reported that they would not accept vaccination of a child with fever. It has also 
been reported that children who are perinatally infected with HIV are less likely to be up-
to-date with their vaccines at 12 and 24 months of age than HIV-exposed uninfected 
children125.  
In addition, it has been reported that parental perceptions of the likelihood of survival of an 
infant are known to influence the decision to seek curative care93. These perceptions may 
also influence the decision to seek preventative care such as vaccination services. This 
attitude may be more common for fragile, small LBW infants, and may be more common 
for infants with additional barriers to vaccination, such as poorer infants born to 
uneducated mothers47. 
Given their potential increased risk of infectious disease related illness and mortality and 
their increased risk of being vaccinated late, LBW infants may be under-served by routine 
vaccination services, and may be a high-risk group for under-vaccination.  
1.7.3. Capturing under-vaccination of LBW infants using routine methods of 
vaccine programme evaluation.  
As discussed in Section 1.4, routine estimates of vaccine uptake report on uptake at 52 
weeks of age using all infants alive at 52 weeks of age as the denominator (except for 
vaccines given at birth, like BCG, which use all live born infants as the denominator)12. 
These estimates will not illustrate poorer uptake rates among infants who die before 52 
weeks of age. Thus they are unlikely to accurately reflect uptake rates among infants, such 
as LBW infants, who are at higher risk of mortality in the first 52 weeks of life, or who due 
to their fragility are more likely to be delayed in getting vaccinated. LBW infants who 
survive to one year of age will mostly catch-up in their growth and may largely resemble 
NLBW infants, including in terms of their vaccination status.  As they gain weight over time, 
and become less fragile, their mothers may be more likely to bring them for vaccination.   
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1.7.4. Improving uptake of vaccination of LBW infants 
Exploiting routine contacts with health care providers at vaccination clinics and other 
contacts with the health service could provide a convenient and cost-effective way of 
increasing timely vaccination among both LBW infants and other infants who are under-
served by vaccination. This is in accordance with the recommendations of the latest Global 
Vaccine Action Plan4 which, as discussed in Section 1.5, advocates that all contacts with 
health care providers should be used as opportunities to verify an infants’ vaccination 
status and to vaccinate when indicated. 
1.8. METHODS TO ASSESS OPPORTUNITIES FOR VACCINATION.  
In the literature, opportunities are typically defined as a contact with a health care provider 
that could be used to administer a vaccine for which an infant is eligible41,126-134. 
Opportunities are usually counted from the date the infant becomes eligible for receipt of 
the vaccine41,127. The denominator for analyses of opportunities for vaccination has 
variously been all surveyed children126,127 or children having opportunities16,41.  
1.8.1. The use of opportunities to improve vaccination in SSA 
A number of studies16,41,126-132,134,135 have investigated the potential of using opportunities to 
improve the delivery of vaccines in SSA. All but two of these studies are more than twenty 
years old, and none have specifically looked at groups that are under-served by vaccination, 
such as LBW infants. These studies include one systematic review dating from 1993129, four 
analyses of vaccine coverage data16,41,126,127, and six facility-based  surveys128,130-134. Most of 
these studies are descriptive in nature; only one study has investigated risk factors for 
missed opportunities127.   
An analysis of DHS data collected between 1996 and 2005 on 217706 children from 45 
LMICs, including 25 countries from SSA, reported that 29% to 82% of all opportunities for 
vaccination were missed16. In SSA, the percentages of missed opportunities reported in this 
study ranged from 17% to 71%.  
A community based cross-sectional survey of 668 randomly sampled children aged <2 years 
conducted in 1992 in Mozambique127 reported that 25.7% of children had experienced a 
missed opportunity for vaccination. Children had a mean of 1.73 opportunities each. This 
was the only study that quantitatively analysed determinants of vaccination. It identified 
facility birth (aOR=2.29; 95%CI:1.37-3.83) and mothers being single, divorced or widowed 
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(compared to married or cohabiting) (aOR=1.68; 95%CI:1.07-2.64) as predictors of missing 
opportunities.  
A population-based national vaccine coverage survey of 642 children aged 12 to 23 months, 
conducted in the Central African Republic in 199041 reported that 61% of opportunities for 
DTP1 vaccination, 62% for DTP2 vaccination and 70% for measles vaccination were missed. 
For each of these respective vaccines, 19%, 11% and 28% of all opportunities occurred 
when another vaccine was given. Had all opportunities been exploited, the coverage of all 
scheduled doses would have increased by 74% (from 34% to 59% at 21 months of age) and 
the days at risk of contracting measles would have declined by a mean of 74 days per 
subject. 
Cutts et al126, analysed data from seven community based vaccine uptake surveys in 
Mozambique and one in Conakry, Guinea, conducted between 1987 to 1989. These surveys 
included qualitative interviews with mothers on their knowledge, attitudes and practices 
relating to vaccination. The authors reported that, among those with vaccination records, 
19% of children in Conakry, and 6% of children in Mozambique would have been fully 
vaccinated if all contacts with health care providers had been used to vaccinate.  
A 1991 review of studies of missed opportunities for vaccination from 45 countries, 
including 19 studies from 15 African countries129, reported that a median of 41% of children 
(range 0-99%) in developing countries had missed opportunities for vaccination. The review 
reported that missed opportunities in developing countries (based on an analysis of 10 
studies) were more common at curative care visits (median prevalence = 42% (range 14-
91%)) than preventative care (median prevalence = 32% (range 2-54%)) visits. The study 
also described the reasons for missing opportunities. These include failure to administer 
vaccines simultaneously, false contraindications to vaccination, fear of wasting vaccine by 
opening a vial for a small number of children, lack of assessment of vaccination status when 
the child visited a clinic, vaccine shortages, poor organisation of vaccine clinics, and a lack of 
a daily vaccination clinic. 
A study133 of missed opportunities for vaccination in Sudan, included a qualitative 
component whereby mothers exiting the clinic were asked about why a child had not been 
vaccinated. Mothers reported refusing vaccination if their child was ill. This has also been 
reported as a reason for non-vaccination by both mothers and vaccine providers124, as 
 40 
 
previously discussed. Given the greater fragility and possible increased incidence of illness 
in LBW infants, it may be that they are more likely to miss opportunities for vaccination.  
In summary, studies have reported that opportunities for vaccination exist and that many 
of these opportunities are missed. There is however a lack of up-to-date information on the 
frequency, use, and potential impact of such opportunities to improve the timely delivery 
of vaccines in Africa. In particular, the potential of using such opportunities to improve the 
vaccination of LBW infants has not been investigated.  
1.9. RATIONALE FOR THE PHD 
It is evident that a number of important gaps exist in the data relating to LBW infants in 
SSA. There is a paucity of population-based estimates of mortality and illness for LBW 
infants in SSA, in particular in the postneonatal period, and in particular for VLBW infants 
(as discussed in Section 1.6). Access to care seeking and preventative care services for 
these infants in SSA have been poorly described. There has been little direct research into 
whether they are an under-served group for vaccination (as discussed in Section 1.7), and 
into how to improve their vaccination by utilising routine health care contacts as 
opportunities for vaccination (as discussed in Section 1.7.4). Data on how the association 
between birth weight and these outcomes relate to or are influenced by other socio-
demographic factors are lacking. 
Between June 2010 and January 2013, a large trial to assess the impact of neonatal vitamin 
A supplementation on infant mortality was conducted in the Brong-Ahafo region of Ghana. 
The Neovita trial (described in detail in Chapter 2) recruited almost 23,000 infants from a 
population-based pregnancy surveillance system. High quality data on birth weight and 
vaccination were collected on all infants enrolled in the trial. As the trial epidemiologist this 
afforded me an excellent opportunity to address these specific gaps in the evidence, 
particularly in relation to LBW infants’ access to routine vaccination.  
1.10. PHD AIMS AND OBJECTIVES  
Overall in this PhD, I aimed to investigate whether LBW is a risk factor for under-vaccination 
among infants in Ghana; to frame their access to vaccination services within the broader 
context of their risk of mortality, illness, failure to seek care, and health facility admissions; 
and to investigate ways to improve their vaccine uptake.  
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With this in mind, I defined four overall objectives for the PhD (which will be further 
detailed and expanded upon in the corresponding papers in Chapters 4 to 7). These are:  
1. To assess whether LBW was a determinant of mortality, illness, care seeking, and health 
facility admission in the first year of life, and in each of the neonatal, early and late infant 
periods. 
This was addressed by: 
a) Quantifying the association between birth weight and mortality and illness, and 
among those reporting illness, generating estimates of the association between 
birth weight and care seeking, and health facility admissions in the first year of life. 
b) Investigating how these estimates varied between the neonatal, early and late-
infant periods 
c) Assessing whether the association between birth weight and mortality varied by 
distance to the nearest health facility, and by SES. 
2. To investigate birth weight and other factors as determinants of the timeliness of 
postneonatal vaccination (using DTP1 and DTP3 as indicator vaccines). 
This was addressed by: 
a) Assessing whether LBW was a determinant of DTP1 and DTP3 vaccination 
b) Assessing whether maternal education or SES modified the association between 
birth weight and vaccination with DTP1 and DTP3 
c) Quantifying other determinants of delayed DTP1 and DTP3 vaccination  
3. To investigate birth weight and other factors as determinants of neonatal BCG 
vaccination. 
This was addressed by: 
a) Evaluating whether birth weight was a determinant of neonatal BCG vaccination 
b) Assessing whether the association between birth weight and neonatal BCG 
vaccination varied by place of delivery or infant illness 
c) Quantifying other determinants of neonatal BCG vaccination 
 
4. To investigate the potential for using routine contacts with health care providers to 
improve vaccine uptake, including among LBW infants, and to assess whether birth weight 
and other factors were determinants of uptake of opportunities. 
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This was addressed by: 
a) Quantifying the number and types of opportunities for vaccination, and the 
associated missed opportunities for vaccination in the first year of life  
b) Identifying the determinants of uptake of those opportunities 
c) Assessing how using the first opportunity for vaccination could increase the uptake 
of vaccines included in the routine childhood immunisation schedule. 
1.11. THESIS STRUCTURE  
This thesis is structured as a thesis by publication. In Chapters 2 and 3 I present the 
methodology for both the Neovita trial and for the PhD. This is followed by a results section 
comprising four chapters (Chapters 4 to 7) presenting four papers that have been, or are in 
the process of being published in peer-reviewed scientific journals. When applicable, I 
provide additional materials, such as further details of the methods, results and further 
discussion that were not included in the published papers. I close with a final section 
comprising a chapter (Chapter 8) presenting an overall discussion of, and conclusions from 
the research findings. This includes a critique of the strengths and limitations of the 
research, an assessment of the implications of the findings for public health policy, and 
recommendations arising from these findings.  
1.12. ROLE OF THE CANDIDATE  
I was the trial epidemiologist on the Neovita trial, within which this PhD was nested. I was a 
member of the trial management team, and I was based in the field in Kintampo, the 
location of the trial, for the three-year duration of the trial. Whilst in Kintampo, I managed 
the collection of the trial data (subsequently used in this PhD). I played an integral role in all 
aspects of trial management, with major contributions to the training of field staff, 
supervision of field work, development and operation of the data management system, 
supervision of data management, preparation of datasets for the trial analysis, and analysis, 
write-up and dissemination of the trial findings. I took lead responsibility for ensuring the 
quality of the data collected for the trial, including the vaccination data used in this PhD.  I 
remained as the trial epidemiologist after I registered for this PhD.  
With the help of my supervisors, I developed the concept for the PhD, and I designed the 
analytical plans for each of the analyses. I developed the datasets for the analyses, 
 43 
 
conducted all the analyses, and drafted all the papers, with input from my supervisors, 
statistical advisor and co-authors. Similarly, I also wrote all the supporting PhD chapters.  
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CHAPTER 2: OVERVIEW OF THE 
NEOVITA TRIAL AND ITS 
METHODOLOGY 
Preamble 
This chapter presents an overview of the methods of the Neovita trial, including a 
description of the setting of the trial (Ghana), the study area, the trial design, an overview of 
the recruitment and data collection processes, and a description of the process of data 
management.  
2.1. THE NEOVITA TRIAL 
Neovita was a randomised double blind placebo controlled trial, undertaken in the Brong 
Ahafo region of Ghana between June 2010 and January 2013. Neovita aimed to assess the 
impact of neonatal vitamin A supplementation (50,000 IU) on all-cause mortality at four, 26 
and 52 weeks of age.  
A team from the Faculty of Epidemiology and Population Health at the London School of 
Hygiene & Tropical Medicine (LSHTM), in partnership with the Kintampo Health Research 
Centre (KHRC), conducted the trial. I was the epidemiologist on the trial and I explain my 
role in Neovita in Section 1.12. The trial protocol and results have been published1,2. 
2.2. GHANA, THE SETTING OF THE NEOVITA TRIAL 
Ghana is situated in the Gulf of Guinea in West Africa (Figure 2.1) and has an estimated 
population of 24.7 million people, including an estimated 3.4 million children aged less than 
5 years3.  The gross national income per capita is approximately $1550 and 29% of the 
population live below the national poverty line. The current life expectancy at birth is 61 
years4.   
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Figure 2.1:  Map of a) Ghana5 and b) the Neovita study area 
A.  B.  
2.2.1 Mortality rates and neonatal and postneonatal cause of death 
The 2013 under-5 mortality rates in Ghana, overall, and in each of the early neonatal, late 
neonatal, postneonatal, and childhood periods, have been estimated (Table 2.1)6.  
Table 2.1: Under-5 mortality per 1000 live births by time-period, Ghana, 20136. 
Time-period Mortality rate per 1000 live births (95%CI) 
Early neonatal (0-6 days) 21.9 (19.1-24.8) 
Late neonatal (7-28 days) 5.9 (5.1-6.8) 
Postneonatal (29-364 days) 18.3 (14.9-22.1) 
Childhood (1-4 years) 27.2 (21.5-34.2) 
Under-5 years 71.4 (62.4-82.3) 
 
Mortality remains high throughout the postneonatal period and childhood. Little change in 
this rate is projected to occur by 20357.  There is also considerable variation in mortality by 
geographic region (Figure 2.2). In Brong Ahafo, the neonatal mortality rate is estimated to 
be 27 per 1000 live births in the neonatal period, 10 per 1000 live births in the postneonatal 
period, 38 per 1000 live births in the infant period and 57 per 1000 live births among under-
fives8, lower than for most other regions in Ghana (Figure 2.2). 
Almost 70% of deaths among infants aged 1 to 59 months were estimated to be due to 
infectious causes7 (Figure 2.3). Most deaths in the neonatal period were due to non-
infectious causes such as intrapartum complications. VPM data is subject to several 
limitations9-11, including the potential for misclassification of cause of death10,11, so these 
data should be interpreted with caution.   
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Figure 2.2: Under-five mortality rate, stratified by time-period and geographical region, 
Ghana, 20148. 
 
 
Figure 2.3: Estimated cause-specific under-5 mortality from a) 1-27 days, and b) 1-59 
months, Ghana, 2013*. 
 
 
* Modified from Liu et al, 20157 
0
20
40
60
80
100
120
D
ea
th
s 
/ 
1
0
0
0
 li
ve
 b
ir
th
s
Neonatal Postneonatal Infant Child Under-5
1318, 
6%
7159, 31%
6858, 30%
4747, 20%
958, 4%
1984, 9% 86, 0%
a) 1 to 27 days
Pneumonia
Preterm birth
Intrapartum related
complications
Sepsis / meningitis /
tetanus
Other disorders
4664, 12%
532, 1%
2729, 7%
12365, 32%
470, 1%1093, 3%
8991, 24%
762, 2%
6815, 18%
b) 1-59 months
Diarrhoea
Measles
Injury
Malaria
AIDS
Meningitis
Other disorders
 54 
 
There is a lack of population-based data on neonatal and postneonatal cause of death in 
Ghana. Neonatal and postneonatal cause of death data are available from two health and 
demographic surveillance (HDSS) systems in Dodowa (near Accra) and Navrongo (Northern 
Ghana); although there is considerable variation in the rates reported at each site (Table 
2.2)12. Cause-specific mortality was consistently higher in Navrongo compared to Dodowa, 
which reflects its higher infant (40 versus 18 deaths/1000 live births) and under-5 (75 
versus 41 deaths/1000 live births) mortality rates. The neonatal mortality incidence rate 
due to prematurity was high in both sites, but particularly in Navrongo. In both sites the 
most common cause of postneonatal mortality was pneumonia.  
Table 2.2: Neonatal and postneonatal cause cause-specific mortality rates per 1000 person 
years of follow-up, Dodowa and Navrongo Health and Demographic Surveillance Systems12. 
 
 Cause of Death Dodowa 
(2006-2012) 
Navrongo 
(2000-2012) 
N
eo
n
at
al
 Birth Asphyxia 11.17 52.57 
Neonatal Infections 15.45 43.80 
Congenital abnormalities - 0.95 
Prematurity 5.94 57.14 
P
o
st
n
eo
n
at
al
 Diarrhoea 0.51 3.14 
HIV/AIDS 0.39 0.99 
Malaria 0.36 2.59 
Pneumonia 3.47 4.93 
Other Infections 
 
0.23 2.09 
 
2.2.2. Burden of low birth weight and vaccine preventable diseases 
Data from the most recent DHS8  indicated that approximately 10% of infants born in Ghana 
are LBW; although birth weight data were only available for 60% of infants3. To my 
knowledge, there are no available data on the incidence of VPDs in Ghana. In 2014 there 
were a total of 151 cases of VPDs reported; 124 of measles, 26 of rubella, and 1 of tetanus; 
undoubtedly a gross underestimation of the true burden of VPDs in the country13. 
2.3. ORGANISATION OF VACCINATION SERVICES IN GHANA 
2.3.1. The infant vaccination schedule in Ghana 
Routine vaccination in Ghana is delivered by the Ghana Health Service (GHS) through the 
Expanded Programme on Immunisation (EPI) according to a standardised schedule14 (Table 
2.3).  
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Table 2.3: Recommended schedule for the delivery of childhood vaccines in Ghana14.  
Scheduled 
Vaccine 
Birth 6 weeks 10 weeks 14 weeks 9 months 
BCG Y     
Polio Y Y Y Y  
DTP/HiB/HepB†  Y Y Y  
Pneumococcal*  Y Y Y  
Rotavirus*  Y Y   
Measles     Y 
Yellow Fever     Y 
† Given as a single injection and hereafter referred to as DTP 
* Introduced in May 2012 
 
2.3.2. Organisation of vaccination services 
Vaccines that are scheduled to be administered at birth (BCG and birth OPV) are usually 
given to infants born in health facilities (hospitals, maternity homes and community based 
health facilities) before they leave the facility following delivery. Women attending ANC are 
advised to bring their infants for vaccination after birth, and traditional birth attendants 
(TBAs) and community based surveillance volunteers (CBSVs) have been trained to advise 
mothers delivering at home to bring their newborns for vaccination. Consequently, infants 
born at home should be taken to child health clinics to get these vaccines. Vaccines 
scheduled for administration in the postneonatal period are given at child health clinics. 
Child health clinics are held at health facilities, but also at Community Health Planning 
System (CHPS) compounds in the community and are delivered by vaccine-providers (both 
community health nurses and community health officers). In addition to these clinics, 
mobile teams hold clinics at outreach points in the community. These mobile clinics target 
areas that are not served by a static health clinic, that are hard-to-reach or that have low 
vaccine uptake. Private health facilities such as private maternity homes increasingly deliver 
vaccines, and those that do are integrated within the routine system for vaccine 
procurement, delivery and reporting.  
2.3.3. Documentation of vaccination 
Staff at the child health clinics and private facilities record all vaccines administered, 
including the date, the place of administration and the vaccine batch number, usually in the 
infant’s child health book (Figure 2.4).  
These data may also be documented on a vaccination card or in the mother’s antenatal 
card. The staff advise the mother of the next scheduled date for vaccination. Staff refer to 
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these cards to determine what vaccines need to be administered. The clinics also retain 
their own registers of what vaccines were given to whom at each clinic. If the child never 
attends for vaccination, the child may not be in possession of a vaccination card.  
Figure 2.4: A typical vaccination record from Ghana 
 
2.3.4. Supplementary Immunisation Activities 
In addition to these routine vaccination activities, supplementary immunisation activities 
(SIAs), primarily targeting polio, but also targeting measles, are conducted. These involve 
mobile vaccination teams visiting communities and going from house to house to offer 
vaccination. The administration of these vaccines is not documented. These vaccines are 
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given in addition to, and not in lieu of the routinely scheduled vaccines. The SIAs conducted 
in Ghana during the trial period are summarised (Table 2.4).  
Table 2.4: Summary of supplementary immunisation activities in Ghana during the trial 
period. 
Year Supplementary immunisation activity Level Dates 
2010 Integrated measles / vitamin A campaign National 3rd – 6th November 
2011 National polio immunisation days National 24-26 March 
Ghana Integrated Child Health Campaign 
(Polio, vitamin A & de-worming) 
National 12-14 May 
National polio immunisation days National 27-29 October 
Yellow fever campaign (Kintampo North & 
South) 
District 22-28 November 
2012 National polio immunisation days National 22-29 March 
There was one national measles campaign in 2010, three national polio SIAs and one 
district level yellow fever SIA in 2011 and one national polio SIA in 2012. For polio these 
SIAs are held as part of the drive towards polio eradication. SIAs for other vaccines are held 
to either boost uptake, or as exemplified by the yellow fever campaign conducted in the 
study area in 2011, part of disease control measures in response to outbreaks of specific 
VPDs. 
2.3.5. Evaluation of the routine childhood vaccination programme 
The routine childhood vaccination programme in Ghana is evaluated by WHO, UNICEF and 
other international organisations using the standard indicators recommended by WHO and 
UNICEF15,16, including vaccine uptake for all vaccines at 52 weeks of age and drop-out rates. 
These data are compiled using monthly returns on vaccines administered at all child health 
clinics. The reported data from Ghana is subject to all the limitations associated with 
registry and survey data for estimating uptake as previously described in Section 1.317.  
2.4. UPTAKE, TIMING AND DETERMINANTS OF VACCINATION IN 
GHANA.  
Vaccination uptake is improving annually. The 2014 Ghana DHS reported 52 week uptake 
rates among children aged 12 to 23 months of over 95% for BCG and DTP1 and of over 85% 
for three doses of polio and DTP3. However, deficiencies in vaccine delivery remain. For 
instance, only 51% of infants aged 12-23 months were reported to have been fully 
vaccinated (received all of the recommended doses in the routine schedule), and this varied 
considerably with geographic location (Figure 2.5). Brong Ahafo had some of the highest 
 58 
 
rates of up-to-date vaccination in Ghana. However, only 71% had received all their basic 
vaccinations (BCG, measles and three doses each of OPV and DTP)8.   
Figure 2.5: Percentage of children aged 12-23mths who were fully vaccinated by geographic 
region, Ghana 2014. 
 
Adapted from the Ghana DHS 20148 
Previous research from Ghana (and from the Neovita study area) indicates that many 
infants receive their vaccines over four weeks late (20% for BCG and measles vaccine and 
40% for the final dose of polio vaccine)18. Low socioeconomic status, low maternal 
educational attainment and rural place of residence have all been found to be associated 
with delayed vaccination18. The association with birth weight has not been studied.  
2.5: THE NEOVITA STUDY AREA 
Figure 2.6: The study area 
   
Brong Ahafo is the second largest region in Ghana and has an estimated population of 
2,310,9833. The largest ethnic group in the area is Asante. Twi is the main language spoken. 
The population is widely dispersed, clustering in small villages of primarily mud compounds. 
Subsistence farming and small-scale trading are the primary sources of income.  
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The Neovita study area has an estimated size of 12,000 square kilometres and is comprised 
of seven contiguous districts (Kintampo North, Kintampo South, Nkoranza North, Nkoranza 
South, Tain, Techiman and Wenchi) (Figure 2.1).  The estimated population in these 
districts is over 600,000, including an estimated 120,000 women of reproductive age1. The 
study area is served by four district hospitals and 69 fixed site health facilities. 
2.6. ELIGIBILITY CRITERIA FOR NEOVITA 
Enrolment into Neovita was restricted to those infants who i) were going to stay in the 
study area for at least 26 weeks post-dosing; ii) were aged three days old or less at the time 
of enrolment and iii) were well enough to suck or feed and therefore to receive an oral 
dose of vitamin A or placebo.  The number of infants screened, excluded and enrolled in 
Neovita is summarised (Figure 2.7), and the process for their screening and enrolment is 
described in Section 2.7. Of 27330 live births identified in the study area, 26414 (94.7%) 
were screened for inclusion in Neovita and 22955 (84.0%) were enrolled.  
Figure 2.7: Recruitment and enrolment of infants in the Neovita trial, Ghana 2010-2013*.  
27330 live births identified in 
study area
26414 screened for eligibility 
(96.7%)
22955 enrolled (84.0%)
916 not screened (3.3%)                                             
- 282 could not be reached by study 
team (1.0%)                                                                                  
- 298 died before screening (1.1%)                        
- 336 did not provide consent (1.2%)
3459 excluded (12.7%)                                                 
- 2500 would not stay for 6 months 
(9.2%)                                                                                    
- 800 aged > 3 days (2.9%)                                          
- 84 not able to feed / unable to 
assess feeding (0.3%)                                                                
- 75 other reason (0.3%)    
 
* Percentages are of all live births 
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2.7. RECRUITMENT 
For the trial, village based fieldworkers enumerated all compounds in the study area and 
visited them at 12 week intervals to identify women of reproductive age (aged 15 to 49 
years). The fieldworkers registered all women who were planning to remain in the study 
area for at least 26 weeks in a reproductive surveillance system, allocated them a unique 
anonymous identification number and visited them at 12-week intervals to determine if 
they were pregnant. The fieldworkers visited pregnant women every four weeks during 
their pregnancy and daily during their final month of pregnancy to ensure prompt 
identification of all births (Figure 2.8).   
Newborns were screened for enrolment in Neovita by trained dosing supervisors who 
visited all villages and health facilities in their area daily to ascertain births. They worked 
with a network of key informants in the community (surveillance field workers, TBAs, health 
facility staff and CBSVs) to identify births promptly. All infants born at home or in a health 
facility were screened for enrolment in the trial and informed written consent was obtained 
from all mothers prior to enrolment.  Each enrolled infant was allocated a unique 
anonymous identification number and dosed with either vitamin A or a placebo by the 
dosing supervisors. Infants were visited at day one and three post-dosing and at four 
weekly intervals for the first 52 weeks of life or until their vital status at 52 weeks of age 
was determined (Figure 2.8).  
Fieldworkers were directed to visit compounds, registered women, pregnant women and 
infants at set intervals using automated weekly listings distributed to all fieldworkers. 
All field staff were educated to at least high-school level, and received extensive training in 
the Neovita study procedures and were fluent Twi speakers. I helped to train the field 
workers in the study procedures, both at the start of the trial, and at periodic refresher 
trainings until the end of fieldwork. I also directly supervised the work of the fieldworkers, 
through a process of direct observation and real-time feedback, in the field.  
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2.8. DATA COLLECTION 
2.8.1. Neovita data collection processes 
All data were collected on standardised paper questionnaires (Annex 2) and were linked 
using the unique identification numbers assigned to either the mother or the infant. The 
schedule and process for the collection of data are summarised (Figure 2.8, Table 2.5). 
Figure 2.8: Overview of fieldwork and data collection procedures for Neovita.  
Reproductive surveillance every 12 weeks to identify pregnancies
- Issue ID number, collect data on woman name & compound
Woman age 
15-49 years 
registered
Pregnancy 
Identified
Pregnancy surveillance every 4 weeks to identify births
Woman 
gives birth
Screened for 
enrolment into 
trial within 3 
days of birth
Enrolled
Post-dosing 
visit (day 1 
& 3 after 
enrolment)
Monthly 
follow-up 
(from age 
4 weeks)
Event Field Work Activity
Data 
collected 
on infants1
1. Enrolment Form: Eligibility 
for enrolment, infant ID 
number, date of birth, birth 
weight, infant sex
2. Baseline Form: Place of 
birth, multiple birth, religion, 
ethnicity, family size, maternal 
age, education & occupation, 
household assets, cooking 
arrangements
Post-dosing 
Form
Vital status, date 
of death2,
Illness,
hospitalisation
(completed at 
post-dosing visits
Infant Form
Vital status, date of 
death2, vaccination 
(vaccinated yes/no, 
name & date of vaccine, 
maternal recall of 
vaccination)
illness, care-seeking, 
hospital admission, 
cause of admission 
 
 
1. Enrolment & baseline form completed at enrolment; postdosing form completed at the postdosing visit between 1 & 6 days 
of age, depending on age at enrolment; infant form completed at monthly follow up visits from 4 weeks of age until vital 
status at 1 year of age established 
2. Date of death verified at verbal post-mortem, conducted for all infants who died 
 
An enrolment and baseline form were completed for all infants who were screened for 
inclusion in the study. For those who were enrolled and supplemented, a post-dosing form 
was completed at both days one and three after supplementation (between one and six 
days of age, depending on the age at enrolment). An infant form was completed for each 
enrolled infant at four weekly follow-up visits until vital status at 52 weeks of age was 
determined (Figure 2.8). In addition, a verbal post-mortem (VPM) form was completed for 
all enrolled infants who died.  
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Table 2.5: Overview of data collection processes for the Neovita trial. 
Visit Frequency Target 
Population 
Purpose Data collected Associated 
forms 
R
ep
ro
d
u
ct
iv
e 
su
rv
ei
lla
n
ce
 
Every 12 
weeks 
All women 
aged 15-45 
residing in 
the study 
area 
Identify women of 
reproductive age to 
register in surveillance 
 
Enumeration of 
compounds 
 
Locate women who 
have moved to a 
different compound & 
assign them to the 
new compound 
 
Identify women who 
have left the study 
area or who have 
newly entered the 
study area 
Names  
 
Women ID 
numbers 
 
Compound 
numbers                                                                                                                                     
Moves form 
 
Compound 
enumeration 
form 
P
re
gn
an
cy
 s
u
rv
ei
lla
n
ce
 Every four 
weeks, and 
then daily 
in the final 
month of 
pregnancy 
All pregnant 
women aged 
15-45 
residing in 
the study 
area 
Identify new 
pregnancies 
 
Monitor outcomes of 
pregnancies 
 
Identify new deliveries 
Details of pregnant 
women 
 
End dates of 
pregnancies 
 
Details of newly 
delivered women 
Pregnancy 
form 
En
ro
lm
en
t 
Following 
an infant 
delivery 
All women in 
the study 
area who 
have given 
birth 
Document outcomes 
of pregnancies 
 
Screen infants for 
inclusion in Neovita 
 
Enrol infants in 
Neovita 
 
Collect data on all 
infants born in the 
study area 
Outcomes of 
pregnancies 
 
Details of mothers 
who have delivered 
and newly 
delivered infants 
 
Infant ID numbers 
 
Infant status 
 
Infant birth weight 
 
Infant, maternal 
and household 
characteristics 
Enrolment 
form 
 
Baseline form 
Continued….. 
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Table 2.5 continued 
Visit Frequency Target 
Population 
Purpose Data collected Associated 
forms 
P
o
st
-
d
o
si
n
g 
vi
si
t Days 1 and 3 
post-dosing 
Infants 
enrolled in 
Neovita 
Document vital status 
of infant 
Monitor adverse 
events 
Infant status & 
location 
illnesses & any 
adverse events 
Post-dosing 
form 
In
fa
n
t 
fo
llo
w
-u
p
 
vi
si
t 
Every 4 
weeks from 
four weeks of 
age until vital 
status at 52 
weeks of age 
ascertained 
Infants 
enrolled in 
Neovita 
Document vital status 
of infant 
Collect data on care 
seeking, 
hospitalisations and 
vaccinations in the 
previous month 
Infant status & 
location 
 
Care seeking, 
hospitalisations 
and vaccinations 
Infant form 
In
fa
n
t 
ve
rb
al
 p
o
st
 
m
o
rt
e
m
 Following the 
death of an 
infant 
All Neovita 
infants who 
died 
To allow a cause of 
death to be assigned* 
Signs, symptoms 
and circumstances 
surrounding the 
death of an infant 
Verbal post-
mortem form 
* Cause of death data were not available at the time of the conduct of this PhD 
2.8.2. Data collected as part of the Neovita trial 
This section gives a brief description of the data collected for the Neovita trial that were 
subsequently used in the PhD analyses. Further details on how these data were managed, 
transformed, coded, and used for the PhD analyses are given in Chapter 3. 
2.8.2.1. Birth weight data 
Data on birth weight were collected by the dosing supervisors, who received weight 
standardisation training using a standardised protocol devised by the WHO19. They 
weighed the infants at enrolment using either electronic or spring scales (calibrated 
every four weeks).  
Figure 2.9: Weighing an infant in a compound 
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The electronic scales could record birth weights to the nearest 0.1kg and the spring scales 
to the nearest 0.2kg. Infants were weighed between zero and 87 hours after delivery; 73% 
(16434) were weighed within 24 hours of delivery; 0.2% (5) were weighed more than 72 
hours after delivery. 
2.8.2.2. Vaccination data 
The process for the recording of vaccination data during routine vaccination is described 
(Section 2.3). For the trial, at each monthly follow-up visit, caretakers (usually the mother) 
were asked if the infant had been vaccinated since the last visit. If they answered yes, they 
were asked to detail what type of vaccination the infant received (specifically whether they 
received oral medicine given by mouth, an injection into the leg, or an injection into the 
arm). The field worker asked them to recall the name of the vaccine and specifically asked if 
the infant had received BCG, polio, DTP, measles or yellow fever vaccination. The field 
worker did not ask the caretaker to specify which dose of polio or DTP was given. The field 
worker then undertook a visual inspection of the infant’s arms to identify whether there 
was a BCG scar, and asked for the infant’s written vaccination record. All possible sources of 
written information on vaccination (hereafter known as the vaccination card) were 
checked. Data collected on vaccination at each follow-up visit were transcribed onto the 
infant form (Annex 2). 
In the event that we did not have up-to-date vaccination data for infants who died, their 
families were revisited to collect and verify this information. We had incomplete 
vaccination data for 232 (32%) of the 715 Neovita enrolled infants who died. Caretakers of 
176 (76%) of these 232 infants were interviewed to collect additional information on their 
infant’s vaccination status prior to death. Of these 176 infants, 136 (77%) were reported to 
have received vaccines before death. For these 136, a vaccination card was available for 59 
(43%) of infants. This increased the completeness of vaccination data for infants who died 
from 68% (483/715) to 76% (542/715). Those who did not have a vaccination card reported 
that the card had been lost or thrown away.  
2.8.2.3. Mortality and morbidity data 
Data on vital status and the date of death for infants who died were collected at post-
dosing and infant follow-up (Post-dosing and Infant Forms, Annex 2). For those infants who 
died, the date of death was verified at the time of the VPM (VPM Form, Annex 2).  
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Data on illness, care seeking and cause-specific facility admissions were collected during the 
monthly infant follow-up visits (Infant Form, Annex 2). Mothers were asked if their infant 
had been ill since the previous visit and the number of illnesses the infant had. For up to 
two episodes of illness, data were collected on i) the start and end dates of the illness; ii) 
whether the illness was ongoing at the time of the visit; iii) whether care was sought 
outside the home for the illness and iv) if the infant was admitted to stay overnight for at 
least one night in a health facility. For infants who were admitted to a facility, fieldworkers 
documented the number of facilities where they were admitted, their associated facility 
codes, and for each admission, the following causes of admission: acute lower respiratory 
tract infection (ALRI), diarrhoea, fever / malaria and other specified causes. The causes of 
illness that did not result in an admission were not collected. 
When mothers did not know the date the illness started, the date was coded as 08080808 
(unknown). When mothers did not know the date the illness ended, or if the illness was 
ongoing at the time of the interview, the date was also coded as 08080808.   
2.8.2.4. Illness, care seeking and medical treatment during fatal illnesses 
A VPM (Annex 2) was conducted for infants who died, to collect data on the illness that led 
to their death, to assign a cause of death. Data were collected on the onset and duration of 
illness, on whether care was sought for the illness, when and where care was sought, and 
the place of death. For infants who were admitted to a health facility, data were collected 
on any medical therapy they received. Cause of death data were not available at the time of 
this PhD. 
2.8.2.5. Other data collected 
Data on the village and compound of residence of the mother were collected at registration 
in reproductive surveillance and were updated every time she moved compound. Data on 
additional factors such as infant and maternal characteristics, household assets and other 
household characteristics were collected at enrolment (Table 2.6 and Enrolment and 
Baseline Forms, Annex 2). The data collected on maternal and household characteristics 
are described in Table 2.6, along with the associated variables derived from these data. The 
process for deriving these additional variables is described in Chapter 3.   
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Table 2.6: Summary of source variables on infant, maternal and household characteristics, 
collected at enrolment, and any associated derived variables. 
Source 
Variable 
Coding / Categories Data Form Derived Variable 
Infant Factors  
Infant Sex Female 
Male 
Enrolment  n/a 
Number of 
babies born 
Single Birth 
Twins 
Triplets 
Baseline  Multiple birth 
Yes 
No 
Place of 
delivery 
Compound 
Facility 
Other 
Baseline  Facility birth 
Yes 
No 
Maternal Factors  
Number of 
living 
children, 
excluding 
current child 
Continuous variable  Baseline  No. children in family  
0-1 
2-3 
4 or more 
Age-group 15-19 years 
20-24 years 
25-29 years 
30-34 years 
35-39 years 
40-44 years 
45-49 years 
Not known 
Baseline  Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
 
Occupation Government employee 
Private employee 
Self-employed 
Farming only 
Does not work 
Other 
Baseline Maternal occupation 
Government/Private/Ot
her 
Self-employed 
Farming 
Does not work 
Highest 
education 
level 
None 
Primary school 
Middle, continuation school, 
JSS 
Technical, commercial, SSS, 
Secondary school 
Post-middle college, 
secretarial 
Post-secondary, nursing, 
polytechnic 
University 
Not known 
Baseline Maternal Education 
None 
Primary school 
Post-primary / tertiary 
 
Continues…. 
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Table 2.6 continued 
Source 
Variable 
Coding / Categories Data Form Derived Variable 
Household characteristics  
Religion of 
head of 
household 
Christian 
Muslim 
None 
Traditional African 
Other 
Baseline Religion  
Christian 
Muslim 
Other 
 
Ethnic group Akan (Bono, Ashanti, Fanti 
etc.) 
Bimoda, Chokosi 
Dagarti, Frafra, Kusasi 
Fulani 
Ga, Adangbe, Ewe 
Gonja, Dagomba, Mamprusi 
Konkomba, Basare 
Mo 
Sisala, Wala 
Zambraba 
Banda / Pantra 
Other 
Baseline Ethnicity  
Akan 
Other  
 
Fuel used 
for cooking 
Electricity 
LPG / Natural Gas 
Kerosene 
Coal / Lignite 
Charcoal 
Wood 
Straw / shrub / grass 
Agricultural crop waste 
Dung cakes 
Biogas, Other 
Baseline Exposure to Indoor 
Smoke 
No 
Yes 
Where food 
is cooked 
Inside 
Outside 
Other 
Baseline Exposure to Indoor 
Smoke 
No 
Yes 
Main source 
of drinking 
water  
Piped water 
Public tab 
Hand pump or closed 
borehole 
Open well 
Closed well 
Tanker truck 
Small cart with tank 
Surface water 
(river/dam/lake/pond/strea
m/canal/irrigation channel) 
Bottled Water 
Rain water 
Other 
Baseline Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
Continues…. 
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Table 2.6 continued 
Source 
Variable 
Coding / Categories Data Form Derived Variable 
Household Assets  
Toilet facility Flush or pour toilet 
Pit latrine 
Dry toilet 
Bucket latrine 
No facility / uses open spaces 
or filed 
Other 
Baseline Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
Household 
ownership 
Sole ownership 
Joint ownership 
Renting 
Family / relative’s house 
House provided rent free 
Perching 
Other 
Baseline Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
Ownership 
of land 
Yes / No Baseline Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
Presence of 
specific 
household 
assets 
Electricity 
Chickens 
Sheep 
Other animals 
Mattress 
Stove or cooker 
Chair 
Cot or bed 
Divider 
Table 
Electric fan 
Radio or transistor 
Television 
Sewing machine 
Mobile telephone 
Mosquito net 
Computer 
Refrigerator 
Watch or clock 
Bicycle 
Motorcycle or scooter 
Animal drawn cart 
Car 
Thresher 
Tractor 
Baseline Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
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2.9: DATA MANAGEMENT 
2.9.1: Quality control and data processing 
All paper forms were reviewed by the fieldworkers, supervisors and coordinators and any 
identified errors were corrected prior to submission from the field for data entry. 
Data were processed at the KHRC using the SQL Server data management system 
(Microsoft® SQL Server™ 2008 Windows®). I contributed to the design of some of the data 
tables. All data were double entered. A series of automated verification, range and 
consistency (R&C) checks and inter-database (IDB) checks was performed weekly. I 
contributed to designing the R&C and IDB checks. I reviewed all queries generated from 
these checks and I either resolved these immediately, or I sent them as queries to the field 
to be resolved. I supervised all changes to the database. All changes to the data were 
documented using an electronic audit trail and were also marked on the original forms.  
I conducted additional checks for infants who had vaccination dates which were 
inconsistently reported at successive follow-up visits, or when dates were consistently out 
of range (for instance if the date was before the infant was born, or later than the date of 
visit) or unknown at successive follow-up visits. These checks included requesting that the 
field-workers revisit the infant to re-check and verify the vaccination cards, and to take 
photocopies of the written record of vaccination. I reviewed these photocopies and I made 
the final decision about the corrections to the vaccination data.  
2.9.2: Data Security and Protection 
All electronic data were stored on secure password protected computers at LSHTM and 
KHRC. All paper forms were stored in a secure archive at KHRC. Only authorised members 
of the study team had access to the data.  
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CHAPTER 3: ADDITIONAL 
METHODOLOGY FOR THE PHD 
Preamble 
This chapter presents the methodology specific to the PhD, including the use, generation 
and coding of variables used in the different analyses, and an overview of the design and 
methodology for the different analyses. I also describe the ethics and funding for the trial 
and for this PhD.  
3.1. MANAGEMENT OF MISSING ILLNESS DATES. 
A large proportion of illness dates were unknown (Table 3.1). Start dates were unknown for 
43% of all illnesses (26386/61083). Among those with unknown start dates, only 1833 (3% 
of all illness episodes) had a known end date. A further 24553 (40% of all illness episodes) 
were missing both the start and end dates.  
As a secondary outcome of the Neovita trial was admissions to hospital in the first year of 
life, a process for the assignment and imputation of illness dates resulting in an admission 
was devised by the senior trial management team, and implemented for the main Neovita 
trial analysis. I was a member of the trial management team and actively contributed to the 
development of this process. Dates on up to two episodes of illness were assigned for each 
infant. 
We assigned illness dates as follows: 
1. For infants who were ill and admitted to hospital at delivery, the illness start date 
was the date of birth 
2. For infants whose illness start date was unknown and whose illness end date was 
known, five days (the median duration of illness among infants with known start 
and end dates) was subtracted from the end date, to impute the start date. 
3. For infants for whom both the start and end dates were unknown, a start date of 
illness was imputed using the midpoint between the date the illness was reported 
and the date of the previous infant visit.  
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A total of 6% (1585) of unknown illness start dates were imputed in this way for the main 
trial analysis. I imputed the outstanding 94% of unknown illness start dates using the same 
algorithm as for the main trial analysis (Table 3.1).  
Table 3.1: Completeness of the illness data. 
Morbidity Data Summary Statistics 
A. Total illnesses 61083 
B. Total missing start date of illness 
C. Unknown start date, known end date 
26386 (43%) 
1833 (3%) 
D. Missing both start and end date of illness 24553 (40%) 
E. Missing start date, date imputed for main trial analysis 
F. Outstanding missing start dates following imputation for 
main trial analysis 
1585 (3%) 
24801 
G. Of F, those also missing end date of illness 23111 (38% of all illnesses) 
 
3.1.1. Review of imputed dates 
I assessed the imputed dates for the potential to introduce bias and for potential 
misclassification by reviewing their distribution by birth weight, and by time-period (Table 
3.2).  
Table 3.2: Distribution of imputed illness dates by time-period, birth weight and process of 
imputation  
Time-
period 
Birth 
Weight 
Total 
illness 
dates1 
Date known Missing 
illness start 
date, 
imputed 
from illness 
end date – 
5 days 
Missing both 
illness start and 
end dates, 
Imputed from 
interval 
between visit 
illness reported 
& previous visit 
Observations for 
which outcome 
could be 
misclassified by 
time-period2 
Neonatal NLBW 2359 1552 (65.8) 6 (0.3) 801 (34.0) 801 (34.0) 
LBW 565 393 (69.6) 1 (0.2) 172 (30.4) 172 (30.4) 
Total 2924 1945 (66.5) 7 (0.2) 973 (33.3) 973 (33.3) 
Early 
Infant 
NLBW 15246 7914 (51.9) 408 (2.7) 6924 (45.4) 1827 (12.0) 
LBW 2740 1384 (50.5) 89 (3.2) 1267 (46.2) 338 (12.3) 
Total 17986 9298 (51.7) 497 (2.8) 8191 (45.5) 2165 (12.0) 
Late 
Infant 
NLBW 30510 17807 (58.4) 984 (3.2) 11719 (38.4) 1745 (5.7) 
LBW 5367 3012 (56.1) 197 (3.7) 2158 (40.2) 302 (5.6) 
Total 35877 20819 (58.0) 1188 (3.3) 13877 (38.7) 2047 (5.7) 
1. Excludes illnesses which occurred at >365 days of age & duplicate illnesses (illnesses having same start dates) 
2. For neonatal period, misclassification refers to observations for which illness was imputed as neonatal, but was 
reported in early infant period (as a % of all neonatal illnesses), and similarly for the early and late infant periods, 
with observations in the late infant period being reported at >1 year of age 
The proportion of imputed dates was lowest in the neonatal and highest in the early infant 
periods. There was little difference in the proportion of imputed dates among LBW 
compared to NLBW in each time-period. The proportion of illnesses which could have 
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potentially been misclassified to the wrong time-period (as they were reported in a later 
time-period) was also similar by birth weight, and with the exception of the neonatal period 
(33%), the proportion was relatively small (12% in the early infant period, and 6% in the late 
infant period). The large number of neonatal illnesses reported in the early infant period 
reflects the fact that infant follow-up, which was the main source of data on infant illness, 
did not start until the early infant period. For those missing both start and end dates, 79% 
of episodes were reported within 30 days of a previous infant visit, 17% were reported 
between 31-60 days following the previous visit, and 3% were reported at >60 days 
following a previous visit. The median interval between the date of reporting of the illness 
and the previous visit was 25 days (IQR=8).  
3.1.2. Multiple admissions for single episodes of illnesses 
I assigned a 28-day window to identify admissions for related causes that could potentially 
be attributed to a single episode of illness. This approach has been used elsewhere1. These 
illnesses were then reviewed by Professor Karen Edmond (Consultant Paediatrician and 
Principal Investigator for Neovita), for review. When recommended by her, I recoded these 
into a single illness. In this way, in 245 instances where two admissions were reported 
within 28 days of each other, I classified them as a single illness. 
3.2. CODING OF CAUSE SPECIFIC ADMISSIONS 
Maternal report of cause of illness is known to have low specificity, therefore the potential 
for misclassification is high2. Given this, I grouped the data on cause specific admissions 
(ALRI, Diarrhoea, Fever/Malaria, Injury, Other) collected during the monthly follow-up visits 
into three broad categories: infection, non-infection and unspecified other (for other 
illnesses). I categorised ALRI, diarrhoea, and fever / malaria as infections. I categorised 
injury as non-infection.  
Mothers independently reported additional symptom data at follow-up in a separate 
category entitled other. I extracted these data and sent them to Professor Edmond for 
review. Under her direction, I grouped these miscellaneous symptoms into a series of 
intermediate categories recommended by her (entitled corresponding broad cause in Table 
3.3), and then into to the final broad categories of infection, non-infection and other. The 
re-categorisation of these is detailed (Table 3.3). 
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Table 3.3: Cause specific admissions 
Other documented at follow-
up 
Total 
reports 
Corresponding Broad Cause  Category for 
analysis 
EAR 9 Infection Infection 
EYE 59 Infection Infection 
LRTI 15 Infection Infection 
Malaria 65 Infection Infection 
MEASLES 1 Infection Infection 
SEPSIS 281 Infection Infection 
SKIN PROBLEM 207 Infection Infection 
SWELL 16 Infection Infection 
SWOLLEN TESTICLES 4 Infection Infection 
TETANUS 1 Infection Infection 
UNSPECIFIED FEVER 7 Infection Infection 
URINARY INFECTION 3 Infection Infection 
URTI 87 infection Infection 
YELLOW FEVER 1 Infection Infection 
ANAEMIA 34 Blood problem Non Infection 
BLEEDING 20 Blood problem Non Infection 
JAUNDICE 67 Blood problem Non Infection 
LEUCOPAENIA 1 Blood problem Non Infection 
CARDIAC  1 Cardiac problem Non Infection 
ABDOMINAL DISTENSION 8 Gastroenterological Problem Non Infection 
FEEDING PROBLEM 22 Gastroenterological Problem Non Infection 
UNSPECIFIED ABDOMINAL 
PAIN 
97 Gastroenterological Problem Non Infection 
VOMIT 359 Gastroenterological Problem Non Infection 
BROAD NEUROLOGICAL 109 neurological problem Non Infection 
CONVULSION 100 neurological problem Non Infection 
NERVE PALSY 1 neurological problem Non Infection 
BREATHING PROBLEM 44 Non Infection Non Infection 
OTHER NON-INFECTION 51 Non Infection Non Infection 
ASPHYXIA 25 Other problem specified cause Non Infection 
BIRTH DEFECT 24 Other problem specified cause Non Infection 
CIRCUMCISION 
COMPLICATION 
2 Other problem specified cause Non Infection 
CONSTIPATION 17 Other problem specified cause Non Infection 
CORD PROBLEM 1 Other problem specified cause Non Infection 
EYE PROBLEM / NON 
INFECTION 
46 Other problem specified cause Non Infection 
HEADACHE 12 Other problem specified cause Non Infection 
HERNIA 17 Other problem specified cause Non Infection 
IRRITABILITY 5 Other problem specified cause Non Infection 
LBW/PREMATURITY 79 Other problem specified cause Non Infection 
URINARY PROBLEM 12 Other problem specified cause Non Infection 
UNSPECIFIED OTHER 67 Unspecified other problem Unknown Other 
 
  
 76 
 
3.3. VACCINATION STATUS 
I defined infants according to their vaccination status as follows:  
1. Vaccination card seen, vaccinated, date known – if there was a legible, plausible 
and consistent date documented on the vaccination card (including all possible 
sources of written information on vaccination as described in Section 2.8.2). 
2. Vaccination card seen, vaccinated, date unknown – if the infant was reported as 
vaccinated, but the date was either illegible, conflicting over time, or implausible 
(for instance if it predated the date of birth, was much earlier than the scheduled 
date (for instance DTP1 given in the first week of life), or later than the date of visit 
during which vaccination was first reported). 
3. Vaccination card seen, known not vaccinated – If there was no evidence on the card 
that the infant had been vaccinated 
4. Vaccination card not seen, known not vaccinated – this categorisation only applied 
if the infant’s caretaker consistently reported that the infant was not vaccinated at 
all visits and if the card was never viewed at any follow-up visit.  
5. Vaccination status unknown  
Infants were categorised as status unknown if a) they were never seen at follow-up and if 
there was no information at all on their vaccination status (including all infants who died in 
the neonatal period and who were never seen in follow-up (which started at 4 weeks of 
age); b) they were seen at follow up, but the card was never seen, and their mother 
reported that they had been vaccinated (and the vaccine was not specified). 
The choice to include an additional category for non-vaccinated infants (Category 4, infants 
whose vaccination card was never seen, and who were consistently reported as never 
having been vaccinated) was taken to maximise the retention in the analyses of infants who 
never attended child health clinics or vaccination clinics, and who, as a consequence may 
never have been issued a vaccination card. If I had relied solely on written record of 
vaccination to assign vaccination status, I would automatically have excluded these infants; 
however, these were the very infants that I was interested in for my analysis. As shown in 
Section 5.6, Table 5.9, the numbers in this category were very small (<1% for all vaccines), 
and so they were unlikely to have greatly impacted on the effect estimates in the various 
associated analyses. In order to verify their potential to bias the estimates, for certain 
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analyses, I undertook additional sensitivity analyses (described in Chapter 5), whereby I also 
excluded these infants.  
For certain analyses, I additionally categorised infants with incomplete follow-up data as 
vaccination status unknown. This will be further explained in Chapter 5.  
3.4. OUTCOME VARIABLES 
The Neovita data were used to define a number of outcomes for the analyses conducted for 
this PhD, including uptake of vaccination services (neonatal & postneonatal vaccination and 
uptake of opportunities for vaccination), mortality, illness, care seeking for illness, and 
health facility admissions. The outcomes are defined in Section 3.8 and in the associated 
papers (Chapters 4 to 7).  
3.5. SELECTION AND DEFINITION OF EXPLANATORY VARIABLES FOR 
INCLUSION IN THE PHD ANALYSES 
As outlined in Section 1.10, I sought in this PHD to investigate the association between 
birth weight and a number of child health outcomes The effects of additional determinants 
were also investigated for some of the analyses conducted in the PhD.  
Table 3.4 lists the explanatory variables included in specific analyses for this PhD.  
Table 3.4: Variables used in the PhD 
Factors Variables Associated analyses 
In
fa
n
t 
 
Birth Weight All 
Infant sex All 
Multiple birth All 
Season due vaccine Uptake of vaccination (Chapters 5 & 6) 
Illness Uptake of vaccination (Chapters 5 & 6) 
M
a
te
rn
a
l  
 Maternal occupation All 
Maternal education All 
Maternal age  All 
Maternal illness in the year 
before delivery 
All 
H
o
u
se
h
o
ld
 
Ethnicity All 
Religion All 
Exposure to indoor smoke Mortality, illness & care seeking (Chapter 4) 
Distance to nearest health 
facility 
All 
Number of living children in 
family 
All 
Socioeconomic status All 
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Sections 3.6 and 3.7 describe how these explanatory variables were defined and generated 
from the underlying Neovita data. Section 3.8.3 describes their use in the models 
developed for the PhD analyses and the general approach to model building. 
3.6. GENERATION OF ADDITIONAL VARIABLES FOR THE PHD ANALYSES 
1. Birth weight 
I grouped the continuous birth weight data into four standard3-5 categories of birth weight 
(≥2.5kg (NLBW), 2.00-2.49kg, 1.50-1.99kg (MLBW), <1.50kg (VLBW)).  
2. Socioeconomic status 
As outlined in Chapter 1, household wealth and income are recognised as important distal 
determinants of child health6-8, and of access to vaccination and other health services in 
low income settings9-11, including in our study area12. Consequently, it was important for me 
to adjust for these effects in my analyses.  
SES has been defined as comprising social class and position13. Position is influenced by 
multiple factors including ownership of assets, income and consumption. It includes 
different aspects of economic and social wellbeing, which allows the distinction of people 
across different social classes13.  
A number of indicators of SES have been developed, including occupational class, 
education, household income, crowding, household consumption expenditure, and 
ownership of assets14,15. There is no single best indicator of SES. Each indicator will capture 
a particular aspect of socioeconomic inequality, and many indicators are correlated with 
each other15. 
Wealth and income are difficult to quantify, especially in populations where income is 
frequently not derived from wages, and where few people save money13. As a pragmatic 
response to the absence of a readily available indicator of SES in low income settings, the 
World Bank developed an asset based index9, generated from DHS data on household 
ownership of fixed assets, through a process known as principal components analysis 
(PCA)9. The DHS does not collect data on income or expenditure, but does collect data on 
durable assets, housing characteristics and access to utilities and services which may 
directly influence health16. The asset index measures household level SES and it reflects 
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material living standards16, and it is resilient to economic shocks and to variations in income 
and expenditure16,17.  
PCA is a multivariable statistical technique that allows several variables in a dataset to be 
transformed into a smaller number of components, where each component is a linear 
weighted combination of the initial variables18. Components are ordered so that the first 
component explains the largest amount of variation in the original data. The second 
component explains additional but less variation, and so on down through the additional 
components18. Components which are more unequally distributed are given greater weight 
than those which are more common across all households18. 
The asset index is now used widely in low-income settings, and it was the method used for 
measuring SES in the Neovita trial. Its widespread use in health research in Africa facilitates 
comparative research. For these two reasons, I used the same approach to measure SES for 
my PhD. 
Two main issues are observed with PCA: clumping of households into a small number of 
distinct clusters, and truncation, whereby the index although more evenly distributed, is 
spread over a narrow range, making it difficult to differentiate between different groups. 
These issues are best addressed by adding more variables to the analysis, and by using 
variables related to a variety of determinants of socioeconomic status, such as ownership 
of durable assets, access to utilities, and other variables that capture inequality among 
households18.   
Asset indices are more strongly influenced by community level infrastructure than 
consumption expenditure, and so are prone to an urban bias16. Those living in urban areas 
may reside in houses constructed of better quality materials, and they often have better 
access to water and sanitation infrastructure, and to utilities such as electricity. This may 
lead to misclassification of poor households in urban areas as wealthy, and wealthy 
households in rural areas as poor16. Again, inclusion of a wide variety of indicators helps to 
minimise this problem16.  
I used a programme provided by Lisa Hurt (member of the Neovita trial management team) 
to convert the data collected on household assets into an asset index18. A total of 44 
indicators were included in the model (Table 2.6), covering ownership of durable assets, 
home and land ownership and access to utilities. In this model, ownership of land was 
ordered first to explain the largest variation in the data. The resulting asset index was then 
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categorised into quintiles of SES, with category 1 representing the poorest and category 5 
the richest quintile of the population. 
In order to assess how reliably the PCA derived index reflected SES in our study population, 
I reviewed the distribution of other key indicators of SES (education, occupation and 
distance to the nearest health facility) across the quintiles of SES derived from the PCA 
analysis (Table 3.5).  
Table 3.5: Distribution of other indicators of socioeconomic status by quintile of 
socioeconomic status as derived by PCA  
Other indicator of 
socioeconomic status n (% 
of total in category) 
Quintile of socioeconomic status 
1 
(Poorest) 
2 3 4 5 
(Richest) 
Maternal education - none 2723 (60) 1763 (39) 1185 (26) 953 (21) 503 (11) 
Maternal education – 
secondary / tertiary 
66 (2) 164 (4) 270 (6) 452 (10) 1330 (29) 
Maternal occupation - 
farmer 
2757 (61) 1946 (43) 1276 (28) 559 (12) 133 (3) 
Maternal occupation - 
government employee 
56 (1) 122 (3) 162 (4) 251 (5) 634 (14) 
Distance to health facility 
>5km 
1778 (39) 1113 (25) 593 (13) 252 (5) 66 (1) 
Place of delivery –  
Non-facility 
2425 (54) 1420 (31) 900 (20) 469 (10) 160 (3) 
There was good agreement between the classification of infants by SES and these other 
indicators. For instance, a higher proportion of infants who were in the poorest category of 
SES were born to mothers with no education, who were farmers, who lived more than 5km 
from a health facility, and who did not give birth in a health facility. This demonstrates 
consistency in the categorisation of infants by SES and by these other indicators of low SES.  
3. Exposure to indoor smoke 
I used the data on household cooking facilities to categorise households according to their 
exposure to solid fuel indoor smoke. I defined exposure to indoor smoke as cooking indoors 
using coal, lignite, charcoal, wood, straw, shrubs, grass, agricultural crop waste, dung cakes 
or other types of fuel, versus either cooking outdoors or cooking indoors with electricity, 
natural gas, biogas or kerosene, in accordance with a definition previously used by the 
WHO19. 
4. Distance to health facility 
Each infant enrolled in the trial had an assigned compound number. Every time the infant 
moved compound, the compound number was updated. Each compound number was 
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comprised of a three-letter village code and a four-digit number. Each village code 
corresponded to a defined geographical unit in our study area. These codes were used to 
categorise infants by their distance to the nearest health facility. 
Robin Nesbitt from the University of Heidelberg kindly provided data on distance to the 
nearest health facility. She calculated distance by generating Euclidean (straight-line) 
distances between village centroids and health facilities, using methods described in detail 
elsewhere20. Briefly, GPS coordinates of the health facilities in the study area, of 433 village 
centroids and of 47537 compounds in 173 larger villages were taken as part of demographic 
surveillance for previous field trials conducted in the study area. These co-ordinates were 
then translated into straight-line distances using ArcMap version 10.0. I assigned these 
distances to the corresponding village code for each infant. I then assigned the infants to 
three categories of distance (<1km, 1-5km, >5km).  
For analyses relating to vaccine uptake and timing, I used the distance at the time the 
vaccine was scheduled to be given. For all other outcomes, I used the distance at the time 
the outcome was measured. For example, for analyses relating to death, I used the distance 
relating to the compound where the infant resided at the time of death.  
5. Season when vaccine was due 
For analyses relating to uptake and timing of vaccination, I categorised infants according to 
whether the specified vaccine was due in the wet or the dry season. Based on advice from 
colleagues at the KHRC, I defined the wet season as composing of April, May, June, July, 
October, and November, with all remaining months comprising the dry season.  
6. Infant illness 
For analyses relating to uptake and timing of vaccination, I categorised infants according to 
whether their caregivers reported that they had an illness close to the time before the 
vaccine was due. This was based on caregiver’s report of illness since the previous visit, 
reported at the first visit following the due date for vaccination. Similarly, for analyses 
relating to uptake of opportunities for vaccination, I categorised infants according to 
whether their caregivers reported that they had an illness close to the time of the 
opportunity. 
7. Infant time-periods 
I defined a number of time-periods within infancy for use in the different analyses 
including: a) the neonatal period (0 to 27 days or 0 to 3 completed weeks of age (weeks 0, 
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1, 2 and 3)); b) the postneonatal period (28 to 364 days or 4 to 51 completed weeks of age); 
c) the early infant period (28 to 182 days or 4 to 25 completed weeks of age); d) the late 
infant period (183 to 364 days or 26 to 51 completed weeks of age); and e) the infant 
period (0 to 364 days or 0 to 51 completed weeks of age).  
3.7. RECODING OF VARIABLES 
Some of the infant, maternal and household variables collected for the Neovita trial 
comprised data with many categories, and the number of infants within some of these 
categories was very small. To avoid problems with small numbers in my analyses, I 
generated new variables with fewer categories for these factors. The re-categorised 
variables are described in Table 2.6.  
3.8. OVERVIEW OF PHD ANALYSES 
In order to meet the overall objectives of the PhD, I conducted a series of analyses, the 
results of which are presented in Chapters 4 to 7 as a series of papers. In this section, I 
present a brief overview of these analyses. I discuss in detail the specific methodological 
considerations associated with each analysis in the corresponding results chapters.   
I describe in greater detail my general approach to model building in Section 3.8.3. 
3.8.1. Study population for each analysis 
The process for recruitment and enrolment of infants in Neovita is described in Sections 2.6 
and 2.7 and in Figure 2.8. All infants enrolled in Neovita were eligible for inclusion in the 
analyses. Infants were excluded from each analysis if they had incomplete data on any of 
the explanatory variables included in the analyses for that paper, or if they were missing 
data on the outcome. Additional inclusion and exclusion criteria for each of the analyses are 
summarised individually in each associated paper. 
3.8.2. Analytical approach 
The specific objectives and outcomes for each paper are summarised in Table 3.6. For all 
analyses, I conducted a univariable analysis of the association between each explanatory 
variable and the outcome. In order to explore how the association between birth weight 
and the outcome (the primary association) was affected by the other explanatory variables, 
I first constructed two by two tables of the primary association, stratified in turn by each of 
the other explanatory variables. I then conducted a bivariable analysis of this association, 
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adjusted in turn for each of the other explanatory variables. I conducted a preliminary 
assessment of confounding between birth weight and the other explanatory variables by 
examining how the estimate of the association between birth weight and the outcome 
changed when adjusted for the other explanatory variable. For all papers, I fit a causal 
model to assess the association with birth weight and other determinants and the outcome 
of interest. I adjusted for all possible confounders (selected a priori based on the known 
determinants of these outcomes (detailed in Chapter 1), as described in Table 3.4. 
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Table 3.6: Summary of the methodology for each PhD paper 
Paper Specific objectives of the paper Methods Outcome measures 
Paper 1: Declining birth 
weight as a risk factor 
for mortality, illness, 
care seeking and 
admissions during 
infancy in Ghana 
 
1) To generate estimates of the association between birth weight, and i) 
mortality and ii) illness, and among those reporting illness, estimates of the 
association between birth weight and iii) care seeking, and iv) health facility 
admissions in the first year of life. 
  
2) To assess how these estimates vary between the neonatal, early and late-
infant periods 
 
3) To assess whether the association between birth weight and mortality varies 
by distance to the nearest health facility, and by SES. 
Kaplan Meier curves 
of probability of 
survival 
Cox regression, 
random effects 
Poisson regression, 
random effects 
logistic regression  
1) Mortality hazard 
ratios 
 
2) Illness rate ratios 
 
3) Care seeking odds 
ratios 
 
4) Admission odds 
ratios 
Paper 2: Delayed 
Vaccination of Low Birth 
Weight Infants in Rural 
Ghana: Results from a 
Population-based 
Prospective Cohort 
Study 
1) To assess whether LBW is a determinant of DTP1 and DTP3 vaccination 
  
2) To assess whether maternal education or SES modifies the association 
between birth weight and vaccination with DTP1 and DTP3 
 
3) To quantify other determinants of delayed DTP1 and DTP3 vaccination 
Kaplan Meier curves 
of time to 
vaccination 
 
Poisson regression 
Vaccination rate ratios 
for:  
 
DTP1 between a) 0-
10, b) 0-14 and c) 0-
18 weeks of age,  
 
And 
 
DTP3 between a) 0-
18, b) 0-22 and c) 0-
26 weeks of age. 
Continued…..  
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Table 3.6 continued 
Paper 3: Neonatal 
vaccination of LBW 
infants in Ghana 
1) To evaluate whether birth weight is a determinant of neonatal BCG 
vaccination 
 
2) To assess whether the association between birth weight and neonatal BCG 
vaccination varies by place of delivery and infant illness 
 
3) To identify other determinants of neonatal BCG vaccination 
Logistic regression Odds ratios for BCG 
vaccination by the 
end of the neonatal 
period. 
  
 
Paper 4: Missed 
opportunities for infant 
vaccination in Ghana, 
and the potential 
impact of their 
utilisation on vaccine 
uptake and timing. 
1) To quantify the number and types of opportunities for vaccination, and the 
associated missed opportunities for vaccination in the first year of life 
 
2) To identify the determinants of uptake of those opportunities 
 
3) To assess how using the first opportunity for vaccination could theoretically 
increase the uptake of vaccines included in the routine childhood immunisation 
schedule. 
Descriptive 
analyses, logistic 
regression, Kaplan 
Meier curves of the 
probability of 
vaccination 
1) Primary care based 
and facility-based 
opportunities for 
vaccination  
 
2) Odds ratios for 
taking an opportunity 
 
3) Actual and 
theoretical vaccine 
uptake rates 
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3.8.3. Causal frameworks 
Child health outcomes are known to be influenced and driven by a wide variety of social, 
economic, biological and environmental factors21, which inter-relate in complex and 
sometimes poorly understood ways, through processes of mediation, effect modification 
and confounding. Therefore, in order to understand and estimate the effect of these risk 
factors, including birth weight on these outcomes, consideration of how these risk factors 
relate to and influence each other is required. 
Mosley and Chen21 proposed that these factors could be arranged and described in a 
hierarchical framework comprising distal socioeconomic factors, which operate through 
intermediate and proximal factors, which themselves influence the likelihood of the 
outcome. This approach provides a useful framework from which to organise and structure 
the analyses of these associations22. 
With this in mind, I constructed a hierarchical framework (Figure 3.1) of the recognised 
determinants of vaccination10-12 in order to guide most of the analyses conducted for the 
PhD. This framework was modified slightly for specific analyses. The model was comprised 
of distal, intermediate and proximal variables. I hypothesized that the intermediate and 
proximal variables mediated the effects of the distal variables, and that the proximal 
variables mediated the effects of the intermediate variables. I hypothesized that illness 
mediated the effect of birth weight. 
For the multivariable analyses, I initially constructed a model comprised of the distal 
determinants, I then added the intermediate determinants, and assessed how these 
changed the effect size of the distal determinants. I then added the proximal determinants 
and assessed how they changed the effect size of the intermediate and distal determinants. 
I finally added any mediating variables, and again assessed changes to the effect sizes. 
Unless otherwise indicated, I retained all explanatory variables in the final model, to adjust 
for all possible confounding effects. 
For all models, I assessed the strength of the evidence of an association using 95%CIs and 
either Wald tests (for univariable analyses) or likelihood ratio tests (for multivariable 
analyses). 
 87 
 
Figure 3.1: Hierarchical framework of the determinants of vaccination* 
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* Mediation is indicated by arrows linking the variables across different levels. 
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When indicated, I undertook additional investigations of whether the association between 
birth weight and the outcome was modified by other factors by fitting interaction terms 
(combining birth weight and the possible modifying factor) to the final model. 
3.8.4. Study Power 
The sample size for these analyses was determined by the number of infants enrolled in the 
Neovita trial. A total of 22955 infants were enrolled in Neovita, as discussed in Section 2.6. 
Based on this total number of enrolled infants, and an assumed loss to follow-up of 10%, 
giving an available sample of 20660 infants, I undertook power calculations for the 
mortality analysis (Paper 1) and the postneonatal vaccination analysis (Paper 2). 
Approximately 14% of infants in SSA are LBW23, equating to 17768 NLBW infants and 2892 
LBW infants in our sample. Before analysing these data, there were no available estimates 
on the proportion of LBW infants that were MLBW (weighing 1.50-1.99kg) and VLBW 
infants (weighing <1.50kg). These sample size calculations were based on two theoretical 
distributions of LBW (one theoretical distribution of 10% of infants weighing 2.00-2.49kg, 
3% MLBW and 1% VLBW, and a second distribution of 11% of infants weighing 2.00-2.49, 
2.5% MLBW and 0.5% VLBW).  
3.8.4.1. Power to detect the association between birth weight and infant mortality 
The infant mortality rate (IMR) in Ghana has been estimated at 41/1000 live births24. This 
power calculation was based on two different theoretical scenarios of varying mortality 
rates among the different categories of LBW compared to NLBW infants. In the first 
scenario infants weighing 2.00-2.49kg had a mortality hazard ratio (MHR) of two compared 
to NLBW infants, MLBW infants had a MHR of five and VLBW infants had a MHR of 15. In 
the second more conservative scenario, the MHRs were 1.5 for infants weighing 2.00-
2.49kg, 2.5 for MLBW infants and 5 for VLBW infants.  
Table 3.7 presents the power to detect these various mortality hazard ratios among the 
different categories of LBW infants compared to NLBW infants in the overall infant period, 
based on the two distributions of birth weight and on the two distributions of MHR.  
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Table 3.7: Power to detect the mortality hazard ratio (MHR) for different distributions of 
birth weight and different distributions of MHR. 
  Scenario 1 Scenario 2 
 No of infants (%) Estimated MHR Power Estimated MHR Power 
≥2.50kg 17768 (86%) ref  ref  
2.00-2.49kg 2066 (10%) 2 99% 1.5 98% 
1.50-1.99kg 620 (3%) 5 99% 2.5 99% 
<1.50kg 206 (1%) 15 99% 5 99% 
      
≥2.50kg 17768 (86%) ref  ref  
2.00-2.49kg 2272 (11%) 2 99% 1.5 98% 
1.50-1.99kg 517 (2.5%) 5 99% 2.5 99% 
<1.50kg 103 (0.5%) 15 99% 5 99% 
 
These calculations indicated that there was good power to detect moderate differences in 
mortality among the different categories of LBW compared to NLBW infants.  
3.8.4.2. Power to detect the association between birth weight and DTP1 and DTP3 
vaccination. 
It has previously been reported in the Neovita study area25 that the uptake for each of DTP1 
and DTP3 at four weeks after the vaccination due date (10 and 18 weeks of age) was 78% 
and 46% respectively. I assumed that this uptake was equivalent to that of NLBW infants. 
This power calculation was based on two different scenarios of varying proportions of 
vaccination among the different categories of LBW compared to NLBW infants. In the first 
scenario infants weighing 2.00-2.49kg had a 10% lower vaccine uptake at 4 weeks after the 
due date compared to NLBW infants. This corresponds to a vaccine uptake of 70.2% for 
DTP1 and 41.4% for DTP3. I assumed that for MLBW infants, the uptake was 20% lower, 
corresponding to a DTP1 uptake of 62.4% and a DTP3 uptake of 36.9%. For VLBW infants, I 
assumed vaccine uptake was 30% lower, corresponding to a DTP1 uptake of 54.6% and a 
DTP3 uptake of 32.3%.  
The second scenario assumed that infants weighing 2.00-2.49kg had a vaccine uptake 20% 
lower than that of NLBW infants (62.4% for DTP1 and 36.8% for DTP3), MLBW infants had a 
vaccine uptake that was 30% lower (54.6% for DTP1 and 32.2% for DTP3) and that VLBW 
infants had a vaccine uptake that was 40% lower (46.8% for DTP1 and 27.6% for DTP3). 
Table 3.8 presents the power to detect these various differences in vaccine uptake among 
the different categories of LBW infants compared to NLBW infants within 4 weeks of the 
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vaccine due date for each of DTP1 and DTP3, based on the two distributions of birth weight 
and on the two distributions of vaccine uptake. 
Table 3.8: Power to detect differences in vaccine uptake for different distributions of birth 
weight and different distributions of vaccine uptake, at 4 weeks after the due date for each 
of DTP1 (10 weeks of age) and DTP3 (18 weeks of age). 
   DTP1 at 10 weeks of age DTP3 at 18 weeks of age 
 No of 
infants (%) 
Reduction 
in Uptake 
Estimated % 
Vaccine Uptake 
Power Estimated % 
Vaccine Uptake 
Power 
≥2.50kg 17768 (86%) Ref 78 - 46 - 
2.00-
2.49kg 
2066 (10% 10% 70.2 99% 41.4 98% 
1.50-
1.99kg 
620 (3%) 20% 62.4 99% 36.9 99% 
<1.50kg 206 (1%) 30% 54.6 99% 32.3 98% 
       
≥2.50kg 17768 (86%) Ref 78 - 46 - 
2.00-
2.49kg 
2272 (11%) 20% 62.4 99% 36.8 99% 
1.50-
1.99kg 
517 (2.5%) 30% 54.6 99% 32.2 99% 
<1.50kg 103 (0.5%) 40% 46.8 99% 27.6 97% 
 
The results of these calculations suggested that there was good power to detect moderate 
differences in vaccine uptake at four weeks after the vaccine due date for each of DTP1 and 
DTP3. 
3.8.5. Management of co-linearity 
When I thought two explanatory variables might be co-linear, I undertook an assessment of 
co-linearity, by monitoring inflation of the log standard errors of the explanatory variables 
when the model of the primary association was adjusted for both possible co-linear 
variables, compared to when it was adjusted for them individually. Where I identified 
instances of co-linearity, I generated composite variables of the co-linear explanatory 
variables. 
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The work undertaken for this PhD was covered by the ethics approval granted for the 
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CHAPTER 4: LOW BIRTH WEIGHT AS A 
RISK FACTOR FOR MORTALITY, ILLNESS, 
CARE SEEKING AND ADMISSIONS 
Preamble 
In this chapter, I present the first of four PhD papers that have been submitted to or 
published in peer-reviewed journals. The paper addresses the first objective of the PhD, 
namely to assess whether LBW is a determinant of mortality, illness, care seeking, and 
health-facility admissions in the first year of life, and in each of the neonatal, early and late 
infant periods. Section 4.1 presents a short introduction to the paper. I present the paper 
itself in Section 4.2. I provide an additional explanation of the methods in Section 4.3, and 
additional results and discussion in Section 4.4.  
4.1. INTRODUCTION 
As highlighted in Chapter 1, the overall aim of the PhD was to assess whether LBW is a 
marker for under-vaccination. Infants at risk of under-vaccination, including LBW infants 
may be more likely to contract or die from VPDs, due to their prolonged or increased risk of 
infection. Due to a lack of diagnostic data on VPDs in the Neovita study population, I was 
not able to investigate the association between an infant's vaccination status and their risk 
of VPDs. In the absence of this, and in order to contextualise the vaccination practices for 
LBW infants in relation to other important child health outcomes, I investigated the extent 
to which LBW infants are at increased risk of illness and death, and the extent to which they 
seek and receive care for illness. The study population for the analyses of illness and death 
were 22906 infants who were enrolled in the Neovita trial, and who had complete covariate 
data. The study population for the analyses of care seeking and admissions were 19292 
Neovita enrolled infants, with complete covariate data, who reported illness in the first year 
of life. I used Cox regression to investigate the association between birth weight and 
mortality, and random-effects Poisson regression to investigate the association between 
birth weight and illness (as many infants had more than one episode of illness). I used 
logistic regression to investigate the association between birth weight and both absence of 
care seeking, and health facility admissions. All effect estimates were adjusted a priori for 
potential confounders. 
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4.2. PAPER 1: LOW BIRTH WEIGHT AS A RISK FACTOR FOR MORTALITY, 
ILLNESS, CARE SEEKING AND ADMISSIONS DURING INFANCY IN 
GHANA: A PROSPECTIVE POPULATION-BASED COHORT STUDY.   
  


 98 
 
Low birth weight as a risk factor for mortality, illness, care seeking and admissions during 
infancy in Ghana: a prospective population-based cohort study.   
Authors: Maureen O’Leary1, Karen Edmond2, Sian Floyd1, Sam Newton3, Gyan Thomas4, 
Sara L. Thomas1. 
1. Faculty of Epidemiology and Population Health, London School of Hygiene and 
Tropical Medicine, Keppel St, London, WC1E 7HT, UK. 
2. School of Paediatrics and Child Health, University of Western Australia, Crawley WA 
6009, Australia. 
3. Department of Community Health, Kwame Nkrumah University of Science and 
Technology, Accra Rd, Kumasi, Ghana. 
4. Kintampo Health Research Centre, Kintampo, Ghana. 
 
Corresponding Author: 
Maureen O’Leary, 
Department of Infectious Disease Epidemiology,  
Faculty of Epidemiology and Population Health, 
London School of Hygiene and Tropical Medicine, 
Keppel St, WC1E 7HT, 
London, 
UK. 
maureen.oleary@lshtm.ac.uk 
Tel: +44 (0)7793 540 704 
 99 
 
Abstract 
Background 
We used randomised-controlled-trial data from rural Ghana to investigate the effect of 
birth weight on infant mortality, illness, care seeking and health-facility admissions. 
Methods 
We compared low birth weight (LBW) (2.00-2.49kg, 1.50-1.99kg (moderately LBW, MLBW), 
<1.50kg (very LBW, VLBW)) and non-LBW (NLBW, ≥2.5kg) infants. Our outcomes were 1) 
mortality, 2) illness, and among those with illness, 3) absence of care seeking and 4) health-
facility admissions in infancy (0-364 days), and in the neonatal (0-27), early (28-182) and 
late (183-364) infant periods.  We generated adjusted mortality hazard ratios (aHR) using 
Cox regression, illness rate ratios (aRR) using random-effects Poisson regression (allowing 
for multiple illnesses) and odds ratios (aOR) for non-care seeking and admissions using 
logistic regression, adjusted for infant, maternal and household factors.  
Results 
Among 22906 infants, those weighing 2.00-2.50kg were twice (aHR=2.13; 95%CI: 1.76-
2.59); MLBW infants eight times (aHR=8.21; 95%CI:6.26-10.76), and VLBW infants 25 times 
(aHR=25.38; 95%CI:18.36-35.10) more likely to die in infancy. The effect varied by time-
period (p-interaction <0.0001). VLBW infants had 48 times the mortality rate in the 
neonatal period (aHR=48.45; 95%CI:32.81-71.55), and eight times the rate in late infancy 
(aHR=8.42; 95%CI:3.09-22.92). Birth weight was not associated with illness overall but the 
association varied over time (p-interaction=0.0013). MLBW (aRR=1.57; 95%CI:1.27-1.95) 
and VLBW (aRR=1.58; 95%CI:1.13-2.21) infants had higher illness rates in the neonatal 
period. MLBW infants had an absence of care-seeking in the neonatal (aOR=3.30; 
95%CI:1.98-5.48) and early (aOR=1.74; 95%CI:1.26-2.39) infant periods. We found no 
association with admissions overall or by time-period.  
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Conclusions 
Strategies to minimise mortality throughout infancy and to improve care seeking are 
needed.  
Introduction  
Approximately 14% of infants in low and middle income countries are born weighing <2.5kg 
at birth;1 many are preterm. Most research on mortality and illness among low birth weight 
(LBW) infants has focused on the neonatal period, when a disproportionate number of 
deaths occur2. Few studies3-6 have generated population-based estimates from sub-Saharan 
Africa (SSA) on postneonatal outcomes, particularly for very low birth weight (VLBW) 
infants (born weighing <1.50kg)7, of whom almost all are preterm8. Lower care seeking for 
sick neonates has been reported when families think they are likely to die9. This may be 
more common for fragile, small LBW infants, adversely impacting their mortality risk, and 
for infants with additional barriers to care seeking such as poorer infants living far from a 
health facility9. 
We used data from a randomised controlled trial assessing neonatal vitamin A 
supplementation impact on infant mortality in rural Ghana, to investigate birth weight as a 
risk factor for mortality and illness in infancy.  
Our primary objective was to determine the extent to which LBW infants were at increased 
risk of mortality and illness in the first year of life. Secondary objectives were a) to assess 
among sick infants the association between birth weight and care seeking and health 
facility admissions; b) to examine how the effect of birth weight varied between the 
neonatal, early and late infant periods, and c) to investigate whether any effect of birth 
weight on mortality varied by distance to the nearest health facility or by socioeconomic 
status. 
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Methods 
The Neovita study was conducted at the Kintampo Health Research Centre (KHRC) in the 
Brong-Ahafo region of rural Ghana. The study has been described in detail elsewhere10,11. 
The study area is served by four district hospitals and 69 health facilities. All pregnancies 
and deliveries among women aged 15-49 years between August 2010 and November 2011 
were identified through a population-based prospective surveillance system. Newborns 
residing in the study area for at least six months, who were aged ≤3 days at screening, and 
who could suck or feed were enrolled.  
Fieldworkers weighed the infants using calibrated electronic or spring scales. The electronic 
scales recorded weights to the nearest 0.1kg, and the spring scales to the nearest 0.2kg. 
Most infants (73%, 16434) were weighed within 24 hours of delivery; 0.2% (5) were 
weighed >72 hours after delivery.   
Fieldworkers collected data from pregnant women on the date of their last menstrual 
period (LMP) during pregnancy surveillance and at enrolment. Data on infant, maternal and 
household characteristics were collected at enrolment. At monthly follow-up visits for the 
first year of life, field workers collected data on infant illness (with start and end dates) 
since the last visit, and on care seeking and facility admissions among those reporting 
illness. All illness-related data were based on maternal recall as data from health services 
and child health records were unavailable. Data were also collected on the infant’s vital 
status, and when applicable, date of death.  
Our primary outcomes were 1) mortality and 2) illness in the first year of life. For each 
illness, we investigated 3) absence of care seeking and 4) admissions to a health facility.  
For 3% of illness episodes missing the illness start date, this date was imputed as the end 
date minus five days (the median duration of illness). For the 40% of illnesses missing both 
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start and end dates, the start date was imputed as the midpoint between the date the 
illness was reported and the date of the previous follow-up visit. Facility admissions 
occurring within 28 days of a previous admission were reviewed to assess whether they 
were a single ongoing illness. For two infants missing date of death (0.3% of all deceased 
infants), we imputed this date as the midpoint between the first report of death and the 
last report of the infant being alive.  
The primary exposure was birth weight, in standard7,8,12 categories (≥2.5kg (NLBW), 2.00-
2.49kg, 1.50-1.99kg (moderately LBW, MLBW), <1.50kg (VLBW)).  
Data on LMP were missing (57% (16398/28498)) or inconsistently reported (7% 
(1935/28498)) for 64% of pregnancies. Given this, and the known discordance between 
LMP and ultrasound in gestational age assessment13-15, we did not investigate the 
association between gestational age and our outcomes.  
Follow-up for all analyses started at birth and ended at a) 364 days of age for infants alive 
and in follow-up throughout the study; b) the date of death for infants who died before day 
364 and c) the last date the infant was seen, for live infants who exited the study before 
day 364.   
Data analysis 
All analyses were conducted using STATA 13.1 (STATACORP, 2013).  
We generated Kaplan-Meier curves of the probability of survival in LBW compared to NLBW 
infants and calculated mortality rates for the first year of life. As mortality rate changes 
rapidly, particularly in the early neonatal period, we used multivariable Cox regression to 
calculate adjusted hazard ratios for the association between birth weight and mortality.  
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To allow for repeated illness events, we used random effects Poisson regression to 
calculate adjusted rate ratios for the association between birth weight and infant illness.  
Restricting the analyses to reported episodes of illness, and allowing for multiple illnesses 
for each infant, we used random effects logistic regression to calculate adjusted odds ratios 
for the association between birth weight and a) absence of care seeking, and b) admission 
for the illness.  
For each analysis, we assessed whether the effect of birth weight varied between the 
neonatal (0-27 days), early (28-182 days) and late infant (183-364 days) periods, by fitting 
birth weight as an interaction term with time-period. Similarly, for mortality, we assessed 
whether the effect of birth weight varied by a) distance to the nearest health facility, or b) 
socioeconomic status. 
For all analyses we used likelihood ratio tests and 95% confidence intervals (95%CI) to 
assess the statistical evidence for an association between birth weight and each outcome. 
In each analysis we adjusted a priori for infant (sex, multiple birth), maternal (education, 
age, occupation, illness), and household (religion, ethnicity, socioeconomic status, exposure 
to indoor smoke, distance to nearest health facility, number of children in the family) 
factors.  
Funding and Ethics 
Neovita was funded by the Bill and Melinda Gates Foundation. Ethics approval for the 
collection of data included in this study was granted by the Ethics Committees of the World 
Health Organisation (WHO), the London School of Hygiene & Tropical Medicine and the 
KHRC. 
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Results 
Of the 22955 Neovita enrolled infants, we included 22906 (99.8%) with complete covariate 
data in the analyses, of whom almost 16% (3584) were LBW (Table 1). Of included LBW 
infants, 13% weighed between 2.00-2.49kg, approximately 2% were MLBW, and 0.5% were 
VLBW.  
Infant mortality 
Three percent (698/22906) of infants died in infancy; 277 (39.7%) of these deaths were in 
the neonatal period, 248 (35.5%) in early infancy, and 173 (24.8%) in late infancy. Infant 
mortality rates per 1000 live births were 30.5 overall, 22.4 for NLBW infants, 48.6 for 2.00-
2.49kg infants, 160.0 for MLBW infants, and 402.0 for VLBW infants. 
Monthly mortality declined with age but was consistently higher for LBW infants compared 
to NLBW infants (Figure 1). The smaller the baby at delivery, the more likely they were to 
die (p-trend<0.0001). After adjusting for all potential confounders, infants weighing 2.00-
2.50kg were twice (aHR=2.13; 95%CI:1.76-2.59); MLBW infants were eight times (aHR=8.21; 
95%CI:6.26-10.76), and VLBW infants 25 times (aHR=25.38; 95%CI:18.36-35.10) more likely 
to die than NLBW infants in the first year of life (Table 2).  
There was strong evidence that the effect of birth weight varied over the infant period (p-
interaction <0.0001) (Table 3). The trend of higher mortality with lower birth weight was 
seen in each time-period but the magnitude of the association declined over time (Table 3). 
For example, compared to NLBW infants, VLBW infants had 48 times the mortality rate in 
the neonatal period (aHR=48.45; 95%CI:32.81-71.55), declining to eight times the rate in 
the late infant period (aHR=8.42; 95%CI:3.09-22.92). Similar patterns were seen for MLBW 
infants (aRR=14.71 (95%CI:10.37-20.86) in the neonatal period and 1.61 (95%CI:0.59-4.39) 
in the late infant period) and to a lesser extent for infants weighing 2.00-2.49kg (aRR=2.29 
(95%CI:1.66-3.15 versus 1.60 (95%CI:1.09-2.35)).   
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The effect of birth weight on mortality did not vary by either distance to the nearest health 
facility or socioeconomic status (p-values for interaction all > 0.2). 
Infant illness 
Mothers reported 56610 episodes of illness for 19292 infants. Following an initial spike in 
the neonatal period, age-specific illness rates increased over time (Figure 2). Upon 
adjustment for other factors, birth weight was not associated with infant illness overall 
(Table 3); although the association varied with time (p-interaction=0.0013). Compared to 
NLBW infants, both MLBW (aRR=1.57; 95%CI:1.27-1.95) and VLBW (aRR=1.58; 95%CI:1.13-
2.21) infants had higher illness rates in the neonatal period; there was little evidence of an 
association later in infancy (Table 3).  
Care seeking 
There was evidence that care was less likely to be sought for LBW infants, specifically 
MLBW infants, in infancy (aOR for an absence of care seeking=1.46; 95%CI:1.18-1.81). On 
univariable analysis an association was found for VLBW infants (OR=1.76; 95%CI:1.18-2.63), 
but upon adjustment for infant age and other covariates this association was no longer 
apparent (aOR=1.05; 95%CI:0.68-1.63) (Table 2). Care seeking varied between the neonatal, 
early and late infant periods (p-interaction=0.0002), although in each period an association 
was only evident for MLBW infants. Absence of care seeking for MLBW infants was three 
times and almost twice as likely in the neonatal (aOR=3.30; 95%CI:1.98-5.48) and early 
infant periods (aOR=1.74; 95%CI:1.26-2.39) respectively. No association was found in the 
late infant period. 
Admissions 
A total of 4187 admissions were reported for 3485 infants. We found no association 
between birth weight and admissions in the first year of life (Table 2), nor did this 
association vary by time-period (p-interaction=0.1383).   
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Additional analyses 
To further understand how illness, care seeking and admissions related to mortality, we 
undertook additional post-hoc exploratory analyses of VPM data for infants who died. We 
compared disease progression, care seeking and admissions during the fatal illness among 
NLBW and LBW (<2.5kg) infants using proportions and chi-square tests. (Table 4). Data on 
cause of death were unavailable. 
VPM data were available for 684/698 (98%) of infants who died. Care was less likely to be 
sought for LBW infants than NLBW infants (77.1% compared to 87.0%; p=0.001). Of those 
for whom care was sought care, professional medical care (seeking care from a hospital, 
clinic, doctor, nurse or pharmacy) was sought for a smaller proportion of LBW infants 
(85.6%) than NLBW infants (93.5%) (p=0.002). There was little evidence of differences in 
the duration of illness, in the time to seek care, and in the proportions for whom care was 
sought from non-medically trained sources, who were admitted to a health facility or who 
died in a health facility (Table 4).  
Discussion 
LBW continues to adversely impact on infant outcomes throughout the first year of life. 
LBW infants, especially VLBW infants, have substantively higher mortality rates throughout 
infancy, with a notable trend of increasing mortality with decreasing birth weight.  
Although several studies have investigated the association between mortality and LBW in 
SSA5,16-21; few have generated population-based mortality estimates for MLBW and VLBW 
infants. A single 20 year old study from Malawi21 reported neonatal mortality rates 13 times 
higher, and infant mortality rates five times higher among infants with birth weights 
<2.00kg, similar to our estimates for MLBW infants. VLBW is considered a sensitive and 
specific marker for preterm birth22,23. Given this, we compared our results for VLBW infants 
to those of two studies6,24 which investigated mortality among preterm and small for 
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gestational age (SGA) infants. Katz et al reported that infants in low and middle income 
countries who were both preterm and SGA were over 16, 19 and 6 times more likely to die 
in each of the early neonatal, late neonatal and postneonatal periods. A study from 
Tanzania reported that preterm SGA infants were 15 and 3 times more likely to die in each 
of the neonatal and postneonatal periods. Our estimates for VLBW infants in these time-
periods are substantively higher.   
The marked association between birth weight and mortality in our study was not reflected 
in corresponding associations with illness (except in the neonatal period), or facility 
admissions. Interestingly our data suggest lower care seeking for LBW infants, specifically 
for MLBW infants in the first year of life in the neonatal and early infant periods, and also 
during fatal illnesses. 
 Few studies have investigated the association between birth weight and illness in Africa, 
with varying results. Several studies have reported no association between birth weight and 
infant illness, clinic attendance or admissions3,25-28.  In contrast, an analysis of hospital 
admissions (based on both written record and maternal recall) collected from a peri-urban 
area  in a Neovita sister site in Tanzania29 found that infants weighing ≤2.00kg were more 
likely to be hospitalised in the first year of life compared to NLBW infants (aHR=2.74; 
95%CI:1.66-4.54); there was little evidence of an association for infants weighing 2.01-
2.50kg (aHR=1.05; 95%CI:0.85-1.29). This analysis was restricted to district hospital 
admissions, so the severity of illnesses among those admitted was likely to be greater than 
in our analysis, which included admissions to any facility. A study in urban South Africa30 
reported that infants born at <32 weeks’ gestation were more likely to be hospitalised for 
respiratory syncytial virus, bronchiolitis and pneumonia in childhood. The association 
between preterm delivery and pneumonia was also reported by another South African 
study, although no association was found for LBW infants3.  
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A number of factors may explain why, in a population where birth weight was so strongly 
associated with death, there was little association with illness or admissions. Our data on 
illness, care seeking and admissions were based on maternal recall. Recognition of 
childhood illnesses in low and middle income settings is poor31, possibly leading to 
underreporting of illness. We don’t know if under-recognition or underreporting in our 
study was differential by birth weight. Qualitative data from Uganda reported poor 
recognition of LBW as a danger sign and a consequent lack of care seeking for neonatal 
illness32. A failure to recognise and appreciate the severity of illness among LBW infants 
who die has also been reported33.  
As health facility admission is a notable event, underreporting is less likely.  Admission is a 
marker for severe disease. However, lack of care-seeking for LBW infants may decrease the 
opportunity for hospital admission. Although severity is recognised as an important 
determinant of care seeking31, it has previously been reported in our study area that care is 
not sought for up to 50% of severe illnesses34. We found an absence of care seeking for 
LBW infants for all illnesses, including fatal illnesses. Reduced care seeking will have led to 
reduced opportunities to be admitted, and may have increased the risk of death. This may 
explain the discordance between our reported admission and mortality rates, especially if 
absence of care seeking is because care-givers think the infant has a low chance of survival9. 
This would mostly affect the weakest infants at greatest risk of dying. Furthermore, in our 
study area, some illnesses are considered “not for hospital” and untreatable by modern 
medicine34. We do not know if “not for hospital” illnesses were more prevalent among LBW 
infants and if this perception overly impacted on care seeking behaviour for LBW infants in 
our study area.  
Short duration of severe illness, suggesting sudden onset or rapid progression, may be 
more frequent among LBW compared to NLBW infants, resulting in little time to seek care 
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and higher mortality rates. We lacked data on duration for illnesses reported during routine 
follow-up. Our analyses of fatal illnesses suggested no differences in illness duration or time 
to seeking care by birth weight; however, this analysis was limited by low sample size.  
Strengths 
Due to the population-based nature of the cohort and low numbers excluded from the 
analyses, our results are likely to be generalisable to the underlying population. The large 
sample size provided sufficient power for us to generate estimates of mortality for several 
categories of LBW, including VLBW infants. Our study further benefited from low rates of 
loss-to-follow-up (<3%) and from highly complete data on mortality, including date of 
death. This will have minimised bias and potential misclassification of deaths by time-
period in our study.  
Limitations 
We lacked data on gestational age (GA), and so could not generate separate estimates by 
levels of prematurity or for SGA infants. Data were unavailable for time to illness onset, 
time to care seeking, type of care sought (other than admissions to a health facility) and for 
disease severity, factors which may differ among LBW and NLBW infants and which may 
modify the association between birth weight and illness and mortality. We also lacked 
health service data on diagnoses of illness and data on cause of death, limiting investigation 
of the role of LBW in cause-specific morbidity and mortality. Despite the large sample size, 
the study was under-powered to detect moderate differences in illness or admissions by 
birth weight, especially in the smaller categories of birth weight stratified by time-period. 
Recall of dates of illness in our study population was poor, with over 40% of illness start 
dates reported as unknown. We relied on imputation to assign these illness dates, which 
may have led to some misclassification by time-period. However, the frequent (monthly) 
nature of data collection throughout the study allowed almost 75% of all imputed dates to 
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be imputed within a 30-day window, thus minimising the occurrence of misclassification of 
dates by time-period. 
Conclusions and Recommendations 
LBW infants are more likely to die throughout the first year of life and their mothers are 
less likely to seek care for them when they are sick. Strategies to minimise their mortality 
should target the entire infant period. Efforts to improve their care seeking are needed. 
This could include educating mothers of LBW infants about the potential of simple 
caregiving practices and timely care seeking to improve their infant’s chance of survival. 
Our study highlights the need for robust, prospective, population-based studies in Africa to 
further investigate the association between birth weight and infant illness, care seeking and 
care-giving, and how these relate to infant mortality.  
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Tables and Figures 
Table 1: Characteristics of infants included in the analyses 
 
  
  
  
Infants included 
(N=22906) n (%) 
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
 
19322 (84.4) 
3023 (13.2) 
444 (1.9) 
117 (0.5)) 
 
Religion of head of household 
Christian 
Muslim 
Other 
 
 
15961 (69.7) 
5486 (24.0) 
1459 (6.4) 
 
Ethnicity of household 
Akan 
Other  
 
 
10690 (46.7) 
12216 (53.3) 
 
Maternal education 
None 
Primary school 
Post-primary / tertiary 
 
 
7101 (31.0) 
4232 (18.5) 
11573 (50.5) 
 
Maternal occupation 
Government/Private/Other 
Self-employed 
Farming 
Does not work 
 
 
1223 (5.3) 
8934 (39.0) 
6642 (29.0) 
6107 (26.7) 
 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
 
 
4489 (19.6) 
4539 (19.8) 
4576 (20.0) 
4638 (20.2) 
4664 (20.4) 
 
Exposure to indoor smoke 
Yes 
Missing 
13033 (56.9) 
 
Place of delivery 
Facility 
Non-facility 
Missing 
 
17552 (76.6) 
5354 (23.4) 
 
Distance to nearest health facility 
<1.00km 
1.00-4.99km 
>=5.00km 
Missing 
 
13856 (60.5) 
5282 (23.1) 
3768 (16.4) 
 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
Missing 
 
2644 (11.5) 
5880 (25.7) 
6149 (26.8) 
4611 (20.1) 
3622 (15.8) 
 
No. children in family  
0-1 
2-3 
4 or more 
Missing 
 
6722 (29.3) 
9137 (39.9) 
7047 (30.8) 
 
Maternal illness  
Yes 
Missing 
 
1122 (4.9) 
 
Infant sex 
Female 
 
11286 (49.3) 
Multiple Birth 
Yes 
 
845 (3.7) 
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Figure 1: Probability of survival in the first year of life, by birth weight 
 
 
 
 
Figure 2: Illness rates by birth weight in the first year of life 
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Table 2: The association between birth weight and infant mortality, illness, absence of care 
seeking and health facility admissions in the first year of life 
 
     
Birth 
weight 
Outcome / 
PDOFUa 
Outcome / 1000 YOFUb Unadjusted HR (95%CI) 
 
AdjustedC HR (95%CI) 
 
Mortality 
>=2.50kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
433/7326996 
147/1119524 
71/146813 
47/29181 
21.6 (19.6-23.7) 
48.0 (40.8-56.4) 
176.6 (140.0-222.9) 
588.3 (442.0-783.0) 
Ref 
2.21 (1.83-2.66) 
7.92 (6.16-10.18) 
24.51 (18.13-33.12) 
p<0.0001 
Ref 
2.13 (1.76-2.59) 
8.21 (6.26-10.76) 
25.38 (18.36-35.10) 
p<0.0001 
Birth 
weight 
Outcome / 
PDOFUa 
Outcome / 1000 YOFUb Unadjusted RR (95%CI) AdjustedC RR (95%CI) 
Illness 
>=2.50kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
47969/6832406 
7379/1041876 
1029/136089 
233/26638 
2564.4 (2541.5-2587.4) 
2586.9 (2528.5-2646.6) 
2761.7 (2598.1-2935.7) 
3194.9 (2809.9-3632.6) 
Ref 
1.01 (0.98-1.04) 
1.10 (1.01-1.19) 
1.32 (1.12-1.57) 
p=0.0012 
Ref 
0.99 (0.96-1.03) 
1.06 (0.98-1.14) 
1.15 (0.98-1.36) 
p=0.1557 
Birth 
weight 
Outcome / 
Total 
Proportion with outcome 
(95%CI) 
Unadjusted OR (95%CI) AdjustedC OR (95%CI) 
Absence of care seeking 
>=2.50kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
7680/48115 
1214/7405 
235/1031 
52/236 
16.0 (15.6-16.3) 
16.4 (15.6-17.3) 
22.8 (20.3-25.5) 
22.0 (17.2-27.8) 
Ref 
1.03 (0.95-1.12) 
1.72 (1.41-2.08) 
1.76 (1.18-2.63) 
p<0.0001 
Ref 
1.00 (0.91-1.09) 
1.46 (1.18-1.81) 
1.05 (0.68-1.63) 
p=0.0069 
Admissions 
>=2.50kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
3496/48115 
580/7405 
88/1031 
23/236 
7.3 (7.0-7.5) 
7.8 (7.2-8.5) 
8.5 (7.0-10.4) 
9.7 (6.6-14.2) 
Ref 
1.10 (0.98-1.23) 
1.16 (0.88-1.52) 
1.46 (0.86-2.48) 
p=0.1428 
Ref 
1.12 (1.00-1.26) 
1.12 (0.84-1.48) 
1.41 (0.82-2.43) 
p=0.1537 
a) PDOFU = person days of follow-up; b) YOFU = years of follow-up; c) adjusted for religion, ethnicity, maternal education, 
maternal occupation, socioeconomic status, exposure to indoor smoke, place of delivery, distance to the nearest health 
facility, maternal age, number of living children in family, maternal illness, infant sex, multiple birth. 
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Table 3: Stratum specific estimates of the association between birth weight and infant mortality, illness, absence of care seeking and health facility 
admissions in the neonatal, early and late infant periods 
 Neonatal Early Infant Late Infant 
Birth weight Outcome / 
PDOFU 
Outcome / 1000 years 
of follow-up 
Adjusteda HR 
(95%CI) 
Outcome / 
PDOFU 
Outcome / 1000 years 
of follow-up 
Adjusteda HR 
(95%CI) 
Outcome / 
PDOFU 
Outcome / 1000 years 
of follow-up 
Adjusteda HR 
(95%CI) 
Mortality1 
>=2.50kg 
 
2.00-2.49kg 
 
1.50-1.99kg 
 
<1.50kg 
144/518319 
 
53/80502 
 
45/11146 
 
35/2502 
97.9 
(83.1-115.2) 
231.9 
(177.2-303.6) 
1357.1 
(1006.5-1829.9) 
4947.3 
(3552.1-6890.4) 
Ref 
 
2.29 
(1.66-3.15) 
14.71 
(10.37-20.86) 
48.45 
(32.81-71.55) 
157/2884213 
 
61/442344 
 
22/57927 
 
8/11717 
19.1 
(16.3-22.4) 
47.1 
(36.3-61.0) 
151.2 
(101.4-225.6) 
249.6 
(124.8-499.1) 
Ref 
 
2.45 
(1.81-3.31) 
7.22 
(4.57-11.42) 
12.95 
(6.30-26.60) 
132/3450857 
 
33/522731 
 
4/67449 
 
4/12897 
14.1 
(11.8-16.7) 
23.2 
(16.5-32.6) 
21.8 
(8.2-58.0) 
113.9 
(42.8-303.6) 
Ref 
 
1.60 
(1.09-2.35) 
1.61 
(0.59-4.39) 
8.42 
(3.09-22.92) 
Birth weight Outcome / 
PDOFU 
Outcome / 1000 years 
of follow-up 
Adjusteda RR 
(95%CI) 
Outcome / 
PDOFU 
Outcome / 1000 years 
of follow-up 
Adjusteda RR 
(95%CI) 
Outcome / 
PDOFU 
Outcome / 1000 years 
of follow-up 
Adjusteda RR 
(95%CI) 
Illness2 
>=2.50kg 
 
2.00-2.49kg 
 
1.50-1.99kg 
 
<1.50kg 
2343/537087 
 
411/83316 
 
106/11533 
 
42/2534 
1593.4 
(1530.2-1659.2) 
1801.8 
(1635.8-1984.7) 
3357.0 
(2775.1-4061.0) 
6053.9 
(4473.9-8191.7) 
Ref 
 
1.00 
(0.89-1.12) 
1.57 
(1.27-1.95) 
1.58 
(1.13-2.21) 
14644/2882964 
 
2246/441850 
 
324/57927 
 
67/11543 
1855.3 
(1825.5-1885.6) 
1856.6 
(1781.4-1935.0) 
2042.9 
(1832.2-2277.9) 
2120.1 
(1668.7-2693.7) 
Ref 
 
0.99 
(0.94-1.04) 
1.10 
(0.97-1.23) 
1.10 
(0.85-1.43) 
30776/3412047 
 
4689/516711 
 
596/66629 
 
122/12561 
3294.5 
(3257.9-331.5) 
3314.5 
(3221.0-3410.8) 
3267.2 
(3015.1-3540.3) 
3547.5 
(2970.7-4236.3) 
Ref 
 
0.99 
(0.96-1.03) 
0.99 
(0.89-1.08) 
1.07 
(0.87-1.32) 
Birth weight Outcome / 
Total 
Proportion with 
outcome (95%CI) 
Adjusteda OR 
(95%CI) 
Outcome / Total Proportion with 
outcome (95%CI) 
Adjusteda OR 
(95%CI) 
Outcome / Total Proportion with 
outcome (95%CI) 
Adjusteda OR 
(95%CI) 
Absence of care seeking3 
>=2.50kg 
 
2.00-2.49kg 
 
1.50-1.99kg 
 
<1.50kg 
1210/2378 
 
217/420 
 
78/107 
 
30/44 
50.9 
(48.9-52.9) 
51.7 
(46.9-56.4) 
72.9 
(63.7-80.5) 
68.2 
(53.0-80.3) 
Ref 
 
1.04 
(0.81-1.34) 
3.30 
(1.98-5.48) 
2.07 
(0.97-4.43) 
2549/15227 
 
403/2331 
 
82/333 
 
8/70 
16.7 
(16.2-17.3) 
17.3 
(15.8-18.9) 
24.6 
(20.3-29.5) 
11.4 
(5.8-21.3) 
Ref 
 
1.03 
(0.90-1.19) 
1.74 
(1.26-2.39) 
0.63 
(0.27-1.46) 
3921/30510 
 
594/4654 
 
75/591 
 
14/122 
12.9 
(12.5-13.2) 
12.8 
(11.8-13.8) 
12.7 
(10.2-15.6) 
11.5 
(6.9-18.5) 
Ref 
 
0.97 
(0.86-1.09) 
0.98 
(0.72-1.32) 
0.85 
(0.43-1.66) 
Continues…. 
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Continued…. 
Admissions4 
 Neonatal Early Infant Late Infant  Neonatal Early Infant Late Infant  Neonatal 
Birth weight Outcome / 
Total 
Proportion with 
outcome (95%CI) 
Adjusteda OR 
(95%CI) 
Outcome / Total Proportion with 
outcome (95%CI) 
Adjusteda OR 
(95%CI) 
Outcome / Total Proportion with 
outcome (95%CI) 
Adjusteda OR 
(95%CI) 
>=2.50kg 
 
2.00-2.49kg 
 
1.50-1.99kg 
 
<1.50kg 
250/2378 
 
48/420 
 
7/107 
 
6/44 
10.5 
(9.3-11.8) 
11.4 
(8.7-14.8) 
6.5 
(3.1-13.1) 
13.6 
(6.2-27.4) 
Ref 
 
1.11 
(0.77-1.60) 
0.56 
(0.24-1.29) 
1.59 
(0.59-4.27) 
1019/15227 
 
194/2331 
 
28/333 
 
6/70 
6.7 
(6.3-7.1) 
8.3 
(7.3-9.5) 
8.4 
(5.9-11.9) 
8.6 
(3.9-17.9) 
Ref 
 
1.35 
(1.12-1.63) 
1.19 
(0.75-1.89) 
1.34 
(0.51-3.52) 
2227/30510 
 
338/4654 
 
53/591 
 
11/122 
7.3 
(7.0-7.6) 
7.3 
(6.6-8.0) 
9.0 
(6.9-11.6) 
9.0 
(5.1-15.6) 
Ref 
 
1.03 
(0.89-1.18) 
1.24 
(0.88-1.75) 
1.36 
(0.65-2.85) 
a) adjusted for religion, ethnicity, maternal education, maternal occupation, socioeconomic status, exposure to indoor smoke, place of delivery, distance to the nearest health facility, maternal age, number of living 
children in family, maternal illness, infant sex, multiple birth. p-values for interaction by time-period = 1) <0.0001, 2) 0.0029, 3) 0.0002, 4) 0.1383
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Table 4: Comparison of illness, care seeking and care-giving behaviour during fatal illnesses 
among LBW compared to NLBW infants  
 
Indicator 422 NLBW (%) 262 LBW (%) p-value 
Duration of illness 
Duration of fatal illness 
<1d 
1-7d 
>7d 
 
21 (5.0) 
216 (51.2) 
185 (43.8) 
 
12 (4.6) 
142 (54.2) 
108 (41.2) 
 
 
 
0.7440 
Care seeking behaviour 
Sought care 
No 
Yes 
 
55 (13.0) 
367 (87.0) 
 
60 (22.9) 
202 (77.1) 
 
 
0.0010 
Among 569 infants who sought care:    
Days ill before care sought  
<1d 
1-3d 
>3d 
 
135 (36.8) 
174 (47.4) 
58 (15.8) 
 
71 (35.2) 
86 (42.6) 
45 (22.3) 
 
 
 
0.1510 
Sought professional medical care  
(from a hospital, clinic, doctor, nurse or 
pharmacy) 
No 
Yes 
 
 
 
24 (6.5) 
343 (93.5) 
 
 
 
29 (14.4) 
173 (85.6) 
 
 
 
 
0.0020 
Sought care elsewhere 
No 
Yes 
 
228 (62.1) 
139 (37.9) 
 
116 (57.4) 
86 (42.6) 
 
 
0.2730 
Care-giving behaviour (among 516 infants who sought professional medical care) 
Admitted to a health facility  
No 
Yes 
 
179 (52.2) 
164 (47.8) 
 
82 (47.4) 
91 (52.6) 
 
 
0.3040 
Received medical therapy1 
No 
Yes 
 
52 (15.2) 
291 (84.8) 
 
38 (22.0) 
135 (78.0) 
 
 
0.0540 
Died in hospital  
No 
Yes 
 
162 (47.2) 
181 (52.8) 
 
88 (50.9) 
85 (49.1) 
 
 
0.4350 
1. Infants who were prescribed medicine or received surgery 
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4.3. FURTHER DISCUSSION ON THE METHODOLOGY USED FOR THE 
ANALYSES 
4.3.1. Considerations in the choice of analytical methodology 
The rate of mortality varies rapidly over time in the first year of life. In particular, the rate 
declines rapidly each day in the first week of life1. Given this rapidly changing mortality rate, 
I considered Cox proportional hazards to be the most appropriate technique to use to 
assess the relationship between birth weight and mortality. I therefore used it to generate 
hazard ratios of the association between birth weight and infant mortality, adjusted for all 
other possible confounders using a causal modelling approach, as described in Section 
3.7.3. In order to assess the assumption of proportional hazards (that the estimated hazard 
ratios were proportional over time), I generated a log-log plot (a plot of the log of survival 
compared to the log of the analysis time). I examined this plot to ensure that there was 
neither convergence nor divergence of the plots (that the plots were parallel), as 
confirmation that this assumption was not violated.  
Unlike mortality, illness rates do not change rapidly with age. In order to be able to estimate 
morbidity rates directly from the model, I used random effects Poisson regression to 
generate rate ratios of the association between birth weight and illness, adjusted for all 
possible confounders. As infants were followed up monthly for the first year of life, they 
could experience more than one episode of illness between follow-up visits. I used random 
effects modelling to control for clustering associated with multiple events per infant. 
I did not have data on person-time from the onset of illness to the time of care seeking or 
hospitalisation. Therefore, I used random-effects logistic regression to assess whether, 
among infants who fell ill, birth weight was associated with whether care was sought for the 
infant, or whether the infant was admitted to a health facility.  
4.3.2. Why I did not generate estimates by gestational age. 
Women who fell pregnant during the Neovita trial were asked to estimate the date of their 
LMP, both when they were visited every month as part of pregnancy surveillance, and 
when they delivered. LMP is often used to estimate the GA of infants, and to categorise 
infants as preterm or term. If I had used these data in this way, I could potentially have 
generated estimates of mortality and morbidity according to whether the infant was 
preterm or not. This would have allowed a more direct comparison between my results and 
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those of other studies, and it would have allowed me to better characterise the risk of 
illness and death due to preterm delivery and that due to growth retardation.  
Overall, the quality of our data on LMP was poor. In our study population, data on LMP was 
missing for 57.5% of pregnancies (16398/28498) and was inconsistently reported (from one 
pregnancy surveillance visit to another) for 16.0% (1935/12100) of women reporting to 
know their LMP. In addition, women in our study area report their pregnancies late, which 
may have affected the accuracy of our data on LMP.  
Furthermore, the use of LMP data to estimate GA can be inaccurate for a number of 
reasons. Firstly, a number of factors, including uncertain recall of dates, bleeding which is 
not in fact associated with menses, and delayed ovulation can lead to problems with the 
reporting of LMP2. Data from high-income settings indicate that women with certain LMP 
dates are systematically different to those with uncertain dates. Those with uncertain dates 
are more likely to be young, primiparous, and to have lower educational attainment, 
factors which are also associated with LBW3. Consequently, GA based on LMP may be 
misclassified, and this misclassification may be more common among women who deliver 
LBW infants. LMP is also subject to digit preference2.   
Secondly, there is poor concordance between GA as assessed by ultrasound (the gold 
standard for GA assessment) and that estimated using LMP. Therefore, GA estimated from 
LMP is prone to misclassification. For example, in an analysis of 80 pregnancies in the 
Gambia4, LMP classified 18.4% of infants as preterm, compared to 2.5% for ultrasound. 
Although the mean GA was similar using both methods, there was greater variation for 
LMP. Another study of 1342 pregnancies in South Africa reported that ultrasound refuted 
LMP based GA dating in 45% of the studied pregnancies5.  
Given the large volume of missing and inconsistently reported data on LMP in my study 
population, and given the potential for misclassification of GA based on LMP, particularly 
for infants at risk of LBW, illness and death I opted not to use these data to estimate GA, as 
I did not think it would be possible to categorise infants accurately according to whether 
they were preterm or not.   
4.3.3. Why I did not adjust for the effects of breastfeeding.  
Breast feeding is known to be associated with the risk of mortality and illness during 
infancy6,7. During the monthly postneonatal follow-up conducted for the Neovita trial, we 
collected data on infant feeding in the previous 24 hours. It may have been possible to 
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categorise infants according to whether they were exclusively, partially, or not breastfed, 
and to examine whether any association between birth weight and illness or death was 
mediated by breastfeeding. I opted not to do this for a number of reasons. Firstly, this 
would have entailed categorising an infant’s feeding status based on data for one day out 
of 30. However, during weaning infants may oscillate between exclusive and partial 
breastfeeding. Furthermore, these data were frequently collected for a time-period that did 
not coincide with the actual illness (if the illness did not occur in the 24 hours before the 
follow-up visit). In the event of the data being collected at the time of an illness, infant 
feeding practices could be influenced by an infant’s illness. Sick babies may have altered 
feeding practices, and so their feeding practices around the time of illness may not reflect 
their usual feeding practices.  Based on the available data, I reasoned that I could not 
accurately classify infants’ feeding status at the time of illness or death. 
4.4. CAUSE-SPECIFIC ADMISSIONS 
I describe the process for assigning cause specific illness in Section 3.2. Briefly, data on 
cause of illness were only collected for admissions to health facilities and were based on 
maternal recall only. These data were categorised into three broad categories of infection, 
non-infection and unknown other, due to the potential for misclassification by cause of 
illness as described in Section 3.2. As reported in the paper, 4187 admissions were reported 
for 3485 infants who reported illness. Of these admissions 4137 (98.8%) were associated 
with infections, 586 (14.0%) with non-infections, and 81 (1.9%) with unknown causes. 
Multiple causes were reported for 459 (11.0%) admissions (including 158 (3.8%) reporting 
all three causes).  
As discussed in Section 4.1, if LBW infants are less likely to be vaccinated, they may be 
more likely to contract VPDs. In the absence of data on VPDs, I was interested in 
investigating whether LBW infants were more likely to contract infectious diseases. 
However, I only had data on admissions due to infectious diseases. As the overwhelming 
majority of admissions (98.8%) had an associated infectious cause, and as overall, no 
association was found between birth weight and admissions, there was unlikely to be an 
association between birth weight and infection related admissions. Nonetheless, I 
investigated this by repeating the analysis of the association between birth weight and 
admissions, restricting the analysis to infection-related admissions. There was little 
evidence of an association between birth weight and infection related admissions, in the 
overall infant period (Table 4.2). There was some evidence that the association varied by 
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time-period (p-value for interaction = 0.0395) (Table 4.3). However, evidence of a greater 
likelihood of infection-related admissions was restricted to infants weighing 2.00-2.49kg in 
the early infant period only, and the adjusted rate ratios showed no clear pattern.  
Although as discussed in the paper, there is some evidence of an association between birth 
weight and illness in the neonatal period, there is little evidence of an association with 
overall and infection-related admissions. As these data are based on maternal recall, and as 
recognition of infant illness is known to be poor8 these data should be interpreted with 
caution. Data on whether recognition of illness is worse among LBW infants are lacking; 
however, it is suspected that this may be the case. The question of whether illness 
recognition is worse among LBW infants merits further research. 
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Table 4.2: The association between birth weight and infection-related admissions in the first year of life  
Birth weight Outcome / 
Total 
Proportion 
with outcome 
(95%CI) 
Unadjusted OR 
(95%CI) 
Adjusted1 OR 
(95%CI) 
>=2.50kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
3488/48115 
543/7405 
88/1031 
18/236 
7.2 (7.0-7.5) 
7.3 (6.8-7.9) 
8.5 (7.0-10.4) 
7.6 (4.9-11.8) 
Ref 
1.02 (0.90-1.15) 
1.14 (0.86-1.53) 
1.08 (0.59-1.98) 
p=0.8151 
Ref 
1.03 (0.91-1.17) 
1.10 (0.81-1.48) 
1.06 (0.57-1.96) 
p=0.8979 
1) adjusted for religion, ethnicity, maternal education, maternal occupation, socioeconomic status, exposure to indoor smoke, place of delivery, distance to the nearest health facility, maternal age, number of living 
children in family, maternal illness, infant sex, multiple birth 
 
Table 4.3: The association between birth weight and infection related admissions in the neonatal, early, and late infant periods1. 
 
 Neonatal Early Infant Late Infant 
Birth weight Outcome / 
Total Illness 
Episode 
Proportion 
with outcome 
(95%CI) 
Adjusted2 OR 
(95%CI) 
Outcome / 
Total Illness 
Episode 
Proportion 
with outcome 
(95%CI) 
Adjusted OR 
(95%CI) 
Outcome / 
Total Illness 
Episode 
Proportion 
with outcome 
(95%CI) 
Adjusted OR 
(95%CI) 
>=2.50kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
202/2378 
38/420 
5/107 
3/44 
8.5 (7.4-9.7) 
9.0 (6.6-12.2) 
4.7 (1.9-10.8) 
6.8 (2.2-19.3) 
Ref 
1.05 (0.70-1.59) 
0.47 (0.17-1.27) 
0.86 (0.23-3.19) 
1016/15227 
188/2331 
27/333 
5/70 
6.7 (6.3-7.1) 
8.1 (7.0-9.2) 
8.1 (5.6-11.6) 
7.1 (3.0-16.1) 
Ref 
1.30 (1.07-1.58) 
1.11 (0.68-1.80) 
1.00 (0.34-2.92) 
2270/30510 
317/4654 
56/591 
10/122 
7.4 (7.2-7.7) 
6.8 (6.1-7.6) 
9.5 (7.4-12.1) 
8.2 (4.5-14.6) 
Ref 
0.92 (0.79-1.07) 
1.25 (0.87-1.78) 
 1.19 (0.53-2.64) 
1) p-value for interaction by time-period = 0.0395 
2) adjusted for religion, ethnicity, maternal education, maternal occupation, socioeconomic status, exposure to indoor smoke, place of delivery, distance to the nearest health facility, maternal age, number of 
living children in family, maternal illness, infant sex, multiple birth  
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CHAPTER 5: DELAYED VACCINATION 
OF LOW BIRTH WEIGHT INFANTS  
Preamble 
The paper presented in this chapter addresses PhD objective 2, namely to investigate birth 
weight and other factors as determinants of postneonatal vaccination, using DTP1 and DTP3 
as indicator vaccines. In Section 5.1. I provide a brief overview of the paper. In Section 5.2. I 
present the paper itself, which was published in the Bulletin of the World Health 
Organisation in June 2016. In Sections 5.3. and 5.4. I outline factors considered in the design 
of the study and in the choice of methods used for the statistical analysis. In Section 5.5. I 
discuss the extent to which the design of the study may have biased the estimates of the 
association between birth weight and vaccination. In Section 5.6. I present the results of 
two sensitivity analyses to assess the impact of my decision to include infants in my analyses 
who were missing vaccination cards, but whose mothers consistently reported them as not 
vaccinated, (as originally discussed in Chapter 3). In Section 5.7. I present additional results 
that were excluded from the main paper, and I include a discussion of these results.  
5.1. INTRODUCTION 
This paper presents the results of a prospective population-based cohort study to 
investigate birth weight and other factors as determinants of DTP1 and DTP3 vaccination in 
the postneonatal period. The study population for each of the DTP1 and DTP3 analyses 
comprised 22361 and 22192 infants respectively with known vaccination status, and full 
covariate data who were in follow-up at the respective vaccine due dates. The outcomes for 
each of the analyses were vaccination rate ratios at 10, 14 and 18 weeks after birth for 
DTP1, and at 18, 22 and 24 weeks after birth for DTP3 (4, 8 and 12 weeks after each of the 
vaccine due dates), calculated using Poisson regression. I adjusted all estimates a priori for 
potential confounders.  
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5.2. PAPER 2: VACCINATION TIMING OF LOW-BIRTH-WEIGHT INFANTS 
IN RURAL GHANA: A POPULATION-BASED, PROSPECTIVE COHORT 
STUDY 
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Introduction
Approximately 14% of infants born in low- and middle-
income countries have a low birth weight (weighing < 2.50 kg 
at birth).1 It has been reported that in high-income set-
tings, low-birth-weight infants have an increased risk of 
vaccine-preventable diseases, such as pertussis,2 invasive 
pneumococcal disease3–5 and Haemophilus influenzae type b 
(Hib).6 However, it is not known whether such risk exists in 
low-income settings. Timely vaccination of low-birth-weight 
infants, including booster doses, is important because these 
infants have lower passive immunity before vaccination7 and 
may respond sub-optimally to primary vaccination.8 Vac-
cination has similar efficacy and safety in low-birth-weight 
infants compared with non-low-birth-weight infants,8 and 
therefore vaccination is recommended at the same chrono-
logical age as other infants.9
Studies from high-income settings indicate that low-birth-
weight infants are vaccinated later than non-low-birth-weight 
infants.10,11 Regardless of whether they are at increased risk, 
delayed vaccination of low-birth-weight infants prolongs their 
risk period for contracting vaccine-preventable diseases, es-
pecially Hib and Streptococcus pneumoniae,3,12 which are most 
prevalent in the first few months of life. Studies of the effect of 
low birth weight on timely vaccination in low-income settings, 
however, are lacking.
We aimed to measure the timing of vaccination of low-birth-
weight infants compared with non-low-birth-weight infants by 
analysing data from a population-based, prospective cohort 
study in Ghana. Our primary objectives were to assess whether 
low birth weight is a determinant of delayed first and third dose 
diphtheria–tetanus–pertussis (DTP1 and DTP3) vaccination; 
and whether maternal education or socioeconomic status modi-
fied the association between birth weight and vaccination with 
DTP1 and DTP3. As a secondary objective, we aimed to quantify 
other determinants of delayed DTP1 and DTP3 vaccination.
Methods
Study design and setting
We studied a cohort of infants nested within a large random-
ized, double-blind, placebo-controlled trial of neonatal vita-
min A supplementation conducted in Ghana between August 
2010 and February 2013.13 The trial was conducted at the Kin-
tampo Health Research Centre in Kintampo, Ghana. The trial 
procedures and study area have been described elsewhere.14
Ethics approval for the study was granted by the ethics 
committees of the World Health Organization (WHO), the 
Objective To investigate delays in first and third dose diphtheria–tetanus–pertussis (DTP1 and DTP3) vaccination in low-birth-weight infants 
in Ghana, and the associated determinants.
Methods We used data from a large, population-based vitamin A trial in 2010–2013, with 22 955 enrolled infants. We measured vaccination 
rate and maternal and infant characteristics and compared three categories of low-birth-weight infants (2.0–2.4 kg; 1.5–1.9 kg; and < 1.5 kg) 
with infants weighing ≥ 2.5 kg. Poisson regression was used to calculate vaccination rate ratios for DTP1 at 10, 14 and 18 weeks after birth, 
and for DTP3 at 18, 22 and 24 weeks (equivalent to 1, 2 and 3 months after the respective vaccination due dates of 6 and 14 weeks).
Findings Compared with non-low-birth-weight infants (n = 18 979), those with low birth weight (n = 3382) had an almost 40% lower DTP1 
vaccination rate at age 10 weeks (adjusted rate ratio, aRR: 0.58; 95% confidence interval, CI: 0.43–0.77) and at age 18 weeks (aRR: 0.63; 95% 
CI: 0.50–0.80). Infants weighing 1.5–1.9 kg (n = 386) had vaccination rates approximately 25% lower than infants weighing ≥ 2.5 kg at these 
time points. Similar results were observed for DTP3. Lower maternal age, educational attainment and longer distance to the nearest health 
facility were associated with lower DTP1 and DTP3 vaccination rates.
Conclusion Low-birth-weight infants are a high-risk group for delayed vaccination in Ghana. Efforts to improve the vaccination of these 
infants are warranted, alongside further research to understand the reasons for the delays.
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DTP vaccination in Ghana is rec-
ommended at 6, 10 and 14 weeks of 
age. Children are vaccinated at health 
facilities, community health planning 
system compounds or mobile outreach 
clinics. For each administered vaccine, 
the date and place of administration 
and vaccine batch number are usually 
documented in the child health record 
book. These may also be documented 
on a vaccination card or in the mother’s 
antenatal card. Infants who have never 
attended a child health clinic may not 
have a written record.
Enrolment and data collection
Trained fieldworkers enrolled all con-
senting women aged 15–49 years resid-
ing in the study area into a reproductive 
surveillance system to document preg-
nancies and deliveries. All infants born 
in the study area were assessed for eligi-
bility (eligible infants were aged ≤ 3 days 
at screening, could suck or feed and were 
staying in the study area for 6 months af-
ter enrolment) and mothers were asked 
for informed written consent for enrol-
ment in the trial. Infants were weighed 
using calibrated electronic (38%; 8723 
of enrolled infants) or spring (62%; 
14 232) scales, to record birth weights to 
the nearest 0.1 kg (electronic scales) or 
0.2 kg (spring scales). Only five (0.2%) 
infants were weighed later than 72 hours 
after delivery. The fieldworkers col-
lected data on infant (sex and multiple 
delivery), maternal (age, education, 
occupation, and illness before delivery) 
and household characteristics (ethnicity, 
religion, socioeconomic status, distance 
to health facility and number of children 
in household).
The enrolled infants were visited 
monthly for the first year of life to col-
lect data on the types and dates of 
vaccines given. We looked for written 
documentation of vaccines from all pos-
sible sources, including the child health 
record book, the mother’s antenatal 
card and vaccination cards. The infant’s 
caregiver (usually the mother) was also 
asked to recall what vaccines had been 
given. We also collected data on the in-
fant’s vital status and on illnesses since 
the previous visit.
Follow-up started at birth. It ended 
at the vaccination date for vaccinated 
infants, and the end of the risk period for 
unvaccinated infants not lost to follow-
up. For those lost to follow-up before the 
end of the risk period, follow-up ended 
on the last date the written record was 
viewed, for unvaccinated infants whose 
record was viewed; or on the last date the 
infant was seen, for unvaccinated infants 
whose record was never viewed; or on 
the date of death, for unvaccinated in-
fants who died before the end of the risk 
period and whose record was viewed 
after their death.
For the analyses we included all in-
fants from the trial with known vaccina-
tion status and dates and with complete 
data on covariates. We excluded infants 
who were lost to follow-up or died be-
fore the vaccination due date.
Definitions
We classified infants’ vaccination status 
as follows: (i) vaccinated, date known 
(written record had a plausible vac-
cination date); (ii) vaccinated, date un-
known (record had clearly documented 
vaccination but with the date missing, 
illegible or implausible); (iii) unvacci-
nated (record was seen but had no docu-
mented vaccination date or any evidence 
of vaccination; or record was never seen 
and mother consistently reported infant 
had never been vaccinated); or (iv) vac-
cination status unknown (mother re-
ported that infant had been vaccinated 
but did not specify the vaccine; or infant 
was never seen in follow-up).
We categorized birth weight into 
four standard categories: ≥ 2.5 kg (i.e. 
non-low birth weight); 2.0–2.4 kg; 
1.5–1.9 kg; < 1.5 kg.1,15
Outcome measures
The study outcomes were delayed receipt 
of DTP1 and DTP3. There is no standard 
Fig. 1. Hierarchical framework of determinants of infant vaccination in the prospective cohort study in rural Ghana, 2010–2013
Religion Ethnicity
Vaccination
Sex Maternal
occupation
Maternal
education
Multiple 
birth
Maternal 
age
No. of children
in family
Birth
weight
Infant
illness
Maternal
illness
Distance to
health facility
Place of
birth
Season when
vaccine due
Socioeconomic status
DISTAL 
VARIABLES
INTERMEDIATE 
VARIABLES
PROXIMAL 
VARIABLES
Note: The effects of distal variables were hypothesized to be mediated by intermediate and proximal variables, and intermediate variables by the proximal 
variables. Among the proximal variables, illness was hypothesized to mediate the effect of birth weight. Mediation is indicated by arrows linking the variables 
across different levels.
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approach to the assessment of delayed 
vaccination and several definitions 
based on predefined cut-offs have been 
described.16–18 To assess how the effect 
of birth weight may vary over time, we 
defined risk periods for delayed vaccina-
tion up to 4, 8 and 12 weeks after the vac-
cination due date. For DTP1 we therefore 
analysed vaccination rates from birth up 
to 10, 14 and 18 weeks of age. For DTP3 
we analysed vaccination from birth up 
to 18, 22 and 26 weeks of age.
Data analysis
The data were double-entered and pro-
cessed at the Kintampo Health Research 
Centre using the SQL Server 2008 data 
management system (Microsoft Corp., 
Redmond, USA). Inconsistencies and 
errors in the vaccination dates were cor-
rected, with senior fieldworkers visiting 
mothers to review the written record 
and verify the dates if necessary.
All analyses were conducted us-
ing the Stata package version 13.1 
(StataCorp, College Station, USA). 
We generated Kaplan–Meier curves of 
time to vaccination in low-birth-weight 
compared with non-low-birth-weight 
infants in the first year of life for DTP1 
and DTP3. Vaccination rate ratios, 
adjusted for a priori selected factors, 
were obtained for each risk period us-
ing multivariable Poisson regression, 
informed by a hierarchical framework 
of the recognized determinants of 
vaccination (Fig. 1).12,16–18 The initial 
model included distal determinants of 
vaccination, then intermediate deter-
minants were added, followed by birth 
weight and, finally, infant illness at the 
time the vaccine was due (as this was 
considered to be a possible mediator of 
the association between birth weight 
and vaccination).19 We assessed the 
statistical association between vacci-
nation and each explanatory variable 
using likelihood ratio tests and 95% 
confidence intervals (CI). We also inves-
tigated whether the association between 
birth weight and vaccination varied by 
maternal education or socioeconomic 
status by testing the interaction of birth 
weight with these variables.
Two sets of sensitivity analyses were 
undertaken. First, to assess whether de-
layed DTP3 vaccination simply reflected 
delayed DTP1 vaccination, we repeated 
the DTP3 analyses, starting follow-up at 
receipt of DTP1 vaccination and ending 
12 weeks after receipt of DTP1. Second, 
to examine the effect of possible misclas-
sification of vaccine status for infants 
categorized as never vaccinated but 
whose written record was never viewed, 
we excluded these infants and repeated 
the analyses of DTP1 vaccination up to 
18 weeks from birth and DTP3 vaccina-
tion up to 26 weeks.
Results
Of 27 330 live births identified in the 
study area, 26 414 infants were screened 
for eligibility for the trial and 22 955 
were enrolled (Fig. 2); 22 361 (97.4%) 
and 22 192 (96.7%) infants were in-
cluded in the analysis of DTP1 and 
DTP3 respectively. Low-birth-weight 
infants were more likely to be excluded 
from our analysis, as were those with 
illness reported around the vaccination 
due date, those from multiple births 
and those born to mothers of lower 
socioeconomic status, of non-Akan eth-
nicity, with lower education, with lower 
employment grades or living more than 
5.0 km from a health facility (Table 1). 
Of the infants included in the DTP1 
analysis, 18 979 (84.9%) were normal 
birth weight and 3382 (15.1%) were 
low birth weight: 2916 (13.0%) weighed 
2.0–2.4 kg, 386 (1.7%) 1.5–1.9 kg and 80 
(0.4%) < 1.5 kg. The birth weight distri-
bution was the same for infants in the 
DTP3 analysis: 18 850 (84.9%) weighed 
≥ 2.5 kg, 2886 (13.0%) 2.0–2.4 kg, 378 
(1.7%) 1.5–1.9 kg and 78 (0.4%) < 1.5 kg 
(Table 1).
Delayed vaccination
Birth weight
Although uptake of vaccination was 
high (> 95%) for all infants by 1 year 
of age, low birth weight was associated 
with later vaccination for both DTP1 
and DTP3. Median ages at DTP1 vac-
cination were 8 weeks (interquartile 
range, IQR: 6.7–9.6 weeks) for infants 
Fig. 2. Identification, recruitment and inclusion of participants in the prospective 
cohort study on infant vaccination in rural Ghana, 2010–2013
27 330 live births 
identified in study area
26 414 infants screened 
for eligibility (94.7%)
22 955 infants enrolled 
(86.9%)
22 361 infants included in 
analysis of DTP1 (97.4%)
22 192 infants included in 
analysis of DTP3 (96.7%)
916 infants not screened (3.4%)                                                                
• 282 could not be reached by study team (1.0%)               
• 298 died before screening (1.1%)                                                           
• 336 did not provide consent (1.2%)
3459 infants excluded (13.1%)                                                                                                                
• 2500 moving house within 6 months (9.5%)                                
• 800 aged > 3 days (3.0%)                                                                                                                       
• 84 unable to feed or be assessed for feeding (0.3%) 
• 75 other reason (0.3%)    
763 infants excluded (3.3%)                                 
• 408 missing data on vaccination 
status (1.8%)                                                                                                                         
• 274 died or lost to follow-up before 
98 days of age (1.2%)                                                                   
• 38 vaccinated but date of 
vaccination unknown (0.2%)                                     
• 43 missing covariate data (0.2%)  
594 infants excluded (2.6%)                                           
• 398 missing data on vaccination      
status (1.7%)                                                                   
• 124 died or lost to follow-up before 
42 days of age (0.5%)                                    
• 27 vaccinated but date of 
vaccination unknown  (0.1%)                                  
• 45 missing covariate data (0.2%)  
DTP1: first dose of diphtheria–tetanus–pertussis vaccine; DTP3: third dose of diphtheria–tetanus–
pertussis vaccine.
Note: Overall and disaggregated percentages may not agree due to rounding.
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Table 1. Characteristics of infants vaccinated with first and third doses of diphtheria–tetanus–pertussis vaccine in the prospective 
cohort study in rural Ghana, 2010–2013
Characteristic No. (%)
DTP1 DTP3
Included infants 
(n = 22 361)
Excluded infants 
(n = 594)
Included infants 
(n = 22 192)
Excluded infants (n = 763)
Distal determinants
Religion of head of household
  Christian 15 616 (69.8) 363 (61.1) 15 497 (69.8) 482 (63.2)
  Muslim 5 333 (23.8) 178 (30.0) 5 294 (23.9) 217 (28.4)
  None/traditional/other 1 412 (6.3) 53 (8.9) 1401 (6.3) 64 (8.4)
Ethnicity of household
  Akan 10 470 (46.8) 223 (37.5) 10 410 (46.9) 283 (37.1)
  Other 11 891 (53.2) 371 (62.5) 11 782 (53.1) 480 (62.9)
Socioeconomic statusa
  1 (poorest) 4 356 (19.5) 155 (26.1) 4 299 (19.4) 212 (27.8)
  2 4 407 (19.7) 143 (24.1) 4 363 (19.7) 187 (24.5)
  3 4 469 (20.0) 113 (19.0) 4 440 (20.0) 142 (18.6)
  4 4 544 (20.3) 100 (16.8) 4 523 (20.4) 121 (15.9)
  5 (richest) 4 585 (20.5) 83 (14.0) 4 567 (20.6) 101 (13.2)
Maternal occupation
  Government/private/other 1 200 (5.4) 25 (4.2) 1 199 (5.4) 26 (3.4)
  Self-employed 8 752 (39.1) 194 (32.7) 8 716 (39.3) 230 (30.1)
  Farming 6 472 (28.9) 199 (33.5) 6 411 (28.9) 260 (34.1)
  Not working 5 937 (26.6) 176 (29.6) 5 866 (26.4) 247 (32.4)
Maternal education
  None 6 913 (30.9) 214 (36.0) 6 845 (30.8) 282 (37.0)
  Primary school 4 115 (18.4) 121 (20.4) 4 081 (18.4) 155 (20.3)
  Secondary/tertiary 11 333 (50.7) 245 (41.2) 11 266 (50.8) 312 (40.9)
  Missing values 0 (0.0) 14 (2.4) 0 (0.0) 14 (1.8)
Season when vaccine due: wet 14 176 (63.4) 382 (64.3) 10 406 (46.9) 347 (45.5)
Infant sex: female 11 025 (49.3) 281 (47.3) 10 938 (49.3) 368 (48.2)
Intermediate determinants
Maternal age (years)
  < 20 2 550 (11.4) 95 (16.0) 2 514 (11.3) 131 (17.2)
  20–24 5 714 (25.6) 173 (29.1) 5 657 (25.5) 230 (30.1)
  25–29 6 017 (26.9) 137 (23.1) 5 986 (27.0) 168 (22.0)
  30–34 4 522 (20.2) 95 (16.0) 4 497 (20.3) 120 (15.7)
  ≥ 35 3 558 (15.9) 64 (10.8) 3 538 (15.9) 84 (11.0)
  Missing value 0 (0.0) 30 (5.1) 0 (0.0) 30 (3.9)
No. of children in family
  0–1 6 516 (29.1) 216 (36.4) 6 450 (29.1) 282 (37.0)
  2–3 8 946 (40.0) 209 (35.2) 8 887 (40.0) 268 (35.1)
  ≥ 4 6 899 (30.9) 169 (28.5) 6 855 (30.9) 213 (27.9)
Maternal illness: yes 1 093 (4.9) 30 (5.1) 1 090 (4.9) 33 (4.3)
Distance from health facility 
(km)
  < 1.0 13 545 (60.6) 342 (57.6) 13 461 (60.7) 436 (57.1)
  1.0–4.9 5 147 (23) 117 (19.7) 5 106 (23.0) 151 (19.8)
  ≥ 5.0 3 669 (16.4) 133 (22.4) 3 625 (16.3) 169 (22.1)
  Missing value 0 (0.0) 2 (0.3) 0 (0.0) 7 (0.9)
Place of birth: health facility 17 155 (76.7) 426 (71.7) 17 047 (76.8) 534 (70.0)
Multiple birth 795 (3.6) 52 (8.8) 784 (3.5) 63 (8.3)
(continues. . .)
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weighing ≥ 2.5 kg at birth; 8.3 weeks 
(IQR: 6.9–9.9) for those 2.0–2.4 kg; 
8.4 weeks (IQR: 6.9–10.7) for those 
1.5–1.9 kg and 9 weeks (IQR: 7.4–11.9) 
for those < 1.5 kg. For DTP3, the cor-
responding median ages at vaccination 
were 18.4 weeks (IQR: 16.3–22.1), 18.6 
weeks (IQR: 16.6–22.3), 19.6 weeks 
(IQR: 16.6–23.3) and 20.4 weeks (IQR: 
17.7–25.1), respectively.
The Kaplan–Meier curves showed 
that DTP1 vaccination rates over the 
days since birth were also lower for 
infants weighing < 1.5 kg and those 
weighing 1.5–1.9 kg compared with 
those weighing ≥ 2.5 kg (Fig. 3). After 
adjustment for other variables, there 
was evidence of progressively delayed 
vaccination with decreasing birth 
weight (P-value for trend < 0.0001). 
Infants weighing < 1.5 kg at birth had 
a DTP1 vaccination rate approximately 
40% lower than non-low-birth-weight 
infants by the age of 10 weeks (ad-
justed rate ratio, aRR: 0.58; 95% CI: 
0.43–0.77) and age 18 weeks (aRR: 
0.63; 95% CI: 0.50–0.80). Infants 
weighing 1.5–1.9 kg had vaccina-
tion rates approximately 25% lower 
than non-low-birth-weight infants 
at these time points (aRR: 0.71; 95% 
CI: 0.62–0.81 and aRR: 0.76; 95% CI: 
0.69–0.85, respectively; Table 2, avail-
able at: http://www.who.int/bulletin/
volumes/94/5/15-159699).
Similar results were observed for 
DTP3 (Fig. 3). The findings were also 
similar for DTP1 and DTP3 vaccination 
at 8 weeks after the due date (Table 2).
Adjusting for illness had little effect 
on the magnitude of the association be-
tween birth weight and vaccination for 
both DTP1 and DTP3 (Table 2).
Other variables
Younger maternal age, lower educational 
attainment, and longer distance to the 
nearest health facility were associated 
with moderate reductions in the DTP1 
and DTP3 vaccination rates of approxi-
mately 10–20% at ages 10 and 18 weeks, 
whereas higher employment grade was 
associated with moderate increased 
vaccination rates at these ages (Table 3, 
available at: http://www.who.int/bulw-
letin/volumes/94/5/15-159699). In the 
final model (after adjusting for potential 
mediating variables) low socioeconomic 
status of mothers was associated with a 
15% increased DTP3 vaccination rate 
at 18 weeks, whereas no association 
with DTP1 vaccination was observed. 
Muslim religion and larger family size 
were associated with > 10% reduction 
in DTP3 vaccination rates but had no, 
or only a small, association with DTP1 
vaccination rates. None of the other 
variables measured had notable associa-
tions with DTP1 or DTP3 vaccination 
rates at any ages.
Sensitivity analyses
Adjusting for late vaccination with 
DTP1 decreased the effect size for the 
association between birth weight and 
the rate of DTP3 vaccination for infants 
weighing 1.5–1.9 kg (12 weeks after 
DTP1 aRR: 0.98; 95% CI: 0.85–1.13) 
compared with an aRR of 0.82 (95% CI: 
0.73–0.92) at 12 weeks after the DTP3 
due date, but the effect size for infants 
weighing < 1.5 kg was largely unchanged 
(Table 2).
Excluding unvaccinated infants 
whose written record was never seen had 
little impact on the effect size of the ex-
planatory variables for DTP1 or DTP3.
Modifying factors
When we looked at other factors that 
might modify the association between 
birth weight and delayed vaccination 
there was no evidence that the effect of 
birth weight on vaccination with DTP1 
or DTP3 varied by socioeconomic status 
(P-values for interaction all > 0.4), or 
that the rate of vaccination with DTP1 
varied by maternal education, when 
measured at age 10 weeks (P = 0.3338) 
or age 18 weeks (P = 0.2675). How-
ever, for DTP3 vaccination there was 
some evidence that the effect of birth 
weight on the vaccination rate at age 
18 weeks (P = 0.0219) and age 26 weeks 
(P = 0.0813) varied with maternal edu-
cation, with a more pronounced reduc-
tion in vaccination rate among smaller 
infants born to mothers with higher 
educational attainment (aRR for infants 
weighing < 1.50 kg at age 18 weeks: 0.37; 
95% CI: 0.19–0.72; aRR at 26 weeks: 
0.63; 95% CI: 0.50–0.80). When infants 
with delayed receipt of DTP1 were ex-
cluded from the analysis, this effect was 
no longer apparent.
Discussion
The results of this study provide evi-
dence that low-birth-weight infants 
in Ghana are vaccinated later than 
non-low-birth-weight infants. The ef-
Characteristic No. (%)
DTP1 DTP3
Included infants 
(n = 22 361)
Excluded infants 
(n = 594)
Included infants 
(n = 22 192)
Excluded infants (n = 763)
Distal determinants
Birth weight (kg)
  ≥ 2.5 18 979 (84.9) 382 (64.3) 18 850 (84.9) 511 (67.0)
  2.0–2.4 2 916 (13.0) 115 (19.4) 2 886 (13.0) 145 (19.0)
  1.5–1.9 386 (1.7) 58 (9.8) 378 (1.7) 66 (8.7)
  < 1.5 80 (0.4) 37 (6.2) 78 (0.4) 39 (5.1)
  Missing value 0 (0.0) 2 (0.3) 0 (0.0) 2 (0.3)
Mediating variables
Infant illness: yes 2 748 (12.3) 155 (26.1) 3 429 (15.5) 277 (36.3)
  Missing value 0 (0.0) 261 (43.9) 0 (0.0) 329 (43.1)
DTP1: first dose of diphtheria–tetanus–pertussis vaccine; DTP3: third dose of diphtheria–tetanus–pertussis vaccine.
a  Socioeconomic status was calculated by principal components analysis from an inventory of household assets.
(. . .continued)
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fect persisted up to 12 weeks after the 
vaccination due date and was evident 
for both DTP1 and DTP3, even after 
controlling for other determinants of 
delayed vaccination.
The results are consistent with 
previous reports from high-income 
countries of delayed vaccination in 
low-birth-weight infants.10,11,20–22 In ad-
dition, a study of low-birth-weight in-
fants in Guinea-Bissau, which did not 
look at timeliness, reported lower up-
take of DTP1 at 8 weeks of age among 
smaller low-birth-weight infants 
compared with larger low-birth-weight 
infants.23 A North American study re-
ported that both parents and vaccine-
providers had erroneous beliefs that 
initiation of vaccination depended 
on the degree of prematurity and the 
infant’s weight.22 In addition, a review 
of 47 studies in the grey literature 
from low-income settings reported 
parental reluctance to bring sick, weak 
or malnourished children for vaccina-
tion for reasons of social stigma and 
fatalism; these have also been cited as 
reasons for non-vaccination by vaccine 
providers.19
Low-birth-weight infants in low-
income settings are known to have 
higher rates of illness and death in 
the first year of life than non-low-
birth-weight infants.15,24–27 Data from 
high-income settings indicate that they 
also have higher rates of illness from 
vaccine-preventable diseases.2–4,6 The 
risk and consequences of illness related 
to vaccine-preventable diseases in low-
birth-weight infants in low-income 
settings is not known and may differ 
from those in high-income settings. 
Without this information it is difficult 
to fully understand the implications 
of delayed vaccination on clinical out-
comes for these infants. However, we do 
know that delayed vaccination of these 
infants will prolong their risk period for 
contracting these diseases and may also 
reflect an underuse of health services 
by the caregivers of these infants. Given 
this increased risk of illness and death, 
it is essential that all opportunities for 
vaccination and health care for low-
birth-weight infants be exploited.
We also identified several addi-
tional determinants of delayed vaccina-
tion – low maternal age and educational 
attainment and longer distance to the 
nearest health facility – that reflect 
persisting inequities in access to and 
uptake of vaccination in our study 
population. This is consistent with 
previous findings from the study area16 
and the issue of inequities in coverage 
of vaccination have featured in global 
vaccine policy.28
The strengths of our study include 
the high quality population-based sur-
veillance system and low loss to follow-
up. Almost all infants were weighed 
within 72 hours of delivery by trained 
fieldworkers using calibrated scales, thus 
minimizing the likelihood of misclassi-
fication of infants by birth weight. Simi-
larly, we collected high quality data on 
vaccination – from both written records 
and maternal recall – and we employed 
a rigorous approach to resolving incon-
sistencies in these data. Although recall 
data is used in the generation of routine 
vaccine uptake estimates,29 their validity 
may vary.30,31 The validity of our recall 
data was maximized by the continuous 
nature of the data collection in our study. 
Infants with recall data accounted for 
less than 0.6% of all infants included 
in the analyses and had little impact on 
our estimates. Furthermore, the inclu-
sion of over 22 000 infants ensured that 
the study had sufficient power to show 
effects in small subgroups.
Aspects of this study that may have 
affected the generalizability of our find-
ings are that our study sample may have 
experienced more timely vaccination 
Fig. 3. Time to vaccination with first dose and third dose of diphtheria–tetanus–
pertussis vaccine, by birth weight in the prospective cohort study in rural Ghana, 
2010–2013
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Bull World Health Organ 2016;94:442–451D| doi: http://dx.doi.org/10.2471/BLT.15.159699448
Research
Delayed vaccination of infants in Ghana Maureen O’Leary et al.
compared with the general population. 
A higher proportion of low-birth-weight 
infants than non-low-birth-weight in-
fants were excluded from our analyses, 
either because they did not meet the in-
clusion criteria for enrolment in the trial 
or because more of them were lost to 
follow-up or had missing data (including 
missing vaccination data) than non-low-
birth-weight infants. Those excluded 
could have experienced greater delay in 
receiving their vaccines compared with 
the included low-birth-weight infants, 
possibly causing some underestimation 
of the association between low birth 
weight and timely vaccination in our 
population. As less than 5% of enrolled 
infants were excluded, this was unlikely 
to have changed the results appreciably 
and important delays in vaccination 
were still observed among low-birth-
weight infants. Mothers of enrolled 
infants were asked about their infant’s 
vaccination status at monthly visits, 
possibly increasing their awareness of 
the need to vaccinate their infants. This 
increased awareness, however, would 
not have been differentially affected by 
birth weight and would lead to an overall 
underestimation of delayed vaccination.
Other limitations are that we did 
not have reliable data on gestational 
age and therefore we were not able to 
assess whether delayed vaccination 
was associated with prematurity or 
whether all low-birth-weight infants 
were affected regardless of gestational 
age. This study was also not designed to 
assess the association between delayed 
vaccination and clinical outcomes such 
as vaccine-preventable diseases or hos-
pitalizations. Consequently, we do not 
know whether those infants who had 
delayed vaccination were more likely to 
contract vaccine-preventable diseases 
or to report elevated rates of illness or 
hospitalization. Eleven explanatory vari-
ables were included in our secondary 
analysis, thus increasing the potential 
for type 1 errors (finding statistically 
significant results by chance alone). 
Finally, we did not collect any qualita-
tive data on the reasons for delayed 
vaccination of low-birth-weight infants 
in our study sample. This limits our 
interpretation of the findings. It may be 
that vaccination was delayed for reasons 
beyond the control of both the caregiv-
ers and the vaccine providers, such as 
lack of vaccines or staff, although it is 
reasonable to assume that these would 
not be distributed differently among 
low-birth-weight compared with non-
low-birth-weight infants.
Recommendations
Current global policy on vaccination 
advocates the identification of groups 
that are underserved by vaccination,28 
yet data on uptake and timeliness of 
vaccination in low-birth-weight infants 
are not currently included in routine 
evaluations of vaccination programmes. 
These data are feasible to collect in 
low-income settings; doing this would 
contribute to a more comprehensive 
evaluation of the performance of vac-
cination programmes and would inform 
the development of strategies to improve 
uptake and timing of vaccination in all 
countries.28 Even though several or-
ganizations in high-income countries 
have made specific recommendations 
about vaccination of low-birth-weight 
infants,9,32 international guidelines are 
lacking.
Efforts to improve the vaccina-
tion of low-birth-weight infants, for 
example by education of caregivers and 
vaccine-providers, are warranted. Fur-
ther research is needed in low-income 
countries to understand the reasons for 
delayed vaccination of low-birth-weight 
infants and to inform strategies to im-
prove the timeliness of vaccination. ■
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صخلم
 :اناغ في ةيفيرلا قطانلما في ةمزلالا تاحاقلل ةدلاولا دنع نزولا ضيفخنم عضرلا لافطلأا يقلت ديعاوم ديدتح
ةيناكس تاعاطق لىع ةمئاق ةيقابتسا ةيبارتأ ةسارد
 حاقللا نم ةثلاثلاو لىولأا ةعرلجا يقلت في رخأتلا ءاصقتسا ضرغلا
 يثلاثلا حاقللا ةعرج( يكيدلا لاعسلاو سوناتيتلاو ايترفدلا دض
 دنع  نزولا  ضيفخنم  عضرلا  لافطلأا  دنع  )DTP3و  DTP1
.كلذب ةطبترلما تاددحلماو ،اناغ في ةدلاولا
 يتلا  فلأ  ينماتيف  ةبرتج  نم  ةدمتسلما  تانايبلا  انمدختسا  ةقيرطلا
 نم ةترفلا  في اهؤارجإ مت يتلاو ةنيعم ةيناكس تاعاطق لىإ دنتست
 اًسايق انيرجأ .هليجست مت عيضر 22,955  لىع 2013  لىإ 2010
 لافطلأاو  تاهملأاب  ةقلعتلما  صئاصلخاو  حاقللا  يقلت  لدعلم
 عضرلا  لافطلأا  نم حئاشر ثلاث ينب  ةنراقم  انيرجأ  ماك  ،عضرلا
 ؛غلك 1.9 – 1.5و ؛غلك 2.4 – 2.0( ةدلاولا دنع نزولا ضيفخنم
 منهزو غلبي نمم عضرلا لافطلأاو بناج نم )غلك 1.5 نم لقلأاو
 جذومن مادختسا متو .رخآ بناج نم كلذ نع ديزي وأ غلك 2.5
 ةعرج نأشب حاقللا يقلت لدعم بسن باستحلا نوساوبل فوحتلا
 دعب  اًعوبسأ  18و  14و  10  غولب  دنع  DTP1  يثلاثلا  حاقللا
 22و 18 غولب دنع DTP3 يثلاثلا حاقللا ةعرج نأشبو ،ةدلاولا
 اًعوبسأ 14و 6 رورم دعب رهشأ 3و 2و 1 يواسي ماب( اًعوبسأ 24و
.)لياوتلا لىع ةروكذلما تاحاقللا يقلت بوجو خيراوت لولح دعب
 دنع  DTP1  يثلاثلا  حاقللا  ةعرج  يقلت  لدعم  ناك  جئاتنلا
 )3382  =  ددعلا(  ةدلاولا  دنع  نزولا  ضيفخنم  عضرلا  لافطلأا
 نوناعي لا نمم عضرلا لافطلأاب ًةنراقم 40% نم برقت ةبسنب لقأ
 في  كلذو  ،)18,979  =  ددعلا(  ةدلاولا  دنع  نزولا  ضافخنا  نم
 ةبسنو  ؛aRR: 0.58  ،ةححصلما  لدعلما  ةبسنب(  عيباسأ  10  رمع
 اًعوبسأ 18 غولب دنعو )0.77 – 0.43 :% 95 اهرادقم ةيحجرأ
 .)0.80–0.50 :% 95  اهرادقم ةيحجرأ ةبسنو ؛aRR: 0.63(
 منهزو غلبي نمم عضرلا لافطلأا دنع حاقللا يقلت تلادعم تناكو
 ًةنراقم  25%  نم  برقت  ةبسنب  لقأ  )386  =  ددعلا(  1.9  -  1.5
 تاقولأا  في  رثكأ  وأ  غلك  2.5  منهزو  غلبي  نمم  عضرلا  لافطلأاب
 ةعرجب  قلعتي  مايف  كلذل  ةبهاشم  جئاتن  تظحول  دقو  .ةروكذلما
 ،تاهملأا نس رغص ينب طابترا ةمث ناكو .DTP3 يثلاثلا حاقللا
 برقأ  لىإ  لوصولل  ةمزلالا  ةفاسلما  دعبو  ،نهميلعت  ةدم  صرقو
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 حاقللا  ةعرج يقلت  تلادعم ضافخناو بناج نم ةيحص ةأشنم
.رخآ بناج نم DTP3و DTP1 يثلاثلا
 ةدلاولا  دنع  نزولا  وضفخنم  عضرلا  لافطلأا  لثمي  جاتنتسلاا
 يقلت  رخأتب  قلعتي  مايف  رطلخا  نم  ةيلاع  ةجردل  ةضرعم  ةعوممج
 زيزعتل  دوهلجا  لذب  ةجالحا  ضيتقتو  .اناغ  في  ةمزلالا  تاحاقللا
 نم ديزلما ءارجإ بناج لىإ ،تاحاقلل عضرلا لافطلأا ءلاؤه يقلت
.كلذ في رخأتلا بابسأ كاردلإ ثوحبلا
摘要
加纳农村地区低出生体重婴儿疫苗接种时间 ： 基于群体的前瞻性定群研究
目的 旨在调查加纳低出生体重婴儿在进行第一次和第
三次白喉、破伤风、百日咳（DTP1 和 DTP3）疫苗接
种时的延误情况和相关因素。
方 法 我 们 所 采 用 的 数 据 来 源 于 2010-2013 年 间
在 22 955 名接受调查的婴儿中开展的基于群体的大规
模维生素 A 试验。 我们衡量了疫苗接种率和母亲及
婴儿特征，并将三类低出生体重婴儿（2.0–2.4 公斤 ；
1.5–1.9 公斤 ；和不足 1.5 公斤）与出生体重大于或等
于  2.5 公斤的婴儿相比较，并在出生 10、14 和 18 周
后使用泊松回归分析计算 DTP1 疫苗接种率，在 18、
22 和 24 周后计算 DTP3 接种率【相当于两个接种截
止日期（即 6 周和 14 周）后的第 1、2 和第 3 个月】。
结 果 低 出 生 体 重 婴 儿 (n = 3382) 在 第 10 周
时 的 DTP1 接 种 率 大 约 比 非 低 出 生 体 重 婴
儿 (n = 18 979) 低 40% （ 调 整 后 的 优 势 比，aRR: 
0.58; 95% CI: 0.43–0.77），第 18 周 (aRR: 0.63; 95% CI: 
0.50–0.80)。 在所取时间节点，体重在 1.5–1.9 公斤
的婴儿 (n = 386) 接种率大约比体重大于或等于  2.5 公
斤 的 婴 儿 低 25%。 DTP3 的 观 察 结 果 相 似。 较 低
的 DTP1 和 DTP3 接种率与孕产年龄较低、受教育程
度较低和距离最近的医疗机构较远有关。
结论 低出生体重儿童是加纳接种延迟的高危人群。 
努力提高这些婴儿的免疫接种率是必要的，同时开展
进一步调查，以了解延误原因。
Résumé
Âge de vaccination des nourrissons au faible poids de naissance dans les zones rurales du Ghana: une étude prospective de 
cohorte menée dans la population
Objectif Examiner les retards d’administration de la première et de 
la troisième dose de vaccin diphtérie–tétanos–coqueluche (DTP1 et 
DTP3) chez les nourrissons au faible poids de naissance au Ghana, 
ainsi que les déterminants associés.
Méthodes Nous avons utilisé les données issues d’un vaste essai 
sur la vitamine A, mené dans la population en 2010–2013, et qui 
portait sur 22 955 nourrissons. Nous avons déterminé le taux de 
vaccination ainsi que les caractéristiques des mères et des enfants 
et avons comparé trois catégories de nourrissons au faible poids de 
naissance (2,0–2,4 kg; 1,5–1,9 kg; et < 1,5 kg) avec des nourrissons 
pesant ≥ 2,5 kg. Une régression de Poisson nous a permis de calculer 
les ratios des taux de vaccination pour le DTP1 à 10, 14 et 18 semaines 
après la naissance et, pour le DTP3, à 18, 22 et 24 semaines (ce qui 
équivaut respectivement à 1, 2 et 3 mois après l’âge normal de 
vaccination qui est de 6 et 14 semaines).
Résultats Comparés aux nourrissons n’ayant pas un faible poids de 
naissance (n = 18 979), ceux au faible poids de naissance (n = 3382) 
avaient un taux de vaccination DTP1 presque 40% plus faible à l’âge 
de 10 semaines (ratio des taux ajusté, RTa: 0,58; IC 95%: 0,43–0,77) et 
à l’âge de 18 semaines (RTa: 0,63; IC 95%: 0,50-0,80). Les nourrissons 
pesant de 1,5 à 1,9 kg (n = 386) avaient un taux de vaccination à ces 
âges environ 25% plus faible que ceux pesant ≥ 2,5 kg. Des résultats 
similaires ont été observés pour le DTP3. Le plus jeune âge des 
mères, leur niveau d’instruction et les distances plus longues jusqu’à 
l’établissement de soins le plus proche étaient associés à de plus 
faibles taux de vaccination DTP1 et DTP3.
Conclusion Les nourrissons au faible poids de naissance sont un 
groupe à haut risque en matière de retard de vaccination au Ghana. 
Des efforts devraient être entrepris pour améliorer la vaccination 
de ces enfants, parallèlement à d’autres recherches permettant de 
comprendre les raisons de ce retard.
Резюме
Сроки проведения вакцинации в сельской местности Ганы для грудных детей со сниженной массой 
тела при рождении: популяционное проспективное когортное исследование
Цель Изучить несоблюдение сроков первой и третьей 
вакцинации против дифтерии, коклюша и столбняка (АКДС1 и 
АКДС3) грудных детей со сниженной массой тела при рождении 
в Гане и связанные с этим определяющие факторы.
Методы Были использованы данные, полученные в результате 
обширного популяционного исследования приема витамина A, 
которое проводилось в 2010–2013 гг. при участии 22 955 грудных 
детей. Был определен охват вакцинацией матерей и грудных 
детей, были выявлены их характеристики, и были сопоставлены 
три категории грудных детей со сниженной (≥2,5 кг) массой тела 
при рождении: 2,0–2,4; 1,5–1,9 и <1,5 кг. С помощью регрессии 
Пуассона были подсчитаны отношения рисков вакцинации 
для вакцинации АКДС1, проведенной на 10, 14 и 18-й неделе 
после рождения, и для вакцинации АКДС3, проведенной на 18, 
22 и 24-й неделе (что соответствует задержке на 1, 2 и 3 месяца 
по сравнению с установленными сроками такой вакцинации, 
проводимой на 6-й и 14-й неделях).
Результаты Для младенцев, имевших сниженную массу 
тела при рож дении (n = 3382) ,  охват  вакцинацией 
АКДС1 был приблизительно на 40% ниже по сравнению 
с  ос тальными м ладенцами (n  = 18 979)  в  возрас те 
10 недель (стандартизированное отношение рисков, СОР: 0,58; 
95%-й ДИ: 0,43–0,77) и в возрасте 18 недель (СОР: 0,63; 95%-й 
ДИ: 0,50–0,80). Охват вакцинацией для младенцев с массой тела 
Bull World Health Organ 2016;94:442–451D| doi: http://dx.doi.org/10.2471/BLT.15.159699450
Research
Delayed vaccination of infants in Ghana Maureen O’Leary et al.
1,5–1,9 кг (n = 386) был приблизительно на 25% ниже, чем для 
младенцев с массой тела ≥2,5 кг на тот же момент времени. 
Такие же результаты были получены для АКДС3. Более молодой 
возраст и меньший уровень образования матери, а также 
большее расстояние до ближайшего медицинского учреждения 
коррелировали с меньшим охватом вакцинациями АКДС1 и 
АКДС3.
Вывод Грудные дети со сниженной массой тела при рождении 
входят в группу высокого риска несоблюдения сроков 
вакцинации в Гане. Требуется предпринять меры для повышения 
охвата вакцинацией этих грудных детей, а также провести 
дополнительные исследования для понимания причин задержек.
Resumen
Cronograma de vacunación de los recién nacidos con insuficiencia ponderal en la Ghana rural: un estudio poblacional de 
cohortes prospectivo
Objetivo Investigar los retrasos de la primera y tercera dosis de la vacuna 
contra la difteria, el tétanos y la tos ferina (DTP1 y DTP3) en recién nacidos 
con insuficiencia ponderal en Ghana, así como los determinantes 
relacionados con las mismas.
Métodos En 2010–2013, se utilizaron datos de un ensayo poblacional 
de vitamina A a gran escala basado en la población con 22 955 recién 
nacidos inscritos. Se midió la tasa de vacunación y las características 
tanto de las madres como de los recién nacidos, y se compararon tres 
categorías de recién nacidos con insuficiencia ponderal (2,0–2,4 kg; 
1,5–1,9 kg; y < 1,5 kg) con recién nacidos con un peso de ≥ 2,5 kg. Se 
utilizaron modelos de regresión de Poisson para calcular los coeficientes 
de la tasa de vacunación para DTP1 las semanas 10, 14 y 18 después 
del nacimiento, y para DTP3 las semanas 18, 22 y 24 (lo que equivale 
a 1, 2 y 3 meses tras las fechas de vencimiento de las vacunaciones 
correspondiente de las semanas 6 y 14).
Resultados En comparación con los recién nacidos sin insuficiencia 
ponderal (n = 18 979), los que nacieron con bajo peso (n = 3 382) tenían 
una tasa de inmunización sistemática de DTP1 casi un 40% inferior a 
la edad de 10 semanas (razón de tasa ajustada, aRR: 0,58; IC del 95%: 
0,43–0,77) y a la edad de 18 semanas (aRR: 0,63; IC del 95%: 0,50–0,80). 
Los recién nacidos con un peso de 1,5–1,9 kg (n = 386) tenían unas 
tasas de vacunación de alrededor de un 25% inferior a los que pesaban 
≥ 2,5 kg a la misma edad. Para DTP3 se observaron los mismos resultados. 
Se asociaron la juventud maternal, el bajo nivel educativo y la larga 
distancia hasta la instalación sanitaria más cercana con las bajas tasas 
de vacunación de DTP1 y DTP3.
Conclusión Los recién nacidos con insuficiencia ponderal se encuentran 
en un grupo de alto riesgo para sufrir un retraso de la vacunación en 
Ghana. Se han garantizado esfuerzos para mejorar la vacunación de 
estos recién nacidos, junto con una investigación más profunda para 
comprender las razones de dichos retrasos.
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5.3. CONSIDERATIONS INFLUENCING THE STUDY DESIGN 
As discussed in Chapter 1, standard reporting of vaccine uptake at 52 weeks of age does 
not capture uptake rates among infants who die before reaching 52 weeks of age and who 
may be more likely to be under-vaccinated. These infants may also be more likely to be 
LBW. Similarly, any effect of birth weight on vaccination rate may be most apparent earlier 
in life, before LBW babies have had a chance to catch up with their growth. 
As uptake rates among LBW infants are not routinely reported, there are no 
recommendations on appropriate indicator vaccines that could facilitate an assessment of 
their vaccination status and that would capture lower rates of vaccination among LBW 
infants. For this group of infants, an earlier indicator of uptake may be more appropriate. 
5.3.1. Selection of DTP1 and DTP3 as indicator vaccines 
With the above issues in mind, I chose to use DTP1 and DTP3 vaccines as indicator vaccines 
for adherence to the routine infant vaccination schedule. Both DTP1 and DTP3 are 
scheduled to be given relatively early in life, with DTP1 scheduled at 6 weeks of age, and 
DTP3 at 14 weeks of age. I therefore reasoned that these vaccines would be good indicators 
for assessing any effect of birth weight on adherence to the schedule. I decided to analyse 
time to vaccination rather than uptake at specific ages, so that so all infants would 
contribute person-time for as long as they were in follow-up, and so that I could maximise 
the inclusion of infants (including LBW infants) in the analyses. In addition, DTP3 is one of 
the most commonly reported indicators in vaccine programme evaluation. By investigating 
DTP3 vaccination, I was able to relate my findings to other published data. 
5.3.2. Defining the risk periods for the analyses 
Given the changing nature of both infant weight and vaccination uptake over time, the 
choice of time-point for measuring delayed vaccination was critical in order to capture the 
effect of fragility associated with birth weight. Consequently, I chose to measure time to 
vaccination at a number of progressively later time points (four, eight and twelve weeks 
after the due date for vaccination). The selection of these time points was justified for a 
number of reasons. A vaccination delay of 12 weeks or more after the due date is very late 
for the administration of a vaccine, and represents a noteworthy deviation from the 
schedule. Furthermore, WHO recommends that the full DTP schedule be completed by six 
months of age in areas where pertussis is especially a risk to young infants28. A 12-week 
delay in the administration of either DTP1 or DTP3 would result in an infant not completing 
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the DTP schedule by this time point. Finally, as well as being sensitive time-points to 
capture any effect of birth weight, this approach also allowed me to consider the changing 
effect of birth weight on vaccination over time. 
5.4. CONSIDERATIONS IN THE CHOICE OF ANALYTICAL METHODOLOGY 
As discussed in Section 1.5.4, LBW infants were expected to have higher rates of mortality, 
and this was confirmed in the analyses reported in Chapter 4.  
As mentioned above, my outcomes for these analyses (vaccination with DTP1 and DTP3) 
were likely to vary over time. I generated Kaplan Meier curves of time to vaccination to 
describe and compare the probability of vaccination among LBW and NLBW infants over 
time. Cox regression is a commonly used approach for regression analysis of time-varying 
outcome data, particularly outcomes that vary rapidly over time. Although vaccination does 
vary over time, I did not expect the rate to change so rapidly within the time-periods of 
interest (up to 12 weeks after the vaccine due date) to necessitate the use of Cox 
regression. Cox regression does not allow for the estimation of underlying rates, and for this 
reason, I opted to use Poisson regression to calculate adjusted vaccination rate ratios of the 
association between birth weight and vaccination, and for the investigation of other 
determinants of vaccination. I split the follow-up time into one month intervals to create a 
time variable, and I included this time-variable in all of the multivariable models to adjust 
for variations in vaccination rate by infant-age. I used a causal modelling approach to model 
building, as described in Section 3.7.3. I repeated the analysis of the final multivariable 
model using Cox regression. There was little difference in the effect estimates generated by 
Poisson and Cox regression (Table A5.1, Appendix 5.1). 
5.5. DID THE CATEGORISATION OF INFANTS BY VACCINATION STATUS 
BIAS THE ESTIMATES OF ASSOCIATION? 
As explained in the paper, in these analyses, I defined the end of follow up as the 
vaccination date for vaccinated infants, and the end of the risk period for unvaccinated 
infants not lost-to-follow-up. For those lost-to-follow-up before the end of the risk period, I 
defined the end of follow-up as a) the last date the written record was viewed for 
unvaccinated infants whose record was viewed, b) the last date the infant was seen for 
unvaccinated infants whose record was never viewed or c) the date of death for 
unvaccinated infants who died before the end of the risk period and whose record was 
 145 
 
viewed after their death. An illustrated example for DTP1 vaccination is given (Figure 5.1). 
Infants with unknown vaccination status did not contribute any follow-up time to the 
analyses. 
Figure 5.1: Defining the follow-up period for the analysis of time to DTP1 vaccination, based 
on vaccination status & duration of follow-up 
  
Throughout the first year of life LBW infants were consistently over-represented among 
infants who died (Table 5.1).   
Table 5.1: Percentage of LBW and NLBW infants who died per month 
 
1.  one death with unknown birth weight 
2. % of all LBW infants 
3 % of all NLBW infants 
 
As explained in Section 5.4, the use of Poisson regression allowed me to maximize the 
retention of infants who died and who had a known vaccination status in my analyses, thus 
minimizing any bias associated with the excess rates of mortality among these LBW infants. 
However, using DTP1 as an example, it is evident that infants who died were also more likely 
A
B
C
Last date 
card seen
D
Last date 
infant seen
E
Date of 
death
F
Date of 
death
0 6 10 52
Age (weeks) Due date 
DTP1
Outcome 
measured
A. Vaccinated, date known Time in follow-up
B. Not vaccinated, not lost to follow-up
C. Unvaccinated, LTFU, card seen Card seen
D. Unvaccinated, LTFU, card never seen
E. Infant died, unvaccinated, card seen after death
F. Infant died, card not seen, vaccination status unknown, followed up but did not contribute time to the analysis
 Deaths1 
Age in Days LBW n/N (%)2 Non-LBW n/N (%)3 
0-27 137/3440 (3.8) 150/19141 (0.8) 
28-59 33/3400 (4.8) 54/19054 (1.1) 
60-89 10/3381 (5.0) 24/18997 (1.2) 
90-119 14/3359 (5.4) 28/18936 (1.3) 
120-149 15/3329 (5.9) 19 (18893 (1.4) 
150-179 15/3311 (6.3) 26/18827 (1.6) 
180-209 6/3294 (6.5) 29/18772 (1.7) 
210-239 7/3275 (6.7) 26/18704 (1.9) 
240-269 10/3254 (6.9) 26/18639 (2.0) 
270-299 6/3240 (7.1) 13/18583 (2.1) 
300-329 8/3222 (7.3) 24/18494 (2.2) 
330-365 4/3196 (7.5) 14/18377 (2.3) 
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to be categorised as vaccination status unknown (Table 5.2), and therefore to be excluded 
from the analyses.  
Overall, 46% (323/699) of infants who died in the first year of life died before they were 
eligible for vaccination. These infants were not included in the analysis. Of the 323 who died 
before they were eligible for vaccination, most (215, 67%) were vaccination status unknown 
(Table 5.2).  
Table 5.2: DTP1 vaccination status by vital status and follow-up status 
  Vaccination Status 
 A. 
Total  
Card seen, 
vaccinated, 
date 
known 
Card seen, 
date 
unknown, 
vaccination 
date 
imputed 
Card seen, 
known not 
vaccinated 
Reported as 
not 
vaccinated, 
card not seen 
Status 
unknown 
(% of A. 
total) 
All infants 22955 22104 33 288 125 404 (1.8) 
Live infants 22256 21805 33 181 58 179 (0.8) 
Died (all) 699 299 0 107 67 226 (32) 
Died < 6 weeks 323 1 0 56 51 215 (67) 
Died 6-10 weeks 59 9 0 32 11 7 (12) 
Died 6-14 weeks 97 38 0 41 11 7 (7) 
Died 6-18 weeks 134 68 0 46 12 8 (6) 
LTFU < 6 weeks 615 9 0 77 125 404 (66) 
LTFU 6-10 weeks 169 65 0 104 0 0 (0) 
LTFU 6-14 weeks 3481 213 1 134 0 0 (0) 
LTFU 6-18 weeks 5221 374 1 147 0 0 (0) 
 
Discounting these ineligible infants, the number of infants who died in the risk periods used 
for the DTP1 analyses were small. For example, 134 infants (0.6% of all enrolled infants) 
died between 6 and 18 weeks of age (Table 5.2). A further 179 infants who did not die (0.8% 
of all enrolled infants) were also vaccination status unknown (Table 5.2). Given the small 
numbers involved, the fact that LBW infants were more likely to die and were more likely to 
be categorised as vaccination status unknown is unlikely to have had any great impact on 
the generalisability of the results. 
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5.6. DID INCLUDING INFANTS WITH MISSING VACCINATION CARDS 
BIAS THE ESTIMATES OF THE ASSOCIATION BETWEEN BIRTH WEIGHT 
AND VACCINATION?  
As discussed in Section 3.2, I categorised infants whose vaccination card was never seen, 
and who were consistently reported as never having been vaccinated, as not vaccinated. 
This was to maximise the inclusion of infants who were never issued a vaccination card 
simply because they never attended child health or vaccination clinics. As the 
categorisation of these infants was based on maternal recall, their vaccination status may 
have been misclassified due to poor maternal recall. If this misclassification were 
differential by birth weight, this may have biased the estimates of the association between 
birth weight and vaccination. As shown in Table 5.3 the numbers in this category were very 
small (<1% for all vaccines), and so they were unlikely to have greatly influenced the effect 
estimates in the analyses of vaccination status.  
Table 5.3: Infant vaccination status for each vaccine included in the routine vaccination 
programme 
 Category of Vaccination Status 
N (% of all enrolled infants) 
Vaccine Card seen, 
vaccinated, 
date known 
Card seen, 
vaccinated, 
date 
unknown 
Card seen, 
known not 
vaccinated 
Card not 
seen, not 
vaccinated 
Status 
unknown 
BCG 22002 (95.8) 243 (1.1) 348 (1.5) 0 (0.0) 362 (1.6) 
Birth OPV 14831 (64.6) 487 (2.1) 6699 (29.2) 0 (0.0) 938 (4.1) 
OPV1 21739 (94.7) 80 (0.3) 603 (2.6) 127 (0.6) 406 (1.8) 
OPV2 21583 (94.0) 48 (0.2) 791 (3.4) 127 (0.6) 406 (1.8) 
OPV3 20644 (89.9) 167 (0.7) 1611 (7.0) 127 (0.6) 406 (1.8) 
DTP1 22105 (96.3) 27 (0.1) 291 (1.2) 130 (0.6) 402 (1.8) 
DTP2 21698 (94.5) 17 (0.1) 708 (3.1) 127 (0.5) 405 (1.8) 
DTP3 21099 (91.9) 38 (0.2) 1282 (5.6) 123 (0.5) 413 (1.8) 
Measles 18472 (80.5) 58 (0.3) 3247 (14.1) 0 (0.0) 1178 (5.1) 
Yellow Fever 18402 (80.2) 93 (0.4) 4009 (17.5) 101 (0.4) 350 (1.5) 
 
In order to further explore whether this categorisation had biased the estimates, for the 
analyses of DTP1 and DTP3 vaccination at 12 weeks after the vaccine due date, I undertook 
additional sensitivity analyses (Appendix 5.1, Table A5.2 and A5.3 (at the end of Chapter 
5), whereby I also excluded these infants. Table 5.4 presents the effect estimates in the 
final model (adjusted for distal, intermediate and proximate determinants, and the 
mediating effect of infant illness), in models including and excluding these infants. It can be 
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seen that excluding these infants made little difference to the size of the effect estimates, 
indicating that their inclusion in the analyses did not bias the estimates.  
Table 5.4. Comparison of estimated effect of determinants of DTP1 and DTP3 vaccination, 
including (A) and excluding (B) infants reported not vaccinated but whose card was never 
seen. 
  DTP1 between 0 and 18 weeks DTP3 between 0 and 26 weeks 
  A B A B 
 Rate Ratios1 
aRR (95%CI)  
Rate Ratios1 
aRR (95%CI)  
Rate Ratios1 
aRR (95%CI) 
Rate Ratios1 
aRR (95%CI) 
Distal Determinants      
Religion 
Christian 
Muslim 
None/Traditional/ 
Other 
 
ref 
0.92 (0.89-0.95) 
0.96 (0.90-1.01) 
 
(<0.0001) 
 
ref 
0.93 (0.89-0.96) 
0.95 (0.90-1.01) 
 
(0.0001) 
 
ref 
0.82 (0.79-0.85) 
0.94 (0.88-1.00) 
 
(<0.0001) 
 
ref 
0.82 (0.79-0.86) 
0.93 (0.88-0.99) 
 
(<0.0001) 
Ethnicity of 
household 
Akan 
Other  
  
ref 
1.03 (0.99-1.06) 
(0.1196) 
  
ref 
1.02 (0.98-1.05) 
(0.2996) 
  
ref 
0.97 (0.94-1.01) 
(0.1889) 
  
ref 
0.97 (0.93-1.01) 
(0.1172) 
Socioeconomic 
status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
0.94 (0.89-0.99) 
0.99 (0.95-1.04) 
0.99 (0.95-1.04) 
0.99 (0.95-1.03) 
ref 
(0.1676) 
  
0.96 (0.91-1.01) 
1.01 (0.96-1.05) 
1.00 (0.96-1.04) 
0.99 (0.95-1.03) 
ref 
(0.2478) 
  
1.09 (1.03-1.16) 
1.14 (1.08-1.20) 
1.11 (1.05-1.16) 
1.06 (1.01-1.11) 
Ref 
(0.0001) 
  
1.10 (1.04-1.17) 
1.15 (1.09-1.21) 
1.11 (1.06-1.16) 
1.06 (1.01-1.11) 
ref 
(<0.0001) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
1.08 (1.01-1.15) 
ref 
0.97 (0.93-1.01) 
0.99 (0.96-1.03) 
(0.0229) 
  
1.08 (1.01-1.15) 
ref 
0.96 (0.93-1.00) 
0.99 (0.96-1.03) 
(0.0179) 
  
1.07 (1.01-1.15) 
ref 
1.09 (1.04-1.13) 
1.02 (0.98-1.06) 
(0.0006) 
  
1.08 (1.01-1.15) 
ref 
1.09 (1.04-1.13) 
1.02 (0.98-1.07) 
(0.0006) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
0.88 (0.84-0.91) 
0.93 (0.89-0.96) 
ref 
(<0.0001) 
  
0.88 (0.85-0.92) 
0.93 (0.89-0.96) 
ref 
(<0.0001) 
  
0.78 (0.75-0.82) 
0.83 (0.80-0.87) 
ref 
(<0.0001) 
  
0.78 (0.75-0.82) 
0.83 (0.80-0.87) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
ref 
1.00 (0.97-1.02) 
(0.7494) 
  
ref 
0.99 (0.97-1.02) 
(0.6030) 
  
ref 
0.96 (0.92-0.98) 
(0.0002) 
  
ref 
0.95 (0.92-0.98) 
(0.0003) 
Continued…. 
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Table 5.4 continued 
 DTP1 between 0 and 18 weeks DTP3 between 0 and 26 weeks 
 A B A B 
 Rate Ratios1 
aRR (95%CI)  
Rate Ratios1 
aRR (95%CI)  
Rate Ratios1 
aRR (95%CI) 
Rate Ratios1 
aRR (95%CI) 
Sex 
Male 
Female 
  
ref 
1.02 (1.00-1.05) 
(0.0804) 
  
ref 
1.02 (0.99-1.05) 
(0.1714) 
  
ref 
1.04 (1.01-1.07) 
(0.0191) 
  
ref 
1.03 (1.00-1.06) 
(0.0304) 
Intermediate Determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
0.84 (0.79-0.89) 
0.93 (0.89-0.97) 
ref 
1.02 (0.98-1.07) 
1.02 (0.97-1.07) 
(<0.0001) 
  
0.84 (0.79-0.89) 
0.93 (0.89-0.97) 
ref 
1.03 (0.99-1.07) 
1.02 (0.97-1.07) 
(<0.0001) 
  
0.80 (0.75-0.85) 
0.91 (0.87-0.95) 
ref 
1.07 (1.02-1.12) 
1.06 (1.01-1.12) 
(<0.0001) 
  
0.80 (0.75-0.85) 
0.90 (0.87-0.94) 
ref 
1.07 (1.02-1.12) 
1.06 (1.01-1.12) 
(<0.0001) 
Number of living 
children in family  
0-1 
2-3 
4 or more 
  
 
1.05 (1.01-1.09) 
ref 
0.95 (0.91-0.99) 
(0.0007) 
  
 
1.05 (1.01-1.09) 
ref 
0.95 (0.91-0.99) 
(0.0008) 
  
 
1.07 (1.03-1.12) 
ref 
0.88 (0.85-0.92) 
(<0.0001) 
  
 
1.07 (1.03-1.12) 
ref 
0.88 (0.84-0.92) 
(<0.0001) 
Maternal illness 
No 
Yes 
  
ref 
1.03 (0.97-1.10) 
(0.2998) 
  
ref 
1.03 (0.97-1.09) 
(0.4033) 
  
ref 
0.98 (0.92-1.05) 
0.6288 
  
ref 
0.98 (0.92-1.05) 
(0.5719) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
 
ref 
0.96 (0.93-0.99) 
0.87 (0.83-0.91) 
(<0.0001) 
  
 
ref 
0.96 (0.93-0.99) 
0.87 (0.84-0.91) 
(<0.0001) 
  
 
ref 
0.98 (0.95-1.02) 
0.81 (0.77-0.85) 
(<0.0001) 
  
 
ref 
0.98 (0.95-1.02) 
0.81 (0.78-0.85) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
  
ref 
0.94 (0.91-0.98) 
(0.0011) 
  
ref 
0.94 (0.91-0.98) 
(0.0012) 
  
ref 
0.95 (0.91-0.99) 
(0.0120) 
  
ref 
0.95 (0.91-0.99) 
(0.0120) 
Multiple birth 
No 
Yes 
  
ref 
1.08 (1.00-1.17) 
(0.0539) 
  
ref 
1.08 (1.00-1.17) 
(0.0473) 
  
ref 
1.07 (0.98-1.16) 
(0.1298) 
  
ref 
1.07 (0.98-1.17) 
(0.1197) 
Distal Determinants 
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
ref 
0.92 (0.89-0.96) 
0.77 (0.69-0.85) 
0.64 (0.51-0.80) 
(<0.0001) 
 
ref 
0.92 (0.89-0.96) 
0.76 (0.69-0.85) 
0.63 (0.50-0.79) 
(<0.0001) 
  
ref 
0.95 (0.91-1.00) 
0.82 (0.73-0.92) 
0.60 (0.46-0.79) 
(<0.0001) 
  
ref 
0.95 (0.91-1.00) 
0.82 (0.73-0.92) 
0.60 (0.45-0.79) 
(<0.0001) 
Mediating Variables        
Infant illness 
No 
Yes 
 
ref 
0.94 (0.90-0.98) 
(0.0028) 
  
ref 
0.95 (0.91-0.99) 
(0.0039) 
  
ref 
1.03 (0.99-1.07) 
(0.1498) 
  
ref 
1.02 (0.98-1.07) 
(0.1151) 
1. Effect estimates adjusted for infant age-band, for distal, intermediate and proximal variables, and for the mediating effects 
of infant illness. 
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5.7. ADDITIONAL RESULTS AND DISCUSSION 
In this section, I present additional tables of results not included in the published paper and 
I discuss these results.  
5.7.1: How does vaccine uptake by birth weight in the Neovita study population 
relate to international targets? 
Table 5.5 summarises the monthly DTP1 and DTP3 uptake rates by birth weight among 
infants included in my analyses. This table clearly illustrates delayed vaccination in our 
entire study population, as well as declining uptake with declining birth weight for both 
DTP1 and DTP3. For DTP1, ≥90% uptake (the target stipulated in the current Global Vaccine 
Action Plan1) was achieved for all categories of birth weight by age 17 weeks (120 days), 11 
weeks after the DTP1 due date. For DTP3, it took substantively longer for infants to reach 
this target. For NLBW infants, and infants weighing 2.00-2.49kg, this target was only 
reached by 16 weeks after the vaccine due date (at 210 days / 30 weeks of age), MLBW 
infants reached the target 20 weeks after the vaccine due date (at 240 days / 34 weeks of 
age). For VLBW infants, it took an additional 29 weeks beyond the due date (until 300 days 
/ 43 weeks of age) to meet this target.  
5.7.2: How do the reported estimates of vaccine uptake in the Neovita study 
population relate to other published estimates for Ghana? 
The estimated 99% DTP1 uptake at 52 weeks of age for all categories of birth weight (Table 
5.5) is higher than officially reported WHO/UNICEF estimates for Ghana during the study 
period (94% for 2011 and 92% for 2012)2, but is equal to that reported in a previous 
analysis of vaccination in the study area using data on infants born in 2008 and 20093.  
The DTP3 uptake rates, which were in excess of 97% for all infants except those weighing 
<1.50kg were higher than the 91% and 92% uptake rates reported by WHO/UNICEF2 and 
were slightly higher than the 94% uptake previously reported in the study area3. The slightly 
higher uptake rates in my analyses may reflect 1) the better health outcomes in the Brong 
Ahafo region as compared to Ghana as a whole (as discussed in Chapter 2), 2) the fact that 
this was a trial population who were being reminded on a monthly basis about vaccination 
(as discussed in the paper), and 3) improvements to the delivery of vaccines in the study 
area over time.  
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Table 5.5: Monthly uptake rates by birth weight for a) DTP1 and b) DTP3 
 % uptake DTP1 
Uptake by  
Non-LBW 
(95%CI) 
2.49-2.00 kg 
(95%CI) 
1.99-1.5kg 
(95%CI) 
<1.5kg 
(95%CI) 
Day 30 0.6 (0.5-0.7) 0.6 (0.4-0.9) 0.3 (0.0-1.8) 0.0 (0.0-0.0) 
Day 42 8.5 (8.1-8.9) 7.5 (6.6-8.5) 8.9 (6.4-12.2) 2.5 (0.6-9.6) 
Day 60 60.2 (59.5-60.9) 56.0 (54.2-57.8) 50.6 (45.7-55.7) 40.0 (30.2-51.6) 
Day 70 79.6 (79.0-80.2) 76.3 (74.7-77.8) 67.3 (62.6-72.0) 58.8 (48.3-69.6) 
Day 90 92.2 (91.8-92.6) 90.2 (89.0-91.2) 87.0 (83.4-90.1) 81.3 (72.0-88.9) 
Day 98 94.5 (94.2-94.8) 92.9 (91.9-93.8) 92.3 (89.3-94.7) 87.5 (79.3-93.6) 
Day 120 97.4 (97.2-97.6) 96.8 (96.1-97.4) 95.8 (93.4-97.5) 93.8 (87.0-97.7) 
Day 126 97.8 (97.6-98.0) 97.3 (96.6-97.8) 96.8 (94.7-98.3) 93.8 (87.0-97.7) 
Day 150 98.7 (98.5-98.8) 98.4 (97.9-98.8) 98.4 (96.7-99.3) 95.0 (88.7-98.4) 
Day 180 99.2 (99.0-99.3) 98.9 (98.5-99.2) 98.7 (97.1-99.5) 96.3 (90.4-99.0) 
Day 210 99.3 (99.2-99.4) 99.0 (98.6-99.4) 98.7 (97.1-99.5) 96.3 (90.4-99.0) 
Day 240 99.4 (99.3-99.5) 99.1 (98.8-99.4) 99.0 (97.5-99.7) 98.8 (94.0-99.9) 
Day 270 99.5 (99.3-99.6) 99.2 (98.8-99.5) 99.0 (97.5-99.7) 98.8 (94.0-99.9) 
Day 300 99.5 (99.4-99.6) 99.3 (98.9-99.6) 99.0 (97.5-99.7) 98.8 (94.0-99.9) 
Day 330 99.5 (99.4-99.6) 99.3 (99.0-99.6) 99.7 (98.4-100.0) 98.8 (94.0-99.9) 
Day 365 99.5 (99.4-99.6) 99.3 (99.0-99.6) 99.7 (98.4-100.0) 98.8 (94.0-99.9) 
 % uptake DTP3 
Uptake by  
Non-LBW 
(95%CI) 
2.49-2.00 kg 
(95%CI) 
1.99-1.5kg 
(95%CI) 
<1.5kg 
(95%CI) 
Day 30 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 
Day 60 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 
Day 90 0.3 (0.3-0.4) 0.2 (0.1-0.5) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 
Day 98 2.0 (1.8-2.2) 1.7 (1.3-2.3) 2.7 (1.5-4.9) 0.0 (0.0-0.0) 
Day 120 35.2 (34.5-35.9) 32.5 (30.8-34.3) 29.9 (25.5-34.9) 18.9 (11.7-29.8) 
Day 126 44.6 (43.9-45.4) 43.2 (41.4-45.0) 36.8 (32.1-41.9) 23.1 (15.0-34.5) 
Day 150 69.3 (68.6-70.0) 67.8 (66.1-69.5) 63.4 (58.4-68.3) 55.3 (44.3-66.9) 
Day 154 72.2 (71.6-72.9) 71.0 (69.3-72.6) 66.5 (61.6-71.3) 56.7 (45.6-68.2) 
Day 180 84.6 (84.1-85.2) 83.1 (81.7-84.5) 81.7 (77.5-85.5) 70.8 (60.0-80.8) 
Day 182 85.3 (84.7-85.8) 84.0 (82.6-85.3) 81.9 (77.8-85.7) 72.2 (61.6-82.0) 
Day 210 91.3 (90.8-91.7) 90.4 (89.2-91.4) 89.3 (85.8-92.2) 78.1 (67.9-86.9) 
Day 240 94.3 (93.9-94.6) 93.6 (92.6-94.5) 91.9 (88.8-94.5) 81.0 (71.1-89.2) 
Day 270 95.8 (95.5-96.1) 95.1 (94.2-95.8) 95.1 (92.5-97.0) 87.3 (78.2-93.9) 
Day 300 96.5 (96.3-96.8) 95.9 (95.1-96.6) 96.5 (94.2-98.1) 90.5 (82.0-96.0) 
Day 330 97.0 (96.7-97.2) 96.7 (95.9-97.3) 97.7 (95.7-98.9) 92.1 (84.0-97.0) 
Day 365 97.4 (97.1-97.6) 97.1 (96.3-97.7) 98.1 (96.1-99.2) 93.7 (86.0-97.9) 
5.7.3. Mediation of the observed effects by more proximal variables. 
Table 5.6 presents detailed results for the hierarchical modelling of DTP1 vaccination 
between 0 and 10 weeks of age (unadjusted and fully adjusted estimates presented in 
Table 3 of the published paper). Detailed results for the hierarchical modelling of DTP1 
vaccination between 0 and 14 weeks, and 0 and 18 weeks are given in Appendix 5.1 (Tables 
A5.4 and A5.5). With the exception of SES, there was little evidence of mediation of distal 
level factors by intermediate factors, or that either distal or intermediate factors were 
mediated by birth weight or infant illness. For SES, DTP1 vaccination by each of 10 and 14 
weeks of age was, in distal models, observed to be up to 15% lower amongst the poorest 
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quintile. This association was no longer observed once adjusted for the intermediate 
variables, suggesting that it was largely explained by intermediate factors such as maternal 
age and distance to the nearest health facility.   
Similarly, for DTP3 (Table 5.7 and Appendix 5.1, Tables A5.6 and A5.7), there was little 
evidence of mediation of any variables by other more proximal factors. Again, the only 
exception to this was for SES. At up to 18 weeks of age (4 weeks after the vaccine due date) 
(Table 5.7), the evidence of an association with vaccination was weak in distal models, but 
evidence of an association increased once adjusted for the intermediate variables. A small 
association was consistently observed across all models at 8 and 12 weeks after the vaccine 
due date, whereby infants in the lower categories of deprivation had a moderately (<20%) 
increased vaccination rate compared to those in the highest category. This association may 
be an artefact of delayed receipt of DTP1, as will be further discussed in Section 5.7.4.  
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Table 5.6: Determinants of DTP1 vaccination between age 0 and 10 weeks 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight and illness 
      RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Infant age-band (in days) 
<29.5 
29.5-60.0 
>90.0 
  
130/670092 
13098/524434 
4004/642711 
  
0.02 (0.02-0.02) 
2.50 (2.46-2.54) 
6.23 (6.04-6.43) 
  
0.01 (0.01-0.01) 
ref 
2.49 (2.41-2.58) 
(<0.0001) 
  
 
_ 
_ 
  
0.01 (0.01-0.01) 
ref 
2.52 (2.44-2.61) 
(<0.0001) 
  
0.01 (0.01-0.01) 
ref 
2.54 (2.45-2.63) 
(<0.0001) 
 
0.01 (0.01-0.01) 
ref 
2.55 (2.46-2.64) 
(<0.0001) 
 
0.01 (0.01-0.01) 
ref 
2.55 (2.46-2.64) 
(<0.0001) 
Distal Determinants                 
Religion of head of 
household 
Christian 
Muslim 
None/Traditional/Other 
  
 
12242/876372 
3933/301612 
1057/80813 
  
 
1.40 (1.37-1.42) 
1.30 (1.26-1.35) 
1.31 (1.23-1.39) 
  
 
ref 
0.93 (0.90-0.97) 
0.94 (0.88-1.00) 
(0.0002) 
  
 
ref 
0.91 (0.88-0.95) 
0.90 (0.85-0.96) 
  
 
ref 
0.94 (0.90-0.98) 
0.98 (0.92-1.04) 
(0.0196) 
 
 
ref 
0.95 (0.91-0.99) 
0.99 (0.93-1.06) 
(0.0371) 
 
 
ref 
0.95 (0.91-0.99) 
0.99 (0.93-1.06) 
(0.0357) 
 
 
ref 
0.95 (0.91-0.99) 
0.99 (0.93-1.06) 
(0.0382) 
Ethnicity of household 
Akan 
Other  
  
 
8331/587695 
8901/671102 
  
 
1.42 (1.39-1.45) 
1.33 (1.30-1.35) 
  
 
ref 
0.94 (0.91-0.96) 
(<0.0001) 
  
 
ref 
0.92 (0.89-0.95) 
  
 
ref 
1.04 (1.00-1.08) 
(0.0613) 
  
 
ref 
1.04 (1.00-1.08) 
(0.0602) 
  
 
ref 
1.04 (1.00-1.08) 
(0.0805) 
  
 
ref 
1.04 (1.00-1.08) 
(0.0728) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
3107/249692 
3349/249775 
3471/252903 
3587/254568 
3718/251859 
  
1.24 (1.20-1.29) 
1.34 (1.30-1.39) 
1.37 (1.33-1.42) 
1.41 (1.36-1.46) 
1.48 (1.43-1.52) 
  
0.84 (0.80-0.88) 
0.91 (0.87-0.95) 
0.93 (0.89-0.97) 
0.95 (0.91-1.00) 
ref 
(<0.0001) 
  
0.78 (0.74-0.81) 
0.86 (0.82-0.90) 
0.88 (0.84-0.93) 
0.92 (0.88-0.97) 
ref 
  
0.86 (0.81-0.91) 
0.92 (0.88-0.97) 
0.93 (0.89-0.98) 
0.95 (0.91-1.00) 
ref 
(<0.0001) 
  
0.95 (0.89-1.01) 
0.99 (0.94-1.04) 
0.98 (0.93-1.03) 
0.98 (0.93-1.03) 
ref 
(0.4947) 
  
0.96 (0.90-1.02) 
0.99 (0.94-1.05) 
0.98 (0.93-1.03) 
0.98 (0.94-1.03) 
ref 
(0.5364) 
  
0.96 (0.90-1.02) 
1.00 (0.94-1.05) 
0.98 (0.93-1.03) 
0.98 (0.94-1.03) 
ref 
(0.5398) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
1001/65037 
6937/487861 
4754/370833 
4540/335066 
  
1.54 (1.45-1.64) 
1.42 (1.39-1.46) 
1.28 (1.25-1.32) 
1.35 (1.32-1.39) 
  
1.08(1.01-1.16) 
ref 
0.90 (0.87-0.94) 
0.95 (0.92-0.99) 
(<0.0001) 
  
1.14 (1.06-1.21) 
ref 
0.86 (0.83-0.89) 
0.93 (0.90-0.97) 
  
1.09 (1.02-1.17) 
ref 
0.93 (0.89-0.97) 
0.94 (0.91-0.98) 
(<0.0001) 
  
1.09 (1.02-1.16) 
ref 
0.95 (0.91-0.99) 
0.99 (0.95-1.03) 
(0.0039) 
  
1.09 (1.02-1.17) 
ref 
0.95 (0.91-0.99) 
0.99 (0.95-1.03) 
(0.0033) 
  
1.09 (1.02-1.17) 
ref 
0.95 (0.91-0.99) 
0.99 (0.95-1.03) 
(0.0031) 
Continued…… 
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Table 5.6 continued 
 Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight and illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
5021/395418 
3115/233158 
9096/630221 
  
1.27 (1.24-1.31) 
1.34 (1.29-1.38) 
1.44 (1.41-1.47) 
  
0.88 (0.85-0.91) 
0.93 (0.89-0.96) 
ref 
(<0.0001) 
  
0.83 (0.80-0.86) 
0.89 (0.86-0.93) 
ref 
  
0.89 (0.85-0.93) 
0.93 (0.89-0.97) 
ref 
(<0.0001) 
  
0.88 (0.84-0.92) 
0.93 (0.89-0.97) 
ref 
(<0.0001) 
  
0.88 (0.84-0.92) 
0.93 (0.89-0.97) 
ref 
(<0.0001) 
  
0.88 (0.84-0.92) 
0.93 (0.89-0.97) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
10996/798445 
6236/460352 
  
1.38 (1.35-1.40) 
1.35 (1.32-1.39) 
  
ref 
0.98 (0.95-1.01) 
(0.2971) 
  
ref 
0.98 (0.95-1.01) 
  
ref 
0.98 (0.95-1.01) 
(0.1892) 
  
ref 
0.98 (0.95-1.01) 
(0.2185) 
  
ref 
0.98 (0.95-1.01) 
(0.1961) 
  
ref 
0.98 (0.95-1.01) 
(0.1817) 
Sex 
Male 
Female 
  
8711/639311 
8521/619486 
  
1.36 (1.33-1.39) 
1.38 (1.35-1.41) 
  
ref 
1.01 (0.98-1.04) 
(0.5352) 
  
ref 
1.01 (0.98-1.04) 
  
ref 
1.01 (0.98-1.04) 
(0.3939) 
  
ref 
1.01 (0.98-1.05) 
(0.3503) 
  
ref 
1.02 (0.99-1.05) 
(0.2095) 
  
ref 
1.02 (0.99-1.05) 
(0.2206) 
Intermediate Determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
1864/145995 
4388/321687 
4752/336462 
3507/253443 
2721/201210 
  
1.28 (1.22-1.34) 
1.36 (1.32-1.41) 
1.41 (1.37-1.45) 
1.38 (1.34-1.43) 
1.35 (1.30-1.40) 
  
0.90 (0.86-0.95) 
0.97 (0.93-1.01) 
ref 
0.98 (0.94-1.02) 
0.96 (0.91-1.00) 
(0.0053) 
  
0.86 (0.82-0.91) 
0.95 (0.91-0.99) 
ref 
0.97 (0.93-1.02) 
0.94 (0.89-0.98) 
  
  
 
  
  
  
0.83 (0.77-0.88) 
0.93 (0.89-0.97) 
ref 
1.02 (0.98-1.07) 
1.02 (0.96-1.07) 
(<0.0001) 
  
0.84 (0.78-0.89) 
0.93 (0.89-0.98) 
ref 
1.03 (0.98-1.07) 
1.02 (0.97-1.08) 
(<0.0001) 
  
0.84 (0.78-0.89) 
0.93 (0.89-0.98) 
ref 
1.03 (0.98-1.07) 
1.02 (0.97-1.08) 
(<0.0001) 
Number of living children 
in family  
0-1 
2-3 
4 or more 
  
 
5061/365082 
6996/502347 
5175/391368 
  
 
1.39 (1.35-1.43) 
1.39 (1.36-1.43) 
1.32 (1.29-1.36) 
  
 
1.00 (0.96-1.03) 
ref 
0.95 (0.92-0.98) 
(0.0103) 
  
 
1.00 (0.96-1.03) 
ref 
0.93 (0.90-0.96) 
  
  
  
  
  
 
1.04 (0.99-1.08) 
ref 
0.96 (0.92-1.00) 
(0.0249) 
  
 
1.05 (1.00-1.09) 
ref 
0.95 (0.91-1.00) 
(0.0068) 
  
 
1.05 (1.00-1.10) 
ref 
0.95 (0.91-1.00) 
(0.0066) 
Continued…… 
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Table 5.6 continued 
 Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight and illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal illness 
No 
Yes 
  
16379/1197898 
853/60899 
  
1.37 (1.35-1.39) 
1.40 (1.31-1.50) 
  
ref 
1.02 (0.96-1.10) 
(0.4939) 
  
ref 
1.04 (0.97-1.12) 
  
  
  
  
ref 
1.05 (0.98-1.12) 
(0.1900) 
  
ref 
1.05 (0.98-1.13) 
(0.1454) 
  
ref 
1.05 (0.98-1.13) 
(0.1319) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
 
10715/754658 
3960/292241 
2557/211898 
  
 
1.42 (1.39-1.45) 
1.36 (1.31-1.40) 
1.21 (1.16-1.25) 
  
 
ref 
0.95 (0.92-0.99) 
0.85 (0.81-0.89) 
(<0.0001) 
  
 
ref 
0.93 (0.89-0.96) 
0.79 (0.76-0.83) 
  
  
  
  
  
 
ref 
0.94 (0.90-0.97) 
0.86 (0.82-0.90) 
(<0.0001) 
  
 
ref 
0.94 (0.90-0.97) 
0.86 (0.82-0.90) 
(<0.0001) 
  
 
ref 
0.94 (0.90-0.97) 
0.86 (0.82-0.91) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
  
  
13485/959719 
3747/299078 
  
  
1.41 (1.38-1.43) 
1.25 (1.21-1.30) 
  
  
ref 
0.89 (0.86-0.92) 
(<0.0001) 
  
  
ref 
0.85 (0.82-0.88) 
  
  
  
  
  
  
ref 
0.94 (0.90-0.98) 
(0.0048) 
  
  
ref 
0.94 (0.91-0.98) 
(0.0072) 
  
  
ref 
0.94 (0.91-0.98) 
(0.0065) 
Multiple birth 
No 
Yes 
  
16648/1213539 
584/45258 
  
1.37 (1.35-1.39) 
1.29 (1.19-1.40) 
  
ref 
0.94 (0.87-1.02) 
(0.1420) 
  
ref 
0.92 (0.85-1.00) 
  
  
  
  
ref 
0.94 (0.86-1.02) 
(0.1256) 
  
ref 
1.04 (0.95-1.13) 
(0.4219) 
  
ref 
1.04 (0.95-1.13) 
(0.4172) 
Proximal Variables         
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
14759/1065163 
2185/166348 
243/22400 
45/4886 
  
1.39 (1.36-1.41) 
1.31 (1.26-1.37) 
1.08 (0.96-1.23) 
0.92 (0.69-1.23) 
  
ref 
0.95 (0.91-0.99) 
0.78 (0.69-0.89) 
0.66 (0.50-0.89) 
(<0.0001) 
  
ref 
 0.92 (0.88-0.96) 
 0.72 (0.64-0.82) 
0.58 (0.43-0.77) 
  
  
 
 
  
  
  
 
  
ref 
0.93 (0.89-0.97) 
0.71 (0.62-0.81) 
0.58 (0.43-0.77) 
(<0.0001) 
  
ref 
0.93 (0.89-0.97) 
0.71 (0.63-0.81) 
0.58 (0.43-0.78) 
(<0.0001) 
Mediating Variables               
Infant illness 
No 
Yes 
  
2040/155146 
15192/1103651 
  
1.31 (1.26-1.37) 
1.38 (1.35-1.40) 
  
ref 
0.96 (0.91-1.00) 
(0.0507) 
  
ref 
0.94 (0.90-0.99) 
  
  
  
    
ref 
0.95 (0.91-1.00) 
(0.0949) 
* all p-values<0.0001 
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Table 5.7: Determinants of DTP3 vaccination between 0 and 18 weeks 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight and illness 
      RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Infant age-band (in days) 
29.5-60.0 
>90.0 
  
72/1991481 
9252/648138 
  
0.00 (0.00-0.00) 
1.43 (1.40-1.46) 
  
0.00 (0.00-0.00) 
Ref 
(<0.0001) 
  
_ 
_ 
  
0.00 (0.00-0.00) 
ref 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
  
0.00 (0.00-0.00) 
ref 
  
0.00 (0.00-0.00) 
ref 
Distal Determinants                 
Religion of head of 
household 
Christian 
Muslim 
None/Traditional/Other 
  
 
6914/1839099 
1826/633930 
584/166590 
  
 
0.38 (0.37-0.38) 
0.29 (0.28-0.30) 
0.35 (0.32-0.38) 
  
 
ref 
0.77 (0.73-0.81) 
0.93 (0.86-1.01) 
(<0.0001) 
  
 
ref 
0.74 (0.71-0.78) 
0.93 (0.85-1.01) 
  
 
ref 
0.81 (0.76-0.85) 
0.99 (0.91-1.08) 
(<0.0001) 
  
 
ref 
0.81 (0.76-0.86) 
1.01 (0.93-1.11) 
(<0.0001) 
 
  
 
ref 
0.81 (0.76-0.86) 
1.01 (0.93-1.10) 
(<0.0001) 
  
 
ref 
0.81 (0.77-0.86) 
1.01 (0.93-1.10) 
(<0.0001) 
Ethnicity of household 
Akan 
Other  
  
4742/1236481 
4582/1403138 
  
0.38 (0.37-0.39) 
0.33 (0.32-0.34) 
  
ref 
0.85 (0.82-0.89) 
(<0.0001) 
  
ref 
0.84 (0.81-0.88) 
  
ref 
1.03 (0.98-1.08) 
(0.2939) 
  
ref 
1.03 (0.97-1.08) 
(0.3212) 
  
ref 
1.03 (0.97-1.08) 
(0.3537) 
  
ref 
1.03 (0.97-1.08) 
(0.3484) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
1643/513227 
1823/518697 
1935/527519 
1925/538101 
1998/542075 
  
0.32 (0.31-0.34) 
0.35 (0.34-0.37) 
0.37 (0.35-0.38) 
0.36 (0.34-0.37) 
0.37 (0.35-0.39) 
  
0.87 (0.81-0.93) 
0.95 (0.89-1.02) 
1.00 (0.94-1.06) 
0.97 (0.91-1.03) 
ref 
(<0.0001) 
  
0.85 (0.80-0.91) 
0.95 (0.89-1.01) 
0.99 (0.93-1.06) 
0.97 (0.91-1.03) 
ref 
  
0.97 (0.90-1.05) 
1.03 (0.96-1.10) 
1.05 (0.98-1.12) 
1.01 (0.95-1.08) 
ref 
(0.2542) 
  
1.12 (1.03-1.22) 
1.15 (1.07-1.23) 
1.13 (1.05-1.20) 
1.05 (0.99-1.12) 
Ref 
(0.0016) 
  
1.13 (1.04-1.23) 
1.15 (1.07-1.24) 
1.13 (1.06-1.21) 
1.05 (0.99-1.12) 
ref 
(0.0011) 
  
1.13 (1.04-1.23) 
1.15 (1.07-1.24) 
1.13 (1.06-1.21) 
1.05 (0.99-1.12) 
Ref 
(0.0010) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
581/141110 
3680/1036780 
2618/764688 
2445/697041 
  
0.41 (0.38-0.45) 
0.35 (0.34-0.37) 
0.34 (0.33-0.36) 
0.35 (0.34-0.36) 
  
1.16 (1.06-1.27) 
ref 
0.96 (0.92-1.01) 
0.99 (0.94-1.04) 
(0.0013) 
  
1.19 (1.09-1.30) 
ref 
0.96 (0.91-1.01) 
0.99 (0.94-1.04) 
  
1.12 (1.02-1.22) 
ref 
1.04 (0.98-1.10) 
0.98 (0.93-1.03) 
(0.0203) 
  
1.11 (1.01-1.21) 
ref 
1.07 (1.00-1.13) 
1.05 (0.99-1.11) 
(0.0372) 
  
1.11 (1.01-1.21) 
ref 
1.07 (1.00-1.13) 
1.05 (0.99-1.11) 
(0.0388) 
  
1.11 (1.01-1.21) 
ref 
1.07 (1.00-1.13) 
1.05 (0.99-1.11) 
(0.0394) 
Continued…… 
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Table 5.7 continued 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight and illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
2473/819833 
1614/486863 
5237/1332923 
  
0.30 (0.29-0.31) 
0.33 (0.32-0.35) 
0.39 (0.38-0.40) 
  
0.77 (0.73-0.81) 
0.84 (0.80-0.89) 
ref 
(<0.0001) 
  
0.74 (0.71-0.78) 
0.82 (0.78-0.87) 
ref 
  
0.77 (0.73-0.82) 
0.84 (0.79-0.89) 
ref 
(<0.0001) 
  
0.77 (0.72-0.81) 
0.85 (0.80-0.90) 
ref 
(<0.0001) 
  
0.77 (0.72-0.81) 
0.85 (0.80-0.90) 
ref 
(<0.0001) 
  
0.77 (0.72-0.81) 
0.85 (0.80-0.90) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
4476/1240162 
4848/1399457 
  
0.36 (0.35-0.37) 
0.35 (0.34-0.36) 
  
ref 
0.96 (0.92-1.00) 
(0.0480) 
  
ref 
0.97 (0.93-1.01) 
  
ref 
0.96 (0.92-1.00) 
(0.0692) 
  
ref 
0.96 (0.92-1.00) 
(0.0580) 
  
ref 
0.96 (0.92-1.00) 
(0.0522) 
  
ref 
0.96 (0.92-1.00) 
(0.0511) 
Sex 
Male 
Female 
  
4679/1340011 
4645/12990608 
  
0.35 (0.34-0.36) 
0.36 (0.35-0.37) 
  
ref 
1.02 (0.98-1.07) 
(0.2602) 
  
ref 
1.03 (0.99-1.07) 
  
ref 
1.03 (0.99-1.07) 
(0.1865) 
  
ref 
1.03 (0.99-1.07) 
(0.1668) 
  
ref 
1.03 (0.99-1.08) 
(0.1145) 
  
ref 
1.03 (0.99-1.08) 
(0.1165) 
Intermediate Determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
947/299973 
2373/670758 
2593/711054 
1931/534971 
1480/422863 
  
0.32 (0.30-0.34) 
0.35 (0.34-0.37) 
0.36 (0.35-0.38) 
0.36 (0.35-0.38) 
0.35 (0.33-0.37) 
  
0.87 (0.80-0.93) 
0.97 (0.92-1.03) 
ref 
0.99 (0.93-1.05) 
0.96 (0.90-1.02) 
(0.0030) 
  
0.85 (0.79-0.92) 
0.97 (0.92-1.03) 
ref 
0.99 (0.93-1.05) 
0.95 (0.89-1.01) 
   
0.76 (0.70-0.84) 
0.93 (0.88-0.99) 
ref 
1.06 (0.99-1.13) 
1.06 (0.98-1.14) 
(<0.0001) 
  
0.77 (0.70-0.84) 
0.93 (0.88-0.99) 
ref 
1.06 (0.99-1.13) 
1.06 (0.99-1.14) 
(<0.0001) 
  
0.77 (0.70-0.84) 
0.93 (0.88-0.99) 
ref 
1.06 (0.99-1.13) 
1.06 (0.99-1.14) 
(<0.0001) 
Number of living children 
in family  
0-1 
2-3 
4 or more 
  
 
2760/764387 
3818/1055899 
2746/819333 
  
 
0.36 (0.35-0.37) 
0.36 (0.35-0.37) 
0.34 (0.32-0.35) 
  
 
1.00 (0.95-1.05) 
ref 
0.93 (0.88-0.97) 
(0.0039) 
  
 
1.00 (0.96-1.05) 
ref 
0.92 (0.87-0.96) 
   
 
1.06 (1.00-1.13) 
ref 
0.92 (0.87-0.98) 
(0.0018) 
  
 
1.07 (1.01-1.13) 
ref 
0.92 (0.86-0.97) 
(0.0007) 
  
 
1.07 (1.01-1.13) 
ref 
0.92 (0.86-0.97) 
(0.0004) 
Maternal illness 
No 
Yes 
  
8869/2510288 
455/129331 
  
0.35 (0.35-0.36) 
0.35 (0.32-0.39) 
  
ref 
1.00 (0.91-1.09) 
(0.9296) 
  
ref 
1.00 (0.91-1.10) 
   
ref 
1.01 (0.92-1.11) 
(0.8125) 
  
ref 
1.02 (0.92-1.12) 
(0.7333) 
  
ref 
1.02 (0.93-1.12) 
(0.7234) 
Continued…… 
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Table 5.7 continued 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate / 
100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight and illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
 
5957/1597445 
2110/608508 
1257/433666 
  
 
0.37 (0.36-0.38) 
0.35 (0.33-0.36) 
0.29 (0.27-0.31) 
  
 
ref 
0.93 (0.88-0.98) 
0.78 (0.73-0.83) 
(<0.0001) 
  
 
ref 
0.92 (0.87-0.96) 
0.76 (0.71-0.80) 
   
 
ref 
0.90 (0.86-0.95) 
0.79 (0.74-0.84) 
(<0.0001) 
  
 
ref 
0.90 (0.86-0.95) 
0.79 (0.74-0.84) 
(<0.0001) 
  
 
ref 
0.90 (0.86-0.95) 
0.79 (0.74-0.84) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
  
7394/2025562 
1930/614057 
  
0.37 (0.36-0.37) 
0.31 (0.30-0.33) 
  
ref 
0.86 (0.82-0.91) 
(<0.0001) 
  
ref 
0.85 (0.81-0.89) 
   
ref 
0.94 (0.88-0.99) 
(0.0213) 
  
ref 
0.94 (0.89-0.99) 
(0.0282) 
  
ref 
0.94 (0.89-0.99) 
(0.0281) 
Multiple birth 
No 
Yes 
  
8997/2546020 
327/93599 
  
0.35 (0.35-0.36) 
0.35 (0.31-0.39) 
  
ref 
0.99 (0.89-1.10) 
(0.8390) 
  
ref 
0.98 (0.88-1.10) 
   
ref 
1.01 (0.90-1.13) 
(0.8669) 
  
ref 
1.10 (0.98-1.24) 
(0.1243) 
  
ref 
1.10 (0.98-1.24) 
(0.1225) 
Proximal Variables         
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
8007/2240325 
1168/344907 
132/45006 
17/9381 
  
0.36 (0.35-0.37) 
0.34 (0.32-0.36) 
0.29 (0.25-0.35) 
0.18 (0.11-0.29) 
  
ref 
0.95 (0.89-1.01) 
0.82 (0.69-0.97) 
0.51 (0.32-0.82) 
(0.0005) 
  
ref 
0.94 (0.88-0.99) 
0.81 (0.68-0.96) 
0.48 (0.30-0.78) 
   
  
  
  
  
  
ref 
0.93 (0.88-0.99) 
0.78 (0.66-0.93) 
0.46 (0.29-0.75) 
(<0.0001) 
  
ref 
0.93 (0.88-0.99) 
0.78 (0.66-0.93) 
0.46 (0.29-0.75) 
(<0.0001) 
Mediating Variables              
Infant illness 
No 
Yes 
  
7935/2232383 
1389/407236 
  
0.36 (0.35-0.36) 
0.34 (0.32-0.36) 
  
ref 
0.96 (0.91-1.02) 
(0.1540) 
  
ref 
0.96 (0.91-1.01) 
     
ref 
1.02 (0.96-1.08) 
(0.2632) 
* all p-values<0.0001 
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5.7.4. How does controlling for delayed administration of DTP1 affect estimates of 
the effect of determinants of DTP3 vaccination rate? 
As discussed in Chapter 3, in Ghana, DTP is recommended to be given in a three-dose 
schedule, with a minimum four-week interval between doses. Consequently, delayed 
administration of DTP1 will necessitate delayed administration of the subsequent doses of 
DTP, in order to comply with the recommended staging of the vaccine. For this reason, 
analyses of vaccination timing which measure vaccination within fixed risk (time) periods 
may include infants who are not in fact late for vaccination, as they are not yet eligible for 
vaccination due to the delayed receipt of earlier doses.  
In my main analyses of DTP3 vaccination I analysed the vaccination rate from the scheduled 
due date of 14 weeks of age, up to 26 weeks of age (12 weeks after the vaccine due date). 
Figure 5.2 illustrates two theoretical scenarios in which infants who were included in this 
analysis could have been misclassified as being vaccinated late, when they were in fact not 
yet eligible for DTP3 vaccination.  
Figure 5.2: Delayed receipt of DTP1 and DTP2, and the subsequent impact on timing of 
DTP3 vaccination.
6 8 10 12 14 16 18 20 22 24 26 28 30
Scheduled dose of DTP 
Eligible for next dose of DTP
Age in 
weeks
Scenario 2
Scenario 1
Longest risk period for the DTP3 
analysis
Receives  dose of DTP vaccine
Four week interval 
 
 
In both scenarios the initiation of DTP vaccination for the infant is late. In the first scenario 
the infant subsequently complies with the schedule and receives each subsequent dose 
four weeks after the previous dose. In the second scenario the infant is also delayed in 
receiving the later doses of DTP. In both scenarios the infant does not become eligible for 
DTP3 until after the end of the risk period for the DTP3 analysis. In both scenarios the infant 
will have been classified as not vaccinated at the end of the risk period, when in fact they 
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were not yet eligible for vaccination with DTP3. In the first scenario delayed receipt of DTP1 
drives delayed receipt of DTP3. In the second scenario delayed receipt of DTP3 is driven not 
only by delayed receipt of DTP1, but also by factors that caused additional delayed 
administration of DTP2 and DTP3. Delayed receipt of DTP1 may influence the determinants 
of DTP3 vaccination.  
Few studies of vaccination timing have actually accounted for delayed receipt of earlier 
doses in the analysis4-7. In an analysis of the determinants of time to DTP2 and DTP3 
vaccination using Cox regression undertaken in Tanzania, infants only contributed time to 
the analysis from the date of the previous dose in the series4. In an American study, Luman 
et al5, when calculating days under-vaccinated due to delayed vaccination in the first two 
years of life, undertook a primary analysis based on the routine schedule, and a secondary 
analysis whereby they applied a catch-up schedule, which incorporated a minimum interval 
between doses, to account for the timing of earlier doses in the series. In this American 
study, accounting for the timing of earlier doses caused a decline in the mean number of 
days under-vaccinated from 172 days to 163 days; there was little difference in the 
proportion of children under-vaccinated for more than six months (37% declined to 36%)5. 
Another American study6 included timely vaccination with each of DTP1, 2 and 3 (defined as 
receiving these vaccines on time, or late (>1 month after the due date)) as explanatory 
variables when modelling the determinants of DTP4 by two years of age, and found that 
timeliness of DTP2 and DTP3 were the biggest predictors of DTP4 vaccination. Similarly, 
Dayan et al7, in an analysis of delayed vaccination in Argentina, reported that late receipt of 
DTP1 was a strong predictor of delayed receipt of DTP4 (not having received DTP4 at 19 
months of age).  
In my primary analyses of DTP3 vaccination, I did not account for delayed receipt of DTP1 
and DTP2. Among the 22192 infants included in this analysis, 2566 (12%) were 
unvaccinated at 26 weeks of age (the latest defined end of the risk period for DTP3). Of 
these 2566, 1388 (54%) were vaccinated with DTP1 more than four weeks after the DTP1 
due date, and 2254 (88%) were vaccinated with DTP2 more than four weeks after the DTP2 
due date. Infants who were delayed in receipt of DTP3 were also delayed in receiving DTP2 
and DTP1.    
In order to explore how delayed receipt of earlier scheduled doses may have affected the 
effect estimates of the determinants of DTP3 vaccination, I undertook an additional 
sensitivity analysis of the DTP3 vaccination rate within 12 weeks of receipt of DTP1. Overall, 
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accounting for delayed receipt of DTP1 made little difference to the results of the analysis 
of determinants of DTP3 vaccination rate (Table 5.8 - DTP3 vaccination within 12 weeks of 
DTP1 vaccination); although there were a small number of exceptions as explained below. 
As discussed in Section 5.7.3, at 12 weeks after the vaccine due date, compared to infants 
from the richest quintile of SES, those from lower quintiles had moderately higher 
vaccination rate ratios (Appendix 5.1, Table A5.5). When late vaccination with DTP1 was 
accounted for, the association between SES and vaccination was similar to that observed 
for DTP1, whereby a weak association was observed in the distal model that was no longer 
observed following adjustment for intermediate variables.  
As discussed in the paper, accounting for delayed DTP1 vaccination made little difference to 
the estimated association between birth weight and DTP3 vaccination, for VLBW infants; 
although the observed size of the association for MLBW infants declined such that the 
vaccination rate for MLBW infants was similar to NLBW infants. This could suggest that the 
lower DTP3 vaccination rate for MLBW infants may be due to their lower DTP1 vaccination 
rate whereas VLBW infants have lower DTP3 vaccination rates, irrespective of when they 
received DTP1. This is interesting as it supports the hypothesis that the effect of fragility 
associated with LBW declines with infant age; here, having accounted for delayed DTP1, we 
can see a persisting effect for only the most fragile, smallest infants.  
Finally, a moderate association between ethnicity and DTP3 vaccination rate was observed 
within 12 weeks of DTP1 vaccination, which was not observed for DTP3 vaccination within 
12 weeks of the due date. Having accounted for delayed DTP1, infants of non-Akan 
ethnicity were observed to have moderately higher vaccination rates than infants of Akan 
ethnicity (aOR=1.10; 95%CI:1.05-1.14). The implications of this finding for the vaccination 
programme are unclear, although the maximum 14% difference (from the upper 95% 
confidence interval) in vaccination rates between Akan and non-Akan may not be of 
substantive public health significance.  
Overall it appears that accounting for delayed receipt of DTP1 makes little difference to the 
factors associated with DTP3 vaccination in the three months after the vaccine due date. 
This is important as it suggests that preventing delayed DTP1 vaccination will not 
automatically eliminate delayed DTP3 vaccination. Strategies to improve the timeliness of 
vaccination will also need to target vaccines due later in the schedule.  
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Table 5.8: Sensitivity analysis 3, Determinants of DTP3 vaccination within 12 weeks of vaccination with DTP1 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate / 
100 days of follow-
up 
Unadjusted Rate 
Ratios 
Rate Ratios adjusted 
for age-band* 
Rate Ratios adjusted 
for distal 
determinants 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight and 
illness 
      RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Infant age-band (in 
days) 
<29.5 
29.5-60.0 
60.1-90.0 
>90.0 
  
0/96426 
207/100911 
10055/200276 
2726/48422 
  
0.00 (0.00-0.00) 
0.21 (0.18-0.24) 
5.02 (4.92-5.12) 
5.63 (5.42-5.85) 
  
0.00 (0.00-0.00) 
ref 
24.47 (21.33-28.09) 
27.44 (23.83-31.61) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
24.42 (21.28-28.02) 
28.42 (24.67-32.74) 
 
  
0.00 (0.00-0.00) 
ref 
24.42 (21.28-28.02) 
28.78 (24.98-32.74) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
24.42 (21.28-28.02) 
28.84 (25.04-33.22) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
24.42 (21.28-28.02) 
28.84 (25.04-33.22) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
24.41 (21.27-28.01) 
28.84 (25.04-33.22) 
(<0.0001) 
Distal Determinants                 
Religion of head of 
household 
Christian 
Muslim 
None/Traditional/Other 
  
 
9591/297907 
2589/116463 
808/31665 
  
 
3.22 (3.16-3.28) 
2.22 (2.14-2.31) 
2.55 (2.38-2.73) 
  
 
ref 
0.69 (0.66-0.72) 
0.79 (0.74-0.85) 
(<0.0001) 
  
 
ref 
0.83 (0.79-0.87) 
0.90 (0.83-0.96) 
 
  
 
ref 
0.83 (0.79-0.87) 
0.90 (0.83-0.96) 
(<0.0001) 
  
 
ref 
0.84 (0.80-0.88) 
0.91 (0.85-0.98) 
(<0.0001) 
  
 
ref 
0.84 (0.80-0.88) 
0.91 (0.85-0.98) 
(<0.0001) 
  
 
ref 
0.84 (0.80-0.88) 
0.91 (0.85-0.98) 
(<0.0001) 
Ethnicity of household 
Akan 
Other  
  
6552/201540 
6436/244495 
  
3.25 (3.17-3.33) 
2.63 (2.57-2.70) 
  
ref 
0.81 (0.78-0.84) 
(<0.0001) 
  
ref 
1.09 (1.04-1.14) 
 
  
ref 
1.09 (1.04-1.14) 
(0.0001) 
  
ref 
1.09 (1.05-1.14) 
(0.0001) 
  
ref 
1.09 (1.05-1.14) 
(0.0001) 
  
ref 
1.10 (1.05-1.14) 
(0.0001) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
2355/95845 
2591/89903 
2728/93108 
2653/86402 
2661/80777 
  
2.46 (2.36-2.56) 
2.88 (2.77-3.00) 
2.93 (2.82-3.04) 
3.07 (2.96-3.19) 
3.29 (3.17-3.42) 
  
0.75 (0.71-0.79) 
0.87 (0.83-0.92) 
0.89 (0.84-0.94) 
0.93 (0.88-0.98) 
ref 
(<0.0001) 
  
0.86 (0.81-0.92) 
0.92 (0.86-0.97) 
0.91 (0.86-0.96) 
0.94 (0.89-0.99) 
ref 
 
  
0.86 (0.81-0.92) 
0.92 (0.86-0.97) 
0.91 (0.86-0.96) 
0.94 (0.89-0.99) 
ref 
(0.2541) 
  
0.94 (0.88-1.01) 
0.97 (0.92-1.04) 
0.95 (0.89-1.00) 
0.97 (0.92-1.02) 
ref 
(0.2953) 
  
0.94 (0.88-1.01) 
0.97 (0.92-1.04) 
0.95 (0.89-1.00) 
0.97 (0.92-1.02) 
ref 
(0.2953) 
  
0.94 (0.88-1.01) 
0.98 (0.92-1.04) 
0.95 (0.90-1.00) 
0.97 (0.92-1.02) 
ref 
(0.3126) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
740/22834 
5045/164173 
3770/131945 
3433/127083 
  
3.24 (3.02-3.48) 
3.07 (2.99-3.16) 
2.86 (2.77-2.95) 
2.70 (2.61-2.79) 
  
1.05 (0.98-1.14) 
ref 
0.93 (0.89-0.97) 
0.88 (0.84-0.92) 
(<0.0001) 
  
1.06 (0.98-1.14) 
ref 
0.99 (0.94-1.04) 
0.93 (0.89-0.97) 
 
  
1.06 (0.98-1.14) 
ref 
0.99 (0.94-1.04) 
0.93 (0.89-0.97) 
(0.1945) 
  
1.04 (0.96-1.13) 
ref 
1.01 (0.96-1.06) 
0.97 (0.92-1.01) 
(0.2128) 
  
1.04 (0.96-1.13) 
ref 
1.01 (0.96-1.06) 
0.97 (0.92-1.01) 
(0.2128) 
  
1.04 (0.96-1.13) 
ref 
1.01 (0.96-1.06) 
0.97 (0.92-1.01) 
(0.2192) 
Continues…. 
 163 
 
Table 5.9 continued 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios adjusted 
for distal 
determinants 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight and 
illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
3599/148371 
2246/81442 
7143/216222 
  
2.43 (2.35-2.51) 
2.76 (2.65-2.87) 
3.30 (3.23-3.38) 
  
0.73 (0.71-0.76) 
0.83 (0.80-0.88) 
ref 
(<0.0001) 
  
0.84 (0.80-0.89) 
0.90 (0.86-0.95) 
ref 
(<0.0001) 
  
0.84 (0.80-0.89) 
0.92 (0.87-0.96) 
ref 
(<0.0001) 
  
0.84 (0.80-0.89) 
0.92 (0.87-0.96) 
ref 
(<0.0001) 
  
0.84 (0.80-0.89) 
0.92 (0.87-0.96) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
6185/203450 
6803/242585 
  
3.04 (2.97-3.12) 
2.80 (2.74-2.87) 
  
ref 
0.92 (0.89-0.95) 
(<0.0001) 
  
ref 
1.00 (0.96-1.03) 
(0.8354) 
  
ref 
1.00 (0.96-1.03) 
(0.7997) 
  
ref 
1.00 (0.96-1.03) 
(0.7997) 
  
ref 
1.00 (0.96-1.03) 
(0.7924) 
Sex 
Male 
Female 
  
6511/228848 
6477/217187 
  
2.85 (2.78-2.92) 
2.98 (2.91-3.06) 
  
ref 
1.05 (1.01-1.08) 
(0.0073) 
  
ref 
1.04 (1.00-1.07) 
(0.0484) 
  
ref 
1.04 (1.00-1.08) 
(0.0294) 
  
ref 
1.04 (1.00-1.08) 
(0.0294) 
  
ref 
1.04 (1.00-1.08) 
(0.0292) 
Intermediate determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
1414/56814 
3283/116673 
3565/118844 
2655/85740 
2071/67964 
  
2.49 (2.36-2.62) 
2.81 (2.72-2.91) 
3.00 (2.90-3.10) 
3.10 (2.98-3.22) 
3.05 (2.92-3.18) 
  
0.83 (0.78-0.88) 
0.94 (0.89-0.98) 
ref 
1.03 (0.98-1.09) 
1.02 (0.96-1.07) 
(<0.0001) 
   
0.82 (0.76-0.88) 
0.95 (0.90-1.00) 
ref 
1.08 (1.03-1.14) 
1.09 (1.02-1.16) 
(<0.0001) 
  
0.82 (0.76-0.89) 
0.95 (0.90-1.00) 
ref 
1.08 (1.03-1.14) 
1.09 (1.02-1.16) 
(<0.0001) 
  
0.82 (0.76-0.89) 
0.95 (0.90-1.00) 
ref 
1.08 (1.03-1.14) 
1.09 (1.02-1.16) 
(<0.0001) 
Number of living children 
in family  
0-1 
2-3 
4 or more 
  
 
3851/131361 
5281/174233 
3856/140441 
  
 
2.93 (2.84-3.03) 
3.03 (2.95-3.11) 
2.75 (2.66-2.83) 
  
 
0.97 (0.93-1.01) 
ref 
0.91 (0.87-0.94) 
(<0.0001) 
   
 
1.08 (1.02-1.13) 
ref 
0.90 (0.86-0.95) 
(<0.0001) 
  
 
1.08 (1.03-1.14) 
ref 
0.90 (0.85-0.95) 
(<0.0001) 
  
 
1.08 (1.03-1.14) 
ref 
0.90 (0.85-0.95) 
(<0.0001) 
Maternal illness 
No 
Yes 
  
12352/425249 
636/20786 
  
2.90 (2.85-2.96) 
3.06 (2.83-3.31) 
  
ref 
1.05 (0.97-1.14) 
(0.2043) 
   
ref 
1.06 (0.98-1.15) 
(0.1490) 
  
ref 
1.07 (0.98-1.16) 
(0.1185) 
  
ref 
1.07 (0.99-1.16) 
(0.1121) 
Continued….  
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Table 5.9 continued 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios adjusted 
for age-band* 
Rate Ratios adjusted 
for distal 
determinants 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight and 
illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
8056/270041 
3089/99637 
1843/76357 
  
2.98 (2.92-3.05) 
3.10 (2.99-3.21) 
2.41 (2.31-2.53) 
  
ref 
1.04 (1.00-1.08) 
0.81 (0.77-0.85) 
(<0.0001) 
    
ref 
1.00 (0.96-1.04) 
0.92 (0.87-0.98) 
(0.0176) 
  
ref 
1.00 (0.96-1.04) 
0.92 (0.87-0.98) 
(0.0191) 
  
ref 
1.00 (0.96-1.04) 
0.93 (0.88-0.98) 
(0.0204) 
Place of birth 
Facility 
Non-facility 
  
10170/331942 
2818/114093 
  
3.06 (3.00-3.12) 
2.47 (2.38-2.56) 
  
ref 
0.81 (0.77-0.84) 
(<0.0001) 
    
ref 
0.93 (0.89-0.97) 
(0.0022) 
  
ref 
0.93 (0.89-0.98) 
(0.0032) 
  
ref 
0.93 (0.89-0.98) 
(0.0032) 
Multiple birth 
No 
Yes 
  
12544/429864 
444/16171 
  
2.92 (2.87-2.97) 
2.75 (2.50-3.01) 
  
ref 
0.94 (0.86-1.03) 
(0.2028) 
    
ref 
0.95 (0.87-1.05) 
(0.3379) 
  
ref 
1.00 (0.91-1.11) 
(0.09652) 
  
ref 
1.00 (0.91-1.11) 
(0.9593) 
Proximal Variables         
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
11090/375642 
1664/60515 
202/7548 
32/2330 
  
2.95 (2.90-3.01) 
2.75 (2.62-2.89) 
2.68 (2.33-3.07) 
1.37 (0.97-1.94) 
  
ref 
0.93 (0.88-0.98) 
0.91 (0.79-1.04) 
0.47 (0.33-0.66) 
(<0.0001) 
   
  
  
  
  
   
ref 
0.93 (0.88-0.98) 
0.98 (0.85-1.13) 
0.65 (0.46-0.92) 
(0.0065) 
  
ref 
0.93 (0.88-0.98) 
0.98 (0.85-1.12) 
0.65 (0.46-0.93) 
(0.0069) 
Mediating Variables            
Infant illness 
No 
Yes 
  
11075/371786 
1913/74249 
  
2.98 (2.92-3.03) 
2.58 (2.46-2.69) 
  
ref 
0.86 (0.82-0.91) 
(<0.0001) 
      
ref 
1.02 (0.98-1.08) 
(0.6120) 
* all p-values<0.0001 
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APPENDIX 5.1 
Table A5.1. Comparison of estimated effect of determinants of DTP1 and DTP3 vaccination, 
analysed by Poisson and Cox regression* 
  DTP1 between 0 and 18 weeks DTP3 between 0 and 26 weeks 
 Rate Ratios  Hazard Ratios  Rate Ratios  Hazard Ratios  
  aRR (95%CI) aHR (95%CI) aRR (95%CI) aHR (95%CI) 
Distal Determinants      
Religion 
Christian 
Muslim 
None/Traditional/Other 
 
ref 
0.92 (0.89-0.95) 
0.96 (0.90-1.01) 
 
ref 
0.82 (0.89-0.95) 
0.95 (0.90-1.01) 
  
ref 
0.82 (0.79-0.85) 
0.94 (0.88-1.00) 
 
ref 
0.82 (0.78-0.85) 
0.94 (0.88-1.00) 
Ethnicity of 
household 
Akan 
Other  
  
ref 
1.03 (0.99-1.06) 
 
ref 
1.04 (1.01-1.08) 
  
ref 
0.97 (0.94-1.01) 
 
ref 
0.98 (0.94-1.01) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
0.94 (0.89-0.99) 
0.99 (0.95-1.04) 
0.99 (0.95-1.04) 
0.99 (0.95-1.03) 
ref 
 
0.93 (0.88-0.98) 
0.98 (0.93-1.02) 
0.97 (0.93-1.02) 
0.98 (0.94-1.02) 
ref 
  
1.09 (1.03-1.16) 
1.14 (1.08-1.20) 
1.11 (1.05-1.16) 
1.06 (1.01-1.11) 
ref 
 
1.09 (1.03-1.16) 
1.14 (1.09-1.21) 
1.11 (1.06-1.17) 
1.06 (1.01-1.11) 
ref 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
1.08 (1.01-1.15) 
ref 
0.97 (0.93-1.01) 
0.99 (0.96-1.03) 
 
1.10 (1.03-1.17) 
ref 
0.95 (0.92-0.99) 
0.99 (0.95-1.03) 
  
1.07 (1.01-1.15) 
ref 
1.09 (1.04-1.13) 
1.02 (0.98-1.06) 
 
1.08 (1.01-1.16) 
ref 
1.09 (1.04-1.13) 
1.02 (0.98-1.07) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
0.88 (0.84-0.91) 
0.93 (0.89-0.96) 
ref 
 
0.86 (0.83-0.90) 
0.92 (0.88-0.95) 
ref 
  
0.78 (0.75-0.82) 
0.83 (0.80-0.87) 
ref 
 
0.77 (0.74-0.81) 
0.83 (0.79-0.86) 
ref 
Season vaccine due 
Wet 
Dry 
  
ref 
1.00 (0.97-1.02) 
 
ref 
1.00 (0.97-1.02) 
  
ref 
0.96 (0.92-0.98) 
 
ref 
0.95 (0.92-0.98) 
Sex 
Male 
Female 
  
ref 
1.02 (1.00-1.05) 
 
ref 
1.03 (1.00-1.05) 
  
ref 
1.04 (1.01-1.07) 
 
ref 
1.04 (1.01-1.07) 
Intermediate determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
0.84 (0.79-0.89) 
0.93 (0.89-0.97) 
ref 
1.02 (0.98-1.07) 
1.02 (0.97-1.07) 
 
0.82 (0.77-0.87) 
0.92 (0.89-0.96) 
ref 
1.03 (0.99-1.07) 
1.02 (0.97-1.07) 
  
0.80 (0.75-0.85) 
0.91 (0.87-0.95) 
ref 
1.07 (1.02-1.12) 
1.06 (1.01-1.12) 
 
0.79 (0.74-0.84) 
0.91 (0.87-0.95) 
ref 
1.07 (1.03-1.12) 
1.07 (1.01-1.12) 
Number of living 
children in family  
0-1 
2-3 
4 or more 
  
 
1.05 (1.01-1.09) 
ref 
0.95 (0.91-0.99) 
 
 
1.06 (1.02-1.11) 
ref 
0.95 (0.91-0.99) 
  
 
1.07 (1.03-1.12) 
ref 
0.88 (0.85-0.92) 
 
 
1.08 (1.03-1.13) 
ref 
0.88 (0.85-0.92) 
Continued…. 
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Table A5.1 continued     
 DTP1 between 0 and 18 weeks DTP3 between 0 and 26 weeks 
 Rate Ratios  Hazard Ratios  Rate Ratios  Hazard Ratios  
 aRR (95%CI) aHR (95%CI) aRR (95%CI) aHR (95%CI) 
Maternal illness 
No 
Yes 
  
ref 
1.03 (0.97-1.10) 
 
ref 
1.04 (0.98-1.11) 
  
ref 
0.98 (0.92-1.05) 
 
ref 
0.98 (0.92-1.05) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
 
ref 
0.96 (0.93-0.99) 
0.87 (0.83-0.91) 
 
 
ref 
0.95 (0.92-0.98) 
0.86 (0.82-0.90) 
  
 
ref 
0.98 (0.95-1.02) 
0.81 (0.77-0.85) 
 
 
ref 
0.98 (0.94-1.01) 
0.81 (0.77-0.85) 
Place of birth 
Facility 
Non-facility 
  
ref 
0.94 (0.91-0.98) 
 
ref 
0.93 (0.90-0.97) 
  
ref 
0.95 (0.91-0.99) 
 
ref 
0.95 (0.91-0.98) 
Multiple birth 
No 
Yes 
  
ref 
1.08 (1.00-1.17) 
 
ref 
1.09 (1.00-1.17) 
  
ref 
1.07 (0.98-1.16) 
 
ref 
1.07 (0.99-1.17) 
Distal Determinants 
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
ref 
0.92 (0.89-0.96) 
0.77 (0.69-0.85) 
0.64 (0.51-0.80) 
 
ref 
0.91 (0.88-0.95) 
0.75 (0.67-0.84) 
0.61 (0.49-0.78) 
  
ref 
0.95 (0.91-1.00) 
0.82 (0.73-0.92) 
0.60 (0.46-0.79) 
 
ref 
0.95 (0.91-0.99) 
0.82 (0.73-0.92) 
0.59 (0.45-0.78) 
Mediating Variables      
Infant illness 
No 
Yes 
 
ref 
0.94 (0.90-0.98) 
 
ref 
0.94 (0.91-0.98) 
  
ref 
1.03 (0.99-1.07) 
 
ref 
0.97 (0.94-1.02) 
* Effect estimates adjusted for infant age-band, for distal, intermediate and proximal variables, and 
for the mediating effects of infant illness. Poisson model adjusted for infant age. 
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Table A5.2: Sensitivity analysis 1: Determinants of DTP1 vaccination between 0 and 18 weeks of age (omitting those infants reported not vaccinated but 
whose card was never seen) 
  Unadjusted Rate 
Ratios 
Rate Ratios adjusted 
for age-band* 
Rate Ratios adjusted for 
distal determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants 
Rate Ratios adjusted for distal 
and intermediate determinants 
and birth weight 
Rate Ratios adjusted for distal 
and intermediate determinants 
and birth weight & illness 
  RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Infant age-band (in days) 
<29.5 
29.5-60.0 
60.1-90.0 
>90.0 
 
0.01 (0.01-0.01) 
ref 
2.25 (2.18-2.31) 
1.57 (1.48-1.67) 
(<0.0001) 
  
_ 
_ 
_ 
_ 
  
0.01 (0.01-0.01) 
ref 
2.29 (2.22-2.36) 
1.64 (1.55-1.74) 
(<0.0001) 
  
0.01 (0.01-0.01) 
ref 
2.31 (2.24-2.38) 
1.67 (1.57-1.77) 
(<0.0001) 
  
0.01 (0.01-0.01) 
ref 
2.32 (2.25-2.38) 
1.68 (1.58-1.78) 
(<0.0001) 
  
0.01 (0.01-0.01) 
ref 
2.32 (2.25-2.39) 
1.68 (1.58-1.78) 
(<0.0001) 
Distal Determinants             
Religion of head of 
household 
Christian 
Muslim 
None/Traditional/Other 
  
 
ref 
0.95 (0.92-0.98) 
0.94 (0.89-0.99) 
(0.0007) 
  
 
ref 
0.88 (0.86-0.91) 
0.87 (0.82-0.92) 
  
 
ref 
0.92 (0.89-0.95) 
0.94 (0.89-1.00) 
(<0.0001) 
  
 
ref 
0.93 (0.89-0.96) 
0.95 (0.90-1.01) 
(0.0001) 
  
 
ref 
0.92 (0.89-0.96) 
0.95 (0.90-1.01) 
(0.0001) 
  
 
ref 
0.93 (0.89-0.96) 
0.95 (0.90-1.01) 
(0.0001) 
Ethnicity of household 
Akan 
Other  
  
ref 
0.95 (0.93-0.98) 
(0.0006) 
  
ref 
0.89 (0.87-0.92) 
  
ref 
1.02 (0.98-1.05) 
(0.3032) 
  
ref 
1.02 (0.99-1.06) 
(0.2601) 
  
ref 
1.02 (0.98-1.05) 
(0.3357) 
  
ref 
1.02 (0.98-1.05) 
(0.2996) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
0.90 (0.86-0.93) 
0.94 (0.90-0.98) 
0.96 (0.92-1.00) 
0.97 (0.93-1.01) 
ref 
(<0.0001) 
  
0.77 (0.74-0.81) 
0.87 (0.83-0.91) 
0.91 (0.87-0.94) 
0.93 (0.90-0.97) 
ref 
  
0.86 (0.82-0.90) 
0.93 (0.89-0.98) 
0.95 (0.91-0.99) 
0.96 (0.92-1.01) 
ref 
(<0.0001) 
  
0.95 (0.90-1.00) 
1.00 (0.95-1.05) 
0.99 (0.95-1.04) 
0.99 (0.95-1.03) 
ref 
(0.2343) 
  
0.96 (0.91-1.01) 
1.00 (0.96-1.05) 
1.00 (0.96-1.04) 
0.99 (0.95-1.03) 
ref 
(0.2535) 
  
0.96 (0.91-1.01) 
1.01 (0.96-1.05) 
1.00 (0.96-1.04) 
0.99 (0.95-1.03) 
ref 
(0.2478) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
1.05 (0.99-1.11) 
ref 
0.94 (0.91-0.97) 
0.97 (0.94-1.01) 
(0.0004) 
  
1.12 (1.06-1.19) 
ref 
0.87 (0.84-0.90) 
0.93 (0.90-0.97) 
  
1.08 (1.01-1.15) 
ref 
0.95 (0.91-0.99) 
0.95 (0.92-0.98) 
(0.0001) 
  
1.08 (1.01-1.15) 
ref 
0.97 (0.93-1.00) 
0.99 (0.96-1.03) 
(0.0223) 
  
0.08 (0.01-1.15) 
ref 
0.96 (0.93-1.00) 
0.99 (0.96-1.03) 
(0.0182) 
  
1.08 (1.01-1.15) 
ref 
0.96 (0.93-1.00) 
0.99 (0.96-1.03) 
(0.0179) 
Continued…..  
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Table A5.2 continued 
 Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios adjusted for 
distal determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants 
Rate Ratios adjusted for distal 
and intermediate 
determinants and birth weight 
Rate Ratios adjusted for distal 
and intermediate 
determinants and birth weight 
& illness 
 RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
0.92 (0.89-0.95) 
0.95 (0.92-0.99) 
ref 
(<0.0001) 
  
0.82 (0.80-0.85) 
0.88 (0.85-0.91) 
ref 
  
0.89 (0.86-0.93) 
0.92 (0.88-0.95) 
ref 
(<0.0001) 
  
0.88 (0.85-0.92) 
0.92 (0.89-0.96) 
ref 
(<0.0001) 
  
0.88 (0.85-0.92) 
0.93 (0.89-0.96) 
ref 
(<0.0001) 
  
0.88 (0.85-0.92) 
0.93 (0.89-0.96) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
ref 
1.00 (0.97-1.03) 
(0.9539) 
  
ref 
0.99 (0.97-1.02) 
  
ref 
0.99 (0.97-1.02) 
(0.6101) 
  
ref 
0.99 (0.97-1.02) 
(0.6972) 
  
ref 
0.99 (0.97-1.02) 
(0.6439) 
  
ref 
0.99 (0.97-1.02) 
(0.6030) 
Sex 
Male 
Female 
  
ref 
1.01 (0.98-1.03) 
(0.6079) 
  
ref 
1.02 (0.99-1.04) 
  
ref 
1.01 (0.99-1.04) 
(0.3246) 
  
ref 
1.01 (0.99-1.04) 
(0.2974) 
  
ref 
1.02 (0.99-1.05) 
(0.1590) 
  
ref 
1.02 (0.99-1.05) 
(0.1714) 
Intermediate Determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
0.94 (0.90-0.98) 
0.98 (0.94-1.01) 
ref 
0.99 (0.95-1.03) 
0.97 (0.93-1.02) 
(0.1103) 
  
0.87 (0.83-0.91) 
0.95 (0.91-0.98) 
ref 
0.97 (0.94-1.01) 
0.94 (0.90-0.98) 
  
  
  
  
  
  
  
0.83 (0.78-0.88) 
0.93 (0.89-0.96) 
ref 
1.03 (0.98-1.07) 
1.02 (0.97-1.07) 
(<0.0001) 
  
0.84 (0.79-0.89) 
0.93 (0.89-0.97) 
ref 
1.03 (0.99-1.07) 
1.02 (0.97-1.07) 
(<0.0001) 
  
0.84 (0.79-0.89) 
0.93 (0.89-0.97) 
ref 
1.03 (0.99-1.07) 
1.02 (0.97-1.07) 
(<0.0001) 
Number of living children 
in family  
0-1 
2-3 
4 or more 
  
1.00 (0.97-1.03) 
ref 
0.97 (0.94-1.00) 
(0.1759) 
  
0.99 (0.96-1.03) 
ref 
0.93 (0.90-0.96) 
  
  
  
  
  
1.04 (1.00-1.08) 
ref 
0.95 (0.92-0.99) 
(0.0049) 
  
1.05 (1.01-1.09) 
ref 
0.95 (0.91-0.99) 
(0.0009) 
  
1.05 (1.01-1.09) 
ref 
0.95 (0.91-0.99) 
(0.0008) 
Maternal illness 
No 
Yes 
  
ref 
1.01 (0.95-1.07) 
  
ref 
1.02 (0.96-1.08) 
  
  
  
  
ref 
1.02 (0.96-1.09) 
(0.5027) 
  
ref 
1.03 (0.96-1.09) 
(0.4304) 
  
ref 
1.03 (0.97-1.09) 
(0.4033) 
Continued… 
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Table A5.2 continued 
 Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios adjusted for 
distal determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants 
Rate Ratios adjusted for distal 
and intermediate 
determinants and birth weight 
Rate Ratios adjusted for distal 
and intermediate 
determinants and birth weight 
& illness 
 RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
 
ref 
0.98 (0.95-1.01) 
0.91 (0.87-0.94) 
(<0.0001) 
  
 
ref 
0.95 (0.92-0.98) 
0.79 (0.77-0.83) 
  
  
  
  
  
 
ref 
0.96 (0.93-0.99) 
0.87 (0.83-0.91) 
(<0.0001) 
  
 
ref 
0.96 (0.93-0.99) 
0.87 (0.83-0.91) 
(<0.0001) 
  
 
ref 
0.96 (0.93-0.99) 
0.87 (0.84-0.91) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
  
ref 
0.93 (0.90-0.96) 
(<0.0001) 
  
ref 
0.84 (0.82-0.87) 
  
  
  
  
ref 
0.94 (0.91-0.97) 
(0.0009) 
  
ref 
0.94 (0.91-0.98) 
(0.0014) 
  
ref 
0.94 (0.91-0.98) 
(0.0012) 
Multiple birth 
No 
Yes 
  
ref 
0.99 (0.92-1.06) 
(0.7293) 
  
ref 
0.96 (0.89-1.03) 
  
  
  
  
ref 
0.98 (0.91-1.05) 
(0.5892) 
  
ref 
1.08 (1.00-1.17) 
(0.0492) 
  
ref 
1.08 (1.00-1.17) 
(0.0473) 
Proximal Variables       
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
ref 
0.97 (0.93-1.00) 
0.90 (0.82-1.00) 
0.81 (0.65-1.02) 
(0.0215) 
  
ref 
0.92 (0.88-0.96) 
0.79 (0.71-0.88) 
0.64 (0.51-0.80) 
  
  
  
  
  
  
  
  
  
  
 
ref 
0.92 (0.89-0.96) 
0.76 (0.69-0.85) 
0.63 (0.50-0.79) 
(<0.0001) 
 
ref 
0.92 (0.89-0.96) 
0.76 (0.69-0.85) 
0.63 (0.50-0.79) 
(<0.0001) 
Mediating Variables            
Infant illness 
No 
Yes 
  
ref 
0.97 (0.93-1.01) 
(0.1219) 
  
ref 
0.93 (0.90-0.97) 
  
  
  
  
  
  
   
ref 
0.95 (0.91-0.99) 
(0.0039) 
* all p-values<0.0001 
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Table A5.3: Sensitivity analysis 2: determinants of delayed DTP3 vaccination in rural Ghana and between 0 and 26 weeks of age (omitting those infants 
reported not vaccinated but whose card was never seen). 
  Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios adjusted for 
distal determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants 
Rate Ratios adjusted for distal 
and intermediate determinants 
and birth weight 
Rate Ratios adjusted for distal 
and intermediate determinants 
and birth weight & illness 
  RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Infant age-band (in days) 
<29.5 
29.5-60.0 
60.1-90.0 
>90.0 
  
0.00 (0.00-0.00) 
ref 
1.92 (1.86-1.98) 
1.78 (1.71-1.85) 
(<0.0001) 
  
_ 
_ 
_ 
_ 
  
0.00 (0.00-0.00) 
ref 
1.96 (1.90-2.02) 
1.87 (1.79-1.94) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
1.97 (1.91-2.04) 
1.90 (1.82-1.97) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
1.98 (1.91-2.04) 
1.9 (1.82-1.98) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
1.98 (1.91-2.04) 
1.90 (1.82-1.98) 
(<0.0001) 
Distal Determinants             
Religion of head of 
household 
Christian 
Muslim 
None/Traditional/Other 
  
 
ref 
0.84 (0.81-0.87) 
0.91 (0.86-0.97) 
(<0.0001) 
  
 
ref 
0.73 (0.70-0.76) 
0.85 (0.80-0.90) 
  
 
ref 
0.81 (0.78-0.85) 
0.92 (0.86-0.98) 
(<0.0001) 
  
 
ref 
0.82 (0.79-0.86) 
0.94 (0.88-1.00) 
(<0.0001) 
  
 
ref 
0.82 (0.79-0.86) 
0.93 (0.88-0.99) 
(<0.0001) 
  
 
ref 
0.82 (0.79-0.86) 
0.93 (0.88-0.99) 
(<0.0001) 
Ethnicity of household 
Akan 
Other  
  
ref 
0.88 (0.86-0.91) 
(<0.0001) 
  
ref 
0.80 (0.77-0.82) 
  
ref 
0.97 (0.93-1.01) 
(0.1107) 
  
ref 
0.97 (0.94-1.01) 
(0.1280) 
  
ref 
0.97 (0.93-1.01) 
(0.1122) 
  
ref 
0.97 (0.93-1.01) 
(0.1172) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
0.90 (0.86-0.94) 
0.98 (0.93-1.02) 
0.99 (0.94-1.03) 
0.99 (0.94-1.03) 
ref 
(<0.0001) 
  
0.83 (0.79-0.87) 
0.96 (0.92-1.00) 
0.99 (0.94-1.03) 
0.98 (0.93-1.02) 
ref 
  
0.96 (0.90-1.01) 
1.04 (0.99-1.09) 
1.04 (0.99-1.09) 
1.02 (0.98-1.07) 
ref 
(0.0031) 
  
1.10 (1.04-1.17) 
1.15 (1.09-1.21) 
1.11 (1.05-1.16) 
1.06 (1.01-1.11) 
ref 
(<0.0001) 
  
1.1 (1.04-1.17) 
1.15 (1.09-1.21) 
1.11 (1.06-1.16) 
1.06 (1.01-1.11) 
ref 
(<0.0001) 
  
1.10 (1.04-1.17) 
1.15 (1.09-1.21) 
1.11 (1.06-1.16) 
1.06 (1.01-1.11) 
ref 
(<0.0001) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
1.07 (1.00-1.14) 
ref 
0.98 (0.94-1.01) 
0.98 (0.94-1.01) 
(0.0428) 
  
1.16 (1.09-1.24) 
ref 
0.96 (0.93-0.99) 
0.97 (0.94-1.01) 
  
1.09 (1.02-1.16) 
ref 
1.05 (1.01-1.10) 
0.97 (0.93-1.01) 
(0.0001) 
  
1.08 (1.01-1.15) 
ref 
0.90 (0.04-0.13) 
1.02 (0.98-1.07) 
(0.0005) 
  
1.08 (1.01-1.15) 
ref 
1.09 (1.04-1.13) 
1.02 (0.98-1.07) 
(0.0006) 
  
1.08 (1.01-1.15) 
ref 
1.09 (1.04-1.13) 
1.02 (0.98-1.07) 
(0.0006) 
Continued…. 
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Table A5.3 continued 
 Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios adjusted for 
distal determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants 
Rate Ratios adjusted for distal 
and intermediate 
determinants and birth weight 
Rate Ratios adjusted for distal 
and intermediate 
determinants and birth weight 
& illness 
 RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
0.85 (0.82-0.87) 
0.89 (0.86-0.93) 
ref 
(<0.0001) 
  
0.73 (0.70-0.75) 
0.79 (0.76-0.82) 
ref 
  
0.79 (0.76-0.82) 
0.82 (0.79-0.86) 
ref 
(<0.0001) 
  
0.90 (0.75-0.82) 
0.90 (0.80-0.87) 
ref 
(<0.0001) 
  
0.78 (0.75-0.82) 
0.83 (0.80-0.87) 
ref 
(<0.0001) 
  
0.78 (0.75-0.82) 
0.83 (0.80-0.87) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
ref 
0.97 (0.94-1.00) 
(0.0550) 
  
ref 
0.96 (0.93-0.99) 
  
ref 
0.95 (0.93-0.98) 
(0.0011) 
  
ref 
0.90 (0.92-0.98) 
(0.0005) 
  
ref 
0.95 (0.92-0.98) 
(0.0004) 
  
ref 
0.95 (0.92-0.98) 
(0.0003) 
Sex 
Male 
Female 
  
ref 
1.02 (0.99-1.05) 
(0.2878) 
  
ref 
1.03 (1.00-1.06) 
  
ref 
1.03 (1.00-1.06) 
(0.0586) 
  
ref 
1.03 (1.00-1.06) 
(0.0464) 
  
ref 
1.03 (1.00-1.06) 
(0.0290) 
  
ref 
1.03 (1.00-1.06) 
(0.0304) 
Intermediate Determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
0.93 (0.88-0.98) 
0.96 (0.93-1.00) 
ref 
1.00 (0.95-1.04) 
0.97 (0.93-1.02) 
(0.0316) 
  
0.88 (0.84-0.93) 
0.94 (0.91-0.98) 
ref 
0.98 (0.94-1.03) 
0.94 (0.89-0.98) 
  
  
  
  
  
  
  
0.79 (0.74-0.84) 
0.90 (0.86-0.94) 
ref 
1.07 (1.02-1.12) 
1.06 (1.01-1.12) 
(<0.0001) 
  
0.8 (0.75-0.85) 
0.9 (0.87-0.94) 
ref 
1.07 (1.02-1.12) 
1.06 (1.01-1.12) 
(<0.0001) 
  
0.80 (0.75-0.85) 
0.90 (0.87-0.94) 
ref 
1.07 (1.02-1.12) 
1.06 (1.01-1.12) 
(<0.0001) 
Number of living children 
in family  
0-1 
2-3 
4 or more 
  
0.99 (0.96-1.03) 
ref 
0.95 (0.92-0.98) 
(0.0063) 
  
1.00 (0.96-1.03) 
ref 
0.89 (0.86-0.93) 
  
  
  
  
  
1.06 (1.02-1.11) 
ref 
0.90 (0.85-0.92) 
(<0.0001) 
  
1.07 (1.03-1.12) 
ref 
0.88 (0.84-0.92) 
(<0.0001) 
  
1.07 (1.03-1.12) 
ref 
0.88 (0.84-0.92) 
(<0.0001) 
Maternal illness 
No 
Yes 
  
ref 
0.98 (0.92-1.05) 
(0.5948) 
  
ref 
0.97 (0.91-1.04) 
  
  
  
  
ref 
0.98 (0.91-1.05) 
(0.5023) 
  
ref 
0.98 (0.92-1.05) 
(0.5535) 
  
ref 
0.98 (0.92-1.05) 
(0.5719) 
Continued….  
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Table A5.3 continued 
 Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios adjusted for 
distal determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants 
Rate Ratios adjusted for distal 
and intermediate 
determinants and birth weight 
Rate Ratios adjusted for distal 
and intermediate 
determinants and birth weight 
& illness 
 RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
 
ref 
1.01 (0.98-1.05) 
0.88 (0.84-0.91) 
(<0.0001) 
  
 
ref 
1.01 (0.97-1.04) 
0.77 (0.74-0.81) 
  
  
  
  
  
 
ref 
0.98 (0.94-1.01) 
0.90 (0.77-0.85) 
(<0.0001) 
  
 
ref 
0.98 (0.94-1.01) 
0.81 (0.78-0.85) 
(<0.0001) 
  
 
ref 
0.98 (0.95-1.02) 
0.81 (0.78-0.85) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
  
ref 
0.92 (0.89-0.95) 
(<0.0001) 
  
ref 
0.86 (0.83-0.89) 
  
  
  
  
ref 
0.95 (0.91-0.99) 
(0.0092) 
  
ref 
0.95 (0.91-0.99) 
(0.0121) 
  
ref 
0.95 (0.91-0.99) 
(0.0120) 
Multiple birth 
No 
Yes 
  
ref 
0.98 (0.91-1.06) 
(0.5997) 
  
ref 
0.95 (0.88-1.03) 
  
  
  
  
ref 
0.99 (0.92-1.08) 
(0.8962) 
  
ref 
1.07 (0.98-1.16) 
(0.1247) 
  
ref 
1.07 (0.98-1.17) 
(0.1197) 
Proximal Variables       
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
ref 
0.97 (0.93-1.02) 
0.92 (0.82-1.03) 
0.73 (0.56-0.97) 
(0.0336) 
  
ref 
0.95 (0.91-0.99) 
0.86 (0.77-0.96) 
0.62 (0.47-0.82) 
  
  
  
  
  
  
 
  
ref 
0.95 (0.91-1.00) 
0.82 (0.73-0.93) 
0.6 (0.45-0.79) 
(<0.0001) 
  
ref 
0.95 (0.91-1.00) 
0.82 (0.73-0.92) 
0.60 (0.45-0.79) 
(<0.0001) 
Mediating Variables           
Infant illness 
No 
Yes 
  
ref 
0.97 (0.93-1.01) 
(0.1191) 
  
ref 
0.95 (0.91-0.99) 
  
  
  
    
ref 
1.02 (0.98-1.07) 
(0.1151) 
* All p-values<0.0001 
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Table A5.4 Determinants of DTP1 vaccination between 0 and 14 weeks 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and birth 
weight and illness 
      RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Infant age-band (in 
days) 
<29.5 
29.5-60.0 
>90.0 
  
 
130/670092 
13098/524434 
7657/140213 
  
 
0.02 (0.02-0.02) 
2.50 (2.46-2.54) 
5.46 (5.34-5.58) 
  
 
0.01 (0.01-0.01) 
ref 
2.19 (2.13-2.25) 
(<0.0001) 
  
  
_ 
_ 
  
 
0.01 (0.01-0.01) 
ref 
2.23 (2.17-2.30) 
(<0.0001) 
  
 
0.01 (0.01-0.01) 
ref 
2.25 (2.19-2.32) 
(<0.0001) 
  
 
0.01 (0.01-0.01) 
ref 
2.26 (2.20-2.33) 
(<0.0001) 
  
 
0.01 (0.01-0.01) 
ref 
2.26 (2.20-2.33) 
(<0.0001) 
Distal Determinants                 
Religion of head of 
household 
Christian 
Muslim 
None/Traditional/Other 
  
 
14757/923943 
4834/324362 
1294/86434 
  
 
1.60 (1.57-1.62) 
1.49 (1.45-1.53) 
1.50 (1.42-1.58) 
  
 
ref 
0.93 (0.90-0.96) 
0.94 (0.89-0.99) 
(<0.0001) 
  
 
ref 
0.88 (0.85-0.90) 
0.88 (0.83-0.93) 
  
 
ref 
0.91 (0.88-0.95) 
0.96 (0.90-1.01) 
(<0.0001) 
  
 
ref 
0.92 (0.88-0.95) 
0.97 (0.91-1.02) 
(<0.0001) 
  
 
ref 
0.92 (0.88-0.95) 
0.97 (0.91-1.02) 
(<0.0001) 
  
 
ref 
0.92 (0.88-0.95) 
0.97 (0.91-1.02) 
(<0.0001) 
Ethnicity of household 
Akan 
Other  
  
9959/617164 
10926/717575 
  
1.61 (1.58-1.65) 
1.52 (1.49-1.55) 
  
ref 
0.94 (0.92-0.97) 
(<0.0001) 
  
ref 
0.89 (0.87-0.92) 
  
ref 
1.03 (0.99-1.06) 
(0.1641) 
  
ref 
1.03 (0.99-1.07) 
(0.1162) 
  
ref 
1.03 (0.99-1.06) 
(0.1532) 
  
ref 
1.03 (0.99-1.06) 
(0.1332) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
3915/269995 
4089/265346 
4223/267384 
4294/268139 
4364/263875 
  
1.45 (1.41-1.50) 
1.54 (1.49-1.59) 
1.58 (1.53-1.63) 
1.60 (1.55-1.65) 
1.65 (1.61-1.70) 
  
0.88 (0.84-0.92) 
0.93 (0.89-0.97) 
0.95 (0.92-1.00) 
0.97 (0.93-1.01) 
ref 
(<0.0001) 
  
0.76 (0.73-0.80) 
0.86 (0.82-0.90) 
0.90 (0.86-0.94) 
0.93 (0.89-0.97) 
ref 
  
0.85 (0.81-0.90) 
0.93 (0.88-0.97) 
0.94 (0.90-0.99) 
0.96 (0.92-1.00) 
ref 
(<0.0001) 
  
0.94 (0.89-0.99) 
0.99 (0.95-1.04) 
0.99 (0.95-1.03) 
0.99 (0.94-1.03) 
ref 
(0.1604) 
  
0.95 (0.89-1.00) 
1.00 (0.95-1.05) 
0.99 (0.95-1.04) 
0.99 (0.95-1.03) 
ref 
(0.1886) 
  
0.95 (0.89-1.00) 
1.00 (0.95-1.05) 
0.99 (0.95-1.04) 
0.99 (0.95-1.03) 
Ref 
(0.1862) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
1149/67828 
8275/513801 
5946/397315 
5515/355795 
  
1.69 (1.60-1.79) 
1.61 (1.58-1.65) 
1.50 (1.46-1.54) 
1.55 (1.51-1.59) 
  
1.05 (0.99-1.12) 
ref 
0.93 (0.90-0.96) 
0.96 (0.93-1.00) 
(<0.0001) 
  
1.12 (1.05-1.19) 
ref 
0.86 (0.83-0.89) 
0.93 (0.89-0.96) 
  
1.08 (1.01-1.14) 
ref 
0.94 (0.90-0.98) 
0.94 (0.91-0.97) 
(<0.0001) 
  
1.08 (1.01-1.14) 
ref 
0.96 (0.92-0.99) 
0.99 (0.95-1.02) 
(0.0088) 
  
1.08 (1.01-1.15) 
ref 
0.95 (0.92-0.99) 
0.99 (0.95-1.03) 
(<0.0001) 
  
1.08 (1.01-1.15) 
ref 
0.95 (0.92-0.99) 
0.99 (0.95-1.02) 
(0.0068) 
Continued…. 
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Table A5.4 continued  
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate / 
100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
and birth weight 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight and illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
6283/425582 
3813/248478 
10789/660679 
  
1.48 (1.44-1.51) 
1.53 (1.49-1.58) 
1.63 (1.60-1.66) 
  
0.90 (0.88-0.93) 
0.94 (0.91-0.98) 
ref 
(<0.0001) 
  
0.81 (0.79-0.84) 
0.88 (0.84-0.91) 
ref 
  
0.88 (0.85-0.92) 
0.92 (0.88-0.95) 
ref 
(<0.0001) 
  
0.88 (0.84-0.91) 
0.92 (0.88-0.96) 
ref 
(<0.0001) 
  
0.88 (0.84-0.91) 
0.92 (0.89-0.96) 
ref 
(<0.0001) 
  
0.88 (0.84-0.91) 
0.92 (0.89-0.96) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
13239/846115 
7646/488624 
  
1.56(1.54-1.59) 
1.56 (1.53-1.60) 
  
ref 
1.00 (0.97-1.03) 
(0.9957) 
  
ref 
0.99 (0.97-1.02) 
  
ref 
0.99 (0.97-1.02) 
(0.6477 
  
ref 
0.99 (0.97-1.02) 
(0.7241) 
  
ref 
0.99 (0.97-1.02) 
(0.6733) 
  
ref 
0.99 (0.97-1.02) 
(0.6309) 
Sex 
Male 
Female 
  
10574/678792 
10311/655947 
  
1.56 (1.53-1.59) 
1.57 (1.54-1.60) 
  
ref 
1.01 (0.98-1.04) 
(0.5133) 
  
ref 
1.02 (0.99-1.05) 
  
ref 
1.02 (0.99-1.04) 
(0.2102) 
  
ref 
1.02 (0.99-1.05) 
(0.1996) 
  
ref 
1.02 (1.00-1.05) 
(0.0955) 
  
ref 
1.02 (1.00-1.05) 
(0.1080) 
Intermediate determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
2334/156279 
5307/341400 
5672/355058 
4241/268454 
3331/213548 
  
1.49 (1.43-1.56) 
1.55 (1.51-1.60) 
1.60 (1.56-1.64) 
1.58 (1.53-1.63) 
1.56 (1.51-1.61) 
  
0.93 (0.89-0.98) 
0.97 (0.94-1.01) 
ref 
0.99 (0.95-1.03) 
0.98 (0.94-1.02) 
(0.0840) 
  
0.87 (0.83-0.91) 
0.95 (0.91-0.98) 
ref 
0.97 (0.94-1.01) 
0.95 (0.91-0.99) 
  
  
  
  
  
  
  
0.84 (0.79-0.89) 
0.93 (0.89-0.97) 
ref 
1.03 (0.98-1.07) 
1.02 (0.97-1.07) 
(<0.0001) 
  
0.85 (0.80-0.90) 
0.93 (0.90-0.97) 
ref 
1.03 (0.99-1.07) 
1.03 (0.98-1.08) 
(<0.0001) 
  
0.85 (0.80-0.90) 
0.93 (0.90-0.97) 
ref 
1.03 (0.99-1.07) 
1.02 (0.98-1.08) 
(<0.0001) 
Number of living 
children in family  
0-1 
2-3 
4 or more 
  
 
6084/386564 
8401/530639 
6400/417536 
  
 
1.57 (1.53-1.61) 
1.58 (1.55-1.62) 
1.53 (1.50-1.57) 
  
 
0.99 (0.96-1.03) 
ref 
0.97 (0.94-1.00) 
(0.1290) 
  
 
0.99 (0.96-1.02) 
ref 
0.93 (0.90-0.96) 
  
  
  
  
  
 
1.03 (0.99-1.07) 
ref 
0.96 (0.92-1.00) 
(0.0233) 
  
 
1.04 (1.00-1.08) 
ref 
0.95 (0.91-0.99) 
(0.0055) 
  
 
1.04 (1.00-1.08) 
ref 
0.95 (0.91-0.99) 
(0.0052) 
Maternal illness 
No 
Yes 
  
19861/1270022 
1024/64717 
  
1.56 (1.54-1.59) 
1.58 (1.49-1.68) 
  
ref 
1.01 (0.95-1.08) 
(0.7150) 
  
ref 
1.02 (0.96-1.09) 
  
  
  
  
ref 
1.02 (0.96-1.09) 
(0.4595) 
  
ref 
1.03 (0.97-1.10) 
(0.3811) 
  
ref 
1.03 (0.97-1.10) 
(0.3535) 
Continued…. 
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Table A5.4 continued  
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate / 
100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
and birth weight 
Rate Ratios adjusted for 
distal and intermediate 
determinants and birth 
weight and illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
 
12750/795837 
4843/308623 
3292/230279 
  
 
1.60 (1.57-1.63) 
1.57 (1.53-1.61) 
1.43 (1.38-1.48) 
  
 
ref 
0.98 (0.95-1.01) 
0.89 (0.86-0.93) 
(<0.0001) 
  
 
ref 
0.95 (0.92-0.98) 
0.79 (0.76-0.82) 
  
  
  
  
  
 
ref 
0.96 (0.93-0.99) 
0.87 (0.83-0.90) 
(<0.0001) 
  
 
ref 
0.96 (0.93-0.99) 
0.87 (0.83-0.91) 
(<0.0001) 
  
 
ref 
0.96 (0.93-1.00) 
0.87 (0.83-0.91) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
  
16169/1012397 
4716/322342 
  
1.60 (1.57-1.62) 
1.46 (1.42-1.51) 
  
ref 
0.92 (0.89-0.95) 
(<0.0001) 
  
ref 
0.84 (0.81-0.87) 
  
  
  
  
ref 
0.94 (0.90-0.97) 
(0.0006) 
  
ref 
0.94 (0.91-0.98) 
(0.0010) 
  
ref 
0.94 (0.90-0.97) 
(0.0009) 
Multiple birth 
No 
Yes 
  
20147/1286294 
738/48445 
  
1.57 (1.54-1.59) 
1.52 (1.42-1.64) 
  
ref 
0.97 (0.90-1.05) 
(0.4567) 
  
ref 
0.94 (0.87-1.01) 
  
  
  
  
ref 
0.96 (0.89-1.03) 
(0.2355) 
  
ref 
1.06 (0.98-1.14) 
(0.1838) 
  
ref 
1.06 (0.98-1.14) 
(0.1773) 
Proximal Variables         
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
17789/1126945 
2680/177815 
347/24482 
69/5497 
  
1.58 (1.56-1.60) 
1.51 (1.45-1.57) 
1.42 (1.28-1.57) 
1.26 (0.99-1.59) 
  
ref 
0.95 (0.92-0.99) 
0.90 (0.81-1.00) 
0.80 (0.63-1.01) 
(0.0064) 
  
ref 
0.91 (0.88-0.95) 
0.79 (0.71-0.88) 
0.63 (0.50-0.80) 
  
  
  
  
  
  
  
  
  
  
  
ref 
0.92 (0.88-0.96) 
0.77 (0.69-0.86) 
0.62 (0.49-0.79) 
(<0.0001) 
  
ref 
0.92 (0.88-0.96) 
0.77 (0.69-0.86) 
0.63 (0.49-0.80) 
(<0.0001) 
Mediating Variables                 
Infant illness 
No 
Yes 
  
2508/165931 
18377/1168808 
  
1.51 (1.45-1.57) 
1.57 (1.55-1.60) 
  
ref 
0.96 (0.92-1.00) 
(0.0626) 
  
ref 
0.93 (0.89-0.97) 
  
  
  
  
  
  
  
  
  
  
ref 
0.94 (0.90-0.98) 
(0.0076) 
* All p-values<0.0001 
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Table A5.5: Determinants of DTP1 vaccination between 0 and 18 weeks.  
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate / 
100 days of follow-
up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios adjusted 
for distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants and 
birth weight & 
illness 
      RR (95%CI) aRR (95%CI) aRR (95%CI) aRR (95%CI) aRR (95%CI) aRR (95%CI) 
Infant age-band (in 
days) 
<29.5 
29.5-60.0 
60.1-90.0 
>90.0 
  
 
130/670092 
13098/524434 
7176/129054 
1272/34095 
  
 
0.02 (0.02-0.02) 
2.50 (2.46-2.54) 
5.56 (5.43-5.69) 
3.73 (3.53-3.94) 
  
 
0.01 (0.01-0.01) 
ref 
2.23 (2.16-2.29) 
1.49 (1.41-1.58) 
(<0.0001) 
  
 
_ 
_ 
_ 
_ 
  
 
0.01 (0.01-0.01) 
ref 
2.27 (2.21-2.34) 
1.56 (1.48-1.66) 
(<0.0001) 
  
 
0.01 (0.01-0.01) 
ref 
2.29 (2.23-2.36) 
1.59 (1.50-1.68) 
(<0.0001) 
  
 
0.01 (0.01-0.01) 
ref 
2.30 (2.23-2.37) 
1.60 (1.50-1.69) 
(<0.0001) 
  
 
0.01 (0.01-0.01) 
ref 
2.30 (2.24-2.37) 
1.60 (1.51-1.69) 
(<0.0001) 
Distal Determinants                 
Religion of head of 
household 
Christian 
Muslim 
None / Traditional / 
Other 
  
 
15229/936775 
5100/332362 
1347/88538 
  
 
1.63 (1.60-1.65) 
1.53 (1.49-1.58) 
1.52 (1.44-1.60) 
  
 
ref 
0.94 (0.91-0.97) 
0.94 (0.89-0.99) 
(0.0003) 
  
 
ref 
0.88 (0.85-0.91) 
0.87 (0.82-0.92) 
  
 
ref 
0.91 (0.88-0.95) 
0.95 (0.89-1.00) 
(<0.0001) 
  
 
ref 
0.92 (0.89-0.95) 
0.96 (0.90-1.01) 
(<0.0001) 
  
 
ref 
0.92 (0.89-0.95) 
0.95 (0.90-1.01) 
(<0.0001) 
  
 
ref 
0.92 (0.89-0.95) 
0.96 (0.90-1.01) 
(<0.0001) 
Ethnicity of 
household 
Akan 
Other  
  
10241/624937 
11435/732738 
  
1.64 (1.61-1.67) 
1.56 (1.53-1.59) 
  
ref 
0.95 (0.93-0.98) 
(0.0003) 
  
ref 
0.89 (0.87-0.92) 
  
ref 
1.03 (0.99-1.06) 
(0.1215) 
  
ref 
1.03 (0.99-1.07) 
(0.1011) 
  
ref 
1.03 (0.99-1.06) 
(0.1387) 
  
ref 
1.03 (0.99-1.06) 
(0.1196) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
4135/277198 
4248/270420 
4364/271157 
4438/271771 
4491/267129 
  
1.49 (1.45-1.54) 
1.57 (1.52-1.62) 
1.61 (1.56-1.66) 
1.63 (1.59-1.68) 
1.68 (1.63-1.73) 
  
0.89 (0.85-0.93) 
0.93 (0.90-0.97) 
0.96 (0.92-1.00) 
0.97 (0.93-1.01) 
ref 
(<0.0001) 
  
0.76 (0.73-0.80) 
0.86 (0.82-0.89) 
0.90 (0.86-0.94) 
0.93 (0.89-0.97) 
ref 
  
0.85 (0.81-0.89) 
0.92 (0.88-0.96) 
0.94 (0.90-0.98) 
0.96 (0.92-1.00) 
ref 
(<0.0001) 
  
0.94 (0.89-0.99) 
0.99 (0.94-1.03) 
0.99 (0.95-1.03) 
0.99 (0.95-1.03) 
ref 
(0.1409) 
  
0.94 (0.89-0.99) 
0.99 (0.95-1.04) 
0.99 (0.95-1.04) 
0.99 (0.95-1.03) 
ref 
(0.1695) 
  
0.94 (0.89-0.99) 
0.99 (0.95-1.04) 
0.99 (0.95-1.04) 
0.99 (0.95-1.03) 
ref 
(0.1676) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
1178/68538 
8527/521463 
6230/405711 
5741/361963 
  
1.72 (1.62-1.82) 
1.64 (1.60-1.67) 
1.54 (1.50-1.57) 
1.59 (1.55-1.63) 
  
1.05 (0.99-1.12) 
ref 
0.94 (0.91-0.97) 
0.97 (0.94-1.00) 
(<0.0001) 
  
1.13 (1.06-1.20) 
ref 
0.86 (0.84-0.89) 
0.93 (0.90-0.96) 
  
1.08 (1.01-1.15) 
ref 
0.95 (0.91-0.99) 
0.95 (0.92-0.98) 
(<0.0001) 
  
1.08 (1.01-1.14) 
ref 
0.97 (0.93-1.01) 
0.99 (0.96-1.03) 
(0.0281) 
  
1.08 (1.01-1.15) 
ref 
0.97 (0.93-1.01) 
0.99 (0.96-1.03) 
(0.0234) 
  
1.08 (1.01-1.15) 
ref 
0.97 (0.93-1.01) 
0.99 (0.96-1.03) 
(0.0229) 
Continued…..  
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Table A5.5 continued  
 Vaccinations / 
Person days of 
follow-up 
Vaccination Rate / 
100 days of follow-
up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
and birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight & illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
6601/436023 
3987/253096 
11088/668556 
  
1.51 (1.48-1.55) 
1.58 (1.53-1.62) 
1.66 (1.63-1.69) 
  
0.91 (0.89-0.94) 
0.95 (0.92-0.99) 
ref 
(<0.0001) 
  
0.81 (0.79-0.84) 
0.88 (0.85-0.91) 
ref 
  
0.88 (0.85-0.92) 
0.92 (0.89-0.96) 
ref 
(<0.0001) 
  
0.88 (0.84-0.91) 
0.92 (0.89-0.96) 
ref 
(<0.0001) 
  
0.88 (0.84-0.91) 
0.93 (0.89-0.96) 
ref 
(<0.0001) 
  
0.88 (0.84-0.91) 
0.93 (0.89-0.96) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
13745/861028 
7931/496647 
  
1.60 (1.57-1.62) 
1.60 (1.56-1.63) 
  
ref 
1.00 (0.97-1.03) 
(0.9801) 
  
ref 
1.00 (0.97-1.02) 
  
ref 
1.00 (0.97-1.02) 
(0.7435) 
  
ref 
1.00 (0.97-1.03) 
(0.8498) 
  
ref 
1.00 (0.97-1.02) 
(0.7956) 
  
ref 
1.00 (0.97-1.02) 
(0.7494) 
Sex 
Male 
Female 
  
10974/690763 
10702/666912 
  
1.59 (1.56-1.62) 
1.60 (1.57-1.64) 
  
ref 
1.01 (0.98-1.04) 
(0.4599) 
  
ref 
1.02 (0.99-1.05) 
  
ref 
1.02 (0.99-1.05) 
(0.1589) 
  
ref 
1.02 (0.99-1.05) 
(0.1524) 
  
ref 
1.02 (1.00-1.05) 
(0.0729) 
  
ref 
1.02 (1.00-1.05) 
(0.0804) 
Intermediate determinants                
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
2436/159626 
5533/347342 
5872/360350 
4379/272899 
3456/217458 
  
1.53 (1.47-1.59) 
1.59 (1.55-1.64) 
1.63 (1.59-1.67) 
1.60 (1.56-1.65) 
1.59 (1.54-1.64) 
  
0.94 (0.89-0.98) 
0.98 (0.94-1.01) 
ref 
0.98 (0.95-1.02) 
0.98 (0.94-1.02) 
(0.1036) 
  
0.87 (0.83-0.91) 
0.95 (0.92-0.99) 
ref 
0.97 (0.93-1.01) 
0.94 (0.91-0.98) 
  
  
  
  
  
  
  
0.83 (0.78-0.88) 
0.93 (0.89-0.97) 
ref 
1.02 (0.98-1.07) 
1.02 (0.97-1.07) 
(<0.0001) 
  
0.84 (0.79-0.89) 
0.93 (0.89-0.97) 
ref 
1.02 (0.98-1.07) 
1.02 (0.97-1.07) 
(<0.0001) 
  
0.84 (0.79-0.89) 
0.93 (0.89-0.97) 
ref 
1.02 (0.98-1.07) 
1.02 (0.97-1.07) 
(<0.0001) 
Number of children in 
family  
0-1 
2-3 
4 or more 
  
 
6328/392562 
8684/539145 
6664/425968 
  
 
1.61 (1.57-1.65) 
1.61 (1.58-1.64) 
1.56 (1.53-1.60) 
  
 
1.00 (0.97-1.03) 
ref 
0.97 (0.94-1.00) 
(0.1335) 
  
 
1.00 (0.97-1.03) 
ref 
0.93 (0.90-0.96) 
  
  
  
  
  
 
1.04 (1.00-1.08) 
ref 
0.95 (0.92-0.99) 
(0.0042) 
  
 
1.05 (1.01-1.09) 
ref 
0.95 (0.91-0.99) 
(0.0008) 
  
 
1.05 (1.01-1.09) 
ref 
0.95 (0.91-0.99) 
(0.0007) 
Maternal illness 
No 
Yes 
  
20612/1291902 
1064/65773 
  
1.60 (1.57-1.62) 
1.62 (1.52-1.72) 
  
ref 
1.01 (0.95-1.08) 
(0.6608) 
  
ref 
1.02 (0.96-1.09) 
  
  
  
  
ref 
1.03 (0.97-1.09) 
(0.3891) 
  
ref 
1.03 (0.97-1.10) 
(0.3228) 
  
ref 
1.03 (0.97-1.10) 
(0.2998) 
Continued…..  
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Table A5.5 continued 
 Vaccinations / 
Person days of 
follow-up 
Vaccination Rate / 
100 days of follow-
up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight & illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Distance to health 
facility  
<1.00km 
1.00-4.99km 
>=5.00km 
  
13195/807717 
5004/313234 
3477/236724 
  
1.63 (1.61-1.66) 
1.60 (1.55-1.64) 
1.47 (1.42-1.52) 
  
ref 
0.98 (0.95-1.01) 
0.90 (0.87-0.93) 
(<0.0001) 
  
ref 
0.95 (0.92-0.98) 
0.79 (0.76-0.82) 
  
  
  
  
  
ref 
0.96 (0.93-0.99) 
0.87 (0.83-0.90) 
(<0.0001) 
  
ref 
0.96 (0.93-0.99) 
0.87 (0.83-0.90) 
(<0.0001) 
  
ref 
0.96 (0.93-0.99) 
0.87 (0.83-0.91) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
  
16712/1027355 
4964/330320 
  
1.63 (1.60-1.65) 
1.50 (1.46-1.55) 
  
ref 
0.92 (0.90-0.95) 
(<0.0001) 
  
ref 
0.84 (0.81-0.87) 
  
  
  
  
ref 
0.94 (0.91-0.97) 
(0.0008) 
  
ref 
0.94 (0.91-0.98) 
(0.0014) 
  
ref 
0.94 (0.91-0.98) 
(0.0011) 
Multiple birth 
No 
Yes 
  
20902/1308502 
774/49173 
  
1.60 (1.58-1.62) 
1.57 (1.47-1.69) 
  
ref 
0.99 (0.92-1.06) 
(<0.0001) 
  
ref 
0.95 (0.89-1.02) 
  
  
  
  
ref 
0.98 (0.91-1.05) 
(0.5596) 
  
ref 
1.08 (1.00-1.17) 
(0.0563) 
  
ref 
1.08 (1.00-1.17) 
(0.0539) 
Proximal Variables         
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
18427/1145653 
2810/181294 
364/25020 
75/5708 
  
1.61 (1.59-1.63) 
1.55 (1.49-1.61) 
1.45 (1.31-1.61) 
1.31 (1.05-1.65) 
  
ref 
0.96 (0.93-1.00) 
0.90 (0.82-1.00) 
0.82 (0.65-1.02) 
(0.0205) 
  
ref 
0.92 (0.88-0.96) 
0.80 (0.72-0.88) 
0.65 (0.51-0.81) 
  
  
  
  
  
  
  
  
  
  
  
ref 
0.92 (0.89-0.96) 
0.76 (0.69-0.85) 
0.63 (0.50-0.80) 
(<0.0001) 
  
ref 
0.92 (0.89-0.96) 
0.77 (0.69-0.85) 
0.64 (0.51-0.80) 
(<0.0001) 
Mediating Variables                 
Infant illness 
No 
Yes 
  
2621/169396 
19055/1188279 
  
1.55 (1.49-1.61) 
1.60 (1.58-1.63) 
  
ref 
0.96 (0.93-1.01) 
(0.0847) 
  
ref 
0.93 (0.89-0.97) 
  
  
  
  
  
  
  
  
  
  
ref 
0.94 (0.90-0.98) 
(0.0028) 
* All p-values<0.0001 
  
 180 
 
Table A5.6: Determinants of DTP3 vaccination between 0 and 22 weeks. 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight and 
illness 
      RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Infant age-band (in days) 
<29.5 
29.5-60.0 
>90.0 
  
72/1991481 
7520/580579 
7918/319792 
  
0.00 (0.00-0.00) 
1.30 (1.27-1.32) 
2.48 (2.42-2.53) 
  
0.00 (0.00-0.00) 
ref 
1.91 (1.85-1.97) 
(<0.0001) 
  
_ 
_ 
_ 
  
0.00 (0.00-0.00) 
ref 
1.96 (1.89-2.02) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
1.97 (1.91-2.04) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
1.97 (1.91-2.04) 
(<0.0001) 
  
0.00 (0.00-0.00) 
ref 
1.97 (1.91-2.04) 
(<0.0001) 
Distal Determinants                 
Religion of head of 
household 
Christian 
Muslim 
None/Traditional/Other 
  
 
11351/2002000 
3223/706599 
936/183253 
  
 
0.57 (0.56-0.58) 
0.46 (0.44-0.47) 
0.51 (0.48-0.54) 
  
 
ref 
0.80 (0.77-0.84) 
0.90 (0.84-0.96) 
(<0.0001) 
  
 
ref 
0.72 (0.70-0.75) 
0.86 (0.81-0.92) 
  
 
ref 
0.80 (0.76-0.84) 
0.93 (0.87-0.99) 
(<0.0001) 
  
 
ref 
0.81 (0.77-0.85) 
0.95 (0.89-1.02) 
(<0.0001) 
  
 
ref 
0.81 (0.77-0.85) 
0.95 (0.89-1.01) 
(<0.0001) 
  
 
ref 
0.81 (0.77-0.85) 
0.95 (0.89-1.01) 
(<0.0001) 
Ethnicity of household 
Akan 
Other  
  
7788/1342699 
7722/1549153 
  
0.58 (0.57-0.59) 
0.50 (0.49-0.51) 
  
ref 
0.86 (0.83-0.89) 
(<0.0001) 
  
ref 
0.80 (0.77-0.83) 
  
ref 
0.98 (0.94-1.02) 
(0.3740) 
  
ref 
0.98 (0.94-1.02) 
(0.4456) 
  
ref 
0.98 (0.94-1.02) 
(0.4034) 
  
ref 
0.98 (0.94-1.02) 
(0.4162) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
2770/567874 
3074/567966 
3172/575659 
3225/588194 
3269/592159 
  
0.49 (0.47-0.51) 
0.54 (0.52-0.56) 
0.55 (0.53-0.57) 
0.55 (0.53-0.57) 
0.55 (0.53-0.57) 
  
0.88 (0.84-0.93) 
0.98 (0.93-1.03) 
1.00 (0.95-1.05) 
0.99 (0.95-1.04) 
ref 
(<0.0001) 
  
0.83 (0.79-0.88) 
0.97 (0.92-1.02) 
1.00 (0.95-1.05) 
0.99 (0.94-1.04) 
ref 
  
0.96 (0.91-1.02) 
1.06 (1.00-1.11) 
1.06 (1.00-1.11) 
1.03 (0.98-1.09) 
Ref 
(0.0014) 
  
1.11 (1.04-1.18) 
1.17 (1.10-1.23) 
1.13 (1.07-1.19) 
1.07 (1.02-1.13) 
ref 
(<0.0001) 
  
1.11 (1.04-1.19) 
1.17 (1.10-1.24) 
1.13 (1.07-1.19) 
1.07 (1.02-1.13) 
ref 
(<0.0001) 
  
1.11 (1.04-1.19) 
1.17 (1.11-1.24) 
1.13 (1.07-1.19) 
1.07 (1.02-1.13) 
ref 
(<0.0001) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
891/152741 
6158/1135396 
4408/840165 
4053/763550 
  
0.58 (0.55-0.62) 
0.54 (0.53-0.56) 
0.52 (0.51-0.54) 
0.53 (0.51-0.55) 
  
1.08 (1.00-1.15) 
ref 
0.97 (0.93-1.01) 
0.98 (0.94-1.02) 
(0.0236) 
  
1.15 (1.07-1.23) 
ref 
0.95 (0.92-0.99) 
0.98 (0.94-1.02) 
  
1.07 (1.00-1.15) 
ref 
1.04 (0.99-1.09) 
0.97 (0.93-1.01) 
(0.0071) 
  
1.06 (0.99-1.14) 
ref 
1.07 (1.02-1.12) 
1.02 (0.98-1.07) 
(0.0138) 
  
1.06 (0.99-1.14) 
ref 
1.07 (1.02-1.12) 
1.02 (0.98-1.07) 
(0.0143) 
  
1.06 (0.99-1.14) 
ref 
1.07 (1.02-1.12) 
1.02 (0.98-1.07) 
(0.0145) 
Continued….. 
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Table A5.6 continued 
 Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight and 
illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
4349/910019 
2709/537430 
8452/1444403 
  
0.48 (0.46-0.49) 
0.50 (0.49-0.52) 
0.59 (0.57-0.60) 
  
0.82 (0.79-0.85) 
0.86 (0.82-0.90) 
ref 
(<0.0001) 
  
0.73 (0.70-0.75) 
0.79 (0.76-0.82) 
ref 
  
0.79 (0.75-0.83) 
0.82 (0.78-0.85) 
Ref 
(<0.0001) 
  
0.79 (0.75-0.82) 
0.82 (0.79-0.86) 
ref 
(<0.0001) 
  
0.79 (0.75-0.82) 
0.82 (0.79-0.86) 
ref 
(<0.0001) 
  
0.79 (0.75-0.82) 
0.82 (0.79-0.86) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
7407/1356296 
8103/1535556 
  
0.55 (0.53-0.56) 
0.53 (0.52-0.54) 
  
ref 
0.97 (0.94-1.00) 
(0.0328) 
  
ref 
0.96 (0.93-0.99) 
  
ref 
0.95 (0.92-0.98) 
(0.0032) 
  
ref 
0.95 (0.92-0.98) 
(0.0016) 
  
ref 
0.95 (0.92-0.98) 
(0.0013) 
  
ref 
0.95 (0.92-0.98) 
(0.0011) 
Sex 
Male 
Female 
  
7792/1469759 
7718/1422093 
  
0.53 (0.52-0.54) 
0.54 (0.53-0.55) 
  
ref 
1.02 (0.99-1.06) 
(0.1446) 
  
ref 
1.04 (1.00-1.07) 
  
ref 
1.04 (1.00-1.07) 
(0.0322) 
  
ref 
1.04 (1.00-1.07) 
(0.0270) 
  
ref 
1.04 (1.01-1.07) 
(0.0176) 
  
ref 
1.04 (1.01-1.07) 
(0.0186) 
Intermediate Determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
1683/330361 
3890/734429 
4280/777120 
3187/585599 
2470/464343 
  
0.51 (0.49-0.53) 
0.53 (0.51-0.55) 
0.55 (0.53-0.57) 
0.54 (0.53-0.56) 
0.53 (0.51-0.55) 
  
0.92 (0.87-0.98) 
0.96 (0.92-1.00) 
ref 
0.99 (0.94-1.03) 
0.97 (0.92-1.01) 
(0.0618) 
  
0.89 (0.84-0.94) 
0.96 (0.92-1.00) 
ref 
0.98 (0.94-1.03) 
0.94 (0.90-0.99) 
  
  
  
  
  
  
  
0.80 (0.75-0.86) 
0.92 (0.87-0.96) 
ref 
1.06 (1.01-1.11) 
1.06 (1.01-1.13) 
(<0.0001) 
  
0.81 (0.75-0.86) 
0.92 (0.87-0.96) 
ref 
1.06 (1.01-1.12) 
1.07 (1.01-1.13) 
(<0.0001) 
  
0.81 (0.75-0.86) 
0.92 (0.87-0.96) 
ref 
1.06 (1.01-1.12) 
1.07 (1.01-1.13) 
(<0.0001) 
Number of living 
children in family  
0-1 
2-3 
4 or more 
  
4563/834703 
6333/1153751 
4614/903398 
  
0.55 (0.53-0.56) 
0.55 (0.54-0.56) 
0.51 (0.50-0.53) 
  
1.00 (0.96-1.03) 
ref 
0.93 (0.90-0.97) 
(0.0003) 
  
1.00 (0.96-1.04) 
ref 
0.89 (0.86-0.93) 
  
  
  
  
  
1.06 (1.01-1.11) 
ref 
0.89 (0.85-0.93) 
(<0.0001) 
  
1.06 (1.02-1.12) 
ref 
0.88 (0.84-0.93) 
(<0.0001) 
  
1.07 (1.02-1.12) 
ref 
0.88 (0.84-0.93) 
(<0.0001) 
Maternal illness 
No 
Yes 
  
14754/2749820 
756/142032 
  
0.54 (0.53-0.55) 
0.53 (0.50-0.57) 
  
ref 
0.99 (0.92-1.07) 
(0.8301) 
  
ref 
0.99 (0.92-1.06) 
  
  
  
  
ref 
1.00 (0.93-1.07) 
(0.9098) 
  
ref 
1.00 (0.93-1.07) 
(0.9731) 
  
ref 
1.00 (0.93-1.08) 
(0.9941) 
Continued….. 
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Table A5.6 continued 
 Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios adjusted for 
distal and intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight and 
illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
 
9606/1743611 
3694/664652 
2210/483589 
  
 
0.55 (0.54-0.56) 
0.56 (0.54-0.57) 
0.46 (0.44-0.48) 
  
 
ref 
1.01 (0.97-1.05) 
0.83 (0.79-0.87) 
(<0.0001) 
  
 
ref 
1.00 (0.96-1.04) 
0.75 (0.72-0.79) 
  
  
  
  
  
 
ref 
0.97 (0.93-1.01) 
0.78 (0.74-0.83) 
(<0.0001) 
  
 
ref 
0.97 (0.93-1.01) 
0.79 (0.75-0.83) 
(<0.0001) 
  
 
ref 
0.97 (0.93-1.01) 
0.79 (0.75-0.83) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
  
12149/2213232 
3361/678620 
  
0.55 (0.54-0.56) 
0.50 (0.48-0.51) 
  
ref 
0.90 (0.87-0.94) 
(<0.0001) 
  
ref 
0.86 (0.82-0.89) 
  
  
  
  
ref 
0.96 (0.91-1.00) 
(0.0399) 
  
ref 
0.96 (0.92-1.00) 
(0.0483) 
  
ref 
0.96 (0.92-1.00) 
(0.0478) 
Multiple birth 
No 
Yes 
  
14983/2788890 
527/102962 
  
0.54 (0.53-0.55) 
0.51 (0.47-0.56) 
  
ref 
0.95 (0.87-1.04) 
(0.2709) 
  
ref 
0.93 (0.86-1.02) 
  
  
  
  
ref 
0.97 (0.89-1.06) 
(0.5549) 
  
ref 
1.05 (0.95-1.15) 
(0.3567) 
  
ref 
1.05 (0.95-1.15) 
(0.3447) 
Proximal Variables         
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
13238/2452731 
1992/378547 
239/49991 
41/10583 
  
0.54 (0.53-0.55) 
0.53 (0.50-0.55) 
0.48 (0.42-0.54) 
0.39 (0.29-0.53) 
  
ref 
0.97 (0.93-1.02) 
0.89 (0.78-1.01) 
0.72 (0.53-0.98) 
(0.0246) 
  
ref 
0.96 (0.91-1.00) 
0.83 (0.73-0.95) 
0.63 (0.46-0.85) 
  
  
  
  
  
   
ref 
0.96 (0.91-1.01) 
0.80 (0.70-0.92) 
0.61 (0.45-0.83) 
(0.0001) 
  
ref 
0.96 (0.91-1.01) 
0.80 (0.70-0.92) 
0.61 (0.45-0.83) 
(0.0001) 
Mediating Variables              
Infant illness 
No 
Yes 
  
13191/2444466 
2319/447386 
  
0.54 (0.53-0.55) 
0.52 (0.50-0.54) 
  
ref 
0.96 (0.92-1.00) 
(0.0726) 
  
ref 
0.95 (0.91-0.99) 
  
  
  
   
ref 
1.03 (0.98-1.08) 
(0.2933) 
* All p-values<0.0001 
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Table A5.7: Determinants of DTP3 vaccination between 0 and 26 weeks 
  Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
and birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight and 
illness 
      RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Infant age-band (in 
days) 
<29.5 
29.5-60.0 
60.1-90.0 
>90.0 
  
 
72/1991481 
7520/580579 
7435/300206 
3374/147403 
 
 
0.00 (0.00-0.00) 
1.30 (1.27-1.32) 
2.48 (2.42-2.53) 
2.29 (2.21-2.37) 
 
 
0.00 (0.00-0.00) 
ref 
1.91 (1.85-1.97) 
1.77 (1.70-1.84) 
(<0.0001) 
 
 
_ 
_ 
_ 
_ 
  
 
0.00 (0.00-0.00) 
ref 
1.95 (1.89-2.02) 
1.85 (1.78-1.93) 
(<0.0001) 
  
 
0.00 (0.00-0.00) 
ref 
1.97 (1.91-2.03) 
1.88 (1.81-1.96) 
(<0.0001) 
  
 
0.00 (0.00-0.00) 
ref 
1.97 (1.91-2.04) 
1.88 (1.81-1.96) 
(<0.0001) 
  
 
0.00 (0.00-0.00) 
ref 
1.97 (1.91-2.04) 
1.89 (1.81-1.96) 
(<0.0001) 
Distal Determinants                 
Religion of head of 
household 
Christian 
Muslim 
None/Traditional/Other 
  
 
13275/2078786 
4004/748312 
1122/192571 
  
 
0.64 (0.63-0.65) 
0.54 (0.52-0.55) 
0.58 (0.55-0.62) 
  
 
ref 
0.84 (0.81-0.87) 
0.91 (0.86-0.97) 
(<0.0001) 
  
 
ref 
0.73 (0.70-0.75) 
0.85 (0.80-0.90) 
  
 
ref 
0.81 (0.78-0.84) 
0.92 (0.86-0.98) 
(<0.0001) 
  
 
ref 
0.82 (0.79-0.85) 
0.94 (0.88-1.00) 
(<0.0001) 
  
 
ref 
0.82 (0.78-0.85) 
0.94 (0.88-1.00) 
(<0.0001) 
  
 
ref 
0.82 (0.79-0.85) 
0.94 (0.88-1.00) 
(<0.0001) 
Ethnicity of 
household 
Akan 
Other  
  
9059/1390660 
9342/1629009 
  
0.65 (0.64-0.66) 
0.57 (0.56-0.59) 
  
ref 
0.88 (0.86-0.91) 
(<0.0001) 
  
ref 
0.79 (0.77-0.82) 
 
ref 
0.97 (0.94-1.01) 
(0.1798) 
 
ref 
0.98 (0.94-1.01) 
(0.2040) 
  
ref 
0.97 (0.94-1.01) 
(0.1814) 
  
ref 
0.97 (0.94-1.01) 
(0.1889) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
  
3367/598063 
3624/592986 
3724/599933 
3807/612809 
3879/615879 
  
0.56 (0.54-0.58) 
0.61 (0.59-0.63) 
0.62 (0.60-0.64) 
0.62 (0.60-0.64) 
0.63 (0.61-0.65) 
  
0.89 (0.85-0.94) 
0.97 (0.93-1.02) 
0.99 (0.94-1.03) 
0.99 (0.94-1.03) 
ref 
(<0.0001) 
  
0.82 (0.79-0.86) 
0.95 (0.91-0.99) 
0.98 (0.94-1.03) 
0.98 (0.93-1.02) 
ref 
  
0.95 (0.90-1.00) 
1.03 (0.98-1.09) 
1.04 (0.99-1.09) 
1.02 (0.98-1.07) 
Ref 
(0.0024) 
  
1.09 (1.03-1.16) 
1.14 (1.08-1.20) 
1.10 (1.05-1.16) 
1.06 (1.01-1.11) 
ref 
(<0.0001) 
  
1.09 (1.03-1.16) 
1.14 (1.08-1.20) 
1.11 (1.05-1.16) 
1.06 (1.01-1.11) 
ref 
(0.0001) 
  
1.09 (1.03-1.16) 
1.14 (1.08-1.20) 
1.11 (1.05-1.16) 
1.06 (1.01-1.11) 
ref 
(0.0001) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
  
1039/157875 
7290/1184880 
5280/879142 
4792/797772 
  
0.66 (0.62-0.70) 
0.62 (0.60-0.63) 
0.60 (0.58-0.62) 
0.60 (0.58-0.62) 
  
1.07 (1.00-1.14) 
ref 
0.98 (0.94-1.01) 
0.98 (0.94-1.01) 
(0.0323) 
  
1.16 (1.09-1.24) 
ref 
0.96 (0.92-0.99) 
0.97 (0.94-1.01) 
 
1.09 (1.02-1.16) 
ref 
1.05 (1.01-1.10) 
0.97 (0.93-1.01) 
(0.0001) 
 
1.07 (1.01-1.15) 
ref 
1.09 (1.04-1.13) 
1.02 (0.98-1.06) 
(0.0006) 
 
1.08 (1.01-1.15) 
ref 
1.09 (1.04-1.13) 
1.02 (0.98-1.07) 
(0.0006) 
  
1.07 (1.01-1.15) 
ref 
1.09 (1.04-1.13) 
1.02 (0.98-1.06) 
(0.0006) 
Continued…..  
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Table A5.7 continued 
 Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for age-
band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight and 
illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
  
5309/961011 
3291/564140 
9801/1494518 
  
0.55 (0.54-0.57) 
0.58 (0.56-0.60) 
0.66 (0.64-0.67) 
  
0.84 (0.81-0.87) 
0.89 (0.86-0.93) 
ref 
(<0.0001) 
  
0.72 (0.70-0.75) 
0.79 (0.76-0.82) 
ref 
  
0.78 (0.75-0.82) 
0.82 (0.79-0.86) 
ref 
(<0.0001) 
  
0.78 (0.75-0.82) 
0.83 (0.80-0.87) 
ref 
(<0.0001) 
  
0.78 (0.75-0.82) 
0.83 (0.80-0.87) 
ref 
(<0.0001) 
  
0.78 (0.75-0.82) 
0.83 (0.80-0.87) 
ref 
(<0.0001) 
Season vaccine due 
Wet 
Dry 
  
8750/1414006 
9651/1605663 
  
0.62 (0.61-0.63) 
0.60 (0.59-0.61) 
  
ref 
0.97 (0.94-1.00) 
(0.0487) 
  
ref 
0.96 (0.93-0.98) 
  
ref 
0.95 (0.92-0.98) 
(0.0009) 
  
ref 
0.95 (0.92-0.98) 
(0.0004) 
  
ref 
0.95 (0.92-0.98) 
(0.0003) 
  
ref 
0.96 (0.92-0.98) 
(0.0002) 
Sex 
Male 
Female 
  
9279/1535926 
9122/1483743 
  
0.60 (0.59-0.62) 
0.61 (0.60-0.63) 
  
ref 
1.02 (0.99-1.05) 
(0.2353) 
  
ref 
1.03 (1.00-1.06) 
  
ref 
1.03 (1.00-1.06) 
(0.0359) 
  
ref 
1.03 (1.00-1.06) 
(0.0299) 
  
ref 
1.04 (1.01-1.07) 
(0.0182) 
  
ref 
1.04 (1.01-1.07) 
(0.0191) 
Intermediate Determinants 
Maternal age (years) 
15 – 19 
20 – 24 
25 – 29 
30 – 34 
35 years and over 
  
2002/346191 
4615/767930 
5044/808652 
3789/610837 
2951/486059 
  
0.58 (0.55-0.60) 
0.60 (0.58-0.62) 
0.62 (0.61-0.64) 
0.62 (0.60-0.64) 
0.61 (0.59-0.63) 
  
0.93 (0.88-0.98) 
0.96 (0.93-1.00) 
ref 
0.99 (0.95-1.04) 
0.97 (0.93-1.02) 
(0.0338) 
  
0.88 (0.83-0.93) 
0.95 (0.91-0.98) 
ref 
0.98 (0.94-1.02) 
0.94 (0.90-0.98) 
  
  
  
  
  
  
  
0.79 (0.74-0.84) 
0.91 (0.87-0.94) 
ref 
1.06 (1.02-1.11) 
1.06 (1.01-1.12) 
(<0.0001) 
  
0.80 (0.75-0.85) 
0.91 (0.87-0.95) 
ref 
1.07 (1.02-1.11) 
1.06 (1.01-1.12) 
(<0.0001) 
  
0.80 (0.75-0.85) 
0.91 (0.87-0.95) 
ref 
1.07 (1.02-1.12) 
1.06 (1.01-1.12) 
(<0.0001) 
Number of living 
children in family  
0-1 
2-3 
4 or more 
  
 
5363/869266 
7458/1201671 
5580/948732 
  
 
0.62 (0.60-0.63) 
0.62 (0.61-0.63) 
0.59 (0.57- 0.60) 
  
 
0.99 (0.96-1.03) 
ref 
0.95 (0.92-0.98) 
(0.0055) 
  
 
1.00 (0.97-1.04) 
ref 
0.90 (0.86-0.93) 
  
  
  
  
  
 
1.07 (1.02-1.11) 
ref 
0.89 (0.85-0.93) 
(<0.0001) 
 
 
1.07 (1.03-1.12) 
ref 
0.88 (0.85-0.92) 
(<0.0001) 
  
 
1.07 (1.03-1.12) 
ref 
0.88 (0.85-0.92) 
(<0.0001) 
Maternal illness 
No 
Yes 
  
17509/2870991 
892/148678 
  
0.61 (0.60-0.62) 
0.60 (0.56-0.64) 
  
ref 
0.98 (0.92-1.05) 
(0.6325) 
  
ref 
0.97 (0.91-1.04) 
  
  
  
  
ref 
0.98 (0.92-1.05) 
(0.5530) 
  
ref 
0.98 (0.92-1.05) 
(0.6086) 
  
ref 
0.98 (0.92-1.05) 
(0.6288) 
Continued…  
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Table A5.7 continued 
 Vaccinations / 
Person days of 
follow-up 
Vaccination Rate 
/ 100 days of 
follow-up 
Unadjusted Rate 
Ratios 
Rate Ratios 
adjusted for 
age-band* 
Rate Ratios 
adjusted for 
distal 
determinants 
Rate Ratios 
adjusted for 
distal and 
intermediate 
determinants 
Rate Ratios 
adjusted for distal 
and intermediate 
determinants and 
birth weight 
Rate Ratios adjusted 
for distal and 
intermediate 
determinants and 
birth weight and 
illness 
   RR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
aRR (95%CI) 
(p-value) 
Distance from health 
facility 
<1.00km 
1.00-4.99km 
>=5.00km 
  
 
11291/1816583 
4335/690858 
2775/512228 
  
 
0.62 (0.61-0.63) 
0.63 (0.61-0.65) 
0.54 (0.52-0.56) 
  
 
ref 
1.01 (0.97-1.05) 
0.87 (0.84-0.91) 
(<0.0001) 
  
 
ref 
1.01 (0.97-1.04) 
0.77 (0.74-0.80) 
  
  
  
  
  
 
ref 
0.98 (0.94-1.01) 
0.81 (0.77-0.85) 
(<0.0001) 
  
 
ref 
0.98 (0.94-1.01) 
0.81 (0.77-0.85) 
(<0.0001) 
  
 
ref 
0.98 (0.95-1.02) 
0.81 (0.77-0.85) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
  
14336/2305655 
4065/714014 
  
0.62 (0.61-0.63) 
0.57 (0.55-0.59) 
  
ref 
0.92 (0.88-0.95) 
(<0.0001) 
  
ref 
0.85 (0.82-0.88) 
  
  
  
  
ref 
0.95 (0.91-0.99) 
(0.0092) 
  
ref 
0.95 (0.91-0.99) 
(0.0121) 
  
ref 
0.95 (0.91-0.99) 
(0.0120) 
Multiple birth 
No 
Yes 
  
17758/2911766 
643/107903 
  
0.61 (0.60-0.62) 
0.60 (0.55-0.64) 
  
ref 
0.98 (0.90-1.06) 
(0.5625) 
  
ref 
0.95 (0.88-1.03) 
  
  
  
  
ref 
0.99 (0.92-1.07) 
(0.8520) 
  
ref 
1.07 (0.98-1.16) 
(0.1356) 
  
ref 
1.07 (0.98-1.16) 
(0.1298) 
Proximal Variables         
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
  
15694/2559854 
2360/395994 
296/52518 
51/11303 
  
0.61 (0.60-0.62) 
0.60 (0.57-0.62) 
0.56 (0.50-0.63) 
0.45 (0.34-0.59) 
  
ref 
0.97 (0,93-1.01) 
0.92 (0.82-1.03) 
0.74 (0.56-0.97) 
(0.0334) 
  
ref 
0.95 (0.91-0.99) 
0.86 (0.77-0.96) 
0.62 (0.47-0.82) 
  
  
  
  
  
   
ref 
0.95 (0.91-1.00) 
0.82 (0.73-0.92) 
0.60 (0.45-0.79) 
(<0.0001) 
  
ref 
0.95 (0.91-1.00) 
0.82 (0.73-0.92) 
0.60 (0.46-0.79) 
(<0.0001) 
Mediating Variables               
Infant illness 
No 
Yes 
  
15628/2551511 
2773/468158 
  
0.61 (0.60-0.62) 
0.59 (0.57-0.61) 
  
ref 
0.97 (0.93-1.01) 
(0.1027) 
  
ref 
0.95 (0.91-0.99) 
  
  
  
    
ref 
1.03 (0.99-1.07) 
(0.1498) 
* All p-values<0.0001 
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CHAPTER 6: NEONATAL VACCINATION 
OF LBW INFANTS 
Preamble 
The paper presented in this chapter addresses PhD objective 3, which is to investigate birth 
weight and other factors as determinants of neonatal BCG vaccination. Section 6.1 presents 
a short overview of the paper. Section 6.2 presents the paper itself. In Section 6.3, I outline 
some of the issues that I considered when I designed the analysis for the study. In Section 
6.4, I discuss the extent to which the design of the analyses may or may not have biased the 
associations reported in the paper.  
6.1. INTRODUCTION 
In the previous chapter I presented the results of an analysis that investigated whether LBW 
was a determinant of DTP vaccination in the postneonatal period. In this chapter, I present 
the results of an analysis to investigate the association between birth weight and neonatal 
BCG vaccination, and to investigate whether this association varies by place of delivery and 
infant illness. I used the data from the prospective population-based Neovita cohort to do 
this analysis. I also investigated other determinants of neonatal BCG vaccination. The study 
population comprised 22217 infants with known vaccination status who were in follow-up 
at the end of the neonatal period. The outcomes were odds ratios for BCG vaccination at 
the end of the neonatal period (0-27 days), calculated using logistic regression, and uptake 
of BCG vaccination at the end of the neonatal period. Methods to define vaccination status, 
birth weight and the other exposures of interest are described in Chapter 3, as are details 
on the process of model building. I adjusted all estimates a priori for potential confounders.  
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6.2. PAPER 3: NEONATAL VACCINATION OF LOW BIRTH WEIGHT 
INFANTS IN GHANA 
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ABSTRACT 
Objectives: 
Global vaccination policy advocates for identifying and targeting groups who are under-
served by vaccination to increase equity and uptake.  We investigated whether birth weight 
and other factors are determinants of neonatal BCG vaccination, in order to identify infants 
under-served by vaccination. 
Methods: 
We used logistic regression to calculate adjusted odds ratios (AOR) for the association 
between birth weight (categorised as non-low birth weight (NLBW) (≥2.50kg) and low birth 
weight (LBW) (2-2.49kg, 1.50-1.99kg and <1.50kg) and non-vaccination with BCG at the end 
of the neonatal period (0-27 days). We assessed whether this association varied by place of 
delivery and infant illness. We calculated how BCG timing and uptake would improve by 
ensuring the vaccination of all facility-born infants prior to discharge. 
Results: 
There was a strong dose response relationship between LBW and not receiving BCG in the 
neonatal period (p-trend<0.0001). Infants weighing 1.50-1.99kg had odds of non-
vaccination 1.6 times (AOR=1.64; 95%CI:1.30-2.08), and those weighing <1.50kg 2.4 times 
(AOR=2.42; 95%CI:1.50-3.88) those of NLBW infants. Other determinants included place of 
delivery, distance to the health facility and socioeconomic status. Neither place of delivery 
nor infant illness modified the association between birth weight and vaccination (p-
interaction all >0.19). Facility-born infants were vaccinated at a mean of 6 days, suggesting 
they were not vaccinated in the facility at birth but were referred for vaccination.  
Conclusions: 
LBW is a risk factor for neonatal vaccination, even for facility-born infants. Ensuring 
vaccination at facility births would substantively improve timing and equitable BCG 
vaccination.  
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INTRODUCTION  
Approximately 3 in 10 deaths among children aged 1-59 months are vaccine preventable,1 
and one in five infants is not fully vaccinated by age 52 weeks. Substantive socio-
demographic inequities in vaccination remain.2 Many infants are vaccinated late.3 4 The 
latest global vaccination policy highlights the need to identify and target those under-
served by vaccination, in order to increase equity and uptake.2  
Using data from a large prospective population-based trial of neonatal vitamin A 
supplementation in Kintampo in rural Ghana (Neovita), we previously reported that LBW 
infants are more likely to be delayed in their DTP1 and DTP3 vaccination.5 For postneonatal 
vaccines, the onus is on the care-taker to bring the infant for vaccination at scheduled 
times. Any vaccination delay may be partly due to care-taker hesitancy to bring infants for 
vaccination, possibly due to their fragility or illness.6 This may not be the case for neonatal 
vaccinations, as the large proportion of facility-born infants automatically have 
opportunities for vaccination.  Consequently, vaccine determinants may differ in these 
periods. In an effort to identify further those under-served by vaccination, we investigated 
birth weight and other factors as determinants of neonatal vaccination.  
In countries with a high prevalence of tuberculosis, the World Health Organisation (WHO) 
recommends “BCG be given to all healthy neonates, or as soon as possible after birth”.7 In 
addition to BCG, in Ghana, a birth dose of polio (OPVB) is recommended at a maximum age 
of two weeks,8 as part of a four dose schedule. Hepatitis B is not given in Ghana until six 
weeks of age. The WHO recommends BCG vaccination by intradermal injection to the arm,7 
whereas OPVB is given orally.9 We selected BCG as an indicator for neonatal vaccination 
due to its longer recommended window for administration (throughout the neonatal 
period), and on the basis that any hesitancy relating to the vaccination of fragile infants 
would be more evident for injected vaccines.  
 
Low birth weight is not a contraindication to BCG vaccination. 7 The WHO advises that 
infants should receive all due vaccines prior to discharge from health facilities.10 Therefore, 
infants born in health facilities should be vaccinated prior to discharge home. 
 
Infant illness has been cited as a reason for non-vaccination by both caregivers and vaccine-
providers.6 Given this, and the opportunities for vaccination associated with being born in a 
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facility, as secondary objectives we investigated whether the association between birth 
weight and neonatal BCG vaccination varied by place of delivery and infant illness.  
 
MATERIALS AND METHODS  
Neovita was undertaken at the Kintampo Health Research Centre (KHRC) in rural Ghana. 
Trial methods have been described in detail elsewhere.11 12 
In Ghana, neonatal vaccines are given either at the health facility following delivery, or at 
child health clinics in health facilities or Community Health Planning System (CHPS) 
compounds in the community. Monthly mobile outreach clinics target areas lacking health 
facilities or CHPS compounds. Following vaccination, the vaccine provider records (on a 
vaccination card, or less commonly, in the mother’s antenatal card) the administrated 
vaccine, the batch-number, date, and clinic name.  
Infants who were up to three days of age at screening, who could suckle or feed, and who 
were staying in the study area for at least six months after enrolment were included in the 
trial.  
Trained field workers used a prospective surveillance system (that monitored registered 
women aged 15-49 years for pregnancies and deliveries) to ascertain all births in the study 
area between August 2010 and November 2011. They enrolled eligible infants of 
consenting mothers in the trial and weighed them using calibrated electronic (38%) or 
spring (62%) scales. They recorded birth weights to the nearest 0.1kg (electronic scales) or 
0.2kg (spring scales). All but five infants (0.2%) were weighed within 72 hours of delivery. At 
enrolment, field workers collected data on infant, maternal and household characteristics. 
Data on vaccination status (written record and maternal recall) were collected at monthly 
follow-up visits.   
Infants were categorised as a) vaccinated, known vaccination date (if they had a plausible 
vaccination date on their vaccination card); b) vaccinated, unknown vaccination date (if 
they had an unknown or implausible date on their card); and c) unvaccinated (if either i) 
their card was viewed and had no evidence of vaccination, or ii) their card was not viewed 
(possibly because they did not have a card) but their caretaker consistently reported that 
they had never been vaccinated). In addition, infants whose card was never viewed and 
whose mothers reported they were vaccinated, but did not report which vaccine they 
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received, were categorised as vaccination status unknown, as were those infants never 
seen in follow-up, with no information on their vaccination status. 
We categorised infants as either non-low birth weight (NLBW) (weighing ≥2.50kg) or low 
birth weight (LBW) (2.00-2.49kg, 1.50-1.99kg, and <1.50kg). Neonatal illness was a health 
facility admission in the neonatal period (0-27 days of age). 
Infants with known vaccination status, in follow-up at the end of the neonatal period, and 
having complete covariate data were eligible for inclusion in the analyses.  
Analytical methods 
We conducted all analyses using STATA 14.1 (STATACORP, 2015). As neonatal BCG 
vaccination is a frequent event, we calculated adjusted odds ratios (AOR) for the less 
frequent outcome of non-vaccination (rather than for vaccination) using multivariable 
logistic regression. The resulting AORs for this less frequent outcome thus approximated 
more closely to risk or rate ratios. Model building was informed by a hierarchical 
framework5 of the determinants of vaccination identified a priori.3 4 13 14 We initially fit a 
model comprising distal determinants (religion, ethnicity, socioeconomic status, maternal 
occupation, maternal education, vaccine due in wet season, infant sex), then added 
intermediate determinants (maternal age/ family size, maternal illness in the year before 
delivery, distance to the nearest health facility, place of delivery, multiple birth), followed 
by birth weight, and finally infant illness, a possible mediator of the association between 
birth weight and vaccination. We used likelihood ratio tests and 95% confidence intervals 
(95%CI) to assess statistical associations between each explanatory variable and 
vaccination.  
We fitted interaction terms of birth weight and i) place of delivery, and ii) neonatal illness 
to the final model to assess whether either of these modified the association between birth 
weight and vaccination.  
For all infants, irrespective of place of birth, we calculated BCG uptake rates at the end of 
the neonatal period and at 8, 12 and 52 weeks of age, stratified by birth weight, to examine 
variation by time since the due date. To assess how ensuring vaccination of facility-born 
infants prior to discharge would affect vaccination, we calculated ‘theoretical’ proportions 
vaccinated by assigning these infants as vaccinated in the neonatal period. We calculated 
the proportional increase in vaccination by dividing the theoretical proportion by the actual 
proportion for each time-period.  
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The ethics committees of the World Health Organisation (WHO), the London School of 
Hygiene & Tropical Medicine (LSHTM) and the KHRC granted approval for the Neovita trial. 
The Bill and Melinda Gates Foundation funded the Neovita trial. 
 
RESULTS  
Of 22955 infants enrolled in Neovita, 22217 (96.8%) were included in the analyses. Among 
738 excluded, 362 were BCG vaccination status unknown, 242 were BCG vaccinated with an 
unknown date, 88 were lost-to-follow up in the neonatal period, and 46 were missing 
covariate data. In total 275 of the 738 excluded infants died in the neonatal period. Table 1 
shows that excluded infants were more likely to have LBW, to live further from a health 
facility, to be a multiple birth and to have poorer mothers. 
Infants were BCG vaccinated at a median of 8 days; 77% were vaccinated by the end of the 
neonatal period. Uptake decreased with declining birth weight, and was lowest (60%) 
among infants weighing <1.50kg. There was a strong dose-response relationship between 
LBW and the odds of non-vaccination in the neonatal period (p-trend<0.0001), after 
adjustment for other variables (Table 2). Infants weighing 1.50-1.99kg (AOR=1.64; 
95%CI:1.30-2.08) and those weighing <1.50kg (AOR=2.42; 95%CI:1.50-3.88) had odds of 
non-vaccination 1.6 times and 2.4 times those of NLBW infants.  
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Table 1: Baseline characteristics of infants included in the analyses of determinants of 
neonatal BCG vaccination.  
 Excluded Included 
Variable Total=738 Total = 22217 
Distal Determinants   
Religion of head of household 
Christian 
Muslim 
None/Traditional/Other 
 
471 (63.8) 
201 (27.2) 
66 (8.9) 
 
15508 (69.8) 
5310 (23.9) 
1399 (6.3) 
Ethnicity 
Akan 
Non-Akan 
 
317 (43.0) 
421 (57.0) 
 
10376 (46.7) 
11841 (53.3) 
Socioeconomic status 
1 (poorest) 
2 
3 
4  
5(richest) 
Missing Values 
 
185 (25.1) 
174 (23.6) 
150 (20.3) 
125 (16.9) 
103 (14.0) 
1 (0. 1) 
 
4325 (19.5) 
4376 (19.7) 
4433 (20.0) 
4519 (20.3) 
4564 (20.5) 
Maternal occupation 
Gov/Private/ Other 
Self-employed 
Farming 
Does not work 
 
31 (4.2) 
232 (31.4) 
251 (34.0) 
224 (30.4) 
 
1194 (5.4) 
8714 (39.2) 
6420 (28.9) 
5889 (26.5) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
Missing Values 
 
264 (35.8) 
138 (18.7) 
322 (43.6) 
14 (1.9) 
 
6863 (30.9) 
4098 (18.5) 
11256 (50.7) 
Vaccine due in wet season 461 (62.5) 14494 (65.2) 
Sex, Female  340 (46.1) 10966 (49.4) 
Intermediate Determinants   
Maternal age / Family size 
<20 years 
20-29, 1-3 children 
20-29, ≥4 children 
≥30, 1-3 children 
≥30, ≥4 children 
Missing Values 
 
114 (15.4) 
263 (35.6) 
120 (16.3) 
29 (3.9) 
182 (24.7) 
30 (4.1) 
 
2531 (11.3) 
7815 (35.2) 
3843 (17.3) 
1108 (5.0) 
6920 (31.2) 
Maternal illness in year before 
delivery 
32 (4.3) 1091 (4.9) 
Distance  
<1.00km 
1.00-4.99km 
>=5.00km 
Missing Values 
 
409 (55.5) 
152 (20.6) 
174 (23.6) 
2 (0.3) 
 
13471 (60.6) 
5133 (23.1) 
3613 (16.3) 
Facility delivery 517 (70.1) 17064 (76.8) 
Multiple birth 52 (7.1) 795 (3.6) 
Proximal Variables   
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
Missing Values 
 
520 (70.5) 
121 (16.4) 
59 (8.0) 
36 (4.8) 
2 (0.3) 
 
18841 (84.8) 
2910 (13.1) 
385 (1.7) 
81 (0.4) 
Mediating Variables   
Neonatal illness 31 (4.2) 426 (1.9) 
 
 197 
 
Table 2: Determinants of non-vaccination with BCG in the neonatal period 
  
Not 
Vaccinated / 
Total  
Proportion not 
vaccinated 
(95%CI) 
Unadjusted Odds 
Ratios 
Adjusted for 
distal 
determinants 
Adjusted for 
distal & 
intermediate 
determinants 
Adjusted for distal, 
intermediate & 
proximal 
determinants (final 
model) 
Final model 
adjusted for 
mediating effects 
of infant illness 
Final model 
among infants 
born in a health 
facility 
      OR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
Distal Variables         
Religion of head of 
household 
Christian 
Muslim 
None/Traditional/Other 
 
3387/15508 
1310/5310 
392/1399 
 
21.8 (21.2-22.5) 
24.7 (23.5-25.8) 
28.0 (25.7-30.4) 
 
Ref 
1.17 (1.09-1.26) 
1.39 (1.23-1.58) 
(<0.0001) 
 
Ref 
1.04 (0.95-1.13) 
0.96 (0.85-1.09) 
(0.5416) 
 
Ref 
1.01 (0.93-1.10) 
0.90 (0.79-1.03) 
(0.2438) 
 
Ref 
1.01 (0.93-1.11) 
0.90 (0.79-1.03) 
(0.2445) 
 
Ref 
1.01 (0.93-1.11) 
0.90 (0.79-1.03) 
(0.2439) 
 
Ref 
1.00 (0.89-1.11) 
0.86 (0.72-1.03) 
(0.2440) 
Ethnicity 
Akan 
Non-Akan 
 
1891/10376 
3198/11841 
 
18.2 (17.5-19.0) 
27.0 (26.2-27.8) 
 
Ref 
0.60 (0.56-0.64) 
(<0.0001) 
 
Ref 
0.91 (0.84-0.99) 
(0.0320) 
 
Ref 
0.94 (0.86-1.02) 
(0.1381) 
 
Ref 
0.93 (0.86-1.02) 
(0.1112) 
 
Ref 
0.93 (0.86-1.02) 
(0.1099) 
 
Ref 
0.96 (0.87-1.06) 
(0.4092) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 
5 (richest) 
 
1618/4325 
1271/4376 
1020/4433 
709/4519 
471/4564 
 
37.4 (36.0-38.9) 
29.0 (27.7-30.4) 
23.0 (21.8-24.3) 
15.7 (14.7-16.8) 
10.3 (9.5-11.2) 
 
5.19 (4.63-5.82) 
3.56 (3.17-3.99) 
2.60 (2.31-2.92) 
1.62 (1.43-1.83) 
Ref 
(<0.0001) 
 
3.90 (3.42-4.44) 
2.91 (2.57-3.29) 
2.27 (2.01-2.57) 
1.50 (1.32-1.70) 
Ref 
(<0.0001) 
 
2.70 (2.35-3.10) 
2.33 (2.05-2.65) 
1.98 (1.75-2.24) 
1.42 (1.25-1.61) 
Ref 
(<0.0001) 
 
2.69 (2.34-3.08) 
2.32 (2.04-2.64) 
1.98 (1.74-2.24) 
1.41 (1.24-1.60) 
Ref 
(<0.0001) 
 
2.68 (2.33-3.08) 
2.32 (2.04-2.64) 
1.98 (1.74-2.24) 
1.41 (1.24-1.60) 
Ref 
(<0.0001)* 
 
2.98 (2.53-3.50) 
2.34 (2.03-2.71) 
1.98 (1.72-2.26) 
1.47 (1.28-1.68) 
Ref 
(<0.0001) 
Maternal occupation 
Gov/Private/Other 
Self-employed 
Farming 
Does not work 
 
158/1194 
1500/8714 
2082/6420 
1349/5889 
 
13.2 (11.4-15.3) 
17.2 (16.4-18.0) 
32.4 (31.3-33.6) 
22.9 (21.9-24.0) 
 
0.73 (0.61-0.87) 
Ref 
2.31 (2.14-2.49) 
1.43 (1.32-1.55) 
(<0.0001) 
 
0.89 (0.75-1.07) 
Ref 
1.33 (1.22-1.46) 
1.19 (1.09-1.30) 
(<0.0001) 
 
0.92 (0.76-1.10) 
Ref 
1.21 (1.11-1.33) 
1.13 (1.03-1.24) 
(0.0001) 
 
0.91 (0.76-1.09) 
Ref 
1.21 (1.11-1.33) 
1.13 (1.03-1.24) 
(0.0001) 
 
0.91 (0.76-1.10) 
Ref 
1.21 (1.11-1.33) 
1.13 (1.03-1.24) 
(0.0001) 
 
0.92 (0.75-1.12) 
Ref 
1.24 (1.11-1.39) 
1.18 (1.06-1.32) 
(0.0001) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
 
2032/6863 
1057/4098 
2000/11256 
 
29.6 (28.5-30.7) 
25.8 (24.5-27.2) 
17.8 (17.1-18.5) 
 
1.95 (1.81-2.09) 
1.61 (1.48-1.75) 
Ref 
(<0.0001) 
 
1.13 (1.03-1.24) 
1.18 (1.08-1.29) 
Ref 
(0.0013) 
 
1.15 (1.05-1.26) 
1.17 (1.07-1.28) 
Ref 
(0.0013) 
 
1.15 (1.05-1.27) 
1.17 (1.06-1.28) 
Ref 
(0.0015) 
 
1.15 (1.05-1.27) 
1.17 (1.06-1.28) 
Ref 
(0.0015) 
 
1.13 (1.01-1.27) 
1.17 (1.05-1.31) 
Ref 
0.0138 
Vaccine due in wet 
season 
Yes 
No 
 
3272/14494 
1817/7723 
 
22.6 (21.9-23.3) 
23.5 (22.6-24.5) 
 
Ref 
1.06 (0.99-1.13) 
(0.1082) 
 
Ref 
1.04 (0.97-1.11) 
(0.2274) 
 
Ref 
1.04 (0.97-1.12) 
(0.2284) 
 
Ref 
1.04 (0.97-1.12) 
(0.2353) 
 
Ref 
1.04 (0.97-1.12) 
(0.2402) 
 
Ref 
1.05 (0.97-1.15) 
0.2121 
Sex 
Male 
Female 
 
2701/11251 
2388/10966 
 
24.0 (23.2-24.8) 
21.8 (21.0-22.6) 
 
Ref 
0.88 (0.83-0.94) 
(0.0001) 
 
Ref 
0.87 (0.82-0,93) 
(<0.0001) 
 
Ref 
0.86 (0.80-0.92) 
(<0.0001) 
 
Ref 
0.85 (0.80-0.91) 
(<0.0001) 
 
Ref 
0.85 (0.80-0.91) 
(<0.0001) 
 
Ref 
0.83 (0.77-0.90) 
(<0.0001) 
Continued….. 
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Not Vaccinated 
/ Total 
Proportion not 
vaccinated (95%CI) 
Unadjusted Odds 
Ratios 
Adjusted for 
distal 
determinants 
Adjusted for distal 
& intermediate 
determinants 
Adjusted for 
distal, 
intermediate & 
proximal 
determinants 
(final model) 
Final model 
adjusted for 
mediating effects 
of infant illness 
Final model; 
among infants 
born in a health 
facility 
    OR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
AOR (95%CI) 
(p-value) 
Intermediate Variables         
Maternal age / Family size 
<20 years 
20-29, 1-3 children 
20-29, ≥4 children 
≥30, 1-3 children 
≥30, ≥4 children 
 
650/2531 
1601/7815 
1008/3843 
173/1108 
1657/6920 
 
25.7 (24.0-27.4) 
20.5 (19.6-21.4) 
26.2 (24.9-27.6) 
15.6 (13.6-17.9) 
23.9 (23.0-25.0) 
 
1.10 (98.8-1.22) 
0.82 (0.76-0.88) 
1.13 (1.03-1.24) 
0.59 (0.50-0.70) 
Ref 
(<0.0001) 
  
1.22 (1.07-1.39) 
1.10 (1.01-1.20) 
1.11 (1.01-1.22) 
0.93 (0.77-1.11) 
Ref 
(0.0080) 
 
1.19 (1.04-1.35) 
1.09 (1.00-1.19) 
1.11 (1.10-1.22) 
0.92 (0.76-1.10) 
Ref 
(0.0186) 
 
1.19 (1.04-1.35) 
1.09 (1.00-1.19) 
1.11 (1.01-1.22) 
0.92 (0.76-1.10) 
Ref 
(0.0191) 
 
1.27 (1.09-1.48) 
1.09 (0.98-1.22) 
1.14 (1.01-1.29) 
0.97 (0.78-1.19) 
Ref 
(0.0194) 
Maternal illness in year 
before delivery 
No 
Yes 
 
4840/21126 
249/1091 
 
22.9 (22.3-23.5) 
22.8 (20.4-25.4) 
 
Ref 
1.00 (0.86-1.15) 
(0.9468) 
  
Ref 
0.94 (0.80-1.09) 
(0.3866) 
 
Ref 
0.93 (0.80-1.08) 
(0.3568) 
 
Ref 
0.93 (0.80-1.08) 
(0.3545) 
 
Ref 
0.92 (0.76-1.11) 
(0.3764) 
Distance from health facility 
<1.00km 
1.00-4.99km 
>=5.00km 
 
2570/13471 
1146/5133 
1373/3613 
 
19.1 (18.4-19.8) 
22.3 (21.2-23.5) 
38.0 (36.4-39.6) 
 
Ref 
1.22 (1.13-1.32) 
2.60 (2.40-2.82) 
(<0.0001) 
  
Ref 
1.06 (0.98-1.16) 
1.37 (1.25-1.50) 
(<0.0001) 
 
Ref 
1.06 (0.98-1.15) 
1.37 (1.25-1.49) 
(<0.0001) 
 
Ref 
1.06 (0.98-1.15) 
1.37 (1.25-1.49) 
(<0.0001) 
 
Ref 
1.06 (0.96-1.17) 
1.60 (1.41-1.81) 
(<0.0001) 
Place of birth 
Facility 
Non-facility 
 
3079/17064 
2010/5153 
 
18.0 (17.5-18.6) 
39.0 (37.7-40.3) 
 
Ref 
2.90 (2.71-3.11) 
(<0.0001) 
  
Ref 
1.83 (1.69-1.98) 
(<0.0001) 
 
Ref 
1.82 (1.69-1.98) 
(<0.0001) 
 
Ref 
1.83 (1.69-1.98) 
(<0.0001) 
 
 
Multiple birth 
No 
Yes 
 
4898/21422 
191/795 
 
22.9 (22.3-23.4) 
24.0 (21.2-27.1) 
 
Ref 
1.07 (0.90-1.26) 
(0.4468) 
  
Ref 
1.08 (0.91-1.29) 
(0.3692) 
 
Ref 
0.93 (0.78-1.13) 
(0.4742) 
 
Ref 
0.93 (0.78-1.13) 
(0.4747) 
 
Ref 
1.00 (0.81-1.23) 
(0.9889) 
Proximal Variables         
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
 
4204/18841 
737/2910 
116/385 
32/81 
 
22.3 (21.7-22.9) 
25.3 (23.8-26.9) 
30.1 (25.7-34.9) 
39.5 (29.4-50.6) 
 
Ref 
1.18 (1.08-1.29) 
1.50 (1.20-1.87) 
2.27 (1.45-3.55) 
(<0.0001) 
   
Ref 
1.08 (0.98-1.19) 
1.64 (1.30-2.08) 
2.41 (1.50-3.88) 
(<0.0001) 
 
Ref 
1.08 (0.98-1.19) 
1.64 (1.30-2.08) 
2.42 (1.51-3.89) 
(<0.0001)* 
 
Ref 
1.12 (0.99-1.27) 
1.69 (1.28-2.22) 
2.29 (1.35-3.90 
(0.0001) 
Mediating Variable         
Neonatal illness 
No 
Yes 
 
5009/21791 
80/426 
 
23.0 (22.4-23.5) 
18.8 (15.3-22.8) 
 
Ref 
0.77 (0.61-0.99) 
(0.0363) 
    
Ref 
0.91 (0.71-1.17) 
(0.4627) 
 
Ref 
0.89 (0.66-1.20) 
(0.4542) 
* p-trend = <0.0001 
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Not being born in a health facility (compared to being born in a health facility), living 5km or 
more from the nearest health facility (compared to living within 1km of a health facility), 
and being in the lowest quintile of socioeconomic status (SES) (compared to the highest) 
were all strongly associated with not receiving BCG in the neonatal period (Table 2). Almost 
40% of home-born infants were BCG unvaccinated, and their odds of non-vaccination were 
1.82 times those of facility-born infants (AOR=1.82; 95%CI:1.69-1.98; p=<0.0001). Infants 
living >5km from a health facility had odds of non-vaccination 1.37 those of infants living 
within 1km (AOR=1.37; 95%CI:1.25-1.49; p=<0.0001), even after adjusting for place of birth 
and other factors. A strong dose response relationship was observed between SES and 
neonatal BCG vaccination (p-trend <0.0001), with infants from the poorest quintile of SES 
having odds of non-vaccination 2.7 times greater than those from the wealthiest quintile 
(AOR=2.69; 95%CI:2.34-3.08) even after adjustment for all other explanatory variables.  
Having a mother who was a farmer or unemployed (compared to being self-employed), 
who had primary school education or no education (compared to secondary/tertiary 
education) and who was less than 20 years of age (compared to being aged 30 or more with 
four or more children) were associated with an increased odds of non-vaccination in the 
final model. Conversely, female infants had lower odds of non-vaccination (Table 2).  
There was little variation in the effect size for the distal factors after adjustment for 
intermediate and proximal mediating variables, and in the effect size for intermediate level 
factors after adjustment for birth weight. Illness did not appear to mediate the effect of 
birth weight or any other determinants of vaccination (Table 2).  
There was little evidence that either place of delivery or infant illness modified the 
association between birth weight and vaccination (p-value for interaction all >0.2). 
Additional analyses of the vaccination of facility-born infants 
As a post-hoc analysis we further explored the vaccination of facility-born infants. We 
analysed their age at vaccination, and analysed their determinants of vaccination.   
Facility-born infants were vaccinated at a median age of 6 days (IQR=17). The effect 
estimates for the determinants of vaccination were very similar to those for the entire 
study population. The biggest change in effect size was for infants living >5km from a health 
facility, (AOR=1.60; 95%CI:1.41-1.81) (Table 2). 
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Impact of vaccinating all facility-born infants before discharge 
Overall BCG uptake was 77.1% (95%CI:76.5-77.6) by the end of the neonatal period, 91.8% 
(95%CI:91.4-92.1) by 8 weeks of age, 95.9% (95%CI:95.6-96.1) by 12 weeks of age, and 
98.7% (95%CI:98.5-98.8) by 52 weeks of age (Table 3). At each of these time points, uptake 
declined with decreasing birth weight, although there was little difference at age 52 weeks 
(Table 3). We calculated that 91.0% (95%CI:90.6-91.3) of all infants, 91.2% (95%CI:87.9-
93.6) of infants weighing 1.50-1.99kg, and 88.9% (95%CI:79.9-94.1) of infants weighing 
<1.50kg may have been vaccinated in the neonatal period if all facility-born infants were 
vaccinated prior to discharge. This represented a respective 18%, 31% and 47% increase in 
vaccine uptake by the end of the neonatal period. Similar smaller gains in vaccine uptake 
would have occurred for the other categories of birth weight (Table 3).  
Table 3: BCG uptake rates at 4, 8, 12 and 52 weeks of age by birth weight, and rates that 
could be achieved if all those born in a facility had been vaccinated prior to discharge from 
the facility. 
BCG Uptake Rates  
Birth weight Actual Theoretical % Increase in Vaccine Uptake 
 Age 4 weeks 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
77.7 (77.1-78.3) 
74.7 (73.1-76.2) 
69.9 (65.1-74.3) 
60.5 (49.4-70.6) 
91.2 (90.8-91.6) 
89.4 (88.2-90.5) 
91.2 (87.9-93.6) 
88.9 (79.9-94.1) 
17.4 
19.7 
30.5 
46.9 
Overall 77.1 (76.5-77.6) 91.0 (90.6-91.3) 18.0 
 Age 8 weeks 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
92.1 (91.7-92.5) 
90.4 (89.3-91.4) 
87.5 (83.8-90.5) 
72.8 (62.1-81.4) 
96.7 (96.4-96.9) 
95.7 (94.9-96.4) 
97.9 (95.9-99.0) 
91.4 (82.9-95.8) 
5.0 
5.9 
11.9 
25.5 
Overall 91.8 (91.4-92.1) 96.5 (96.3-96.8) 5.1 
 Age 12 weeks 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
96.1 (95.8-96.4) 
95.1 (94.2-95.8) 
93.8 (90.9-95.8) 
88.9 (79.9-94.1) 
98.2 (98.1-98.4) 
97.8 (97.2-98.2) 
98.4 (96.6-99.3) 
97.5 (90.6-99.4) 
2.2 
2.8 
4.9 
9.7 
Overall 95.9 (95.6-96.1) 98.2 (98.0-98.4) 2.4 
 Age 52 weeks 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg 
98.8 (98.6-98.9) 
98.1 (97.5-98.5) 
97.4 (95.2-98.6) 
96.3 (89.1-98.8) 
99.5 (99.4-99.6) 
99.1 (98.7-99.4) 
99.5 (97.9-99.9) 
98.8 (91.7-99.8) 
0.1 
1.0 
2.2 
2.6 
Overall 98.7 (98.5-98.8) 99.4 (99.3-99.5) 0.7 
 
DISCUSSION  
Our analyses indicate that LBW infants are at high risk of missing BCG vaccination in the 
neonatal period. There appears to be a dose-response relationship between vaccination 
and birth weight; vaccination declines with decreasing birth weight, regardless of place of 
birth.  
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We excluded sicker weaker infants who were unable to feed at enrolment, as well as those 
who died during the neonatal period. The LBW infants included in our analyses were 
probably well, and illness was probably not a contraindication to vaccination. Our finding 
that neonatal illness did not appear to mediate the association between birth weight and 
vaccination, overall or when stratified by place of delivery, supports this. LBW is not a 
contraindication to vaccination, and LBW infants are recommended to be vaccinated at the 
same chronological age as NLBW infants;15 however, our results indicate that this 
recommendation is not being optimally adhered to in Ghana.  
We identified a number of additional determinants of neonatal BCG vaccination, including 
place of delivery, distance to health facility, SES, and maternal education, occupation and 
age. These were also identified as determinants in our analyses of postneonatal 
vaccination,5 and other analyses,16 and reflect broader inequities in access to care in our 
study population.  
In our study area, > 20% of the 77% of facility-born infants were unvaccinated at the end of 
the neonatal period, demonstrating a lack of compliance with the routine schedule. This 
was double for infants weighing <1.5kg at birth.  
Vaccination was even lower among home-born infants, suggesting parental delay in 
accessing vaccination services, or for those living far from a facility, the monthly scheduling 
of mobile outreach clinics. The fact that home-born LBW infants are even more delayed 
may reflect parental reluctance to bring fragile infants for vaccination, as previously 
documented in a review of unpublished surveys.6  
Facility-born infants were vaccinated at a median age of six days, suggesting that many are 
unvaccinated at discharge following delivery and that they may instead be referred to the 
child health clinic for vaccination. This would explain why birth weight and other maternal 
and household factors remain as vaccine determinants among facility-born infants. If true, 
then this practice is allowing inequities in vaccination to persist. A single vial of BCG 
vaccinates twenty infants. Fear of wastage has previously been cited as a reason for missing 
opportunities for vaccination,17 and may be a motivation for referring facility-born infants 
to the child health clinic for vaccination.  
Overall uptake of BCG vaccination at age 52 weeks was high; however, many infants were 
vaccinated late, including a higher proportion of LBW infants. BCG vaccination is known to 
have an important protective effect against TB meningitis in the first five years of life18. 
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Timely vaccination is important so as not to prolong the risk of infection. Furthermore, 
timeliness of vaccination is increasingly recognised as an important indicator of the overall 
quality of vaccination programmes19, and our finding that LBW infants were less likely to be 
in compliance with the routine schedule, highlights them as a group who are under-served 
by vaccination. The Global Vaccine Action Plan2 advocates for identifying groups who are 
under-served by routine vaccination services so that they can be targeted for vaccination, 
and so that inequities in the delivery of the vaccination programme can be reduced. 
Ensuring vaccination of facility-born infants prior to discharge would optimise compliance 
with the recommended schedule and the timeliness of BCG vaccination.  
Our finding of reduced vaccination of LBW infants is consistent with our previous finding of 
delayed postneonatal vaccination (with DTP1 and DTP3) of LBW infants.5. It also supports 
recent findings20 from Nairobi Kenya, that infants weighing <2.00kg living in informal urban 
settlements took 9 times longer to be vaccinated in the first 90 days of life than NLBW 
infants. The difference in the magnitude of the association between our study and the 
Kenyan study may be due to the exclusion of unvaccinated infants, the lower prevalence of 
LBW (6%), the higher proportion of facility-born infants (96%), and the higher proportion of 
private facility-born infants (67%) in the Kenyan study. 
Data from Guinea Bissau21 also suggested lower BCG vaccination among LBW infants. As 
there was reportedly a national policy of delaying vaccination of LBW infants until they had 
gained weight or attended for DTP vaccination, these results are not generalisable to 
countries, such as Ghana, where no such policy exists.   
A study from Nigeria22 reported delayed vaccination of under-nourished children. This study 
provides indirect evidence of the effect of birth weight, in addition to infant feeding and 
illness (the causes of undernourishment23) on BCG vaccination.  
Strengths 
Our study was strengthened by low loss to follow-up rates (<3%), by the population-based 
nature of the sample and by the collection of high quality data on both birth weight and 
vaccination.  
Limitations 
We lacked qualitative data on the practices associated with vaccination following delivery, 
including the reasons why infants born in health facilities were not getting vaccinated, and 
why LBW infants born in health facilities were less likely to be vaccinated. This limits our 
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understanding of the barriers to neonatal vaccination (among both facility-born and home-
born infants), and to the vaccination of LBW infants.  
A large number of variables were included in our models, thus increasing the possibility of 
type-1 errors. Due to small numbers, our study was underpowered to detect differences in 
analyses where birth weight was stratified by factors such as infant illness. Although we 
demonstrated that vaccinating all facility-born infants prior to discharge could substantively 
improve the timing and equity of delivery of BCG vaccination, this finding may not be 
generalizable to settings where most infants are born at home.  
 
CONCLUSIONS  
Our analyses indicate that LBW is a risk factor for not being vaccinated with BCG in the 
neonatal period, even for facility-born LBW infants. Efforts to improve neonatal 
vaccination, especially for LBW infants, are warranted, regardless of where they are born. 
For LBW infants born in facilities, vaccination prior to discharge is recommended. 
Qualitative studies to understand the reasons for non-vaccination with BCG in the neonatal 
period are needed. In particular studies are needed to understand why infants, including 
LBW infants born in health facilities are not getting vaccinated. 
 
WHAT IS ALREADY KNOWN ON THIS TOPIC 
Delayed BCG vaccination was associated with low birth weight (LBW) among primarily 
facility born infants in urban slums in Kenya. 
Undernourishment (caused by LBW, illness and feeding practices) was also associated with 
delayed BCG vaccination in urban Nigeria. 
 
WHAT THIS STUDY ADDS 
This large, generalisable prospective population-based cohort study in rural Ghana 
demonstrates lower compliance with the BCG vaccination schedule among LBW compared 
to non-LBW infants. 
LBW is a strong determinant of neonatal BCG vaccination, with a dose response 
relationship between birth weight and vaccination. 
The association persists even for facility-born LBW infants, suggesting a lack of compliance 
with policy to vaccinate prior to discharge from the facility. 
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6.3. CONSIDERATIONS IN THE CHOICE OF ANALYTICAL METHODOLOGY 
Whereas in my analysis of postneonatal vaccination I calculated vaccination rates in specific 
risk periods, in this analysis I measured vaccine uptake by the end of the neonatal period. 
As outlined above, the BCG schedule allows for vaccination at any time within the neonatal 
period1. Therefore, an infant vaccinated on the last day of the neonatal period would still 
comply with the schedule. Defining the risk periods from the vaccine due date (as I did for 
the analyses of postneonatal vaccination) would not have allowed an assessment of 
neonatal vaccination. Given this, I measured overall compliance with the schedule at the 
end of the neonatal period, rather than analysing vaccination rate ratios within or starting 
at the end of the neonatal period. 
As BCG vaccination is a common event in the neonatal period, I presented odds ratios for 
(less-common) non-vaccination as they would be a better approximation of the risk ratios 
for any association between birth weight and the other determinants and vaccination2. 
6.4. DID MEASURING BCG UPTAKE AT THE END OF THE NEONATAL 
PERIOD BIAS THE ESTIMATES OF THE ASSOCIATION BETWEEN BIRTH 
WEIGHT AND NEONATAL VACCINATION? 
As discussed in Section 1.4 studies measuring vaccine uptake at pre-defined time-points 
typically exclude individuals whose follow-up is censored before that time point. Infants 
who were unvaccinated at the time they were lost to follow-up, and who were lost to 
follow-up before the time-point, could have been vaccinated between the time they exited 
the study and the time the outcome was measured. I could not know for sure that they 
were still unvaccinated at the time the outcome was measured, and so their vaccination 
status was essentially unknown. These infants would automatically be excluded from the 
analyses. This would not be the case for vaccinated infants whose vaccination status was 
known. In order to avoid preferentially including vaccinated infants in the analysis of 
vaccine uptake at the end of the neonatal period, I decided to only include infants who 
were still in follow-up at that time point, as I had complete data on the vaccination status of 
all of these infants.  
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If infants excluded from the analyses differed to those included, particularly in relation to 
the main exposure of interest, this could lead to a biased estimate of the association for all 
Neovita enrolled infants.  
It is worth considering how the exclusion of infants who died or who were lost to follow-up 
in the neonatal period might have influenced the effect estimates of the association 
between birth weight and BCG vaccination. Table 6.1 summarises the characteristics of 
infants who exited the study in the neonatal period and who were excluded from the 
analysis, according to their vaccination status and birth weight. 
Table 6.1: Vaccination status and birth weight of infants excluded from the analyses. 
Vaccination status LBW  
N (% of total) 
NLBW 
N (% of total) 
Total 
N (% of total) 
Vaccination card seen, 
vaccinated, date known 
21 (28) 54 (72) 761 
Vaccination card seen, 
known not vaccinated 
32 (56) 25 (42) 57 
Vaccination card seen, 
vaccinated, date unknown 
37 (15) 206 (85) 243  
Vaccination card not seen, 
known not vaccinated 
0 0 0 
Vaccination status unknown 125 (35) 235 (65) 362  
Total 216 (29) 522 (71) 738 
1. infant with unknown birthweight  
A total of 738 infants were excluded from the BCG analysis, of whom 216 (29%) were LBW. 
Of these 738, 243 (33%) were vaccinated with an unknown date, and 362 (49%) had an 
unknown vaccination status. LBW infants made up a greater proportion of unvaccinated 
infants (56%) and infants whose vaccination status was unknown (35%). LBW infants 
comprised a smaller proportion of infants with unknown vaccination dates (15%).  
LBW infants were more likely to be excluded from the analyses; however, since less than 
2% of all enrolled infants with known vaccination status were excluded (76 vaccinated 
infants with a known date, 57 infants known not to be vaccinated, and 243 vaccinated 
infants with an unknown date), this is unlikely to have greatly affected the size of the effect 
estimates or the generalisability of the results. 
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CHAPTER 7: USING ROUTINE 
HEALTHCARE CONTACTS TO IMPROVE 
THE VACCINATION OF LBW INFANTS 
Preamble 
The paper presented in this chapter addresses PhD objective 4, which is to investigate the 
potential for using routine contacts with health care providers to improve vaccine uptake, 
including among LBW infants, and to assess whether birth weight and other factors are 
determinants of uptake of opportunities. In Section 7.1, I introduce the paper. I discuss the 
process for defining opportunities for vaccination (the main outcome for these analyses) in 
Section 7.2 and Section 7.3 presents the paper itself, including tables and graphs of results. 
The paper investigated a number of potential determinants of uptake, of which birth weight 
was one. However, as it did not otherwise specifically focus on LBW infants, Section 7.4 
presents an additional analysis that investigates how using opportunities could specifically 
improve the vaccination of LBW infants. Section 7.4 includes a description of the methods 
for this analysis, and it presents and discusses the results of the analysis. 
7.1. INTRODUCTION 
My aim for this paper was to investigate how contacts with the health service could be used 
to improve the vaccination of infants who were due but were not up to date with their 
vaccines. As discussed in Chapter 1, routine contacts with the health service could provide 
an easy and inexpensive way to improve vaccination for all infants, including LBW infants. 
However, in order for this to happen, vaccine and health care providers would need to pro-
actively notice and address under-vaccination.  
In this analysis, I investigated the extent to which health care providers did this in our study 
population, using four indicator vaccines, BCG, OPV3, DTP3 and measles. I investigated a) 
the frequency of opportunities for vaccination, b) the uptake of those opportunities for 
vaccination, and c) the impact that using those opportunities would have on vaccine 
uptake. 
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The outcomes for these analyses were 1) opportunities for vaccination (described in greater 
detail in Section 7.2, and in the paper itself), 2) determinants of uptake of opportunities 
(analysed using logistic regression) and 3) the proportions of infants who would have been 
vaccinated at specific time-points if their first opportunity was taken (2 and 3 described in 
greater detail in the paper). The study population for the analysis of frequency of 
opportunities was infants who were due vaccines, the study population for uptake and 
impact of using opportunities was infants who had opportunities. A more detailed 
description of the study populations for each analysis, including additional inclusion criteria 
is given in the paper.  
7.2. DEFINING OPPORTUNITIES FOR VACCINATION 
As described in Chapters 2 and 3, data were available on 1) reported care seeking for 
illness, 2) reported health facility admissions for illness (identified by dates of admission), 
and 3) visits for vaccination (identified by dates of vaccination).  
I defined opportunities for vaccination as a contact with a health care provider for reasons 
other than to receive the vaccine of interest, for infants who were eligible but not up-to-
date with their vaccines. I classified opportunities as ‘primary-care based’ (during a 
vaccination contact with a primary care provider in the community) and ‘facility-based’ 
(during a health facility admission). Reported care seeking visits were not included as 
opportunities, for the reasons discussed in point 3, below. 
The process of defining opportunities for vaccination was complicated and reflected the 
complexity of the routine vaccination schedule in Ghana, as well as the numerous 
permutations in the actual order of vaccination in our study population. I, with the 
assistance of my supervisors, identified a number of criteria for exclusion from the above 
definition of opportunities: 
1. The contact had to allow the administration of a valid vaccination dose in compliance 
with the recommended schedule. Contacts that occurred before the due date for 
vaccination were excluded. For OPV3 and DTP3, the contact had to be at least four 
weeks after the previously administered doses, as this is the minimum recommended 
gap between doses for these vaccines. 
2. The contact had to be within the first year of life, as I was investigating opportunities 
within the first year of life. 
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3. It had to be possible to administer vaccines at the contact. All health facilities and child 
health clinics have the capacity to give vaccines. For reported care seeking, I did not 
have data on where care was sought. Care may have been sought from a variety of 
sources where there was no capacity to administer vaccines, such as traditional healers, 
pharmacists or drug sellers. For this reason, I excluded reports of care seeking for illness 
from my definition of opportunities, unless it was a documented health facility 
admission. 
4. The contact should not have been specifically for the administration of the due vaccine. 
If a caretaker took a child to a child health clinic solely for the purpose of getting the 
due vaccine, then that could not be counted as an opportunity. The contact had to be 
for another reason to be counted as an opportunity. If I did not have evidence of this, 
the contact was excluded. The only data that allowed me to identify the contact as 
being associated with another activity was the administration of another unrelated (not 
co-scheduled) vaccine or a facility admission. If the contact was associated with the 
administration of a related / co-scheduled vaccine, it was excluded, for the reasons 
outlined below. 
7.2.1. Exclusion of co-scheduled vaccines 
As outlined in Chapter 2, the routine vaccination schedule in Ghana recommends the 
administration of OPV and DTP together at 6, 10 and 14 weeks of age, and the 
administration of measles and yellow fever together at 9 months of age. At the clinic both 
scheduled vaccines should automatically be given together. This analysis aimed to 
investigate the ability of health care providers to proactively identify and respond to 
instances of under-vaccination. Given this, I excluded from my definition of opportunities 
visits for a co-scheduled vaccine with which the vaccine of interest would have been given 
automatically (i.e. for DTP I excluded OPV vaccination visits, for OPV I excluded DTP 
vaccination visits, and for MCV vaccine I excluded yellow fever vaccination visits).  If I had 
included these as opportunities, I would have risked overestimating the number of 
opportunities, and the uptake of opportunities. I discuss this further in Section 7.4. 
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7.3. PAPER 4: OPPORTUNITIES FOR INFANT VACCINATION IN GHANA, 
AND THE POTENTIAL IMPACT OF THEIR UTILISATION ON VACCINE 
UPTAKE. 
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ABSTRACT 
Background 
We analysed how using healthcare contacts (opportunities) would improve vaccination in 
rural Ghana.   
Methods 
For each vaccine (Bacillus Calmette-Guerin (BCG), third dose oral polio vaccine (OPV3) and 
diphtheria-tetanus-pertussis (DTP3), and measles), we counted among eligible infants 
(known vaccination status, due vaccines), the number of opportunities (contacts for 
reasons other than receipt of the vaccine of interest) and their uptake (the proportion 
taken), stratified by type of opportunity: ‘primary-care-based’ (associated with getting an 
unrelated vaccine) and ‘facility-based’ (during an admission). Among those with 
opportunities, we i) calculated adjusted odds ratios (aOR) of the determinants of primary-
care-based opportunity uptake using logistic regression, and ii) calculated how using the 
first opportunity would improve vaccination at 4, 8 and 12 weeks after the due date.  
 
Results 
Of eligible infants, 50.8% (2591/5105) for BCG, 6.7% (1451/21581) for OPV3, 4.8% 
(1046/21689) for DTP3, and 14.8% (3067/20726) for measles needed opportunities. Of 
those needing opportunities, 95.9% (2485/2591) had opportunities for BCG, 38.2% 
(554/1451) for OPV3, 22.2% (232/1046) for DTP3, and 22.3% (685/3067) for measles. Most 
BCG opportunities (94%, 3358) were associated with, and uptake was highest (54%, 
1806/3358) when the infant received DTP/OPV vaccines at 6-14 weeks. Uptake was lower 
for measles/yellow fever contacts at 9 months onwards (10%, 12/125) and facility-based 
contacts (1%, 1/71). Compared to infants who were vaccinated before age 8 weeks, uptake 
of BCG opportunities was 85% less likely (aOR=0.14; 95%CI:0.10-0.19) 24 weeks or more 
after the BCG due date. For BCG, exploiting the first opportunity would have appreciably 
improved uptake at 4 (from 47% to 61%), 8 (from 74% to 91%) and 12 (from 83% to 97%) 
weeks after the due date. 
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Conclusions 
Routine healthcare contacts are under-utilised to vaccinate those under-served by 
vaccination in Ghana, especially contacts occurring 6 months after the due date and those 
associated with admissions.  
Keywords: routine childhood vaccination, missed opportunities, Ghana, epidemiology 
 
INTRODUCTION 
Currently one in five children does not receive the full schedule of vaccines as 
recommended by the Expanded Programme on Immunisation), and many are vaccinated 
late1,2. The Global Vaccine Action Plan (2011-2020)1 stresses that each contact with a 
healthcare provider should be used to verify vaccination status and to vaccinate when 
indicated1. The World Health Organisation (WHO) also recommends that the vaccination 
status of children admitted to health facilities be assessed, and due vaccines administered 
prior to discharge.3  
We aimed to evaluate how exploiting routine contacts with healthcare providers could 
improve vaccination, by analysing data from a large randomised controlled trial undertaken 
in Ghana between October 2010 and February 2013. This trial collected high-quality data on 
vaccination and specific contacts with healthcare providers at monthly intervals for the first 
year of life. The Ghanaian routine vaccination programme recommends the administration 
of Bacillus Calmette-Guerin (BCG) and oral polio vaccine (OPV) at birth, OPV and the 
pentavalent diphtheria, tetanus, pertussis, haemophilus influenza B, and hepatitis B vaccine 
(DTP/HiB/HepB hereafter known as DTP) at 6, 10 and 14 weeks of age, and measles 
containing vaccine (MCV) and yellow fever (YF) at nine months of age. As the potential to 
improve vaccine delivery through exploiting routine healthcare contacts may vary 
depending on the type of vaccine and the recommended age of administration, our 
analyses focused on BCG, third dose OPV (OPV3) and DTP (DTP3), and MCV. 
Our objectives were, for each of these vaccines to 1) quantify among infants’ due 
vaccination, the frequency and uptake of opportunities for vaccination in the first year of 
life, and to assess among infants with opportunities 2) the determinants of opportunity 
uptake, and 3) how using the first opportunity could increase vaccine uptake.  
 
METHODS 
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The Neovita trial, conducted at the Kintampo Health Research Centre (KHRC) in Ghana, 
evaluated the impact of neonatal vitamin A supplementation on infant mortality4. We have 
recounted the trial procedures elsewhere4,5. Trained field staff collected data on infant and 
maternal factors at baseline, and of vaccination and health facility admissions at monthly 
follow-up visits for the first year of life. Data on vaccinations, administered at birth in health 
facilities or given subsequently at child health clinics, Community Health Planning System 
(CHPS) compounds or mobile vaccination clinics, were extracted from the infant’s written 
vaccination record, and supplemented by maternal recall (≤1% of all data). Data on 
admissions, including admission and discharge dates, were based on maternal report.  
The study population for the first objective (quantifying the number of opportunities) were 
infants in follow-up, due vaccination, with known vaccination status and dates. Infants with 
complete covariate data with vaccination opportunities were included in the analysis of the 
second objective (determinants of opportunity uptake). Those with opportunities were the 
study population for the third objective (impact of using the first opportunity). 
Definitions 
We defined infants as: 1) vaccinated (known date) when they had a plausible vaccination 
date on their written record;  2) vaccinated (unknown date) when they had an illegible or 
implausible date on their record; 3) unvaccinated when they consistently had no evidence 
of vaccination on their record and no documented date, or when their record was never 
viewed and their mothers consistently reported them as unvaccinated; 4) vaccination status 
unknown if their record was never viewed and their mother reported them as vaccinated 
without specifying the vaccine, or there was no information on whether they were 
vaccinated as they were never seen in follow-up. 
Among eligible infants due a specific vaccine, we defined opportunities as contacts with a 
healthcare provider for reasons other than to receive the vaccine of interest. We classified 
opportunities as ‘primary-care-based’ (during a contact with a primary-care provider to 
receive an unrelated vaccine) and ‘facility-based’ (during a facility admission).  
As our interest was in capturing healthcare workers’ ability to take advantage of an 
unrelated contact to administer a due vaccine, we excluded contacts in which a due vaccine 
was given on its own without another vaccine or admission, as mothers may have brought 
their infants to the health centre solely to get the vaccine. Similarly, we excluded visits for a 
co-scheduled vaccine with which the vaccine of interest would have been given 
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automatically (for DTP3 we excluded OPV vaccination visits, for OPV we excluded DTP 
vaccination visits, and for MCV vaccine we excluded yellow fever vaccination visits).    
Facility-based opportunities were classified as ‘taken’ if the due vaccine was given between 
the admission and discharge dates.   
We followed the approach of Clark and Sanderson2, Hutchins et al6, and Kahn et al7, and 
counted opportunities from the vaccine due date. For BCG the due date was any time up to 
the end of the neonatal period (4 weeks/28 days of age)8. Follow-up ended at age one year, 
at exit from the study, or when the infant received the vaccine of interest, depending on 
which came first. 
All analyses were conducted using STATA 14.1 (STATACORP, 2015).  
For each vaccine (BCG, OPV3, DTP3 and MCV), we counted the number of opportunities 
and calculated the opportunity uptake rate as the proportion of these opportunities that 
were 'taken’, stratified by type of opportunity (primary-care-based and facility-based).  
 
We used multivariable logistic regression to calculate adjusted odds ratios (aOR) of the 
determinants of opportunity uptake. Model construction was informed by a hierarchical 
framework9 of the determinants of vaccination, starting with an initial model of distal 
determinants (for example socioeconomic status), then adding the proximal determinants 
(like birth weight), and finally adjusting for neonatal infant illness (as a possible mediator of 
uptake of opportunities10). We used robust standard errors to account for clustering 
associated with infants who had more than one opportunity during follow-up.  
For each vaccine we generated Kaplan-Meier curves of the actual times to vaccination 
(using the actual date of vaccination) and the theoretical times to vaccination (if the first 
vaccination opportunity was taken). To assess how exploiting opportunities would improve 
uptake over time, we calculated actual and theoretical uptake rates at 4, 8, and 12 weeks 
after the vaccine due date, and at 52 weeks of age for all vaccines.  
The Ethics Committees of the World Health Organisation (WHO), the London School of 
Hygiene & Tropical Medicine (LSHTM) and the KHRC approved the conduct of the trial. 
The Neovita trial was funded by the Bill and Melinda Gates Foundation. 
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RESULTS 
Of 22,955 Neovita enrolled infants, the numbers eligible for inclusion in the analyses of 
frequency and uptake of opportunities for each vaccine (infants with known vaccination 
status and dates who were in follow-up and who were due vaccination) were a) 5105 (22%) 
for BCG, b) 21581 (94%) for OPV3, c) 21689 (95%) for DTP3 and 20726 infants (90%) for 
MCV (Table 1). Most of these infants were vaccinated at a scheduled visit or were given the 
vaccine on its own before any unrelated healthcare contact (Table 1). Consequently, those 
needing opportunities were, except for BCG, small. For BCG 50.8% (2591/5105) of eligible 
infants needed opportunities, compared to 6.7% (1451/21581) for OPV3, 4.8% 
(1046/21689) for DTP3, and 14.8% (3067/20726) for MCV. Of 2591 infants needing BCG 
opportunities, 2485 (95.9%) had opportunities, compared to 38.2% (554/1451) of those 
needing OPV3 opportunities, 22.2% (232/1046) of those needing DTP3 opportunities, and 
22.3% (685/3067) of those needing MCV opportunities (Table 1).   
Infants had a median of one, and a maximum of seven opportunities for BCG vaccination 
(Web Figure 1). Most BCG opportunities (98%, 3483) were primary-care-based, and almost 
all (94%, 3358) were associated with OPV/DTP vaccination (scheduled at age 6-14 weeks). 
BCG opportunity uptake was highest (54%, 1806/3358) for these earlier OPV/DTP related 
opportunities, and lower for MCV/YF related opportunities (10%, 12/125) (scheduled at 9 
months) or facility-based opportunities (1%, 1/71) (Table 1). Uptake was highest (62.7%) for 
the first primary-care-based opportunity, and declined thereafter (33.4% for the second, 
22.4% for the third, 12.3% for the fourth, and zero for the fifth, sixth and seventh) (Web 
Figure 1).  
There were fewer opportunities for OPV3, DTP3 and MCV vaccination, and a lower 
proportion of these were primary-care-based (63% (394/622) for OPV3, 28% (65/232) for 
DTP3 and 26% (193/736) for MCV). For each of these vaccines, fewer than 10% of all 
opportunities were taken (Table 1). Uptake of opportunities for vaccines other than BCG 
was low, regardless of whether it was the first, second or subsequent opportunity (Web 
figures 2, 3 and 4). 
Due to small numbers of primary-care-based and facility-based opportunities and the small 
number of taken opportunities for OPV3, DTP3 and MCV vaccination (Table 1, Web figures 
1-4), the analysis of determinants of uptake of opportunities was restricted to BCG primary-
care-based opportunities.  
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Compared to all Neovita enrolled infants, (Table 2), the 5105 infants who were BCG 
unvaccinated and in follow up at the end of the neonatal period were more likely to be 
poorer, to be farmers, with lower educational attainment, living further from a health 
facility, and not born in a health facility. Among those 5105, there was little difference 
between the 2439 included in the analyses, compared to those excluded (because they had 
no opportunities (n=2620) or they were missing covariate data (n=46)) (Table 2). 
There was a marked linear decline in the likelihood of opportunity uptake over time, with 
lower uptake the further away the opportunities were from the BCG due date (p-
trend<0.0001) (Table 3), having adjusted for all other explanatory variables. Compared to 
those within eight weeks of the due date, uptake was 30% less likely (aOR=0.70; 
95%CI:0.59-0.83) for opportunities 9-12 weeks after the due date, almost 70% less likely 
(aOR=0.31; 95%CI:0.26-0.38) for opportunities 13-24 weeks after the due date, and >85% 
less likely (aOR=0.14; 95%CI:0.10-0.19) for opportunities >24 weeks after the due date.  
There was some evidence of an association with maternal occupation, with increased 
uptake of BCG opportunities for infants whose mothers were self-employed (aOR=1.46; 
95%CI:1.17-1.80), compared to farmers, even after adjusting for more proximal variables. 
No other factor was observed to have an effect on the uptake of BCG vaccine-provider 
opportunities, nor was infant illness found to have a mediating effect (Table 3). 
Among those with opportunities, exploiting the first opportunity would have increased 
uptake considerably in the 4, 8 and 12 weeks after the due date for each vaccine (Figure 1, 
Table 4).  
For BCG vaccine uptake would have increased from 46.6% (95%CI:44.7-48.6) to 61.1% 
(95%CI:59.2-63.0) at 4 weeks after the due date, from 73.8% (95%CI:72.0-75.5) to 90.8% 
(95%CI:89.7-92.0) by 8 weeks after the due date, and from 83.1% (95%CI:81.6-84.6) to 
97.2% (95%CI:96.6-97.9) by 12 weeks after the due date (Table 4). For OPV3, vaccine 
uptake would have more than doubled at 4 weeks after the due date, from an actual 
uptake of 7.8% (95%CI:5.9-9.7) to 19.5% (95%CI:16.7-22.3), and would have almost doubled 
again by 8 weeks, from 18.7% (95%CI:15.9-21.4) to 31.6% (95%CI:28.4-34.9). By 12 weeks, 
uptake would have increased from 39.9% (95%CI:36.5-43.4) to 45.7% (95%CI:42.1-49.2) 
(Table 4). Similar substantive improvements in uptake of DTP3 and MCV would have 
occurred (Table 4).  
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DISCUSSION 
This study investigated the potential for using health service contacts to improve vaccine 
uptake for infants under-served by vaccination in Ghana. For most vaccines except BCG, the 
percentage of under-served infants who needed opportunities was comparatively small 
(50.8% of eligible infants for BCG, 6.7% for OPV3, 4.8% for DTP3, and 14.8% for MCV), 
however under-served infants are more likely to come from marginalised populations 
where the burden of disease is highest, and where vaccination may have the greatest 
impact. Ensuring their vaccination is essential to fulfil global disease eradication and 
elimination goals1.  
Where opportunities existed, in many cases these were missed by vaccine providers and 
other healthcare providers. Although for BCG, the uptake of primary care opportunities was 
>50%, for other vaccines uptake of these opportunities was <10%, suggesting a failure to 
systematically assess the overall vaccination status of infants attending for routine 
vaccination and to administer due vaccines. Similarly, facility-based opportunities were 
largely unexploited with opportunity uptake of <10% for all vaccines. This suggests a lack of 
compliance with recommendations to assess and vaccinate infants prior to discharge3, and 
a fragmentation of curative care and vaccination services in our study area. Facility-based 
opportunities were particularly important for vaccines scheduled later in the programme, 
as they were for many infants the only opportunities for vaccination.  
For BCG vaccination, vaccine-providers were less likely to administer BCG, the further away 
the opportunity was from the due date. Vaccine-providers may forget about administering 
overdue BCG when they are giving later scheduled vaccines such as measles.  
For those having opportunities, we showed that substantive improvements to uptake could 
be achieved. It is evident from the characteristics of infants with BCG opportunities (born to 
poorer mothers with lower levels of education and occupational grade, living further from 
health facilities and who delivered at home), that ensuring the utilisation of all 
opportunities to vaccinate would help in tackling the known inequities11 in vaccine service 
delivery in our study population11. It is notable however that, for MCV, a large proportion of 
infants who needed opportunities had no known opportunities for vaccination in the three 
months between the due date and the end of follow-up, so even if all contacts were 
exploited, a core group would remain unvaccinated at the end of infancy. In the first year of 
life, infants in Ghana have only one scheduled vaccination visit after OPV3/DTP3 
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vaccination and none after MCV. For MCV, primary-care-based opportunities were 
frequently due to the late administration of BCG, OPV and DTP vaccines. 
Some studies7,12,13 have counted every contact with a healthcare provider as an opportunity 
for vaccination, even those where the infant was specifically being brought for the vaccine 
of interest. We followed the approach of Clark and Sanderson2, and only included contacts 
for reasons other than receipt of the vaccine of interest. Consequently, our definition 
excluded opportunities associated with the administration of co-scheduled vaccines such as 
OPV opportunities for DTP vaccination and vice versa, as we assumed that the vaccine 
would be given automatically and not because the vaccine-provider recognised the need to 
administer a due dose. 
We present minimum estimates of the number of opportunities for vaccination in our study 
area. For instance, we excluded vaccines due and given alone without any other vaccine or 
associated admission, as we didn’t know if the contact was intended for a reason other 
than the administration of that particular vaccine. Regarding contacts associated with 
illness, reported care seeking contacts with healthcare providers that did not result in an 
admission were not counted, as we lacked information on the nature of these contacts and 
whether they could have been used for vaccination. It is likely that the number of 
opportunities for vaccination and their potential to improve vaccination in our study area is 
even greater than our estimates indicate.  
Few studies have investigated vaccination opportunities in Africa, and most available 
data6,7,13 are more than 20 years old. More recently, it has been reported that 26% of 
infants in Mozambique had at least one missed vaccination opportunity12, substantively 
higher than in our study. This difference may reflect a) our more cautious approach to 
defining opportunities as described above, as well as b) lower vaccine uptake rates in the 
Mozambique study area (<75% for all vaccines) compared to our study area. Regarding 
opportunity uptake, the analysis of DHS data collected from 1996- 2005 in 24 African 
countries reported that, among those with opportunities, 17% to 71% of opportunities for 
DTP3 and MCV vaccination were taken (mean=41%)2. Higher uptake rates for primary-care-
based opportunities compared to facility-based opportunities have previously been 
reported7. As suggested by our findings, failure to administer vaccines simultaneously, and 
a lack of assessment of vaccination status have previously been reported as determinants 
of uptake of opportunities6. Additional reported factors, for which we lacked data, include 
false contraindications to vaccination, fear of wasting vaccine by opening a vial for a small 
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number of children (particularly for BCG vaccination), vaccine shortage, poor organisation 
of vaccine clinics, and a lack of a daily vaccination clinic6. 
Strengths and Limitations 
Our study benefited from low loss to follow-up rates (<3%), from the fact that the sample 
was population-based, and from the high-quality of the vaccination data. Vaccination data 
were collected at monthly intervals, using both written record and maternal recall, and we 
employed a rigorous approach to identifying and resolving inconsistencies in these data. 
Similarly, data on admissions, which were based on maternal recall, were collected on a 
monthly basis, thus minimising the potential for under-reporting and misclassification of 
these data.  
Our study was also subject to a number of potential limitations. Due to small numbers we 
were unable to investigate the determinants of uptake of facility-based opportunities or 
primary-care-based opportunities for vaccines other than BCG, and so we were unable to 
assess whether their determinants differed to those of BCG opportunity uptake. We 
included nine explanatory variables in our final multivariable model, thus increasing the risk 
of finding an association due to chance due to multiple testing. However, the strong 
evidence of a graded effect with increasing time since the vaccine due date (p<0.001) 
seems unlikely to be due to a Type 1 error. Finally, the main trial did not collect qualitative 
data on either maternal, vaccine-providers’ or healthcare providers’ reasons for not 
utilising vaccination opportunities, which limits our ability to fully understand the drivers of 
missed vaccination opportunities. Nonetheless, our analyses provide clear evidence that 
failure to co-administer vaccines and poor integration between vaccination and curative 
care services are major contributors to missed opportunities in our study population. 
Since undertaking this study, vaccines against pneumococcus and rotavirus, and a second 
MCV dose have been added to the national childhood vaccination schedule in Ghana. As 
the complexity of the vaccination programme and the number of antigens to be given 
together increases, the importance of exploiting all vaccination opportunities will also 
increase to ensure that children are fully vaccinated.  
 
CONCLUSIONS  
Our study highlights the unexploited potential for using routine healthcare contacts to 
vaccinate those under-served by vaccination in Ghana; doing so may help to address some 
of the persisting inequities in vaccine uptake. This could be easily achieved through simple 
 225 
 
changes to vaccine service delivery, such as assessing all infants who attend vaccination 
clinics to see if they are fully vaccinated and vaccinating them if they are not. Vaccine 
providers should be educated to do this.  Greater integration of vaccination services with 
curative care is needed. Further research on the reasons for missed opportunities should be 
undertaken to address other possible reasons for missing opportunities, such as poor 
scheduling and organisation of clinics, fear of wastage and other false contraindications6. 
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TABLES AND FIGURES 
Table 1: Opportunities and uptake of opportunities for vaccination 
a) Infants included & their opportunities for vaccination 
  Number (%) of infants 
    Needed Opportunities 
Vaccine Eligible1 N (%) 
Vaccinated at 
scheduled visit 
Vaccinated 
alone 
No opportunities, 
not vaccinated 
Had 
opportunities 
BCG 5105 (22.2) -  2514 (49.2) 106 (2.1) 2485 (48.7) 
OPV3 21581 (94.0) 19902 (92.2) 228 (1.1) 897 (4.2) 554 (2.6) 
DTP3 21689 (94.5) 19961 (92.0) 682 (3.4) 814 (3.8) 232 (1.1) 
Measles 20726 (90.3) 17414 (84.0) 245 (1.4) 2382 (11.5) 685 (3.3) 
b) Count and uptake of opportunities by i) type of opportunity, and ii) associated vaccine. 
  i) Type of Opportunity ii) Associated vaccine2 
Vaccine  Facility-based  Primary-care based BCG MCV/YF Any OPV/DTP 
 Total N (% of total) Uptake (%) N (% of total) Uptake (%) Total Uptake (%) Total Uptake (%) Total Uptake (%) 
BCG 3554 71 (2.0) 1 (1.4) 3483 (98.0) 1818 (52.2) - - 125 12 (9.6) 3358 1806 (53.8) 
OPV3 622 228 (36.7) 21 (9.2) 394 (63.3) 6 (1.5) 7 1 (14.3) 387 5 (1.3) - - 
DTP3 232 188 (81.0) 8 (4.3) 65 (28.0) 5 (7.7) 4 1 (25.0) 61 4 (6.6) - - 
Measles 736 543 (73.8) 43 (8.4) 193 (26.2) 6 (3.1) 9 0 (0.0) - - 184 6 (3.3) 
1. In follow-up & unvaccinated at due date 2) For primary-care- based opportunities, opportunities were associated with the delivery of other vaccines. For instance, for BCG opportunities, MCV/YF associated vaccines 
indicates that the BCG opportunity was associated with the delivery of MCV/YF vaccines. 
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Table 2: Baseline characteristics of infants included in the analyses of determinants of 
uptake of BCG primary care based opportunities. 
  5105 eligible1  
 All Enrolled 
Infants 
Excluded (No 
Opportunities (n=2620) or 
missing covariate data) 
(n=46) 
Included (Had 
Opportunities) 
Variable  Total = 22955 Total = 2666 Total = 24392 
Ethnicity/Religion 
Akan 
Non-Akan/Non-Christian 
Non-Akan/Christian 
 
10693 (46.6) 
5879 (25.6) 
6383 (27.8) 
 
994 (37.3) 
765 (28.7) 
907 (34.0) 
 
897 (36.8) 
754 (30.9) 
788 (32.3) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 (richest) 
 
4510 (19.7) 
4550 (19.8) 
4583 (20.0) 
9312 (40.6) 
 
866 (32.5) 
658 (24.7) 
560 (21.0) 
582 (21.8) 
 
760 (31.2) 
617 (25.3) 
463 (18.9) 
599 (24.5) 
Occupation 
Gov/Private/Self-employed/Other 
Farming 
Does not work 
 
10171 (44.3) 
6671 (29.1) 
6113 (26.6) 
 
824 (30.9) 
1149 (43.1) 
693 (26.1) 
 
837 (33.3) 
943 (38.6) 
659 (27.0) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
Missing 
 
7127 (31.1) 
4236 (18.5) 
11578 (50.5) 
14 
 
1080 (40.5) 
552 (20.7) 
1031 (38.7) 
3 (0.1) 
 
964 (39.5) 
505 (20.7) 
970 (39.8) 
Sex 
Male 
Female  
 
11649 (50.8) 
11306 (49.3) 
 
1421 (53.3) 
1245 (46.7) 
 
1291 (53.0) 
1148 (47.0) 
Age/Parity 
<20 
20-29, 1-3 kids 
20-29, 4 or more kids 
>=30, 1-3 kids 
>=30, 4 or more kids 
Missing 
 
2645 (11.5) 
8078 (35.2) 
3963 (17.3) 
1137 (5.0) 
7102 (30.9) 
30 
 
337 (12.6) 
849 (31.8) 
530 (19.9) 
90 (3.4) 
848 (31.8) 
12 (0.5) 
 
314 (12.9) 
753 (30.9) 
478 (19.6) 
84 (3.4) 
810 (33.2) 
 
Distance  
<1.00km 
1.00-4.99km 
>=5.00km 
Missing 
 
13880 (60.5) 
5285 (23.0) 
3787 (16.5) 
3 
 
1379 (51.7) 
617 (23.1) 
669 (25.1) 
1 (0.1) 
 
1197 (49.1) 
532 (21.8) 
710 (29.1) 
Place of birth 
Facility 
Non-facility 
 
17581 (76.6) 
5374 (23.4) 
 
1636 (61.4) 
1030 (38.7) 
 
1451 (59.5) 
988 (40.5) 
Birth weight 
>=2.5kg 
2.00-2.49kg 
1.50-1.99kg 
<1.50kg  
Missing 
 
19361 (84.4) 
3031 (13.2) 
444 (1.9) 
117 (0.5) 
2 
 
2167 (81.3) 
417 (15.6) 
64 (2.4) 
18 (0.7) 
 
2052 (84.1) 
321 (13.2) 
52 (2.1) 
14 (0.6) 
 
1. Unvaccinated & in follow-up at the end of the neonatal period 
2. Excludes 46 infants with opportunities who were missing covariate data
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Table 3: Determinants of uptake of postneonatal BCG primary care based opportunities (n=3438) 
 
Vaccinated / 
Total 
Proportion of 
opportunities taken 
(95%CI) 
Unadjusted odds 
ratio 
Adjusted for distal 
determinants 
Adjusted for distal & 
proximal 
determinants (final 
model) 
Final model adjusted 
for mediating effects 
of infant illness 
   
OR (95%CI) 
(p-value) 
aOR (95%CI) 
(p-value) 
aOR (95%CI) 
(p-value) 
aOR (95%CI) 
(p-value) 
Ethnicity/Religion 
Akan 
Non-Akan/non-Christian 
Non-Akan/Christian 
 
647/1201 
579/1084 
565/1153 
 
53.9 (51.1-56.7) 
53.4 (50.4-56.4) 
49.0 (46.1-51.9) 
 
Ref 
0.98 (0.80-1.21) 
0.82 (0.67-1.00) 
(p=0.1066) 
 
Ref 
1.10 (0.86-1.41) 
0.94 (0.75-1.17) 
(p=0.3370) 
 
Ref 
1.13 (0.90-1.42) 
0.94 (0.76-1.15) 
(p=0.1881) 
 
Ref 
1.13 (0.90-1.43) 
0.94 (0.76-1.16) 
(p=0.1868) 
Socioeconomic status 
1 (poorest) 
2 
3 
4 (richest) 
 
565/1144 
454/891 
329/638 
433/765 
 
49.4 (46.5-52.3) 
51.0 (47.7-54.2) 
51.6 (47.7-55.4) 
57.9 (54.4-61.4) 
 
Ref 
1.06 (0.86-1.32) 
1.09 (0.86-1.39) 
1.41 (1.12-1.78) 
(p=0.0322) 
 
Ref 
0.99 (0.79-1.23) 
0.95 (0.73-1.24) 
1.11 (0.85-1.46) 
(p=0.7156) 
 
Ref 
0.92 (0.75-1.14) 
0.88 (0.69-1.13) 
0.97 (0.74-1.28) 
(p=0.7175) 
 
Ref 
0.93 (0.75-1.14) 
0.90 (0.70-1.15) 
0.99 (0.76-1.30) 
(p=0.7446) 
Maternal occupation 
Gov/Priv/Other/ Self-employed 
Farming 
Does not work 
 
633/1078 
675/1428 
483/932 
 
58.7 (55.8-61.7) 
47.3 (44.7-49.9) 
51.8 (48.6-55.0) 
 
1.59 (1.30-1.94) 
Ref 
1.20 (0.98-1.47) 
(p<0.0001) 
 
1.47 (1.17-1.85) 
Ref 
1.14 (0.91-1.41) 
(p=0.0033) 
 
1.46 (1.17-1.80) 
Ref 
1.23 (0.98-1.55) 
(p=0.0029) 
 
1.46 (1.17-1.80) 
Ref 
1.23 (0.98-1.55) 
(p=0.0029) 
Maternal education 
None 
Primary school 
Secondary / tertiary 
 
715/1424 
370/725 
706/1289 
 
50.2 (47.6-52.8) 
51.0 (47.4-54.7) 
54.8 (52.1-57.5) 
 
0.83 (0.69-1.01) 
0.86 (0.69-1.07) 
Ref 
(p=0.1492) 
 
0.92 (0.72-1.17) 
0.94 (0.74-1.18) 
Ref 
(p=0.7708) 
 
0.97 (0.78-1.22) 
1.01 (0.81-1.26) 
Ref 
(p=0.9411) 
 
0.98 (0.78-1.23) 
1.02 (0.82-1.27) 
Ref 
(p=0.9456) 
Sex 
Male 
Female 
 
960/1772 
831/1666 
 
54.2 (51.9-56.5) 
49.9 (47.5-52.3) 
 
Ref 
0.84 (0.71-0.99) 
(p=0.0433) 
 
Ref 
0.85 (0.72-1.01) 
(p=0.0601) 
 
Ref 
0.90 (0.77-1.05) 
(p=0.1776) 
 
Ref 
0.90 (0.77-1.05) 
(p=0.1702) 
Continued….. 
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Continues…. 
 
Vaccinated / 
Total 
Proportion of 
opportunities taken 
(95%CI) 
Unadjusted odds 
ratio 
Adjusted for distal 
determinants 
Adjusted for distal & 
proximal 
determinants (final 
model) 
Final model adjusted 
for mediating effects 
of infant illness 
 
  
OR (95%CI) 
(p-value) 
aOR (95%CI) 
(p-value) 
aOR (95%CI) 
(p-value) 
aOR (95%CI) 
(p-value) 
Age/Parity 
<20 
20-29, 1-3 kids 
20-29, 4 or more kids 
>=30 
 
223/449 
565/1052 
351/718 
652/1219 
 
49.7 (45.0-54.3) 
53.7 (50.7-56.7) 
48.9 (45.2-52.5) 
0.53 (0.51-0.56) 
 
Ref 
1.18 (0.89-1.55) 
0.97 (0.72-1.31) 
1.17 (0.94-1.45) 
(p=0.0590) 
  
Ref 
1.08 (0.82-1.42) 
1.05 (0.78-1.42) 
1.17 (0.87-1.57) 
(p=0.6714 
 
Ref 
1.08 (0.82-1.43) 
1.06 (0.78-1.42) 
1.18 (0.88-1.58) 
(p=0.6409) 
Distance to health facility 
<1.00km 
1.00-4.99km 
>=5.00km 
 
899/1621 
357/714 
535/1103 
 
55.5 (53.0-57.9) 
50.0 (46.3-53.7) 
48.5 (45.6-51.5) 
 
Ref 
0.80 (0.65-1.00) 
0.76 (0.62-0.92) 
(p=0.0105) 
  
Ref 
0.81 (0.66-0.99) 
0.95 (0.78-1.15) 
(p=0.1233) 
 
Ref 
0.81 (0.66-0.99) 
0.95 (0.78-1.15) 
(p=0.1201) 
Place of birth 
Facility 
Non-facility 
 
1070/1983 
721/1455 
 
54.0 (51.8-56.2) 
49.6 (47.0-52.1) 
 
Ref 
0.84 (0.71-0.99) 
(p=0.0405) 
  
Ref 
0.99 (0.83-1.18) 
(p=0.9165) 
 
Ref 
0.99 (0.83-1.18) 
(p=0.8986) 
Birth weight 
>=2.5kg 
<2.50kg 
 
1518/2883 
273/555 
 
52.7 (50.8-54.5) 
49.2 (45.0-53.4) 
 
Ref 
0.87 (0.69-1.10) 
(p=0.2390) 
  
Ref 
0.97 (0.78-1.20) 
(p=0.7672) 
 
Ref 
0.97 (0.78-1.20) 
(p=0.7875) 
Timing of opportunity  
5-8 weeks post due date 
9-12 week post due date 
13-24 weeks post due date 
25-52 weeks post due date 
 
867/1324 
550/967 
320/879 
54/268 
 
65.5 (62.9-68.0) 
56.9 (53.8-60.0) 
36.4 (33.2-39.6) 
20.1 (15.3-25.0) 
 
Ref 
0.70 (0.59-0.82) 
0.30 (0.25-0.36) 
0.13 (0.10-0.18) 
(p<0.0001) 
  
Ref 
0.70 (0.59-0.83) 
0.31 (0.26-0.38) 
0.14 (0.10-0.19) 
(p<0.0001) 
 
Ref 
0.70 (0.59-0.82) 
0.31 (0.26-0.38) 
0.14 (0.10-0.19) 
(p<0.0001) 
Illness 
No 
Yes 
 
1563/2979 
228/459 
 
52.5 (50.7-54.3) 
49.7 (45.1-54.3) 
 
Ref 
0.89 (0.73-1.09) 
(p=0.2745) 
   
Ref 
0.62 (0.31-1.23) 
(p=0.1710) 
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Figure 1: Probability of A) BCG B) OPV3, C) DTP3, and D) MCV vaccination in the first year of life associated with the actual vaccination date and the 
theoretical vaccination date associated with exploiting the first opportunity for vaccination.  
A.  B.  
C.  D.  
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Table 4: Uptake rates at selected time-points associated with actual vaccination dates and with utilising the first opportunity for vaccination 
 
 Uptake Rate (95%CI) 
 Due date  + 4 weeks Due date + 8 weeks Due date + 12 weeks 52 weeks of age 
Vaccine Actual Theoretical Actual Theoretical Actual Theoretical Actual Theoretical 
BCG* 46.6 
(44.7-48.6) 
61.1 
(59.2-63.0) 
73.8 
72.0-75.5) 
90.8 
(89.7-92.0) 
83.1 
(81.6-84.6) 
97.2 
(96.6-97.9) 
93.1 
(92.1-94.1) 
100.0 
(100.0-100.0) 
OPV3 7.8 
(5.9-9.7) 
19.5 
(16.7-22.3) 
18.7 
(15.9-21.4) 
31.6 
(28.4-34.9) 
28.1 
(25.0-31.3) 
39.9 
(36.5-43.4) 
45.7 
(42.1-49.2) 
100.0 
(100.0-100.0) 
DTP3 25.7 
(22.1-29.3) 
40.3 
(36.3-44.4) 
44.5 
(40.4-48.6) 
61.3 
(57.2-65.3) 
60.0 
(56.0-64.1) 
73.9 
(70.3-77.6) 
83.5 
(80.4-86.5) 
100.0 
(100.0-100.0) 
Measles 0.4 
(0.0-0.9) 
14.6 
(11.5-17.6) 
22.1 
(18.6-25.7) 
73.7 
(70.0-77.5) 
54.6 
(50.4-58.9) 
94.9 
(93.0-96.8) 
75.8 
(72.1-79.5) 
100.0 
(100.0-100.0) 
* uptake rates are calculated at 4, 8 and 12 weeks after the end of the neonatal period (age 4 weeks) 
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Web Appendix 
Web figure 1:  Opportunities and uptake of opportunities for BCG vaccination 
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Continues… 
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Web figure 2: Opportunities and uptake of opportunities for OPV3 vaccination 
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Web figure 3: Opportunities and uptake of opportunities for DTP3 vaccination 
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Web figure 4: Opportunities and uptake of opportunities for measles vaccination 
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7.4. HOW WOULD INCLUDING CO-SCHEDULED VACCINES AS 
OPPORTUNITIES FOR VACCINATION AFFECT THE ESTIMATES OF THE 
FREQUENCY AND UPTAKE OF OPPORTUNITIES? 
As explained in Section 7.2, I excluded opportunities associated with co-scheduled vaccines 
on the basis that these vaccines are normally given together, and so I could not determine 
whether these opportunities would be taken automatically, or because of some action on 
the part of the vaccine provider to actively address under-vaccination of the infant. It is 
useful to consider the number and uptake of these opportunities, so as to assess the impact 
of this decision on my results.  
I present the additional opportunities associated with co-scheduled vaccines, the uptake of 
these opportunities, and how including them would have changed the estimate of 
opportunity uptake in Table 7.1. For each of the included vaccines which were scheduled to 
be given with another vaccine (OPV3, DTP3 and MCV), inclusion of co-scheduled vaccines 
would have dramatically increased the number of opportunities. The uptake of these co-
scheduled vaccines was in excess of 96% for each vaccine, compared to uptake rates of less 
than 8% for non-co-scheduled vaccines.  
Table 7.1: Additional primary care-based opportunities associated with co-scheduled 
vaccines 
Vaccine Primary-
care based 
opps* 
(excluding 
co-
scheduled 
vaccines) 
Uptake of 
primary-
care based 
opps (%) 
Additional 
opps 
associated 
with co-
scheduled 
vaccines  
Uptake of 
opps 
associated 
with co-
scheduled 
vaccines (%) 
Total opps if 
co-
scheduled 
vaccines 
included 
Opp* 
uptake, if co-
scheduled 
vaccines 
included (%) 
OPV3 394 6 (1.5) 23087 22761 (98.6) 23481 23093 (98.3) 
DTP3 65 5 (7.7) 23451 22740 (96.7) 23522 22745 (96.7) 
Measles 193 6 (3.1) 22926 22636 (98.7) 23119 22642 (97.9) 
* Opp = opportunities; Opp = opportunity 
Including co-scheduled vaccines would have masked the poor uptake of opportunities 
associated with contacts for reasons other than to receive co-scheduled vaccines. 
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7.5. How exploiting opportunities would improve the vaccination of 
LBW infants 
Given that this PhD aimed to investigate LBW as a risk factor for under-vaccination, and to 
investigate ways to improve the vaccination of LBW infants, I undertook an additional 
analysis (as described in Section 7.1) to investigate how using the opportunity to vaccinate, 
would improve the uptake of vaccination among LBW infants, compared to NLBW infants.  
7.5.1. Methods 
I repeated the analyses of the potential impact of utilising the first opportunity for 
vaccination on vaccine uptake at 4, 8 and 12 weeks after the vaccine due date, and at 52 
weeks of age, using the same methods described in the paper, but stratified by birth 
weight.  
7.5.2. Results 
For each of BCG, OPV3, DTP3 and measles, vaccine uptake at 4, 8 and 12 weeks after the 
due date was generally lower among LBW compared to NLBW infants for all vaccines, 
although the magnitude of the difference was small, and declined with time since the due 
date. Exploiting the first opportunity resulted in similar improvements in uptake for both 
LBW and NLBW infants (Table 7.2). In accordance with this, I found no association between 
birth weight and uptake of postneonatal BCG vaccine provider opportunities (Table 3 main 
paper). 
Table 7.2: Uptake rates at selected time-points associated with actual vaccination dates and 
with using the first opportunity to vaccinate, stratified by birth weight. 
Vaccine  Actual Theoretical 
B
C
G
 
Due date + 4 weeks 
>=2.5kg 
<2.5kg 
47.4 (45.3-49.5) 
42.4 (37.6-47.3) 
62.2 (60.1-64.3) 
55.3 (50.4-60.2) 
Due date + 8 weeks 
>=2.5kg 
<2.5kg 
74.0 (72.1-75.9) 
72.3 (67.7-76.5) 
91.2 (89.9-92.4) 
88.6 (85.0-91.4) 
Due date + 12 weeks 
>=2.5kg 
<2.5kg 
83.6 (81.9-85.1) 
80.7 (76.5-84.3) 
97.3 (96.5-97.9) 
96.7 (94.4-98.1) 
52 weeks of age 
>=2.5kg 
<2.5kg 
93.4 (92.2-94.4) 
91.9 (88.7-94.2) 
100.0 (100.0-100.0) 
100.0 (100.0-100.0) 
Continues….. 
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Continued….. 
 
O
P
V
3
 
Due date + 4 weeks 
>=2.5kg 
<2.5kg 
2.6 (1.5-4.5) 
0.0 (0.0-0.0) 
8.1 (5.9-11.0) 
3.5 (1.1-10.5) 
Due date + 8 weeks 
>=2.5kg 
<2.5kg 
7.9 (5.8-10.7) 
1.2 (0.2-8.0) 
15.8 (12.7-19.4) 
8.2 (4.0-16.4) 
Due date + 12 weeks 
>=2.5kg 
<2.5kg 
13.2 (10.4-16.6) 
8.2 (4.0-16.4) 
21.3 (17.8-25.3) 
17.6 (10.9-27.3) 
52 weeks of age 
>=2.5kg 
<2.5kg 
26.4 (22.6-30.6) 
18.8 (11.8-28.6) 
100.0 (100.0-100.0) 
100.0 (100.0-100.0) 
 
D
TP
3
 
Due date + 4 weeks 
>=2.5kg 
<2.5kg 
6.2 (3.5-10.6) 
2.7 (0.4-17.4) 
19.5 (14.5-25.7) 
10.8 (4.0-25.9) 
Due date + 8 weeks 
>=2.5kg 
<2.5kg 
19.5 (14.5-25.7) 
5.4 (1.3-19.6) 
36.9 (30.4-44.0) 
24.3 (13.0-40.9) 
Due date + 12 weeks 
>=2.5kg 
<2.5kg 
31.8 (25.6-38.7) 
24.3 (13.0-40.9) 
48.2 (41.2-55.3) 
45.9 (30.5-62.2) 
52 weeks of age 
>=2.5kg 
<2.5kg 
63.6 (56.6-70.1) 
48.9 (32.9-64.6) 
100.0 (100.0-100.0) 
100.0 (100.0-100.0) 
 
M
C
V
 
Due date + 4 weeks 
>=2.5kg 
<2.5kg 
0.4 (0.1-1.4) 
0.0 (0.0-0.0) 
14.0 (11.4-17.2) 
9.0 (5.0-15.6) 
Due date + 8 weeks 
>=2.5kg 
<2.5kg 
17.8 (14.8-21.2) 
18.0 (12.1-25.9) 
66.8 (62.8-70.6) 
67.2 (58.4-75.0) 
Due date + 12 weeks 
>=2.5kg 
<2.5kg 
44.2 (40.2-48.4) 
39.3 (31.0-48.3) 
89.3 (86.5-91.6) 
93.4 (87.4-96.7) 
52 weeks of age 
>=2.5kg 
<2.5kg 
60.2 (56.1-64.2) 
58.2 (49.2-66.7) 
100.0 (100.0-100.0) 
100.0 (100.0-100.0) 
 
7.5.3. Discussion 
I have previously demonstrated that the rate of vaccination of LBW infants is lower than 
that of NLBW infants for DTP1 and DTP3, and that these infants are more likely to be 
vaccinated late (Chapter 5). Similarly, LBW infants were also less likely to receive BCG 
vaccination in the neonatal period. This under-vaccination of LBW infants may reflect 
parental reluctance to bring these infants for vaccination for reasons previously discussed1. 
Vaccine providers in low-income settings have previously reported hesitancy in vaccinating 
sick, weak and malnourished children1. LBW infants may be more likely to have these 
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characteristics in the first year of life, and so it also plausible that these infants may be 
more likely to miss opportunities for vaccination during their routine contacts with the 
health service. I found no evidence of this in my study population. The results of this 
analysis suggest that once a LBW infant has contact with a vaccine provider, they are as 
likely to receive their vaccines as NLBW infants. It appears that exploiting opportunities for 
vaccination is more a factor of how close the contact is to the due date for vaccination, and 
whether the vaccine provider remembers to check and administer all due vaccines at the 
visit, rather than due to any particular characteristic of the infants attending for vaccination 
(such as their birth weight). However, it is important to note that (unlike previous analyses 
in this thesis) it was not possible to stratify by gradation of LBW due to small numbers. All 
infants weighing less than 2.5kg at birth were analysed as a single category, and so I was 
unable to investigate any differential association between lower categories of birth weight 
and uptake of opportunities. It remains possible that uptake of opportunities could be 
lower for the smallest most fragile infants. 
Furthermore, due to the small proportion of opportunities taken, it was not possible to 
undertake an analysis of the determinants of uptake of opportunities for OPV3, DTP3 or 
measles vaccination. Similarly, it was not possible to analyse the determinants of uptake of 
opportunities to vaccinate during admissions to a health facility. Consequently, I was unable 
to investigate further whether there was any association between birth weight and uptake 
of opportunities among those reporting severe illness, which necessitated an admission.  
7.5.4. Conclusions and recommendations 
Regardless of whether birth weight is an actual determinant of uptake of opportunities, 
exploiting routine contacts with health care providers would substantively improve the 
uptake of vaccination among LBW infants who are under-served by vaccination. Given their 
higher risk of delayed vaccination, vaccine providers and health care providers should be 
particularly vigilant in assessing their vaccination status when they have contacts with the 
health service, and should use these contacts to vaccinate where this is indicated. 
ADDITIONAL REFERENCES FOR CHAPTER 7 
1. Favin M, Steinglass R, Fields R, Banerjee K, Sawhney M. Why children are not 
vaccinated: a review of the grey literature. International health 2012; 4(4): 229-38. 
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CHAPTER 8: DISCUSSION, 
CONCLUSIONS, AND 
RECOMMENDATIONS 
Preamble 
In this chapter, I review the key findings of the PhD, I discuss the strengths and weaknesses 
of the thesis, and the implications of my findings for public health policy.  
8.1. KEY FINDINGS 
8.1.1. LBW as a determinant of infant mortality, illness, care seeking and 
admissions 
8.1.1.1. What was known 
As detailed in Chapter 1, a number of studies have reported estimates for SSA of the 
association between either LBW, preterm delivery, or SGA and mortality. Most estimates 
relate to the neonatal period; population-based estimates for the postneonatal period are 
lacking. In particular, estimates for subgroups of LBW, such as MLBW and VLBW are lacking. 
Similarly, few studies have investigated the association between birth weight and illness, 
care seeking and health facility admissions. A number of studies have demonstrated an 
association between either birth weight or gestational age and hospitalisation in 
population-based cohorts. However, these studies were either restricted to admissions to 
district hospitals1 (and so were likely to include a higher proportion of infants with severe 
illness than an analysis including all health facilities), or the analysis investigated admissions 
for particular illnesses such as RSV2. Studies that investigated illness or admissions3-5, 
without restricting to a specific illness or to district hospitals, found no association. 
8.1.1.2. What this study adds 
In this study, I used data from a large population-based cohort, with low loss-to-follow up 
rates, and little missing data, to report estimates of the association between birth weight 
and mortality, illness, care seeking, and health-facility admissions in each of the neonatal, 
early infant and late infant periods, including for sub-categories of birth weight such as 
MLBW and VLBW infants.  
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LBW was strongly associated with increased mortality in each infant time-period. This effect 
was greatest for VLBW infants, who were 25.38 (95%CI:18.36-35.10) times more likely to 
die in the first year of life, and 48.45 (95%CI:32.81-71.55) times, 12.95 (6.30-26.60) times, 
and 8.42 (3.09-22.92) times more likely to die in each of the neonatal, early and late infant 
periods.  
Although there was little evidence of an association between birth weight and illness in the 
first year of life, there was evidence of an association in the neonatal period for MLBW 
(aRR=1.57; 95%CI:1.27-1.95) and VLBW (aRR=1.58; 95%CI:1.13-2.21) infants. 
There was evidence of lower care seeking for LBW infants, although this association was 
restricted to MLBW infants in the neonatal (aOR=3.30; 95%CI:1.98-5.48) and early infant 
(aOR=1.74; 95%CI:1.26-2.39) periods. This was further supported by the analysis of illnesses 
leading to death, where there was evidence that the parents of LBW infants were less likely 
to seek care for their critically ill infants and those who did seek care were less likely to do 
so from professional medical sources, compared to the parents of critically ill NLBW infants.  
There was little evidence of an association with admissions or infection related admissions 
in the first year of life, and this did not vary by infant time-period. 
8.1.2. Postneonatal vaccination of LBW infants in rural Ghana 
8.1.2.1. What was known 
Little research had been conducted into the association between birth weight and 
postneonatal vaccination in SSA. A single study from Guinea Bissau6 of a cohort of LBW 
infants had provided indirect evidence, as it found that smaller LBW infants (those with 
lower anthropometric status) at two months of age were less likely to have received DTP1 
than larger LBW infants (those with higher anthropometric status). Anthropometric status 
at age two months is likely to be influenced by a number of factors including birth weight, 
infant illness and infant feeding practices, and so the observed effect may not have been 
due to LBW alone. 
8.1.2.2. What this study adds 
LBW infants in Ghana were found to have lower vaccination rates than NLBW infants at up 
to 12 weeks after the due date. The smaller the infant at delivery the lower their rate of 
vaccination. This was evident for both DTP1 and DTP3, even after controlling for other 
determinants of delayed vaccination. For DTP1, infants weighing <1.50kg at birth had a 
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vaccination rate approximately 40% lower than NLBW infants at ages 10 (adjusted rate ratio 
(aRR)=0.58; 95%CI:0.43-0.77) and 18 (aRR=0.63; 95%CI:0.50-0.80) weeks. Infants weighing 
1.50-1.99kg had vaccination rates approximately 25% lower than NLBW infants at these 
time points. Similar results were found for DTP3 (aRR for infants weighing <1.50kg at 22 
weeks of age = 0.61 (95%CI:0.45-0.83), at 26 weeks of age = 0.60 (95%CI:0.60-0.79)). 
8.1.3. Neonatal vaccination of LBW infants in Ghana. 
8.1.3.1. What was known 
Whilst working on this PhD, a single study was published7, which reported that LBW infants 
in Kenya were more likely to be delayed in receiving BCG vaccination; however, this was a 
study of an urban slum population, with lower than expected rates of LBW (6%), who were 
almost all (96%) born in health facilities. Consequently, the results are not widely 
generalisable, and are certainly not generalisable to rural populations, or populations with 
lower rates of facility delivery. Another study8 provided indirect evidence of an association, 
as it reported that undernourishment was associated with delayed BCG vaccination among 
children attending for vaccination at health centres in urban Nigeria. The estimates 
reported in this study do not represent the effect of LBW, but rather the effect of LBW plus 
infant feeding practices, infant illness, and other causes of undernourishment. Finally, a 
study from Guinea Bissau9 reported lower BCG uptake rates for hospital born LBW infants 
at 18 months of age, but the authors reported a policy of delaying vaccination of LBW 
infants until they had either gained weight, or they attended for DTP vaccination, and so 
these data are not generalisable to settings where no such policy exists. In conclusion, 
population-based estimates on the association between LBW and neonatal vaccination for 
the general population were lacking, especially for rural populations. 
8.1.3.2. What this study adds 
This study provided further evidence that LBW is a risk factor for under-vaccination, this 
time in the neonatal period. There was strong evidence that LBW infants were less likely to 
receive BCG in the neonatal period, and, similar to the results of the analysis of 
postneonatal vaccination, there was a dose-response relationship between LBW and 
vaccination (p-trend<0.0001). Infants weighing between 1.50 and 1.99kg were 1.6 times 
more likely to be BCG unvaccinated by the end of the neonatal period compared to NLBW 
infants (aOR=1.64; 95%CI: 1.30-2.08); those weighing less than 1.50kg were 2.4 times more 
likely to be BCG unvaccinated (aOR=2.42; 95%CI:1.50-3.88). This effect was evident even for 
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infants born in health facilities (70% of the overall study population), who would 
automatically have opportunities for vaccination.  
8.1.4. Missed opportunities for infant vaccination in Ghana, and the potential 
impact of their utilisation on vaccine uptake and timing.   
8.1.4.1. What was known 
A number of studies have investigated missed opportunities for vaccination in SSA, but 
most were more than 20 years old, most were descriptive in nature and most were facility-
based. Population-based studies were lacking. These studies commonly reported that a 
large proportion of infants had missed opportunities, that a substantive proportion of 
opportunities occurred at a time when another vaccine was given, and that missing 
opportunities was more common at visits for illness than at visits for preventative care. A 
single 1992 study from Mozambique10 quantitatively investigated risk factors for missed 
opportunities. It reported that being born in a health facility and being born to a single, 
divorced or widowed mother (compared to married or cohabiting) were predictors of 
missing opportunities. A number of qualitative and descriptive studies reported that failure 
to administer vaccines simultaneously, false contraindications to vaccination, fear of 
wasting vaccine by opening a vial for a small number of children, lack of assessment of 
vaccination status when the child visits a clinic, vaccine shortages, poor organisation of 
vaccine clinics, and a lack of a daily vaccination clinic were all factors contributing to missed 
opportunities. Infant illness had also been reported as a reason for missing opportunities by 
both mothers and vaccine providers. The association between birth weight and missing 
opportunities had not been studied.  
8.1.4.2. What this study adds 
Of eligible infants, the percentage who needed opportunities was small (50.8% (2591/5105) 
for BCG, 6.7% (1451/21581) for OPV3, 4.8% (1046/21689) for DTP3, 14.8% (3067/20726) 
for measles). Among those needing opportunities, opportunities were most common for 
BCG (due from birth), and most of those opportunities were associated with visits to 
receive OPV/DTP vaccines (scheduled between 6-14 weeks of age). There were fewer 
vaccination opportunities for the later scheduled OPV3, DTP3 and measles vaccines, and a 
higher proportion of these opportunities were facility-based. Uptake of primary-care based 
opportunities was highest for BCG (52%). Over 90% of primary-care based opportunities 
were missed for OPV3, DTP3 and measles, and >90% of facility-based opportunities were 
missed for all vaccines. For BCG, timing of the opportunity was the biggest predictor of 
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uptake. Earlier opportunities that occurred closer to the BCG due date were more likely to 
be taken. Compared to opportunities before age 8 weeks, uptake of BCG opportunities was 
85% less likely (aOR=0.14; 95%CI:0.10-0.19) 24 weeks or more after the BCG due date. Birth 
weight (which due to the small number of opportunities was defined as a binary variable 
with LBW infants defined as weighing <2.50kg) was not a determinant of uptake of 
opportunities. For all vaccines, exploiting the first opportunity for vaccination would have 
substantively improved the uptake of vaccination (by as much as 100%) at 4, 8 and 12 
weeks after the vaccine due date, and would help in reducing inequities in vaccine service 
delivery.  
8.2. STRENGTHS AND LIMITATIONS 
In chapters four to seven I discuss the strengths and limitations for the individual analyses 
conducted for this PhD. In this section, I consider the overall strengths and limitations of 
the PhD.  
8.2.1. Strengths 
1. Large sample size 
A total of 22955 infants were enrolled in Neovita. This large sample size ensured that many 
of the analyses were highly powered to generate estimates for subgroups of the 
population, especially subgroups of LBW infants such as VLBW infants (Section 3.8.4). As 
data on health outcomes for VLBW infants in SSA, especially in the postneonatal period are 
lacking, my ability to generate such estimates is a major strength of this PhD.  
2. Frequent follow-up 
Infants enrolled in Neovita were followed-up on a monthly basis for the first year of life. 
This ensured the collection of highly complete data on the outcomes included in this study, 
and as much as possible, minimised the likelihood of erroneous recall and consequent 
misclassification for outcomes such as illness, care seeking, and admissions, which were 
based on maternal recall. Also for outcomes such as illness dates, where there was a high 
proportion of missing dates, the frequent follow-up visits allowed me to impute these dates 
with some degree of accuracy, thus minimising misclassification by time-period. For infants 
missing illness dates, 79% of illness dates which were reported as unknown, were reported 
within 30 days of the previous visit, and a further 17% were reported between 31 and 60 
days after the previous visit (Section 3.1).  
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3. High quality data on birth weight and other variables 
We collected very high quality data on birth weight for the Neovita trial. We employed a 
higher cadre of field worker to enrol and weigh the infants, and all of these field workers 
received training in measuring birth weight and in calibrating weighing scales according to a 
standardised protocol devised by WHO11. We supplied all participating health facilities with 
a new electronic scale at the start of the trial, which recorded birth weights to the nearest 
0.1kg. Infants born at home were measured using a spring scale, which recorded birth 
weight to the nearest 0.2kg. Overall, 62% of infants were measured using spring scales. 
Scales were calibrated every four weeks. Infants were weighed between zero and 87 hours 
after delivery; 73% (16434) were weighed within 24 hours of delivery; 0.2% (5) of infants 
were weighed more than 72 hours after delivery. The high quality birth weight data was 
reflected in the higher proportion of infants who were classified as LBW in our study 
population (16% compared to a) 9% reported in the latest DHS12 and b) 10% reported in a 
previous analysis of birth weight from the study area which was based on data documented 
in the child health card13).  
The vaccination data collected for the Neovita trial was of very high quality and we 
employed a rigorous approach to resolving inconsistencies in these data, including revisiting 
mothers to verify the vaccination data on the card, and where necessary making copies of 
the vaccination card to further aid the process of resolving inconsistencies. I personally 
supervised this work, and I was the primary decision maker on correcting dates which were 
highly irregular either because they were highly inconsistent, or because they were grossly 
out of range.   
During the trial, we collected data on a large number of variables, which allowed me to 
adjust my analyses for a large number of potential confounders.  These data were highly 
complete, with fewer than 50 out of 22955 infants (approximately 0.2% of all enrolled 
infants) missing covariate data for the analyses. All of these data were double data entered 
and were subjected to a rigorous programme of range and consistency and inter-database 
checks during the data entry cycle, thus maximising the accuracy of the data included in my 
analyses.   
4. Representativeness 
Infants included in the analyses reported in this PhD were recruited from a population-
based surveillance system. This will have minimised bias associated with the selection and 
recruitment of participants into the Neovita cohort. Consequently, the Neovita cohort were 
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likely to be highly representative of the underlying population, especially since recruitment 
was highly complete (84% of all infants born in the study area were enrolled in the trial) 
(Figure 2.7, Section 2.6). Nonetheless the representativeness of the sample and the 
resulting generalisability of the findings of this PhD may have been limited by a number of 
factors which are further discussed in Section 8.2.2. 
5. Low loss to follow-up and maximal retention of infants in the analyses 
The trial benefited from low loss-to-follow up rates (<3%), thus minimising bias associated 
with loss-to-follow up, especially since loss-to-follow-up may have been associated with 
vaccination status.  
In addition, for the analyses of mortality, illness and vaccination timing, I maximised the 
retention of infants in the analyses by using person-time analyses whereby infants 
contributed time to the analyses for as long as they were in follow-up. This approach 
minimised bias where both the outcome (mortality, illness or vaccination) and the effect of 
the main exposure of interest (birth weight) were time varying, as discussed in Chapters 4 
and 5.   
8.2.2. Limitations 
1. Generalisability of the results 
As discussed in Section 8.2.1, those included in Neovita were likely to be highly 
representative of the underlying population. However, several factors relating to the 
selection of infants for inclusion in Neovita, and relating to the study population, may have 
affected the generalisability of the findings to the underlying population in the study area. 
Consequently, the strength of the associations reported in this thesis may be 
underestimates for the general underlying population. 
Only live born infants who were able to suck or feed, who were staying in the study area for 
at least six months, and who were 3 days old or younger at the time of screening were 
enrolled in Neovita.  
Among the reasons for exclusion from the trial (Figure 2.7, Section 2.6), infants who were 
missed entirely by the surveillance system (1.0%), those whose parents declined to 
participate (1.2%), and those whose births were ascertained too late for inclusion in the 
trial (2.9%), may have had characteristics (such as lower socio-economic status or poorer 
engagement with health services) which could have been associated with both birth weight 
and the outcomes measured in this PhD. These infants accounted for 5.1% of the 27330 
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births identified in the study area and so their exclusion was unlikely to have substantively 
affected the generalisability of the data.  
An additional 1.4% of all live born infants were excluded either because they died before 
screening (1.1%) or because they were unable to feed at the time of enrolment (0.3%). 
Sicker, weaker infants were more likely to be excluded, as they would be more likely to 
have problems feeding. Those infants who were unable to feed, or who died before 
screening may have included a higher proportion of LBW infants. LBW infants have higher 
rates of illness and death in the first week of life. In addition, LBW infants may have been 
more likely to be erroneously classified as stillbirths, if they died shortly after delivery. Birth 
weight data was not available for those who died during delivery, and infants who died 
before screening were never weighed. Given this, the Neovita study population was likely 
to be healthier, and to include a lower proportion of LBW infants than the general 
underlying population.  
Furthermore, my study population was enrolled in a randomised control trial, and this may 
have affected the outcomes measured in this study, specifically vaccination status, care 
seeking, illness, admissions and mortality. Field workers visited mothers monthly, and 
asked them about their infant’s vaccination status and advised them to seek care for their 
infants if their infants were sick at the time of the visit. Their participation in the trial may 
have affected the mothers’ health care seeking behaviour, both for vaccination, and for 
curative care. This may have led to overall higher rates of vaccination, care seeking and 
admissions, and lower rates of mortality than that experienced by the general population. I 
cannot confirm whether this differentially affected LBW infants or whether it affected the 
association between birth weight and these outcomes.  
I estimated the infant mortality rate in my study population to be 30.5 per 1000 live births. 
This rate was lower than a) the rate of 38.0 per 1000 live births reported for Brong Ahafo in 
the most recent DHS12 and b) the rate of 46.1 per 1000 live births (the sum of the reported 
rates for the early neonatal, late neonatal and postneonatal periods) estimated for Ghana 
in the 2013 Global Burden of Disease Study14. The lower mortality rate in the Neovita study 
population may be because they benefited from participation in the trial, but also because, 
as described above, sicker, weaker infants, and infants who died in the first three days of 
life were not recruited into the trial. 
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2. Misclassification  
The data that I collected on infant illness, care seeking, and overall and infection-related 
admissions were based on maternal recall. Recognition of childhood illnesses in low and 
middle-income settings is known to be poor15, and may be even poorer for LBW infants. 
This may have led to underreporting of illness and care seeking and to the misclassification 
of the infection-related admissions in my analyses. Unfortunately, data on the association 
between birth weight and recognition of illness in infancy are lacking, and so I cannot 
confirm whether any misclassification was differential by birth weight. As I did not have 
access to data on diagnoses of illness, I was not able to assess the validity of illness recall by 
birth weight in my study population. Given that admission to a health facility is a notable 
event, it is likely that minimal underreporting and misclassification of admissions will have 
occurred, as I would expect mothers to remember such an event.  
I also relied on maternal recall to assign the vaccination status of the small percentage of 
infants (<1%) whose vaccination card was never seen, and whose mothers reported that 
they had never been vaccinated. This was to avoid automatically excluding infants who had 
never accessed vaccination services and who consequently never had a vaccination card. As 
these infants represented a very tiny proportion of infants included in the analyses, their 
inclusion is unlikely to have affected the association between birth weight and vaccination. 
For the investigation of timeliness of postneonatal vaccination, I verified this by doing a 
sensitivity analysis, whereby I excluded these infants. There was little difference in the 
results of the sensitivity analysis compared to the results of the analysis including these 
infants (Section 5.6).  
Data on most of the explanatory variables included in the analyses, such as educational 
attainment and occupation were based on maternal report, and so may have been subject 
to misclassification. Data on validity of maternal report of such factors are lacking. There 
are no data to suggest that misreporting would be differential by birth weight. 
As described in Section 3.6 I attempted to assess possible misclassification of SES by 
reviewing its distribution by other markers of SES, such as maternal education and 
occupation, distance to the nearest health facility, and place of delivery. There was good 
concordance between the distributions of SES by each of these variables (Table 3.5). For 
instance, infants from the lowest category of SES had a higher proportion of mothers with 
no education, who were farmers, who lived >5km from a health facility, and a higher 
proportion of these infants were not born in a health facility. As distance to health facility 
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was measured by GPS (as described in Section 3.6), misclassification of this factor was likely 
to be minimal.  
3. Lack of power and small numbers 
As discussed in Section 8.2.1, my study benefited from a large sample size which allowed 
me to generate estimates for subgroups of the population, most notably subgroups of LBW. 
Nonetheless, it may be that even with this large sample, for some analyses, such as those 
presented in Chapter 4 where I stratified my analyses by time period, small numbers and a 
lack of power may have limited the ability to demonstrate an association.  
Furthermore, for the analysis of uptake of opportunities for vaccination (Chapter 7), the 
proportion of opportunities taken was small. Consequently, as discussed in Section 7.5.3, in 
my analysis of uptake of opportunities for BCG vaccination, I was unable to do an analysis 
by the different categories of LBW, but rather I had to analyse the effect of birth weight 
modelled as a binary variable (with LBW defined as infants weighing <2.50kg). I was 
therefore unable to investigate any differential association between lower categories of 
birth weight and uptake of opportunities. Similarly, due to small numbers, I was unable to 
analyse uptake of opportunities for OPV3, DTP3 or measles vaccination, and I was unable to 
analyse uptake of opportunities associated with health facility admissions.  
4. Multiple testing 
I adjusted for a large number of variables in all of my models, and so it is possible that some 
associations reported in this PhD will have occurred by chance alone (due to type 1 error). 
This thesis tested hypotheses that were developed a priori and that were biologically and 
socially plausible. The development of these hypotheses was informed by evidence from 
other settings. Many of the effect sizes, including those for LBW, were large, with very small 
p-values, lessening the likelihood of type 1 errors.  
5. Outstanding unanswered questions 
A number of key questions remain unanswered at the end of this PhD due to limitations in 
the availability of some key data.  
Although data on LMP were collected for the PhD, these data were missing for almost 60% 
of pregnancies, and were inconsistently reported for a further 16% of pregnancies. Given 
the poor quality of the Neovita data on LMP, and given the well-documented limitations of 
using LMP to estimate gestational age16-18, I was unable to differentiate between the 
varying effects of gestational age and intrauterine growth retardation (as discussed in 
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Section 1.6) for this PhD. This would have allowed a better characterisation of the risk 
based on levels of prematurity and growth retardation, which could inform the 
development of more targeted interventions.  
Furthermore, I was unable to adjust my estimates of the association between birth weight 
and mortality and illness for the mediating effects of breast-feeding, due to the lack of 
complete data on breast-feeding, and the likely reverse causality between illness and 
feeding (Section 4.3). As breastfeeding is protective against mortality19 and illness20,21, if 
LBW infants had lower rates of breastfeeding, this may partially explain the association 
between birth weight and these outcomes.  
My analyses of the association between birth weight and mortality, illness, care seeking and 
admissions (Chapter 4) were further limited by a lack of data on a number of important 
factors including 1) illness recognition, 2) severity of illness, 3) time to care seeking, and 4) 
where and from whom care was sought (except for hospital admissions). These factors may 
have differed among LBW infants compared to NLBW infants and may have partially 
explained why the excessive mortality rates among LBW infants compared to NLBW infants 
were not mirrored by corresponding excessive rates of illness and admissions. For instance, 
poorer recognition of illness among LBW infants would lead to underreporting of illness, to 
no or delayed care seeking for these infants, and it could affect their admission rates. A 
propensity to more severe illness or rapidly progressing illness in LBW infants may affect 
their risk of mortality. If the parents of LBW infants were more likely to seek care from 
traditional healers (perhaps because the infant was deemed to have a not-for-hospital 
illness (as discussed in Chapter 4), this would affect their admission rates and risk of 
mortality. The absence of data on these factors limited my ability to fully investigate the 
association between birth weight and infant illness, care seeking and care giving, and how 
these relate to infant mortality.  
I also lacked data on clinical diagnoses for cause of admissions and on illnesses due to VPDs, 
as I did not have access to the infants’ medical records. I was therefore unable to 
investigate the association between birth weight and cause-specific illness (other than a 
broad analysis restricted to infection-related admissions to minimise potential 
misclassification due to erroneous maternal recall). I was unable to investigate whether 
LBW infants were at increased risk of VPDs, or whether delayed vaccination of LBW infants 
was associated with an increased risk of VPDs. Similarly, I lacked data on physician-coded 
cause of death, and was therefore unable to investigate whether LBW infants were at 
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increased risk of dying from vaccine preventable or infectious diseases. Consequently, I was 
unable to investigate the clinical significance of timely vaccination among LBW infants.  
Finally, this PhD would have benefited from the availability of qualitative data on parental 
and vaccine provider knowledge, attitudes and practices relating to the vaccination and 
uptake of opportunities for vaccination among LBW and NLBW infants. Although I found 
convincing evidence that LBW infants are less likely to be vaccinated in both the neonatal 
and postneonatal periods, I was unable to investigate why they were less likely to be 
vaccinated, or to identify any perceived barriers or erroneous beliefs or attitudes relating to 
their vaccination among either parents or vaccine providers. Similarly, I was unable to 
investigate the reasons for missing opportunities for vaccination, for either primary care 
based or facility-based opportunities. A lack of data on the reasons driving the under-
vaccination of LBW infants and the lack of uptake of opportunities limits the ability to 
identify specific interventions to address these two issues. 
8.3. IMPLICATIONS OF FINDINGS 
This PhD addresses a number of key questions relating to infant health outcomes for LBW 
infants in SSA, which to date have not been widely studied and for which data are lacking. It 
presents the results of an in-depth investigation into the association between birth weight 
and infant vaccination, and it demonstrates that LBW infants are a group that are under-
served by vaccination, both in the neonatal and postneonatal period, with a strong dose 
response relationship between birth weight and vaccination.  
As discussed in Section 1.4, timeliness of vaccination is increasingly recognised as an 
important indicator of the overall quality of vaccination programmes22. Furthermore, as 
discussed in Section 1.5, the Global Vaccine Action Plan23 advocates for identifying groups 
who are under-served by routine vaccination services so that they can be targeted for 
vaccination. The potential of vaccination to reduce child mortality has yet to be fully 
realised. Substantive inequities in the delivery of vaccines remain23. Improving equitable 
access to vaccination will help to address health inequalities and to maximise the 
effectiveness and impact of vaccination. It is also critical to address disease elimination and 
eradication targets23. The results reported in this PhD of delayed BCG and DTP vaccination, 
including among infants born in health facilities, and among LBW infants, highlights an area 
of underperformance in the routine childhood vaccination programme and highlights an 
inequity in vaccine delivery.  
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Delayed vaccination of LBW infants matters. As with any infant who experiences delayed 
vaccination, this will unnecessarily prolong their risk of contracting a VPD. As discussed in 
Chapter 1, in 2013, three out of every ten deaths among children aged one to 59 months 
were estimated to be due to VPDs24, and SSA carries a higher burden of VPDs than other 
regions25. Given their elevated mortality rates (as demonstrated in Chapter 4), every effort 
should be taken to minimise their risk of illness and death, including maximising their 
access to preventative care services such as vaccination.   
As discussed in Section 1.7, there are a number of reasons why adherence to the timing 
and staging of vaccination may be more important among LBW infants. These include lower 
levels of maternal antibodies26,27, lower antibody response to vaccination28, lower 
persistence of antibodies28, and increased susceptibility to the complications of VPDs due to 
conditions associated with LBW such as bronchopulmonary dysplasia29. Whereas some 
studies from high-income settings have reported an increased risk of hospitalisation and 
death among LBW and preterm infants for VPDs that are most prevalent early in infancy29-
32,33, there is a lack of data on the risk of VPDs among LBW infants in SSA (as discussed in 
Section 1.6). Overall, the clinical implications of delayed vaccination for LBW infants in SSA 
are unknown, but there is every reason to believe that the clinical implications are the same 
as for LBW infants in high-income settings.  
Interventions should be targeted at LBW infants to improve their timeliness of vaccination. 
Improving the vaccination of LBW infants will help to improve the overall performance of 
the vaccination programme, and will address an inequity in the programme. However the 
identification of such infants may be challenging, as almost 50% of infants in low income 
settings are not weighed at birth34 (as discussed in Section 1.6.2). This limits the ability to 
use birth weight itself as a marker for under-vaccination. Infants who are not weighed are 
also likely to have other risk factors for non-vaccination, such as being born to mothers with 
lower socio-economic status and educational attainment, and being born at home34-36. 
Given this, it is important not to restrict the findings of this thesis to infants meeting strictly 
defined cut-offs of birth weight, but rather to extrapolate them to include fragile infants 
who may be missing data on their birth weight, and whose first encounter with the health 
service may be some time after delivery. 
I reported some evidence that LBW infants were as likely to be vaccinated as NLBW infants 
when they had opportunities for vaccination, although these results should be interpreted 
with caution as birth weight was modelled as a binary variable, and the analysis was limited 
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by small numbers (as discussed in Sections 7.5.3 and 8.2.2). It may be that delayed 
vaccination of LBW infants is largely driven by parental hesitancy to take LBW infants for 
vaccination. Nonetheless some practices by vaccine providers, such as not vaccinating 
facility born infants prior to discharge, may be contributing to inequitable uptake of 
neonatal vaccination by LBW infants, as birth weight remains a risk factor for non-
vaccination in the neonatal period, even among facility born infants.   
Attending for vaccination represents a contact with the health service, and so it provides an 
opportunity to access general medical care for an infant. Poorer access to vaccination 
services among LBW infants will result in them having fewer contacts for care in general. If 
this is the case, then this is occurring within the context of broader poorer health outcomes 
for these infants, including a dramatically increased risk of dying throughout the first year 
of life, a possible increased risk of illness, and lower rates of care seeking for sick LBW 
infants. This demonstrates a need for the promotion of health care seeking behaviour for 
these infants. 
Currently there is great emphasis on developing strategies to minimise mortality and illness 
among LBW infants in the neonatal period, as this is the time-period when most infant 
deaths occur. However, my analyses demonstrate that LBW infants remain at risk 
throughout the first year of life, and so it highlights the importance of maximising 
preventative and curative care for LBW infants throughout this time-period. 
8.4. RECOMMENDATIONS  
In this section, I outline a number of recommendations indicated by the findings of this 
PhD. These recommendations aim to:  
1. Improve the uptake and timing of vaccination among LBW infants  
2. Clarify policy relating to the vaccination of LBW infants 
3. Improve LBW infant survival and reduce their risk of illness throughout the first 
year of life 
4. Reduce LBW infants inequitable access to health care when they are sick 
5. Improve the uptake of opportunities for vaccination among the under-vaccinated 
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6. Address gaps in the knowledge base relating to a) the reasons for under-
vaccination of LBW infants, and b) the relationship between illness, care seeking 
and mortality among LBW infants. 
8.4.1. Policy recommendations directed at health care providers and care givers 
1. Health care providers should be educated to ensure that LBW infants who are born 
in health facilities receive all their due vaccinations prior to discharge. 
2. Health care providers and vaccine providers should be encouraged to counsel 
caregivers about the importance of vaccinating LBW infants on time, and to assure 
them that birth weight and infant illness are not contraindications to vaccination.  
3. Caregivers of LBW infants should be encouraged to improve their care seeking 
practices for LBW infants, throughout the first year of life.  
4. Health care providers should be trained to verify an infant’s vaccination status at all 
health care contacts (both primary-care based and facility-based), and to 
administer all due vaccines, in order to improve overall vaccine uptake.  
8.4.2. National and International Policy Recommendations 
1. Strategies to minimise illness and mortality among LBW infants throughout the first 
year of life (including both the neonatal and postneonatal periods) should be 
developed as a matter of priority. 
2. The Ghanaian Ministry of Health should stipulate in their national policy guidelines 
on vaccination that LBW is not a contraindication to vaccination and that all infants 
should be vaccinated in accordance with the routine schedule regardless of their 
gestational age or size. 
3. Similarly, the WHO should stipulate in its vaccination policy documents (as it 
previously did) that neither preterm delivery nor LBW are contraindications to 
vaccination.  
8.4.3. Recommendations for research 
1. Further research into the barriers and facilitators of vaccination of LBW infants is 
warranted. This should include qualitative research among care givers and vaccine 
providers to further understand the reasons for delayed or non-vaccination among 
LBW infants 
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2. Strategies to improve the uptake and timing of vaccination among LBW infants 
should be developed and these strategies should be evaluated 
3. Further research into illness and pathways of care among LBW compared to NLBW 
infants, and their association with mortality in SSA is warranted. This will enable a 
better understanding of why the higher mortality rates reported among LBW 
infants do not appear to correspond to higher illness rates. 
8.5. CONCLUSIONS 
LBW infants are an under-served group for vaccination in Ghana. They are also at greatly 
increased risk of mortality throughout the first year of life, and somewhat at increased risk 
of illness. Their lower access to vaccination services is reflected in lower access to care 
during illness, which suggests that these infants are generally disadvantaged when it comes 
to both preventative and curative care seeking. Efforts to maximise their access to health 
care services, including vaccination are warranted in order to increase their chances of 
survival.  
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ANNEX 1: SEARCH TERMS USED TO REVIEW THE LITERATURE 
 
1. Birth weight and vaccination 
(((low birth weight) OR (premature) OR (pre-term) OR (preterm) OR (underweight) OR 
(intra-uterine growth retardation) OR (intra-uterine growth restriction) OR (intra uterine 
growth restriction) OR (intra uterine growth retardation) OR (small for gestational age)) 
AND ((newborn) OR (neonate) OR (infant) OR (baby) OR (babies)) AND ((vaccine#) OR 
(immunization) OR (immunisation)) AND ((uptake) OR (coverage) OR (missed opportunities) 
OR (opportunities) OR (timeliness) OR (time) OR (delay#) OR (age appropriate) OR (age-
appropriate) OR (adherence) OR (compliance)))  
 
2. Birth weight and mortality, illness, care seeking and admissions 
 (((low birth weight) OR (premature) OR (pre-term) OR (preterm) OR (underweight) OR 
(intra-uterine growth retardation) OR (intra-uterine growth restriction) OR (intra uterine 
growth restriction) OR (intra uterine growth retardation) OR (small for gestational age)) 
AND ((newborn) OR (neonat*) OR (postneonat*)  OR (infant) OR (under-five) OR (under 
five) OR (under-5) OR (under 5) OR (child) OR (baby)) AND ((death) OR (mortality) OR 
(disease*) OR (care) OR (careseek*) OR (caregiv*) OR (sick*) OR (infectio*) OR 
(hospitali#tion) OR (admission) OR (admitted OR (illness) OR (ill) OR (morbidity)) AND 
(afric*)))  
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ANNEX 2: NEOVITA DATA COLLECTION FORMS 
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KINTAMPO HEALTH RESEARCH CENTRE 
 
NEOVITA TRIAL 
 
ENROLMENT FORM       22 JUNE 2010 
ENROL Form No.  
FORMNO 
 
FILL ONE FORM FOR EACH BIRTH NOTIFIED EVEN IF MULTIPLE BIRTH OR BABY DIED 
BEFORE DOSING 
 
1.   SCREENING INFORMATION 
1.1 Site of screening …………………………… 11. Compound 12. Facility    13. Other specify PLACESCR 
1.1.1. If facility, please state facility code (NA = 99) ..……………………………………………. 
 
  FACSCR 
1.1.2. If compound, please provide compound number 
          (NA = 99999999)……………………………… 
        COMPSCR 
1.1.3.If other, please specify …... 
 
 OTHSCR 
1.2 Mother’s name .……...  WOMNAME 
1.3 Mother’s Neovita id .….……...……           WOMANID 
1.4 Date of visit (dd/mm/yyyy)…….…………………         DATESCR 
1.5 Staff code ……………………………....………………………..………………………...  
 
 FW 
 
1.6  Is the mother alive? ……………………………..……………………………...…… 
 
1. Yes 
 
2. No 
 
MOALIVE 
 
 
 1.7  Who is the respondent for this 
         interview?.............................. 
11. Mother of  
      baby 
12. Father of  
      baby 
13. Other family  
      member 
14. Other guardian /  
      caretaker 
INFORMANT 
 
2.   CONSENT 
PLEASE READ OUT THE MAIN STUDY INFORMATION SHEET AND CONSENT FORM  
2.1 Does the mother/caretaker give consent for? 
11. Full participation in study including dosing 
      and  follow-up  
12. Only for completing this and baseline form ICONSENT 
 
13. No, does not give consent but baby alive 14. No, does not give consent and baby died  
 
IF ANSWER IS 11, FILL OUT THE REST OF THIS FORM AND THE BASELINE FORM AND DOSE 
THE BABY 
IF ANSWER IS 12, DO NOT DOSE BABY PUT A DOUBLE LINE THROUGH SECTIONS 3-5,  AND 
FILL OUT SECTION 6 AND BASELINE FORM ONLY 
IF ANSWER IS 13 OR 14, END THE INTERVIEW AND DRAW A DOUBLE LINE THROUGH REST 
OF FORM 
3.  ELIGBILITY 
3.1. Date of delivery (dd/mm/yyyy)…….…………….         DATEBIRTH 
3.2 Time of delivery (24 hour clock)………...............………………………….. 
 
    TIMEBIRTH 
NOW LOOK AT DOB AND TODAY’S DATE.  IF THE BABY WAS BORN TODAY, YESTERDAY OR 
DAY BEFORE YESTERDAY THE BABY IS AGE ELIGIBLE AND THE ANSWER TO QUESTION 3.3 
IS 1.YES.     
IF THE BABY IS NOT BORN ON THOSE DAYS THEN THE ANSWER TO QUESTION 3.3 IS 2/NO 
3.3 Is the baby age eligible for enrolment? …………………………………………...………. 1. Yes 2. No AGEELIG 
3.4 Is the infant able to breastfeed or drink other fluids?  
01. Yes 
 
02. No 
 
11. Cannot assess as infant is too  
      ill / admitted in  hospital 
FEED 
12. Cannot assess as baby died  13. Cannot assess for other  
       reason(s) 
3.4.1.If other reasons for not  
         feeding, please specify 
 OTHFEED 
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3.5 Will the infant stay in the study area for the next 6 months? ………….…….………… 1. Yes 2. No STAY 
 
ONLY PROCEED IF Q3.3-3.5 ARE 1/YES. OTHERWISE END HERE PUT DOUBLE LINE 
THROUGH Q3.6-Q3.11 AND MOVE TO Q3.12 
 
NOW DETERMINE IF THERE IS CLEAR WRITTEN INFORMATION ABOUT THE MOTHER’S 
COMPOUND NUMBER. IF NO CLEAR WRITTEN INFORMATION THEN YOU MUST FIND OUT 
THIS INFORMATION BEFORE COMPLETING REST OF FORM (EG ASK FAMILY TO FETCH 
ANC CARD OR FOLLOW MOTHER HOME). 
PLEASE PASS THIS FORM TO THE TRACKING TEAM OR DOSING COORDINATOR IF 
NECESSARY 
3.6  Was the form passed to a member of the tracking team? ……..………………..……. 1. Yes 2. No TRACK 
3.7 If yes, staff code of tracking team member  99=NA…………..……………………… 
 
 
 
TRACKFW 
 
3.8 Is there clear written information about the mother’s compound number? ………….… 1. Yes 2. No CLEARAD 
 
  3.9 What is the source of the mother’s compound number? 
11.  Id card 12. Written on paper e.g. on ANC card 13. Written on compound building SOURCE 
 
 
 
 
 
14. Other specify 99.  NA, No clear address 
3.10 What is this compound number? .…………….….. 
       (NA = 99999999) 
        COMPNO 
 
  3.11 Is this the mother’s  
11.  Usual/permanent  
       Residence 
12. Her mother’s compound  13. The compound of another  
       friend or relative 
COMPTYPE 
 
14. Other specify 99. NA, no clear address  
 
3.12. BASED ON THE INFORMATION ABOVE, PLEASE DECIDE IF THE BABY IS ELIGIBLE FOR 
THE STUDY    
        (THE BABY IS ELIGIBLE IF THE ANSWERS TO 3.3, 3.4, 3.5. 3.8 ARE 1/YES) 
 1. Yes 2. No ELIGIBLE 
 
IF BABY IS ELIGIBLE (Q3.12=1/YES), THEN ENROL BABY AND FILL OUT THE REST OF THIS 
FORM. 
IF BABY IS NOT ELIGIBLE (Q3.12=2/NO), THEN DO NOT ENROL BABY PUT A DOUBLE LINE 
THROUGH SECTIONS 4 AND 5 AND MOVE TO SECTION 6 
 
PRIOR TO DOSING, CONFIRM THAT THE BABY WAS NOT BORN IN THE PREVIOUS 2 HOURS. 
IF BORN IN THE PREVIOUS 2 HOURS, DO NOT ADMINISTER THE SUPPLEMENT. TAKE AN 
APPOINTMENT AND COME BACK LATER.  IF 2 HOURS HAVE PASSED, YOU CAN ENROL AND 
DOSE THE BABY 
4.   ENROLMENT AND DOSING 
 
FIRST CHECK IF THIS WAS A MULTIPLE BIRTH 
4.1.1 How many babies were born 99=NA………………………………………………..   NUMBABY 
4.1.2  How many babies were enrolled 99=NA……………………………………………..   NUMENROL 
4.1.3. If multiple birth, did this baby come out of the womb first, second or third 
11. First born 12.  Second born 13. Third born 99. NA ORDERB 
FIRST ID GOES TO FIRST BORN (EG 100005), SECOND ID TO SECOND BORN (EG 100006), 
THIRD ID TO THIRD BORN (100007)  
 
4.2 Subject id …...…………………………………… 
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[PLEASE STICK LABEL FROM THE CAPSULE STRIP ON THE FORM] 
              SUBJECTID 
 
4.3 This infant’s name … 
 INAME 
USE DAY NAME IF NECESSARY BUT ALSO WRITE TWIN ONE, TWIN TWO FOR TWINS 
 
ALSO COMPLETE A NEOVITA ID CARD WITH ONE OF THE LABELS FROM THE CAPSULE 
STRIP AND FILL OUT THE BABY’S DETAILS. YOU MUST USE THE MOTHERS EXISTING 
NEOVITA ID CARD WHEREEVER POSSIBLE. FILL OUT TWO CARDS FOR TWINS AND THREE 
CARDS FOR TRIPLETS.  
 
NOW PLEASE DOSE THE INFANT BUT WASH YOUR HANDS FIRST 
4.4 Was the first capsule administered to the baby? 
………………….………………………. 
1. Yes 2. No DOSING 
4.5 Did the baby swallow the capsule contents successfully? ……….………………….. 1. Yes 2. No SUCCESS 
4.6 Did the infant spit or vomit the dose? 
………………….…………………………………. 
1. Yes 2. No VOMITTED 
4.7 Date of administration  (dd/mm/yyyy)…… 
 
        DATEDOSE 
4.8 Time of administration (24 hour clock)………….……………………………     TIMEDOSE 
 
 
4.9 Did the DS drop or spill the contents of the capsule? ……………… 1. Yes 2. No 9. NA SPILL 
DO NOT ADMINISTER THE BACKUP CAPSULE IF THE INFANT SPITS OR VOMITS BECAUSE 
THE INFANT IS STILL CONSIDERED TO HAVE RECEIVED THE DOSE.  
ONLY ADMINISTER THE BACK UP CAPSULE IF YOU DROP THE CONTENTS OR CAPSULE 
AFTER CUTTING. IE IF Q 4.9 WAS 1/YES 
4.10 Was the backup capsule administered? …………………………… 1. Yes 2. No 9. NA BACKUPCAP 
4.11 Site of dosing …………………………….. 11. Compound 12. Facility    13. Other specify PLACEDOSE 
4.12.If other, please specify …………………..… 
 
 OTHDOSE 
4.13. If facility, please state facility code (NA = 99) ..……………………………………………. 
 
  FACDOSE 
4.14. If compound, please provide compound number 
          (NA = 99999999) 
        COMPDOSE 
4.15 Specify any other problems in administration of capsule  
 PROBLEMS 
 
5. FOLLOW UP INFORMATION 
PLEASE INFORM THE MOTHER THAT THE BABY WILL BE VISITED TOMORROW 
FULL INFORMATION IS NEEDED THAT WILL HELP LOCATE THE BABY TOMORROW 
 5.1  Please record the mothers phone no 
 
           
 5.2  Please record any other useful  
 phone nos…………….………….. 
           
5.3  Where will the baby be tomorrow? 
11. Facility  12. This compound  13. Other compound  
LOCATIONF 
5.4  Village/town name 
 
 VILLNAMEF 
5.5 Village/town code……………………………………………………………………… 
 
   VILLCODEF 
5.6  If facility, please state facility code (NA = 99)….……………..……………………………. 
 
  FACCODEF 
5.7If another  compound, please provide compound 
      number  (NA = 99999999, NK = 888888888) 
        ANCOMPF 
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5.8 Please provide full details about how to locate the baby tomorrow 
 
 
 
 
6.  ADDITIONAL INFORMATION ABOUT THE BABY 
6.1 What was the sex of the baby? …………………..……………… 11. Male 12. Female SEX 
6.2 Was the baby put to breast or breastfed before dosing? ………...………… 1. Yes 2. No 
9..NA  
  died 
BFDOSE 
6.3   Was the baby given any other fluids or food before dosing? ………...…… 1. Yes 2. No 
9..NA  
  died 
OTHDOSE 
6.4 If yes 
      Specify 
 OTHBEFORE 
6.5  Has the baby been put to breast or breastfed since birth? ...……….…………………… 1. Yes 2. No BFED 
6.6  How many hours after birth did you put the baby to the breast? ……………………… 
      (NA, have not yet put baby to breast = 99) 
  BFSTART 
 
6.7 Since birth, has the baby been offered anything else [PROMPT]: 
6.7.1 Breast milk from another mother? ………………………………… 1. Yes 2. No 8. NK WETNURSE 
6.7.2 Any other milk other than breast milk such as tinned, powdered, or 
fresh animal milk or commercially produced infant formula 
1. Yes 2. No 8. NK OTHMILK 
 
6.7.3 Water ………………………………………………………………… 1. Yes 2. No 8. NK WATER 
 
6.7.4 Medicines, vitamins or ORS ………………………………………… 1. Yes 2. No 8. NK MEDICIN 
6.7.5 Other water based fluids [PROMPT for: water, juice, tea, sugar, 
glucose, traditional medicines] ……………………………………... 
1. Yes 2. No 8. NK OTHFLUID 
6.7.6 Any foods [PROMPT for: any solid foods, porridge, bread, rice, 
cerelac, nutrimix]? ……………………………………………... 
1. Yes 2. No 8. NK SOLID 
 
6.7.7      Has baby been given colostrum? ………….………………………… 1. Yes 2. No 8.NK COLOSTRUM 
NOW A KHRC STAFF MEMBER MUST EITHER WEIGH THE BABY THEMSELVES OR 
DIRECTLY SUPERVISE THE WEIGHING. IF THE WEIGHT HAS BEEN UNSUPERVISED THEN IT 
MUST BE REPEATED. 
6.8.1 Who weighed the baby?   
12. Dosing   
      supervisor 
13. Other KHRC staff 
       Specify:________________ 
14. Doctor  
 
15. Nurse  16. CHO 
WHOWT 
 
 
 
17. CBSV 
18.  Other health professional staff      
       (eg TBA) Specify:_________ 
19. Other person  
       Specify:________ 
99. NA   (i.e. not  
               weighed) 
 
 
6.8.2 If KHRC staff, provide the staff code of the person who weighed the baby (99=NA)…….….. 
 
  CODEWT 
6.8.3 Date baby weighed (dd/mm/yyyy)…….         KBWTDATE 
6.8.4 Time baby weighed (24 hour clock) 8888=NK……………………………     KBWTTIME 
6.8.5 Weight of baby (in kg) 9.99 = NA..................................................................  •   WEIGHT 
6.8.6 What scales were used?   
11. Digital KHRC scales 
 
12. Salter spring KHRC scales 
 
13. Other Scales 
       Specify:________________ 
SCALE 
 
 
 
 
6.9 If the baby was not dosed, what was the reason for not dosing the baby?  
 
99.  Not applicable, baby was dosed 11. Baby died before dosing NOTDOSED 
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12.  Baby was enrolled in another study. Please specify 
study. 
 
13. Mother did not give consent for dosing 
 
 
 
14.  Baby not age eligible  for enrolment 15. Baby unable to feed  
16.  Baby will not remain in the study area for 6 months 
 
17. Other reason, please specify: 
 
 
 
7. How many months pregnant where you when you delivered? (88 = NK)………   
GESTATE 
 
 
 
END OF ENROLMENT FORM, THANK THE RESPONDENT CHECK FORM AND FILL BASELINE FORM 
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KINTAMPO HEALTH RESEARCH CENTRE 
 
NEOVITA TRIAL 
 
BASELINE  FORM    24 JUNE 2010, v1.0 
BASELINE Form No.  
FORMNO 
 
1.  BACKGROUND and ID 
 
1.1 Site of visit …………………………….. 11. Compound 12. Facility    13. Other specify PLACEB 
1.1.1. If facility, please state facility code (NA = 99) ..……………………………………………. 
 
  FACSCR 
1.1.2. If compound, please provide compound number 
          (NA = 99999999) 
        COMPB 
1.1.3.If other, please specify … 
 
 OTHSB 
1.2 Mother’s name .……...  WOMNAME 
1.3 Mother’s Neovita id .….……………           WOMANID 
1.4 Date of visit (dd/mm/yyyy)…….………………….         DATEVISIT 
1.5 Staff code ……………………………....………………………..………………………...  
 
 FW 
 
 
2.  DELIVERY INFORMATION 
 
2.1 Please provide the date of delivery (dd/mm/yyyy) 
      (NA=999999) 
        DATEDEL 
2.2  How many  babies were born ……………… 
11. Single birth 12. Twins 13. Triplets 
SINGELTON 
2.3  How many babies were enrolled in the Neovita study 99=NA……...…..……………………..   NUMENROL 
2.3.1 Infantid (NA = 999999) ……………………………….………       SUBJECTID1 
2.3.2 Infantid (NA = 999999) …………………………………….…       SUBJECTID2 
2.3.3 Infantid (NA = 999999) ……………………………………….       SUBJECTID3 
2.4 Place of birth …………………………….. 
11. Compound 12. Facility    13. Other specify 
PLACEBIR 
2.4.1. If facility, please state facility code (NA = 99) ..……………………………………………. 
 
  FACBIR 
2.4.3. If compound, please provide compound number 
          (NK=88888888 NA = 99999999) 
        COMPBIR 
2.4.4.If other, please specify …………………..… 
 
 BIRTHOTH 
 
PLEASE ASK THE MOTHER 
2.5 What was the type of delivery?......................... 11. Normal  12. Assisted eg 
      forceps 
13. Caesarean TYPEDEL 
 
 
 
2.6 Who conducted the delivery?  
11. Doctor 12. Nurse or  
       midwife 
14. TBA trained or   
       untrained 
15. Community health  
      officer 
ATTENDT 
19. Other health  
    professional, Specify 
16. Relative 17. Neighbour or friend 18. None, woman herself  
 
2.7 Was the baby born ………………………....... 
11. On time or on  
      due date 
12. Early or  
     before due date 
13. Late or after  
      due date 
PRETERM 
2.8 Do you know when you had your last menstrual period? …………………………..…… 1. Yes 2. No LMPKNOW 
269 
 
 
2.9 If YES, what was the first day of the last menstrual period: (dd/mm/yyyy)  (08/08/0808=NK, 09/09/0909 
=NA) 
 
 
        LMP 
 
3. MOTHER’S DETAILS 
 
3.1 How many living children do you have, not including this current child? ………………   ALIVENO 
3.2 Have any of your children died? ………….…………………………………………… 1. Yes 2. No CHDIED 
3.3 If yes, how many of your children have died? (NA = 99) ………………..….…………   DIEDNO 
3.4  Did you have any health problems in the year BEFORE you were pregnant?................ 1. Yes 2. No HEALTHY 
3.5 If YES, specify 
 
 HEALTHS 
 
 
3.6 Were you enrolled in the Obaapavita Trial? …...……….………………… 1. Yes 2. No 8. NK OBVITA 
3.7  Did you receive other vitamin A supplements before delivery? ……….… 1. Yes 2. No 8. NK ANSUPPL 
3.8 If YES, how many months before delivery? (NA = 99, NK = 88)…................................   MOSUPPL 
3.9 Did you receive vitamin A megadose after delivery?..................................... 1. Yes 2.No 8. NK PNSUPPL 
3.10 If YES, how many days after delivery? (NA = 99, NK = 88)….....................................   DAYSUPPL 
3.11 What is your age? (NA = 99, NK = 88)....…………………….…………..…………...  
 
 MOTHERAGE 
 
 
3.12   PLACE THE WOMAN IN ONE OF THE FOLLOWING AGE GROUPS: 
11.15-19 years 12. 20-24 years 13. 25-29 years 14. 30 – 34 years AGEGRP  
15. 35-39 years 16. 40-44 years 17. 45-49 years 88. NK   
 
3.13.1 For how many years did you go to school? (00=None, 88=NK)……………..…………  
 
 MOTHEREDU 
 
3.13.2. What was your highest educational level completed? 
1. None 
 
2. Primary school 3. 
Middle,continuation 
    school, JSS 
4. Technical, 
commercial,  
    SSS, Secondary 
school 
MEDLEV 
5. Post-middle college,  
    secretarial 
6. Post secondary, 
nursing, 
    polytechnic 
7. University 
 
8. Not known 
 
 
3.14  What is your occupation? 
11. Government 
employee 
12. Private employee 14. Self employed MOTHEROCC 
 
15. Farming only 16. Does not work 17. Other 99. NA  
 
3.15 If occupation of woman  is ‘other’ then specify 
 MOCCOTH 
4.  HOUSEHOLD CHARACTERISTICS 
 
PLEASE EXPLAIN TO THE MOTHER WHAT A HOUSEHOLD IS 
4.1 Who is the head of your household?  
11.  Mother of baby 12. Father of baby 13. Grandmother of 
baby 
14. Grandfather of 
baby 
HEAD 
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15. Other specify:  
 
 
4.2 How many years of schooling has the  head of household (00=None, 
88=NK)……………… 
 
 
 FATHEREDU 
 
4.2.1. What was the highest educational level completed for the household head? 
1. None 
 
2. Primary school 3. 
Middle,continuation 
    school, JSS 
4. Technical, 
commercial,  
    SSS, Secondary 
school 
HHMEDLEV 
5. Post-middle college,  
    secretarial 
6. Post secondary, 
nursing, 
    polytechnic 
7. University 
 
8. Not known 
 
 
4.3 What is the occupation of head of household? 
11. Government 
employee 
12. Private employee 13. Self employed FATHEROCC 
 
14. Farming only 15. Does not work 16. Other 99. NA  
 
4.4 If occupation of head of household is ‘other’ then specify 
 FOCCOTH 
4.5 Is the head of the household staying with the family? 
...................................... 
1. Yes 2. No FATHSTAY 
 
 
4.6 What is the main source of drinking water for members of your household? 
11. Piped water 
into dwelling 
12. Public tap 13. Hand pump or 
closed borehole 
14. Open well HOUSEWTR 
 
15. Closed well 16. Tanker truck 17. Small cart with 
tank 
18. Surface water (river / dam / lake / pond 
/ stream / canal / irrigation channel) 
 
 
19. Bottled water 20. Rain water 21. Other  
 
4.7 If source of water is ‘other’ then specify 
 WTROTHER 
 
4.8 What kind of toilet facility do members of your household usually use?  
11. Flush or pour flush toilet 12. Pit latrine 13. Dry toilet TOILET 
 
14. Bucket latrine 15. No facility / uses open space or field 16. Other  
 
4.9 If toilet is ‘other’ then specify 
 TOILETOTH 
4.10 What is the religion of the head of the household? 
11. Christian 12.  Muslim 14.  None 15. Traditional African 16. Other HHRELIG 
 
 
4.11 If religion is ‘other’ then specify 
 RELIGOTH 
4.12 What ethnic group does your household belong to? 
 11. Akan: e.g. Bono,  
      Ashanti, Fanti.etc. 
12. Bimoda,   
      Chokosi 
13. Dagarti,  
      Frafra, Kusasi 
14. Fulani GH_ETHNIC 
15. Ga, Adangbe,    
      Ewe 
16. Gonja, Dagomba,      
Mamprusi 
17. Konkomba, 
      Basare 
18. Mo  
19. Sisala, Wala 20. Zambraba 21. Banda/Pantra 22. Other, specify:  
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4.13 What type of fuel does your household mainly use for cooking? 
11. Electricity 12. 
LPG/Natural 
Gas 
 
 
13. Kerosene  14. 
Coal/Lignite 
15. Charcoal 16. Wood FUELCOOK 
 
17. 
Straw/shrub/  
      grass 
18. 
Agricultural   
crop waste 
19. Dung cakes 20. Biogas 21. Other  
 
 
4.14 If cooking fuel is ‘other’ then specify 
  FUELOTH 
4.15 In the household, is food cooked inside or 
outside? 
11 Inside 12. Outside 13. Other, specify: PLCCOOK  
 
4.16 Do you have a separate room which is used as a kitchen? ………….…………… 1. Yes 2. No KITCHEN 
4.17 How many rooms are there in your household including kitchen? 
………….……… 
  
ROOMS 
4.18 How many persons slept in the household last night? ………….……………………   PERSONS 
4.19 Do you own or rent the house you live in, or do you have another type of arrangement, such as 
“perching”? 
11. Sole Ownership 12. Joint Ownership 13. Renting 14. Family/relative’s house OWNHOUSE 
15. House provided rent 
free 
16. Perching 17. Other: 88. NK  
 
4.20 Does household have: ……………...  4.20.1 Electricity? ....................................... 1. Yes 2. No GH_ELECTR 
 
  4.20.2 Chickens? ………………………… 1. Yes 2. No GH_CHICKEN 
  4.20.3 Sheep? .............................................. 1. Yes 2. No GH_SHEEP 
  4.20.4 Other animals? ……………………. 1. Yes 2. No GH_OTHANIMAL 
  4.20.5 Mattress? .......................................... 1. Yes 2. No GH_MATTRESS 
 
  4.20.6 Stove or cooker? .............................. 1. Yes 2. No GH_PRESCOOK 
 
  4.20.7 Chair? .............................................. 1. Yes 2. No GH_CHAIR 
 
  4.20.8 Cot or bed? ...................................... 1. Yes 2. No GH_BED 
 
  4.20.9 Divider? ........................................... 1. Yes 2. No GH_DIVIDER 
  4.20.10 Table? ............................................ 1. Yes 2. No GH_TABLE 
 
  4.20.11 Electric fan? ................................... 1. Yes 2. No GH_FAN 
 
  4.20.12 Radio or transistor? ........................ 1. Yes 2. No GH_RADIO 
 
  4.20.13 Television? .................................... 1. Yes 2. No GH_BWTV 
 
  4.20.14 Sewing machine? ........................... 1. Yes 2. No GH_SEW 
 
  4.20.15 Mobile telephone? ......................... 1. Yes 2. No GH_MOBILE 
 
  4.20.16 Mosquito net? …………………… 1. Yes 2. No GH_MOSNET 
  4.20.17 Computer? ..................................... 1. Yes 2. No GH_COMP 
 
  4.20.18 Refrigerator? .................................. 1. Yes 2. No GH_FRIDGE 
  4.20.19 Watch or clock? ............................. 1. Yes 2. No GH_WATCH 
 
  4.20.20 Bicycle? …………………………. 1. Yes 2. No GH_BICYCLE 
  4.20.21 Motorcycle or scooter? .................. 1. Yes 2. No GH_MOTOCY 
 
  4.20.22 Animal-drawn cart? ....................... 1. Yes 2. No GH_ANIMCART 
  4.20.23 Car? ……………………………… 1. Yes 2. No GH_CAR 
  4.20.24 Thresher? ....................................... 1. Yes 2. No GH_THRSHR 
  4.20.25 Tractor? ………………………...... 1. Yes 2. No GH_TRACTOR 
 
4.21 Does this household own any land? ………….………………………………….. 
1. Yes 2. No 
OWNLAND 
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5.   MOTHER’S DIET 
Did the mother consume any of the following in the last seven days? 
5.1 Any kind of redmeat (eg goat) 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  REDMEAT 
 
5.2 Any kind of poultry (eg chicken) 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  WHITEMEAT 
 
5.3 Any kind of liver……………. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  LIVER 
 
5.4 Any kind of fish (fresh or dried) 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  FISH 
5.5 Egg………………………… 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  EGG 
5.6 Milk…………………………… 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  MILK 
5.7 Yoghurt/curd/buttermilk……….. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  YOGHURT 
 
5.8 Butter / milk cream…………….. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  BUTTER 
 
5.9 Peanuts…………………………. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  PEANUT 
5.10 Vegetable oil…………………. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  VEGOIL 
5.11 Carrots………………………... 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  CARROT 
5.12 Tomatoes (red)……………… 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  TOMATO 
 
5.13 Pumpkin (yellow)…………….. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  PUMPKIN 
 
5.14 Dark green leafy vegetables… 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  LEAFVEG 
5.15 Beans/peas…………………… 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  PEAS 
5.16 Papaya (yellow)………………. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  PAPAYA 
5.17 Jackfruit (yellow)……………. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  JACK 
 
5.18 Mango (yellow)………………. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  MANGO 
 
5.19 Banana………………………. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  BANANA 
5.20 Orange………………………... 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  ORANGE 
5.21 Watermelon…………………. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  WMELON 
5.22 Melon (yellow)………………. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  MELON 
 
5.23 Guava……………………….. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  GUAVA 
5.24 Red palm oil………………… 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  RPOIL 
5.25 Plantain …………………….. 11. Never 12. Once /w 13. Twice-Four/w 14. Five-six/w 15. Daily  PLANTAIN 
 
 
6. MATERIALS USED IN THE CONSTRUCTION OF THE HOUSE [OBSERVE] 
6.1 Floor of sleeping room 11. Cement 12. Mud/clay 14. Tiled 13. Other: 88. NK FLOOR 
6.2 Roofing ……………... 11. Metal 12. Asbestos 13. Thatch 14. Mud 15. Other: ROOF 
6.3 Wall …………………. 11. Cement 12. Mud 13. Other: WALL 
END OF BASELINE FORM, PLEASE THANK THE RESPONDENT AND CHECK YOUR FORM 
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KINTAMPO HEALTH RESEARCH CENTRE 
 
NEOVITA TRIAL 
 
INFANT  FORM   25 JANUARY 2011, v2.0 
INF Form No.  
FORMNO 
 
1. BACKGROUND and ID 
1.1 Ncluster …………………………………………………….…………….……..     NCLUSTER 
 
 
1.2 Compound no.......................................................... 
 
        COMPNO 
1.3 Woman’s name.……....  WOMNAME 
1.4 Woman’s Neovitaid.………………..           WOMANID 
1.5 Infant’s name.……....  INFNAME 
1.6 Infant’s Neovitaid.……………………………………….……..       SUBJECTID 
1.7 Visit number…………………………………………………………………………..………... 
 
  VAGE 
1.8 Date of visit (dd/mm/yyyy)……….………………         DATEVISIT 
1.9 Staff code ………………………………....…………………………..………………………..  
 
 FW 
 
 
2. STATUS 
 
2.1 Mother status at time of visit: 
11. Present 12. Currently in hospital 13. Temporarily absent  
      (for another reason) 
14. Died 
WSTATUS 
15. Moved out 16. Refused 17.Withdrawn 99. NA 
 
 
2.2 Infant’s status at time of visit: 
11. Present 12. Currently in hospital 13. Temporarily absent  
      (for another reason) 
14. Died 
ISTATUS 
15. Moved out 16. Refused 17.Withdrawn 99. NA 
 
2.3   If died, date of death: (dd/mm/yyyy) …..……… 
        [DRAW A LINE THROUGH IF NA] 
        DATEDIED 
 
2.4 If the baby or mother has moved out (ie Q2.3 = 15) then where has the baby or mother moved? 
11. Another compound in study area  
 
12. A compound outside the study area  88. NK 99.NA 
MOVET 
2.4.1 Village/town name 
 
 VILLNMT 
2.4.2 Village/town code (NA=999 or outside SA, NK=888)…………………………… 
 
   VILLCMT 
2.4.3 Please provide compound no… 
(NA or outside SA = 99999999;NK = 888888888) 
        COMPMT 
 
2.5 Who is the respondent for this interview? 
11. Mother  
 
12. Father 13. Other family  
      member 
14. Other guardian /  
      Caretaker 
15. No card / no  
      respondent 
INFORMANT 
IF MOTHER AWAY USE ANOTHER RESPONDENT. BUT MUST HAVE INFANT’S NEOVITA ID 
CARD. 
 
2.6 Is the interview being conducted by phone? ……………………………… 1. Yes 2. No PHONE 
 
STOP IF NO RESPONDENT OR THE INFANT NOT PRESENT; PUT A DOUBLE LINE ACROSS 
REST OF FORM. 
 
 
3. INFANT FEEDING OVER LAST 24 HOURS 
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3.1 In the last 24 hours, did you breastfeed or put baby to the breast? ………. 1. Yes 2. No 8. NK BREASTM 
 
3.2  In the last 24 hours, was the baby offered anything else [PROMPT]: 
3.2.1 Breast milk from another mother? ………………………………… 1. Yes 2. No 8. NK WETNURSE 
3.2.2 Any other milk other than breast milk such as tinned, powdered, or 
fresh animal milk or commercially produced infant formula?......... 
1. Yes 2. No 8. NK OTHMILK 
3.2.3 Water ………………………………………………………………… 1. Yes 2. No 8. NK WATER 
3.2.4 Medicines, vitamins or ORS ………………………………………… 1. Yes 2. No 8. NK MEDICIN 
3.2.5 Other water based fluids [PROMPT for: juice, tea, sugar, glucose, 
traditional medicines]? …………………………………… 
1. Yes 2. No 8. NK OTHFLUID 
3.2.6 Any foods [PROMPT for: any solid foods, porridge, bread, rice, 
cerelac, nutrimix]? ……………………………………………... 
1. Yes 2. No 8. NK SOLID 
 
4. IMMUNISATIONS 
   4.1 Has the child been vaccinated since the last visit? ……………………… 1. Yes 2. No 8. NK VACC 
IF NO, THEN PUT A DOUBLE LINE THROUGH THIS SECTION 4.2 AND MOVE TO SECTION 4.4 
 
SELF REPORT OF IMMUNISATION 
4.2 What type of immunisations did the child receive?     
4.2.1 Oral medicine given by mouth? ………………………………………… 1. Yes 2. No 8. NK RORAL 
4.2.2 Injection into leg? …………………………………………….………… 1. Yes 2. No 8. NK RLEG 
4.2.3 Injection into arm? …………………………………………...………… 1. Yes 2. No 8. NK RARM 
4.3 What was the name of the vaccination (s)?   
4.3.1 Polio? ………………………………………………………...……… 1. Yes 2. No 8. NK RPOLIO 
4.3.2 BCG? ………………………………………...………………………… 1. Yes 2. No 8. NK RBCG 
4.3.3 DTP/Penta? ……………………………………………………………. 1. Yes 2. No 8. NK RPENTA 
4.3.4 Measles? ………………………………………..……………………… 1. Yes 2. No 8. NK RMEAS 
4.3.5 Yellow fever? …………………………………………………………… 1. Yes 2. No 8. NK RYELLOW 
 
4.4 Is there a BCG scar? (OBSERVE BOTH UPPER ARMS).......................... 1. Yes 2. No 8. NK 9. NA BCGS 
 
NOW ASK FOR WRITTEN RECORD OF VACCINATION  
(PROMPT FOR ANC, Family planning, or child health records or any other written record of vaccination)  
 
4.5 Written vaccination record viewed? ……………………………………… 1. Yes   2. No   VACCCARD 
IF NO PUT A DOUBLE LINE THROUGH THIS SECTION AND MOVE TO SECTION 5 
 
TRANSCRIBE INFORMATION DIRECTLY FROM CARD ONTO THIS FORM  
09090909=Did not receive, 08080808=Received but date not known 
Tuberculosis (BCG) 
4.6. BCG birth dose date received ………….…………         DATEBCG 
Poliomyelitis (Polio) 
4.7.1 Polio birth dose date received ………….………         DATEPOLIOB 
4.7. 2 Polio1 dose date received ……….……….……         DATEPOLIO1 
4.7.3 Polio2 dose date received ………….…………         DATEPOLIO2 
4.7.4 Polio3 dose date received ………….…………         DATEPOLIO3 
Diptheria/Tetanus/Pertussis/Hepatitis B/Hib (Penta) 
4.8.1 DTP1-HepB-Hib (penta) 1 dose date received….         DATEPENT1 
4.8.2 DTP2-HepB-Hib (penta) 2 dose date received...         DATEPENT2 
4.8.3 DTP3-HepB-Hib (penta) 3 dose date received…         DATEPENT3 
Measles 
4.9. 1 Measles dose date received …………………         DATEMEASLES 
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Yellow fever 
4.10.1 Yellow fever dose date received………………          
 
5. VITAMIN A SUPPLEMENTATION 
5.1 Have you or your child received vitamin A supplementation since the last visit? 
1. Child received  2. Mother received  3. Both child and mother received 4. Neither  8. NK VITA 
IF NEITHER OR NK DRAW A DOUBLE LINE THROUGH THIS SECTION AND GO TO SECTION 6 
 
NOW ASK FOR WRITTEN RECORD OF MOTHER’S AND CHILD’S VITAMIN A 
SUPPLEMENTATION  
(PROMPT FOR ANC, Family planning, or child health records or any other written record of supplementation) 
  
Maternal vitamin A supplementation 
5.2.1 Maternal vitamin A record viewed? (9.NA, not received)………. 1. Yes 2. No 9. NA VITACARDM 
5.2.2 Maternal vitamin A dose date received……… 
09090909=Did not receive; Did not view record. 
08080808=Received but date not recorded on record. 
        DATEVITAMAT 
Infant vitamin A supplementation 
5.3.1 Infant vitamin A record viewed? (9.NA, not received)………. 1. Yes 2. No 9. NA VITACARDI 
5.3.2 Infant vitamin A dose 1 date received……… 
09090909=Did not receive; Did not view record. 
08080808=Received but date not recorded on record. 
        DATEVITINF1 
5.3.3 Infant vitamin A dose 2 date received……… 
09090909=Did not receive; Did not view record. 
08080808=Received but date not recorded on record. 
        DATEVITAINF2 
 
6.   HEALTH CARE SINCE LAST VISIT 
6.1.1  Have you had contact with a health care provider or health facility for this  
 child since the last visit? [PROMPT FOR OUTREACH CLINIC,  
 IMMUNISATIONS, ILLNESS]…………………………………………… 
1. Yes 2. No 8. NK CONTACTH 
6.1.2 Has the child been unwell with an illness or injury since the last visit? ........ 1. Yes 2. No 8. NK UNWELL 
IF NO / NK PUT A DOUBLE LINE THROUGH THIS SECTION AND GO TO SECTION 7 
6.1.3 If yes how many different illnesses/injuries…………………………………………….   UNWELLNO 
 
6.2. FIRST ILLNESS/INJURY 
6.2.1 Date illness/injury started (dd/mm/yyyy)………... 
         [IF NK or ONGOING THEN PUT 08080808] 
        STDATE1 
6.2.2 Date illness/injury ended (dd/mm/yyyy)………… 
        [IF NK or ONGOING THEN PUT 08080808] 
        ENDDATE1 
6.2.3 Is the illness ongoing? 1. Yes 2. No 8. NK ONGOING1 
6.2.3 Was care sought outside the home while the child had this illness/injury?..... 1. Yes 2. No 8. NK CARESEEK1 
6.2.4  Was the child admitted to sleep at least one night in a health facility during 
  this illness/injury?.................................................................................. 
1. Yes 2 No 8. NK ADM1 
IF NO DRAW A DOUBLE LINE THROUGH SECTION AND GO TO SECTION 6.3. 
IF THERE IS NO SECOND ILLNESS THEN DRAW A DOUBLE LINE THROUGH SECTION AND GO TO  
SECTION 7. 
6.2.5 How many facilities?................................................................................................... ........   SEEKCARE1 
6.2.6 Facility 1 code ..................................................................................................................    FCODE11 
6.2.7 Facility 2 code ....................................................................................................... .............   FCODE21 
6.2.8 Facility 3 code ....................................................................................................... .............   FCODE31 
6.2.9 What was the reason for the admission? 
Acute lower respiratory tract infection / pneumonia ……………….………… 1. Yes 2. No 8. NK ALRI1 
Diarrhea …….……….……………………………………………..……… 1. Yes 2. No 8. NK DIARRHEA1 
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Fever/malaria ……………………………………………………………….…. 1. Yes 2. No 8. NK FEVMAL1 
Injury …………………………………………………….……………………. 1. Yes 2. No 8. NK INJURY1 
Others ………………………………………………………………………… 1. Yes 2. No 8. NK OTHERS1 
If other, specify ……..  HOSOTHER1 
IF NO SECOND ILLNESS THEN PUT A DOUBLE LINE THROUGH THIS SECTION AND GO TO 
SECTION 7 
 
6.3. SECOND ILLNESS/INJURY 
6.3.1 Date illness/injury started (dd/mm/yyyy)………... 
         [IF NK or ONGOING THEN PUT 08080808] 
        STDATE2 
6.3.2 Date illness/injury ended (dd/mm/yyyy)………… 
        [IF NK or ONGOING THEN PUT 08080808] 
        ENDDATE2 
6.3.3 Is the illness ongoing? 1. Yes 2. No 8. NK ONGOING2 
6.3.3 Was care sought outside the home while the child had this illness/injury?..... 1. Yes 2. No 8. NK CARESEEK2 
6.3.4  Was the child admitted to sleep at least one night in a health facility during 
  this illness/injury?.................................................................................. 
1. Yes 2 No 8. NK ADM2 
IF NO EITHER DRAW DOUBLE LINE THROUGH SECTION AND GO TO SECTION 7. 
6.3.5 How many facilities?...........................................................................................................    SEEKCARE2 
6.3.6 Facility 1 code ..................................................................................................................    FCODE12 
6.3.7 Facility 2 code ....................................................................................................... .............   FCODE22 
6.3.8 Facility 3 code ....................................................................................................... .............   FCODE32 
6.39 What was the reason for the admission? 
Acute lower respiratory tract infection / pneumonia ……………….……… 1. Yes 2. No 8. NK ALRI1 
Diarrhea …….……….………………………………………………..……… 1. Yes 2. No 8. NK DIARRHEA1 
Fever/malaria ……………………………………………………………….…. 1. Yes 2. No 8. NK FEVMAL1 
Injury …………………………………………………….……………………. 1. Yes 2. No 8. NK INJURY1 
Others ………………………………………………………………………… 1. Yes 2. No 8. NK OTHERS1 
If other, specify ……..  HOSOTHER1 
 
 
7. FOLLOW UP INFORMATION 
PLEASE INFORM THE MOTHER THAT THE BABY WILL HAVE A FOLLOW UP INFANT VISIT 
IN ONE MONTH.  
7.1 Where will the baby be at the next visit? ................ 
11. This  compound  12. Other compound  
LOCATION 
IF THIS COMPOUND THEN END HERE AND DRAW A DOUBLE LINE THROUGH THE REST OF 
THE FORM 
7.2 Village/town name  HOUSEID 
 
 
7.3 Village/town code (NK = 888;N A or outside SA = 999) ……………………………    VILLCODE 
 
 
7.4 If another compound please provide no. (NK = 
88888888; NA or outside SA = 99999999)………….. 
        ANCOMP 
 
 
7.5 PLEASE PROVIDE FULL DETAILS ABOUT HOW TO LOCATE THE BABY FOR THE NEXT VISIT 
 
 
END OF INFANT FORM, PLEASE THANK THE RESPONDENT AND CHECK YOUR FORM 
 
  
277 
 
KINTAMPO HEALTH RESEARCH CENTRE 
 
COHORT / NEOVITA PROJECT  
  
INFANT VPM FORM (18 Sept 2012, v1.0 ENGLISH) 
INFANT VPM Form No. 
 
 
 
 
FORMNO 
 
BACKGROUND and ID:  
PLEASE VERIFY ALL THE INFORMATION ON THE PRINTED LABEL BELOW. START BY ASKING FOR THE 
MOTHER’S NEOVITA ID CARD.  IF THE NEOVITA CARD IS MISSING, PLEASE ASK TO EXAMINE THE 
ANC CARD, THE CHILD HEALTH RECORD, or ANY OTHER SOURCE THAT MAY HAVE THE 
INFORMATION.  IF ANY OF THE INFORMATION IS INCORRECT, PLEASE CORRECT IT. 
1.1. Ncluster…………………………………………………………………….. 
    
NCLUSTER 
1.2. Woman’s ID……………………….           WOMANID 
1.3. Woman’s name……..  
WOMNAME 
1.4. Infant ID number….......................................................................       SUBJECTID 
1.5. Date of delivery [080808 = NK]…………...     
    DATEDELIV 
 
1.5.1 Time of delivery [24-hr clock;8888 = NK] 
    TIMEDELIV 
1.6. Date of death [080808 = NK]…………………...     
    DATEDIED 
 
 
CONFIRM THE DATE OF DEATH LISTED ON THE LABEL. IF CONFIRM A DIFFERENT DATE, 
DOUBLE LINE THROUGH DATE ON LABEL AND RECORD CONFIRMED DATE. 
 
1.6.1 Did the infant die during the rainy season or the dry 
season?...............................................................................................  
1. Rainy 2. Dry 8. NK 
SEASON 
1.6.2. IF DATE OF DEATH IS NK (08080808), then ask the woman: how soon after birth did the baby die? 
1.   Within 24 hours of birth 2.   1-13 days 3.   2-3 weeks 4.   4-7 weeks 
AGED 
5.   2-3 months 6.   4-5 months 7.  6-11 months 8. NK 9. NA, date known 
 
 
1.7. PLACE THE INFANT IN ONE OF THE FOLLOWING GROUPS. CONFIRM THIS WITH THE 
RESPONDENT DURING THE INTERVIEW. 
1. Stillbirth = Born dead / child did not cry or move  
                      or breathe after birth after 22w gestation 
2. Early neonatal death = Live birth with age at death  
                                         0 to 6 days 
CLASSIF 
 
 
3. Late neonatal death = Live birth with age at death  
                                       7-27 days 
4. Postneonatal death = Live birth with age at death 28 
                                      days or more 
 
 
 
 
1.8. Did you verify the 
WOMAN’S ID on the 
label?  
1. Yes, verified with 
Neovita card. 
2. Yes, verified without 
Neovita card. 
3. No, Neovita card lost and 
no other source to verify. 
VERIFY 
 
 
1.9. Date of interview: …………………………..........     
    DATEVISIT 
 
1.10. Staff code: ……………………………………………..................…………………………. 
  FW 
 
1.11. Time interview began. 24 hour clock………………………….….................... 
    TIMEBEG 
 
1.12. Time interview finished. 24 hour clock ………………………….................… 
    TIMEFIN 
 
 
2. INFORMATION ABOUT THE RESPONDENT 
ASK TO SPEAK TO THE MOTHER OR TO ANOTHER ADULT CARETAKER WHO WAS 
PRESENT DURING THE ILLNESS THAT LED TO THE INFANT’S DEATH IF THIS IS NOT 
POSSIBLE, ARRANGE A TIME TO VISIT THE HOUSEHOLD WHEN THE MOTHER OR 
CARETAKER WILL BE HOME. 
 
2.1. IS A RESPONDENT AVAILABLE? .............................................................................  1. Yes 2. No 
RESPOND 
 
2.2. CONSENT GIVEN FOR VERBAL AUTOPSY?................ 1. Yes 2. No 9. NA no respondent  VPMCONS 
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IF RESPONDENT DOES NOT GIVE CONSENT, OR THERE IS NO RESPONDENT, PLEASE TRY 
TO FIND ANOTHER RESPONDENT. IF NECESSARY PLEASE RETURN TO THE COMPOUND AT 
ANOTHER TIME TO FIND A RESPONDENT AND COMPLETE THE INTERVIEW. IF THERE 
WILL NEVER BE A RESPONDENT, PLEASE SUBMIT AS PROBLEM FORM.  
2.3. RESPONDENT’S NAME:  RESPNAME 
2.4. RESPONDENT’S AGE………………………………………………………………   RESPAGE 
 
2.5. WHAT IS THE RELATIONSHIP OF THE MAIN RESPONDENT TO THE DECEASED CHILD? 
11. Mother 12. Father 13. Grandmother 14. Grandfather 15. Aunt 16. Uncle 
RELATION 
 
17. TBA 18. Other male: ________________________ 19. Other female : ______________________ 
 
 
 
2.6. Did the respondent live with the deceased child in the period leading to her/his death? 1. Yes  2. No RESLIVE 
 
2.7. TOTAL NUMBER PRESENT WHO PARTICIPATED AT INTERVIEW (EXCLUDING 
        INTERVIEWER[S])? ............................................................................................................ .. 
  
TOTINT 
 
 
2.8. OF THOSE PARTICIPATING IN THE INTERVIEW, WERE THE FOLLOWING PERSONS PRESENT  
       AT THE ILLNESS THAT LED TO STILLBIRTH, DEATH OR HOSPITALISATION? 
                  2.8.1. The infant’s mother………………………………………………………. 1. Yes 2 No PRESDEATH1 
 
                  2.8.2. The infant’s father ………………………………………………………… 1. Yes 2 No PRESDEATH2 
 
                  2.8.3. The infant’s grandmother ……………………………………………….. 1. Yes 2 No PRESDEATH3 
 
                  2.8.4. The infant’s grandfather…………………………………………………. 1. Yes 2 No PRESDEATH4 
 
                  2.8.5. The infant’s aunt………………………………………………………… 1. Yes 2 No PRESDEATH5 
 
                  2.8.6. The infant’s uncle……………………………………………………… 1. Yes 2 No PRESDEATH6 
 
                  2.8.7. TBA……………………………………………………………………… 1. Yes 2 No PRESDEATH7 
 
                  2.8.8. Other, SPECIFY:_____________________________________________ 1. Yes 2 No PRESDEATH8 
 
  
2.9. IF THE RESPONDENT IS NOT THE MOTHER, GIVE THE REASON WHY: 
1. Mother is not resident  
    compound member  
2. Mother is not  
    present  
3. Mother is dead 
4. Mother is not  
   capable of answering 
5. Mother  
   refused 
RESPMO 
 
6. Other: 8. NK 9. NA, mother is informant 
 
 
 
2.10. How is the mother’s health now? 
1. Healthy 2. Ill 3. Not alive 8. NK 9. Not applicable 
MHEALT 
 
 
2.11. IF THE MOTHER IS DEAD: 
2.11.1. HOW MANY DAYS AFTER DELIVERY DID SHE DIE?  
[888 NK, 999 NA / DID NOT DIE, 000 if less than 24 hours or died during delivery] 
   
MODIED 
 
2.11.2. HOW MANY MONTHS AFTER DELIVERY DID SHE DIE?  
[0 – 12; 88 = NK, 99 = NA / DID NOT DIE] 
   
MODIEDMTH 
 
IF THE RESPONDENT IS THE MOTHER, SKIP QUESTIONS 2.12 AND 2.13 AND CONTINUE 
FROM SECTION 3 
 
2.12. If the respondent is not the mother, how old is the respondent?  
[88=NK; 99 = NA; respondent is mother].......................................................................................  
 
 
 R_AGE 
 
   2.13. What is the highest level of schooling or educational attainment you the respondent have attained? 
 11. None 
 
12. Primary school 13. Middle, continuation 
    school, JSS 
14. Technical, commercial,  
    SSS, Secondary school 
RESEDUL 
15. Post-middle college,  
    secretarial 
16. Post secondary, nursing, 
    polytechnic 
17. University 
 
88. NK 99. NA, respondent 
is mother 
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3. INFORMATION ABOUT THE MOTHER 
3.1 How old is the mother?  (IN YEARS; 88=NK)….........................................................………    MAGE 
 
3.2. What is the mother’s nationality / citizenship? 1. Ghanaian  2. Other (SPECIFY): 
 
NATION 
 
3.3. To what ethnic group does the mother belong? 
11. Akan: e.g. Bono, 
Ashanti, Fanti.etc. 
12. Bimoda, Chokosi 13. Dagarti, Frafra, 
Kusasi 
14. Fulani GH_ETHNIC 
15. Ga, Adangbe, Ewe 16. Gonja, Dagomba, Mamprusi 17. Konkomba,asare 18. Mo 
 
 
19. Sisala, Wala 20. Zambraba 21. Banda/Pantra 22. Other, SPECIFY: 
 
 
 
3.4. Is the mother normally resident in the study area ?.....................................  1. Yes 2. No 8. NK 
RESIDENCE 
 
3.5. How many years of schooling did the mother have? [00=None, 88=NK].......................   EDUWOMAN 
 
3.6. What was the mother’s highest level of schooling (or educational attainment)? 
11. None 
 
12. Primary school 13. Middle,continuation 
    school, JSS 
14. Technical, commercial,  
    SSS, Secondary school 
EDUCLEVEL 
15. Post-middle college,  
    secretarial 
16. Post secondary, nursing, 
    polytechnic 
17. University 
 
88. NK 
 
 
3.7. Was the mother able to read or write? ........................................................ 1. Yes 2. No 8. NK READWRITE 
3.8. What was the mother’s main economic activity status in the year prior to the baby’s death? 
11. Mainly employed 12. Mainly unemployed 14. Home maker 15. Student OCCWOMAN 
 
16. Pensioner 17. Does not work 18. Other 88. NK 99. NA  
 
If occupation of woman  was ‘other’ then specify 
 MOCCOTH 
 
3.9. What was the mother’s marital 
status? 
11. Never married / single 12. Married  13. Cohabiting 
 
MARRIED 
 14. Separated 15. Divorced 16. Widowed 88. NK  
 
 
4. INFORMATION ABOUT THE CHILD  
4.1. Was the child a singleton or multiple birth? .............................. 1. Singleton 2. Multiple MULTIPLE 
 
 
[IF TWO OR MORE CHILDREN ARE BORN, IT IS COUNTED AS A MULTIPLE BIRTH, EVEN IF ANY 
BABY IS BORN DEAD. IF MULTIPLE BIRTH THEN FILL A FORM FOR EACH BABY WHO DIES.] 
4.2. If multiple, was this the first, second, or later in birth order? 
1. First 2. Second 3. Third or more 8. NK 9. Not applicable/singleton birth 
BORDER 
 
4.3. Was the baby male or female?............................................................. 1. Male 2 Female 8. NK SEX 
 
4.4. What was the child’s name?   
[Stillbirth = NA, FOR LIVE BIRTH USE DAY NAME IF NO OTHER NAME IS AVAILABLE] 
 CNAME 
 
 
4.5. For how long was the child ill before s/he died?  
[in days, 888 = NK, 000 = died during delivery]............................... 
   
DURILL  
 
4.6. Did the baby die suddenly?............................................................................ 1. Yes 2 No 8. NK 
DIESUDD 
 
 
5. OPEN HISTORY QUESTIONS 
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5.1. Story of the illness 
 
ALLOW THE RESPONDENT TO TELL YOU ABOUT THE PREGNANCY, DELIVERY AND THE BABY’S 
INJURY OR ILLNESS IN HER OWN WORDS. WRITE DOWN WHAT THE RESPONDENT TELLS YOU IN 
HER OWN WORDS. DO NOT PROMPT EXCEPT FOR ASKING WHETHER THERE WAS ANYTHING 
ELSE AFTER THE RESPONDENT FINISHES. KEEP PROMPTING UNTIL THE RESPONDENT SAYS 
THERE WAS NOTHING ELSE. WHILE RECORDING, UNDERLINE ANY UNFAMILIAR TERMS. 
ALSO REMEMBER TO PROMPT ABOUT CARESEEKING DURING PREGNANCY, LABOUR, 
DELIVERY, AFTER THE BIRTH OF THE CHILD AND DURING THE FATAL ILLNESS. ASK WHAT THE 
MOTHER DID AND WHO SHE SOUGHT CARE FROM DURING ALL OF THESE TIMES.  
 
FIRST ASK “Could you tell me about the pregnancy for this child”? 
 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________ 
 
THEN ASK “Could you tell me about the labour and delivery for this child”? 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
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__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
________________________ 
 
THEN ASK “Could you tell me what the baby was like at birth”?  
 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
________________________________ 
THEN ASK “Could you tell me about what happened to the child immediately after delivery”? [IN THIS 
QUESTION WE WANT TO KNOW WHAT HAPPENED TO THE BABY IMMEDIATELY AFTER DELIVERY. 
THAT IS IF THE BABY NEEDED ANY TREATMENT OR SPECIAL CARE AS SOON AS HE/SHE WAS 
BORN.’] 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
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__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
________________________________ 
 
THEN FOR LIVE BIRTHS ONLY ASK “Could you tell me about the child’s illness or accident that led to 
death?” [IF STILLBIRTH PUT A DOUBLE LINE THROUGH THIS SECTION] 
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
__________________________________________________________________________________________
____________ 
 
5.2 Cause of death 
 
NOW PLEASE ASK THE RESPONDENT “What do you think was the cause of death?  
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5.2.1 Cause of death 1   
COD1 
 
5.2.2 Cause of death 2   
COD2 
 
 
6. DETAILS OF PREGNANCY, LABOUR AND DELIVERY 
 
COMPLETE THIS SECTION FOR ALL INFANTS 
 
PLEASE TELL THE RESPONDENT THAT YOU WOULD LIKE TO ASK SOME QUESTIONS 
CONCERNING THE MOTHER AND SYMPTOMS THAT THE DECEASED HAD/SHOWED AT BIRTH 
AND SHORTLY AFTER. PLEASE SAY THAT SOME OF THESE QUESTIONS MAY NOT APPEAR 
TO BE DIRECTLY RELATED TO THE BABY'S DEATH BUT ASK THE RESPONDENT TO PLEASE 
BEAR WITH YOU AND ANSWER ALL THE QUESTIONS. THEY WILL HELP US TO GET A CLEAR 
PICTURE OF ALL POSSIBLE SYMPTOMS THAT THE DECEASED HAD.  
 
6.1. Pregnancy 
6.1.1. How many births including stillbirths did the mother have before this baby? 
1. None 2. One 3. Two 4. Three 5. Four 6. Five or more 
 
8. NK PARITY 
 
6.1.2. Did the mother receive vaccinations since reaching adulthood 
including during this pregnancy?.................................................................... 
1. Yes 2. No 8. NK VACCINATEFULL 
 
6.1.3. How many doses of 
vaccine?... 
 
1. One 2. 
Two 
3. Three 4. 
Four 
5. Five or 
more 
8. NK VACCINDOSE 
 
6.1.4. Did the mother receive tetanus toxoid during this pregnancy?............. 1. Yes 2. No 8. NK TTOXOID 
 
6.1.5. How many tetanus toxoid immunisations did you receive during that pregnancy? 
 [00 = NONE, 88 = NK, ASK TO SEE ANY MEDICAL RECORDS, YELLOW CARD]… 
  TETTOXD 
 
 
6.1.6. How many tetanus toxoid immunisations have you ever received before that pregnancy?  
 [00 = NONE, 88 = NK, ASK TO SEE ANY MEDICAL RECORDS, YELLOW CARD]…......... 
  TETTOXB 
 
 
6.1.7. How many times did you receive antenatal care from a doctor or nurse during that  
          pregnancy? 
[ 00 = NONE, 88=NK, ASK TO SEE ANTENATAL CARE RECORD, EXCLUDE ILLNESS] 
  ANC 
 
6.1.8. During pregnancy did the mother suffer from high blood pressure? …... 1. Yes 2. No 8. NK HIBPPREG 
 
6.1.8.1. Was this in the last 3 months of pregnancy?......................................... 1. Yes 2. No 8. NK LATEPREGBP 
6.1.9. During pregnancy did the mother suffer from excessive vaginal 
bleeding?................................................................................................................  
1. Yes 2. No 8. NK VAGBLEED 
 
6.1.9.1.Was this during the first 6 months of pregnancy? ............................... 1. Yes 2. No 8. NK EARLYVAGBLEED 
 
6.1.9.2.Was this during the last 3 months of pregnancy? ….............................. 1. Yes 2. No 8. NK BLEED3MTHS 
 
6.1.10. At any time during the pregnancy did the mother ever have foul 
smelling vaginal discharge? …............................................................................ 
1. Yes 2. No 8. NK VAGDISC 
 
6.1.10.1.Was this during the last 3 months of pregnancy? ….............................. 1. Yes 2. No 8. NK DISCHARGE 
 
6.1.11. At any time during the pregnancy did the mother ever suffer from 
blurred vision? …..................................................................................................  
1. Yes 2. No 8. NK BLURVIS 
 
 
 
 Did any of the following problems occur during the late part of that pregnancy (last 3 months)?  
6.1.12. Diabetes?................................................................................................  1. Yes 2 No 8. NK DIABETES 
6.1.13. Asthma?....................................................................................................  1. Yes 2 No 8. NK ASTHMA 
6.1.14. Epilepsy?..................................................................................................  1. Yes 2 No 8. NK EPILEPSY 
6.1.15. Malnutrition?............................................................................................  1. Yes 2 No 8. NK MALNUT 
6.1.16. Obesity?....................................................................................................  1. Yes 2 No 8. NK OBESITY 
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6.1.17. Cancer?.....................................................................................................  1. Yes 2 No 8. NK CANCER 
6.1.18. Tuberculosis?...........................................................................................  1. Yes 2 No 8. NK TB 
6.1.19. Sickle cell disease?................................................................................... 1. Yes 2 No 8. NK SICKLE 
6.1.20. Heart Disease?........................................................................................  1. Yes 2 No 8. NK HEART_DIS 
6.1.21. Chronic obstructive pulmonary disease?............................................... 1. Yes 2 No 8. NK COPD 
6.1.22. Dementia?...............................................................................................  1. Yes 2 No 8. NK DEMENTIA 
6.1.23. Depression?............................................................................................  1. Yes 2 No 8. NK DEPRESS 
6.1.24. Stroke?....................................................................................................  1. Yes 2 No 8. NK STROKE 
6.1.25. Arthritis?.................................................................................................  1. Yes 2 No 8. NK ARTHRITIS 
6.1.26. Kidney disease?......................................................................................  1. Yes 2 No 8. NK KIDNEY 
6.1.27. Liver disease?........................................................................... .............. 1. Yes 2 No 8. NK LIVER 
6.1.28. Any bleeding from the vagina?.................................................................. 1. Yes 2 No 8. NK PBLEED 
 
6.1.29. Any vaginal discharge that was abnormal or worrying (because smelly  
          or too much)?...........................................................................................  
1. Yes 2 No 8. NK PDISCHARGE 
 
6.1.30. Health worker tested the blood and said you were short of blood?… 1. Yes 2 No 8. NK PANAEMIA 
 
6.1.31. Health worker said you had malaria…………………………….……… 1. Yes 2. No 8. NK PMALARIA 
 
6.1.32. Health worker said you had jaundice………………………….……….. 1. Yes 2 No 8. NK PJAUNDICE 
 
6.1.33. Severe or persistent abdominal or back pain that was not labour pain… 1. Yes 2 No 8. NK PLONGPAIN 
 
 
6.1.34. Health worker said you had diabetes ………………………….…..…… 1. Yes 2 No 8. NK PDIABETES 
 
 
6.1.35. Positive syphilis test……………………………………….……………. 1. Yes 2 No 8. NK PSYPHILIS 
 
6.1.36. Genital ulcer…………………………………………………………….. 1. Yes 2 No 8. NK PULCER 
 
6.1.37. Hand or facial swelling, or rapid leg swelling……………….…….…… 1. Yes 2 No 8. NK PFACE 
 
6.1.39. Blurring of vision and severe headache………………………….…….. 1. Yes 2 No 8. NK PBLUREYE 
 
 
6.1.40. Severe headache?................................................................................... 1. Yes 2 No 8. NK 
HEADACHE 
6.1.41. Health worker measured the blood pressure and told you it was high… 1. Yes 2 No 8. NK PHIGHBP 
 
6.1.42. Convulsions like in children…………………………………………… 1. Yes 2 No 8. NK PCONVULSE 
 
6.1.43. “Anidane”……………………………………………………………… 1. Yes 2 No 8. NK PANIDANE 
 
6.1.44. Afam /Atare? ….…………………………….……...…………………… 1. Yes 2 No 8. NK PAFAM 
 
6.1.45. Pallor and shortness of breath (both present)……..………...…….…… 1. Yes 2. No 8. NK PALLOR 
 
6.1.46. Puffy face…...........................................................................................  1. Yes 2 No 8. NK PUFFY 
 
6.1.47. Other:……………………………………………………………………. 1. Yes 2. No 8. NK POTHER 
 
6.1.47.1. If other, please specify[NA=DOUBLE LINE]  
 
OTHERSP_ILL 
 
6.2. Labour and delivery 
6.2.1. Was the baby born more than one month early?................................. 1. Yes 2 No 8. NK PREMATURE 
 
6.2.2. Did this child’s pregnancy end early on time or late? ............. 1. Early 2.On 
time 
3. Late 8. NK PREMBAB 
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6.2.3. How many months pregnant were you when the baby was born? [88 = NK] 
......……………………………… 
 
 
 
GESTATE 
 
6.2.4. Was the baby moving in the last few days before birth?   
[9 = NA, respondent not biological mother]......................................................... 
1. Yes 2. No 
 
8. NK BABMOVE 
6.2.5. If the baby stopped moving when did this  
           happen? ........................................................... 
11. Before labour 
started 
12. During 
labour 
88. NK 99. NA MOVWHEN 
 
6.2.6. How many hours before delivery did the baby last move? 
            [00 = baby last moved during labour or delivery; 88 = not known]………...………… 
  MOVDAY 
 
 
  LASTMOVEHRS 
6.2.7. How many days before delivery did the baby last move?  
[DAYS, 00 = baby last moved during labour or delivery; 88 = not known].......................... 
  MOVDAY 
 
 
6.2.8. Did the waters break before labour or during labour? 
1. Before labour /delivery started 2. During labour / delivery 8. NK WATERBRK 
 
6.2.9. Was the baby born 24 hours or more after the water broke?....................... 1. Yes 2 No 8. NK WATERBRK24 
 
 
6.2.10. How much time before labour started did the waters break? 
1. Less than 4 
hours 
2. 4 to 23 
hours 
3. 24 hours or 
more 
8. NK 9. NA, broke during labour 
delivery 
TIMEBRK 
 
 
6.2.11. What was the colour of the liquor when the waters broke? 
1. Green or brown 2. Clear or normal 3. Other, SPECIFY: 8. NK LIQUORC 
 
 
6.2.12. Was the liquor foul-smelling?.................................................................... 1. Yes 2 No 8. NK LIQUORS 
 
 
6.2.13. How long did the labor pains last [88 = not known; 99 = NA, CS]…….....................  
 
 LABDURATN 
 
6.2.14. How long in hours was the labour before the baby was born ?  
88 = not known; 99 = NA, C-section]………………………....................................... 
  LABHOURS 
 
 
 
6.2.15. Did you have problems during the delivery?............................................ 1. Yes 2 No 8. NK COMPDEL 
 
 
5.2.6. Was there excess bleeding on the day labour started? 
................................................ 
1. Yes 2. No 8. NK XSBLEED 
 
6.2.16.1. Heavy bleeding before labour started?................................................... 1. Yes 2. No 8. NK BLDB4LABOR 
6.2.16.2. Heavy bleeding during labour?.............................................................. 1. Yes 2. No 8. NK BLDDURLABOR 
 
6.2.17. Heavy bleeding after delivery………............................………………… 1. Yes 2. No 8. NK DBLEED 
 
 
 
6.2.18. Did the mother have a fever on the day labour started? ........................... 1. Yes 2. No 8. NK DELFEVER 
 
 
Did any of the following problems occur during labour or delivery? [DELIVERY INCLUDES C-SECTION] 
6.2.19. Health worker measured the blood pressure and told you it was high 1. Yes 2 No 8. NK DHIGHBP 
 
6.2.20. Convulsions like in children……………………………………………. 1. Yes 2 No 8. NK DCONVULSE 
 
6.2.21. Fever during labour………………………………….……..…………… 1. Yes 2 No 8. NK DFEVER 
 
6.2.22. Umbilical cord delivered before the baby………………………………. 1. Yes 2. No 8. NK DPROLAPSE 
 
6.2.23. Umbilical cord around the baby’s neck…………………………………. 1. Yes 2. No 8. NK DCORDNECK 
 
6.2.24. Did somebody put their hand inside the womb to remove the placenta?.. 1. Yes 2. No 8. NK DRETPLAC 
 
6.2.25. Other, specify: _____________________________________________ 1. Yes 2. No 8. NK DOTHER 
 
6.2.26 Where did the birth take place? 
1. Clinic/hospital 2. Private maternity home 6. Other health facility 
 
PLACEBIR 
 
4. On the way to  
   the clinic/hospital 
3. At home (e.g. woman’s 
    or anyone’s home) 
5. Other, SPECIFY: 8. NK  
6.2.27. IF THE ANSWER TO 5.2.14. IS 1, 2 or 3, STATE WHERE.  
[USE FACILITY KEY CODE; OTHERWISE ANSWER 99]...………………………… 
  HOSPITAL 
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6.2.28. Was medicine given to make the labour start? ..……………................. 1. Yes 2. No 8. NK AUGMENT1 
 
6.2.29. Was medicine given after labour had already started to make the labour 
progress more quickly? ........................................................................................ 
1. Yes 2. No 8. NK AUGMENT2 
 
 
6.2.30. Was it a normal delivery through the vagina? TYPEDELIV 
1. Normally through 
vagina 
2. Baby was pulled with 
instrument 
3. By C-section 4. Other, SPECIFY:  
 
 
6.2.31. Did you know it was going to be a C-section before labour? 
......................................................................................................................... 
1. Yes 2. No 9. NA,  
No CS 
KNOWCS 
 
 
6.2.32. Who delivered the baby? 
1. Doctor 2. Midwife or nurse  3. Trained TBA 7. Untrained TBA 6. Medical assistant 
 
WHODELIV 
5. Self 9. Relative 4. Other, SPECIFY: 8. NK 
 
 
 
6.2.33. Did a birth attendant listen for fetal heart sounds during labour? .......... 1. Yes 2. No 8. NK LISTEN 
 
62.35. If yes then were they present? ...........…............... 1. Yes 2. No 8. NK 9. NA PRESENT 
 
 
6.2.36. Was the baby abnormally positioned (lying across or bottom first or 
‘breech’ ) before the time of delivery? 
1. Yes 2 No 8. NK POSITIONDEL 
 
 
6.2.37. Which part of the baby came out first? 
1. Head 2. Bottom 4. Feet 5. Hand/arm BPOSN 
 
6. More than one body part (e.g. bottom and foot) 3. C-Section 8. NK  
 
6.3. Status of the baby at the delivery 
 
6.3.1. At what time of the day was the baby delivered? 
1. 5am-7am 2. 8am-12pm 3. 1pm-4pm 4. 5pm-8pm 5. 9pm-1am 6. 2am-4am    TIMEDAY 
 
 
6.3.2. What was used to cut the umbilical cord? 
1. Clinic/hospital instrument: scissors, razorblade, knife,etc 2. New razorblade/knife(not from clinic/hospital) CORDCUT 
 
3. Old razor blade/knife (not from clinic/hospital) 4. Other: 8. NK  
 
 
6.3.3. Was the baby born alive or dead? ...................... 1. Alive  2. Dead 8. NK BORNALIVE 
 
6.3.4. Did the baby ever breathe after birth? ......................................................... 1. Yes 2. No 8. NK BREATHB 
 
6.3.5. Was anything done to try to help the baby breathe at birth? ....................... 1. Yes 2. No 8. NK BREATHAS 
 
6.3.6. Did the baby have difficulty in breathing after birth?…..……............…. 1. Yes 2 No 8. NK DIFFBRATBIRTH 
 
 
 
6.3.7. Did the baby ever move after birth?................................................................ 1. Yes 2. No 8. NK MOVEB 
 
 
6.3.8. Did the baby ever cry after birth?  .............................................................. 1. Yes 2 No 8. NK CRYB 
 
 
6.3.8.1. How long after birth did the baby first breathe? 
1. Within 5 min 2. Within 5-30 min 3. More than 30 min 8. NK 
9. NA/Baby never breathed after 
birth 
FIRSTB 
 
 
6.3.8.2. How long after birth did the baby first cry?  
1. Within 5 min 2. Within 5-30 min 3. More than 30 min 8. NK 9. NA/Baby never cried after birth 
FIRSTCRY 
 
 
6.3.9. How big was the baby when he/she was born? [PROMPT] 
1. Tiny 2. Smaller than average 3. Average  4. Larger than most babies 5. Very big baby 8. NK SIZE 
 
 
6.3.10. RECORD BIRTHWEIGHT. [IN KILOGRAMS; 888 = NO RECORD] [ASK 
FOR ANC RECORD/DISCHARGE SLIP/WEIGHING CARD/HEALTH RECORD] 
 .   BIRTHWT 
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6.3.11. Were there any bruises or marks of injury on the baby’s body at birth?... 1. Yes 2 No 8. NK INJURY 
 
 
6.3.12. If yes then where were the marks or signs of injury or broken bones? 
1. Head 2. Shoulder 3. Hips SITEINJ 
 
4. Face 5. Others, SPECIFY:  9. NA  
 
6.3.13. Were there any signs of paralysis at birth?................................................ 1. Yes 2. No 8. NK BIRPARAL 
 
6.3.14. Was the baby’s body macerated (skin and tissue was soft and pulpy)?.... 1. Yes 2. No 8. NK MACER 
 
6.3.15. Did he/she have any congenital abnormalities at delivery? ..................... 1. Yes 2. No 8. NK ANOMALY 
 
6.3.15.1. Was the head size very small at the time of birth? ................................ 1. Yes 2. No 8. NK ANENC 
 
6.3.15. 2. Was the head size very large at the time of birth? .............................. 1. Yes 2. No 8. NK HYDRO 
 
6.3.15.3. Was there a mass or defect on the back of the head or spine?  1. Yes 2. No 8. NK BIFIDA 
6.3.15.4. Was there any cleft lip or palate? .............................................. 1. Yes 2. No 8. NK CLEFT 
 
6.3.15.5.  Were there any (other) limb defects? .................................................. 1. Yes 2. No 8. NK DEFECT 
 
6.3.15.6. Were there any other malformations?..................................................... 1. Yes 2. No 8. NK OTHMALF 
 
6.3.15.6.1. If yes, specify......................................  
 
OTHMALFSPEC 
6.3.15.7. What was the colour of the baby at birth?  
1. Normal 2. Pale 3. Blue 6. Other, SPECIFY:  
COLBIRTH 
 
 
6.3.15.8. Did the baby become unresponsive or unconscious soon after birth 
(within 24 hours)?..............................................................................................  
1. Yes 2 No 8. NK UNCONS 
 
 
7. NEONATAL AND POSTNEONATAL DEATHS – DETAILS OF FATAL ILLNESS 
 
FOR STILLBIRTHS, PUT A DOUBLE LINE THROUGH SECTIONS 7-10 AND GO TO SECTION 11.  
 
7.1. General  
 
7.1.1. On the day of birth was NAME well?............................................................. 1. Yes 2 No 8. NK DAYWELL 
 
 
7.1.2. How old was NAME at the time the fatal illness started? [ANSWER EITHER 6.1.2.1. OR 6.1.2.2] 
7.1.2.1. IN DAYS [888 = NK, 999=NA, 000 = illness started at birth] ..................    
AGEILLD 
 
OR 
7.1.2.2. IN MONTHS [88 = NK, 99=NA, 00 = illness started at birth] ................................   
AGEILLM 
 
 
7.1.3. How old was NAME at the time of death? [ANSWER EITHER 6.1.3.1. OR 6.1.3.2]. 
7.1.3.1. IN DAYS. [888 = NK, 999=NA] .............................................................    
AGEDIEDD 
 
OR 
7.1.3.2. IN MONTHS [88 = NK, 99=NA] ............................................................................    
AGEDIEDM 
 
 
7.1.4. Was NAME able to cry after birth? ............................................................. 1. Yes 2. No 8. NK CRYNORM 
 
7.1.5. Did NAME stop being able to cry? ............................ 1. Yes 2 No 8. NK 9. NA CRYSTOP 
 
7.1.6. How long did he/she stop crying last in days? (in days) 
[000 = less than 1 day; 888 = not known; 999 = NA, did not stop crying]…...... 
   CRYDAYS 
 
7.1.7. Was NAME growing normally for his/her age?............................ 1. Yes 2. No 8. NK GROW 
 
7.1.8. Did NAME get more sicknesses or illnesses than other children in the  
       family or in the community? ............................................................................ 
1. Yes 2. No 8. NK SICKNESS 
 
 
7.2. Feeding 
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7.2.1. Was the baby ever able to suckle of bottle feed with a cup or spoon? 
................................................................................................................. 
1. Yes 2. No 8. NK SUCKLE 
 
 
7.2.2. How soon after birth did the baby suckle or bottlefeed or feed with a cup /cup and spoon? 
              IN HOURS [888=NOT KNOWN 999=NA]...........................................    FHOURS 
 
              IN DAYS [888=NOT KNOWN 999=NA]..............................................    FDAYS 
 
 
7.2.3. Did the baby stop suckling or bottle feeding or feeding with a 
cup or spoon?................................................ 
1. Yes 2. No 8. NK 9. NA SSUCK 
 
7.2.4. Was the baby able to open his/her mouth at this time?............... 1. Yes 2 No 8. NK 9 NA OPENMOUTH 
 
 
7.2.5. How soon after birth did the baby stop feeding? 
              IN HOURS [888=NOT KNOWN 999=NA]...........................................    SHOURS 
 
              IN DAYS [888=NOT KNOWN 999=NA]..............................................    SDAYS 
 
7.2.6. How soon before s/he died did the baby stop feeding? 
              IN DAYS 00 < 24 HRS; 88=NOT KNOWN 99=NA…………................................  
 
 TIMENOSUCKLE 
 
 
7.2.7. Was the breastfeeding exclusive (In other words was the baby 
given only breast milk and nothing else except vitamins, medicines, 
or ORS)? 
1. Yes 2. No 8. NK 9. NA EBF 
 
7.2.8. Was the child growing normally during the illness that led to death? .......... 1. Yes 2. No 8. NK GROWTH 
 
7.2.9. Did s/he have weight loss? ............................................................................. 1. Yes 2. No 8. NK WTLOSS 
 
7.2.10. For how many days did s/he have weight loss? [IN DAYS, 000 = less 
than 1 day; 888 = not known; 999 = NA, no weight loss]....................................... 
   WTLOSSD  
7.2.11. Did s/he look very thin / wasted?............................................................... 1. Yes 2. No 8. NK FTHIN 
 
 
7.3. Breathing 
 
7.3.1. During the illness that led to death, did NAME have a cough? .................... 1. Yes 2. No 8. NK COUGH 
 
7.3.2. If NAME had a cough, was this severe? ...................................... 1. Yes 2. No 8. NK 9.NA COUGHS 
 
7.3.2.1. Did the child vomit after coughing? ...................................... 1. Yes 2. No 8. NK 9.NA COUGHV 
 
7.3.3 . How many days after birth did the baby start to cough?           
[000 = less than 1 day; 888 = not known; 999 = NA, no cough].......................... 
   COUGHD 
 
7.3.3.1. How long did the cough last in days? (in days)  
[00 = less than 1 day; 88 = not known; 99 = NA, no cough].................................................. 
  COUGHLEN 
 
7.3.4. How many days before death did the baby start to cough?   
1. On the 
same day of 
death 
2. 1 to 3 days 
before death 
3. 4 to 7 days 
before death 
4. More than 1 week 
but within 1 month of 
death 
5. More than 1 
month before death 
8. NK 9. NA COUGHSTART 
 
7.3.6. During the illness that led to death, did NAME have difficult breathing? .... 1. Yes 2. No 8. NK DIFFBR 
 
7.3.7. How old was NAME when the difficult breathing started? (in days)  
[000 = Just born or less than 1 day; 888 = not known; 999 = NA, no difficulty 
breathing]............................................................................................................  
   DIFFBRDAY 
 
7.3.8. For how long before s/he died did the baby have difficulty breathing?  
[00 less than 24 hours; 88 NK; 99 NA]................................................................. 
  TIMEDYSPN 
7.3.9. How long did the difficult breathing last? (in days) 
[00 = less than 1 day; 88 = not known; 99 = NA, no difficulty breathing]............................. 
  DIFFBRNUM 
 
7.3.10. During the illness that led to death, did NAME have breathlessness?......... 
 
1. Yes 2 No 8. NK BREATHLESS 
7.3.10.1 For how long did s/he have breathlessness (in 
days)?....................................................... 
 
 
 BRLESSDURATN 
7.3.11. During the illness that led to death, did NAME have fast breathing? ........ 1. Yes 2. No 8. NK FASTBR 
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7.3.12. How old was NAME in days when the fast breathing started? (IN DAYS) 
[000 = Just born or less than 1 day; 888 = not known; 999 = NA, no fast 
breathing]................................................................................................................  
   FASTBRDAY 
 
7.3.13. How long did the fast breathing last in days? (in days) 
[00 = less than 1 day; 88 = not known; 99 = NA, no fast breathing]...................................... 
  FASTBRNUM 
 
7.3.14. During the illness that led to death did NAME have chest indrawing?.... 1. Yes 2. No 8. NK INDRAW 
 
7.3.14.1. For how long did s/he have chest indrawing? (IN DAYS) 
[000 = less than 1 day; 888 = not known; 999 = NA, no indrawing].................... 
   COUGHIN 
 
7.3.15. During the illness that led to death, did NAME make a whooping sound 
when coughing?.....................................................................................................  
1. Yes 2 No 8. NK WHOOP 
 
7.3.16. During the illness that led to death, did he/she have grunting? 
[DEMONSTRATE]................................................................................................. 
1. Yes 2. No 8. NK GRUNT 
 
7.3.17. During the illness that led to death, did his/her nostrils flare with  
breathing? ...................................................................................................................... 
1. Yes 2. No 8. NK FLARE 
 
7.3.18. During the illness that led to death, did NAME ever stop breathing for a 
long time and start again? ….............................................………………..………. 
1. Yes 2. No 8. NK APNOEA 
7.3.19. During the illness that led to death, did he/she have “pneumonia”?.......... 1. Yes 2 No 8. NK PNEU 
 
 
7.4. Neurological problems 
7.4.1. During the illness that led to death did NAME have convulsions? .............. 1. Yes 2 No 8. NK IFIT 
 
7.4.1.1. How soon after birth did the convulsions start? (IN DAYS)  
[000 = less than 1 day; 888 = not known; 999 = NA, no convulsions].................... 
   FITSTART 
 
7.4.1.2. For how long in days did they have convulsions? (IN DAYS)  
[00 = less than 1 day; 88 = not known; 99 = NA, no fits, spasms or convulsions]................... 
  FITDAY 
 
7.4.1.3. Did s/he become unconscious immediately after the convulsion?........... 1. Yes 2 No 8. NK FITCONSC 
 
7.4.2. Did the baby become stiff and arched backwards? ....................................... 1. Yes 2. No 8.NK ARCH 
 
7.4.3. During the illness that led to death, did he/she have a bulging fontanelle?  1. Yes 2 No 8. NK BULGE 
 
7.4.3.1. How soon after birth did the bulging fontanelle start?  
[000 = less than 1 day; 888 = not known; 999 = NA, no bulging] ....................... 
   BULGES 
 
7.4.3.2. For how many days before death did s/he have the bulging? 
 [00 = less than 1 day; 88 = not known; 99 = NA, no bulging] ............................ 
  BULGED 
 
7.4.4. During the illness that led to death, did he/she have “tetanus”? ...…......... 1. Yes 2 No 8. NK TETANUS 
 
7.4.5. During the illness that led to death, did NAME become unresponsive or  
          unconscious? ................................................................................................. 
1. Yes 2 No 8. NK COMA 
 
7.4.5.1. How soon after birth did NAME become unresponsive or 
unconscious?[000 = less than 1 day; 888 = not known; 999 = NA, no coma] 
   COMAS 
 
7.4.5.2. How long was s/he unresponsive or unconscious? 
 [00 = less than 1 day; 88 = not known; 99 = NA, no coma] .................................................... 
  COMAL 
 
7.4.5.3. Did the unconsciousness start suddenly quickly within a single day or slowly over many days?  
1. Suddenly 2. Over a single day 3. Slowly over many days  8. NK 9. NA 
COMAON 
 
 
7.5. Skin problems  
7.5.1. When you gave birth to the baby, how long did it take you or someone else to dry the baby? 
1. Within 30 minutes of birth 2. 30 minutes or later 3. The baby was never dried 8. NK DRY 
 
 
7.5.2. When you gave birth to the baby, how long did it take you or someone else to wrap the baby? 
1. Within 30 minutes of birth 2. 30 minutes or later 3. The baby was never wrapped 8. NK WRAP 
 
 
7.5.3. From the time you gave birth to the baby till it died, what did you put on the cord? 
1. Nothing, left it 
alone 
2. Hospital / clinic 
medicine 
3. Shea butter  4. Leaves or herbs 5. Palm oil CORDMED 
6. Ground nut oil 7. Other:  8. NK  
 
7.5.4. During the illness that led to death, did he/she have redness of, or  
            drainage from the umbilical cord stump?...............................................  
1. Yes 2. No 8. NK DRAINUMB 
 
7.5.5. During the illness that led to death, did he/she have redness of the 
umbilical cord stump?............................................................................................  
1. Yes 2 No 
 
8. NK UBMILICRED 
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7.5.6. If yes, did the redness of the umbilical cord stump extend on to 
the abdominal skin?................................................................... 
1. Yes 2 No 
 
8. NK 9. NA UMBILICSKINR
ED 
7.5.7. During the illness that led to death, did he/she have pus discharging from 
the umbilical cord stump?............................................................................ 
1. Yes 2 No 
 
8. NK UMBILICALPUS 
7.5.8. Was anything applied to the umbilical cord stump after birth? .................... 1. Yes 2. No 8. NK APPLUMB 
 
If yes, what was it? 
7.5.8.1. Chlorhexidine? ........................................................................ 1. Yes 2. No 8. NK 9. NA CHLOR 
 
7.5.8.2. Gentian violet paint/ blue paint? ............................................. 1. Yes 2. No 8. NK 9. NA BLUE 
 
7.5.8.3. Other, specify: ___________________________________ 1. Yes 2. No 8. NK 9. NA OTHAPPL 
 
7.5.9. During the illness that led to death, were there any of the following on the baby’s skin: 
Bumps containing pus?............................................................................... 1. Yes 2. No 8. NK PUSTULE 
 
Blisters?...................................................................................... ................. 1. Yes 2. No 8. NK BLISTER 
 
Single large area of pus?............................................................................ 1. Yes 2. No 8. NK EMPYEMA 
 
Redness with swelling?............................................................................... 1. Yes 2. No 8. NK ERYTHEMA 
 
Areas of skin that were hot or peeling?...................................................... 1. Yes 2. No 8. NK SRED 
 
Areas of skin that turned black?................................................................. 1. Yes 2 No 8. NK BLACKSKIN 
 
7.5.10. For how long did the baby have skin bumps containing pus or a single area with 
pus? [01 to 28, 88 NK, 99 NA]...............................................................................................  
  PUSTULEDURAT 
 
 
7.6. Diarrhoea and abdominal symptoms 
 
7.6.1. During the illness that led to death did he/she have any abdominal 
problems?...............................................................................................................  
1. Yes 2 No 8. NK ABDPROB 
 
7.6.2. During the illness that led to death did he/she have frequent loose or  
 liquid stools? .....................................................................................................  
1. Yes 2.  No 8. NK STOOLS 
 
7.6.3. During the illness that led to death did he/she have “diarrhoea”?............. .... 1. Yes 2 No 8. NK DIARR 
 
7.6.4. How long before death did the loose or liquid stools start? (IN DAYS) 
[00 = less than 1 day; 88 = not known; 99 = NA, no loose or liquid stools]…… 
   DIARRSTART 
 
7.6.5. How long did NAME have loose or liquid stools in days? (IN DAYS)  
[000 = less than 1 day; 888 = not known; 999 = NA, no loose or liquid stools].. 
   DIARRDAY 
 
7.6.6. How many stools did he/she have on the day that the diarrhoea / loose or liquid stools 
was most frequent? (IN DAYS) [88 = Not known, 99 = NA / Did not have diarrhoea] 
  
NUMDIARR 
7.6.7. Do you feel that this represented more loose or liquid stools than 
usual for the child? [9 = NA / Did not have diarrhoea]............... 
1. Yes 2. No 8. NK 
 
9. NA DIARRNORM 
7.6.8. During the illness that led to death, was there visible blood in  
the loose or liquid stools? [9 = NA / Did not have diarrhoea].............. 
1. Yes 2 No 
 
8. NK 9. NA BLDIARR 
7.6.9. During the illness that led to death, did he/she have swelling/distension  
of the abdomen? ...................................................................................... 
1. Yes 2. No 8. NK SWABDO 
 
7.6.10. How many days after birth did the baby start to have swelling of the 
abdomen? [000=less than 1 day; 888=not known; 999=NA, no swelling].............. 
   SWABDOD 
 
7.6.11. For how long did s/he have swelling of the abdomen?  
[00 = less than 1 day; 88 = not known; 99 = NA, no swelling]................................................ 
  SWABDOL 
 
7.6.12. Did the swelling develop rapidly within days or 
gradually over months? .................................................. 
1. Rapidly 
over days 
2. Slowly over 
months 
8.NK 9.NA SWABDOR 
 
7.6.13. Did s/he have a mass in the abdomen? ........................................................ 1. Yes 2. No 8. NK MASS 
 
7.6.14. For how long did s/he have a mass in the abdomen?  
[00 = less than 1 day; 88 = not known; 99 = NA, no mass]...................................................... 
  MASSL 
 
7.6.15. Was there a period of a day or longer when s/he did not pass any stools? . 1. Yes 2. No 8. NK CONSTIP 
 
7.6.16. During the illness that led to death, did he/she vomit everything?............... 1. Yes 2. No 8. NK IVOMIT 
 
7.6.17.1. How many days after birth did the baby start to vomit?  
[000 = less than 1 day; 888 = not known; 999 = NA, no vomiting]...................... 
   WHOVOMIT 
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7.6.17.2. When the vomiting was most severe, how many times did the baby vomit in a 
day? [000 = less than 1 day; 88 = not known; 99 = NA, no vomiting]........ 
  WHOVDAY 
 
7.6.18. Did s/he vomit “coffee grounds” or bright red / blood?............................ 1. Yes 2 No 8. NK VOMBLOOD 
 
7.7 Injury 
 
7.7.1. Did NAME die from an injury, accident, poisoning, bite, burn, or  
drowning that led to his / her death?.................................................................. 
1. Yes 2. No 8. NK INJURY1 
 
IF THE INFANT DID NOT SUSTAIN AN INJURY THAT LED TO HER DEATH, DRAW A DOUBLE LINE 
THROUGH QUESTIONS 7.7.1.1 TO 7.7.15 AND MOVE STRAIGHT TO SECTION 7.8 OTHER PROBLEMS. 
 
7.7.1.1. Was the injury or accident intentionally inflicted by someone 
else?........................................................................................................ 
 
1. Yes 2 No 8. NK 9. NA INTENTINJ 
 
7.7.2. Was it a road traffic accident?...................................................... 1. Yes 2 No 8. NK 9.NA RTA 
IF NO DRAW A DOUBLE LINE THROUGH Q7.7.2.1 TO Q7.7.2.6.8 AND CONTINUE WITH Q7.7.3. 
If yes:      
7.7.2.1. Was she injured as an occupant in a vehicle (car)?.................... 1. Yes 2 No 8. NK 9.NA CAR 
7.7.2.2 Was she injured as an occupant in a bus or heavy transport?...... 1. Yes 2 No 8. NK 9.NA BUS 
7.7.2.3. Was she on a motorcycle?.......................................................... 1. Yes 2 No 8. NK 9.NA MOTO 
7.7.2.4. Was she on a pedal cycle?.......................................................... 1. Yes 2 No 8. NK 9.NA BIKE 
7.7.2.5. Was she being carried by a pedestrian?...................................... 1. Yes 2 No 8. NK 9.NA PED  
7.7.2.6. Do you know anything about the other vehicle / person hit in 
the road traffic 
.............................accident?.....................................................................
.................. 
1. Yes 2 No 8. NK 9.NA OTHVEH 
If yes, did the accident involve:      
7.7.2.6.1. A pedestrian?........................................................ 1. Yes 2 No 8. NK 9.NA OTHPED 
7.7.2.6.2. A stationary object?............................................... 1. Yes 2 No 8. NK 9.NA OTHSTAT 
7.7.2.6.3. A car?..................................................................... 1. Yes 2 No 8. NK 9.NA OTHCAR 
7.7.2.6.4. A bus or heavy transport vehicle?.......................... 1. Yes 2 No 8. NK 9.NA OTHBUS 
7.7.2.6.5. A motorcycle?......................................................... 1. Yes 2 No 8. NK 9.NA OTHMOTO 
7.7.2.6.6. A pedal cycle?........................................................ 1. Yes 2 No 8. NK 9.NA OTHBICY 
7.7.2.6.7. Something else? .................................................... 1. Yes 2 No 8. NK 9.NA OTHELSE 
7.7.2.6.8. If yes, specify.............  
 
OTHELSE2 
7.7.3. Was she injured in a non-road transport accident?....................... 1. Yes 2 No 8. NK 9.NA NONRTA 
7.7.4. Did she fall?.................................................................................. 1. Yes 2 No 8. NK 9.NA FALL 
7.7.5. Did she drown?............................................................................. 1. Yes 2 No 8. NK 9.NA DROWN 
7.7.6. Was she poisoned?........................................................................ 1. Yes 2 No 8. NK 9.NA POISONED 
7.7. 7. Did she die due to burns?............................................................. 1. Yes 2 No 8. NK 9.NA BURN 
7.7.8. Was she subject to violence or an assault?................................... 1. Yes 2 No 8. NK 9.NA ASSAULT 
7.7.8.1. Was she killed by a firearm / gun?.............................................. 1. Yes 2 No 8. NK 9.NA FIREARM 
7.7.8.2. Was she killed by a sharp object like a knife?............................ 1. Yes 2 No 8. NK 9.NA STAB 
7.7.8.3. Did she die as a result of some other assault or abuse?............. 1. Yes 2 No 8. NK 9.NA OTHASSAULT 
7.7.8.3.1. If yes, please specify...................  
 
OTHASSAULT2 
 
7.7.9. Did she suffer any animal / insect bite that led to her death?...... 1. Yes 2 No 8. NK 9.NA BITE 
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7.7.9.1. Did she die following a dog bite?............................................ 1. Yes 2 No 8. NK 9.NA DOG 
7.7.9.2. Did she die following a snake bite?......................................... 1. Yes 2 No 8. NK 9.NA SNAKE 
7.7.9.3. Did she die following an insect bite?....................................... 1. Yes 2 No 8. NK 9.NA INSECT 
7.7.9.4. Did she die following another animal bite or sting?................. 1. Yes 2 No 8. NK 9.NA OTHBITE 
7.7.9.4.1. If yes, please specify.................  
 
OTHBITE2 
7.7.10. Was s/he injured by a force of nature?........................................ 1. Yes 2 No 8. NK 9.NA NATURE 
7.7.11. Was s/he injured by machinery?.................................................. 1. Yes 2 No 8. NK 9.NA MACH 
7.7.12. Was s/he struck by an animal or object?...................................... 1. Yes 2 No 8. NK 9.NA ANIM 
7.7.13. Did she suffer from some other injury?....................................... 1. Yes 2 No 8. NK 9.NA OTHINJ 
7.7.13.1. If yes, please specify....................  
 
OTHINJ2 
 
7.7.14. How long did NAME survive after the injury, poisoning, bite, burn or drowning? 
1. Died within 24 hours 2. Died 1 day later or more 3. Died at the site of the accident DURINJ 
 
8. NK 9. NA no injury or accident    
 
7.7. 15. After the accident, did she receive medical care before she died?................. 1. Yes 2. No 8. NK MDCARE 
 
7.8. Other problems 
 
7.8.1. During the illness that led to death, did he/she have a fever?……………. 1. Yes 2. No 8. NK IFEVER 
 
7.8.1.1. Was the fever severe?…….................................................... 1. Yes 2. No 8. NK 9. NA FEVSEV 
 
7.8.1.2. Was the fever continuous or on and off?….......................... 1. Yes 2. No 8. NK 9. NA FEVINT 
 
7.8.1.3. Did s/he have chills or rigors?……....................................... 1. Yes 2. No 8. NK 9. NA RIGOR 
 
7.8.2. How old was NAME in days when the fever started?  
[000 = Just born or less than 1 day; 888 = not known; 999 = NA, no fever].......... 
   FEVERDAY 
 
7.8.3. How long did the fever last in days? (IN DAYS) 
[00 = less than 1 day; 88 = not known; 99 = NA, no fever]................................................... 
  FEVERNUM 
 
7.8.3.1. How long before death did this 
fever start?............................................. 
1. On the same day of death 2, 1 – 3 days before 
death 
4. 4 – 7 days 
before death 
FEVSTART 
4. More than one week before death 8. NK 9. NA  
7.8.4. During the illness that led to death, did NAME become cold to touch? ....... 1. Yes 2. No 8. NK COLD 
 
7.8.5. How old was NAME when he/she became become cold to touch? (IN 
DAYS) [000 = Just born or less than 1 day; 888 = not known; 999 = NA, did not 
feel cold]................................................................................................................... . 
   COLDDAY 
 
7.8.6. For how many days did NAME feel cold? (IN DAYS) 
[00 = less than 1 day; 88 = not known; 99 = NA, did not feel cold]......................................... 
  COLDNUM 
 
7.8.7. During the illness that led to death, did NAME become lethargic after  
a period of normal activity? ..................................................................................... 
1. Yes 2. No 8. NK LETHARGY 
 
7.8.8. During the illness that led to death, did NAME have jaundice? .................... 1. Yes 2. No 8. NK IJAUND 
 
7.8.8.1. Did s/he have yellow palms or soles? ..................................................... 1. Yes 2. No 8. NK JAUNDE 
 
7.8.8.2. Did the baby have yellow discoloration of the eyes? ................................. 1. Yes 2. No 8. NK JAUNDS 
 
7.8.8.3. How many days after birth did the yellow discolouration of the eyes 
begin? [000 = less than 1 day; 888 = not known; 999 = NA, no jaundice] ............. 
   JAUNDB 
 
7.8.8.4. For how many days did the yellow discolouration of the eyes last? 
 [00 = less than 1 day; 88 = not known; 99 = NA, no jaundice]............................................... 
  JAUNDL 
 
7.8.9. During the illness that led to death, did he/she have redness of and  
drainage of pus from the eyes?.................................................................................  
1. Yes 2. No 
 
8. NK CONJUNCT 
7.8.10. During the illness that led to death, did he/she bleed from anywhere?......... 1. Yes 2. No 8. NK HDN 
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7.8.11. During the illness that led to death, did he/she have a sunken fontanelle? 1. Yes 2 No 8. NK SUNKFONT 
 
7.8.12. Did NAME have an ongoing chronic illness or was he/she sick 
           before the accident or injury?.............................................. 
1. Yes 2. No 8. NK 9. NA INJURY2 
 
7.8.12.1. If yes, what was the illness? (Please refer to code list)...……………………………   CHRILL 
 
8. POSTNEONATAL DEATHS - ADDITIONAL QUESTIONS ABOUT THE FATAL ILLNESS 
 
COMPLETE THIS SECTION FOR POSTNEONATAL DEATHS ONLY. 
FOR NEONATAL DEATHS PUT A DOUBLE LINE THROUGH THIS SECTION AND GO TO 
SECTION 9.  
FOR STILLBIRTHS PUT A DOUBLE LINE THROUGH SECTIONS 8-10 AND GO TO SECTION 11.  
 
8.1. Nutrition 
 
8.1.1. During the illness that led to death, did NAME become very thin?............ 1. Yes 2. No 8. NK THIN 
 
8.1.2. Did NAME have “marasmus” during the month before he/she died?......... 1. Yes 2. No 8. NK MARASMUS 
 
8.1.3. During the illness that led to death, did NAME have swollen legs or  
          feet?............................................................................................................... 
1. Yes 2. No 8. NK SWELL 
 
8.1.4. How long did the swelling last in days? (IN DAYS) 
[00= less than 1 day; 88 = not known; 99 = NA, no swelling]............................................... 
  SWELLDAY 
 
8.1.5. During the illness that led to death, did NAME have a swollen face? .. 1. Yes 2. No 8. NK SFACE 
 
8.1.6. During the illness that led to death, did NAME have swollen joints? ........... 1. Yes 2. No 8. NK SJOINTS 
 
8.1.7. During the illness that led to death, did NAME have a swollen ankles? ..... 1. Yes 2. No 8. NK SANK 
 
8.1.8. During the illness that led to death, did NAME have swelling of the  
            whole body? ...............................................................................................  
1. Yes 2. No 8. NK SBODY 
8.1.9. For how long did the swelling last? (IN DAYS) 
 [00 = less than 1 day; 88= not known; 99 = NA, no swollen body]....................................... 
  SLAST 
8.1.10. During the illness that led to death, did NAME’s skin flake off in  
          patches? ........................................................................................................ 
1. Yes 2. No 8. NK FLAKE 
 
8.1.11. During the illness that led to death, did NAME’s hair change in colour  
          to a reddish (or yellowish) colour? ................................................................ 
1. Yes 2. No 8. NK COLOR 
 
8.1.11.1. For how long did s/he have reddish/yellowish hair?   
[00 = less than 1 day; 88 = NK; 99 = NA, no hair change]...................................................... 
  COLORD 
 
8.1.12. Did NAME have “kwashiorkor” during the month before he/she died?...... 1. Yes 2. No 8. NK KWASHIOR 
 
8.1.13. During the illness that led to death, did NAME have ‘lack of blood’ or  
          ‘pallor’?..........................................................................................................  
1. Yes 2. No 8. NK BABANAEM 
 
8.1.14. During the illness that led to death, did NAME have pale palms? ............. 1. Yes 2. No 8. NK BABPALE 
 
8.1.15. During the illness that led to death, did NAME have white nails? ............. 1. Yes 2. No 8. NK BABWNAIL 
 
8.1.16.  For how long did s/he look pale or have pale palms or white nails?  [00=less than 1 
day;88=not known;99=NA,none].............................................................................................. 
  BABANL 
 
 
8.2 Breathing 
 
8.2.1. During the illness that led to death, did he/she have noisy breathing?.......... 1. Yes 2. No 8. NK NOISE 
 
8.2.2. During the illness that led to death, did he/she have stridor?  
           [DEMONSTRATE]…..............................................................……………… 
1. Yes 2. No 
 
8. NK STRIDOR 
8.2.3. During the illness that led to death, did he/she have wheeze? 
         [DEMONSTRATE]?....................................................................................... 
1. Yes 2. No 
 
8. NK WHEEZE 
 
 
8.3 Neurological problems  
 
8.3.1 During the illness that led to death, did NAME have a stiff neck?................ 1. Yes 2. No 8. NK STIFFNECK 
 
8.3.2. For how long did she have a stiff neck 
[00 = less than 1 day; 01 to 28; 88 = not known; 99 = NA]..................................... 
  STIFFNECKDUR 
 
8.3.3. During the illness that led to death, did NAME stop being able to grasp?  1. Yes 2. No 8. NK GRASP 
 
8.3.4. How long before he/she died did NAME stop being able to grasp? 
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1. Less than 12 hours 2. 12 hours or more 8. NK 9. NA, did not start or stop grasping STOPGRASP 
 
 
8.3.5. Did s/he have a headache? ............................................................................. 1. Yes 2. No 8. NK HACHE 
 
8.3.6. Was the headache severe? ............................................................ 1. Yes 2. No 8. NK 9. NA HACHES 
 
8.3.7. For how long did the headache last? 
[00 = less than 1 day; 88= not known; 99 = NA, no headache]................................................. 
  HACHEL 
 
 
8.3.8. Did s/he have paralysis of the lower limbs? .................................................. 1. Yes 2. No 8. NK POLIO 
 
8.3.9. Did the paralysis start suddenly quickly within a single day or slowly over many days? 
1. Suddenly 2. Over a single day 3. Slowly over many days  8. NK 9. NA 
POLIOS 
 
 
 
8.3.10. During the illness that led to death, did NAME stop responding to a  
           voice?..........................................................................................................  
1. Yes 2. No 8. NK VOICE 
 
8.3.11. How long before he/she died did NAME stop being able to respond to a voice? 
1. Less than 12 hours 2. 12 hours or more 8. NK 9. NA, did not start or stop responding to voice STOPVOICE 
 
 
8.3.12. During the illness that led to death, did NAME stop being able to follow 
            movements with his/her eyes?.................................................................. 
1. Yes 2. No 
 
8. NK FOLLOW 
8.3.13. How long before he/she died did NAME stop being able to follow movements with his/her eyes? 
1. Less than 12 hours 2. 12 hours or more 8. NK 9. NA, did not start or stop following STOPFOLLOW 
 
 
8.4 Skin problems  
8.4.1. During the month before he/she died, did NAME have a skin rash? .......... 1. Yes 2. No 8. NK RASH 
 
8.4.2. Was the rash all over NAME’s body? ...................... 1. Yes 2. No 8. NK 9. NA no rash GENRASH 
 
8.4.3. Was the rash on NAME’s face? ..................... 1. Yes 2. No 8. NK 9. NA no rash FACRASH 
 
8.4.4. Was the rash on NAME’s trunk? ............................ 1. Yes 2. No 8. NK 9. NA no rash TRUNKRASH 
 
8.4.5. Was the rash on NAME’s arms and legs?................. 1. Yes 2. No 8. NK 9. NA no rash ARMSRASH 
 
8.4.6. How many days did the rash last? (IN DAYS)  
[00 = less than 1 day; 88 = not known; 99 = NA, no rash]..................................................... 
  RASHDAY 
 
8.4.7. What did the rash look like? 
1. Measles rash 2. Rash with clear fluid 3. Rash with pus 8. NK 9. NA no rash RASHAPP 
 
8.4.8. Did the rash have blisters containing clear fluid? .... 1. Yes 2. No 8. NK 9. NA no rash BLISRASH 
 
8.4.9. Did the skin crack/split or peel after the rash 
started? .................................................................. 
1. Yes 2. No 
 
8. NK 9. NA no rash CRKRASH 
8.4.10. Was this illness “measles”?...................................... 1. Yes 2. No 8. NK 9. NA no rash MEASLES 
 
8.4.11. Did s/he have red eyes? ..................................... 1. Yes 2. No 
 
8. NK 9. NA no rash REDEYES 
8.4.12. When the baby had diarrhea, did you give ORS?........................ 1. Yes 2. No 
 
8. NK 9. NA ORT 
8.4.13. During the illness that led to death, did NAME have lumps in the  
            armpits?............................................................................................................. 
1. Yes 2. No 8. NK AXLYMPH 
 
8.4.14. During the illness that led to death, did NAME have lumps in the  
           groin?............................................................................................................  
1. Yes 2. No 8. NK INGLYMPH 
 
8.4.15. During the illness that led to death, did NAME have lumps in the  
           neck?...........................................................................................................  
1. Yes 2. No 8. NK NECKLYMPH 
 
8.4.16. During the illness that led to death, did NAME have lumps in any other  
          place?..............................................................................................................  
1. Yes 2. No 8. NK OTHLYMPH 
 
8.4.17. For how long did these lumps last? 
 [00 = less than 1 day; 88= not known; 99 = NA, no lumps]..................................................... 
  LYMPHL 
 
8.4.18. During the illness that led to death, did NAME have mouth sores or a 
whitish rash inside the mouth or on the tongue?  
1. Yes 2. No 8. NK CANDIDA 
 
8.4.19. For how long did these mouth problems last? 
 [000 = less than 1 day; 888= not known; 999 = NA, no mouth problems]...... 
   CANDL 
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8.5 Abdominal problems   
8.5.1. Did s/he have abdominal pain? ................................................................... 1. Yes 2. No 8. NK APAIN 
 
8.5.2. How long did the abdominal pain last ? (IN DAYS) 
 [00 = less than 1 day; 88 = not known; 99 = NA, no swelling]............................................... 
  APAINL 
8.5.3. Was the abdominal pain severe? ................................................ 1. Yes 2. No 8. NK 9. NA APAINS 
 
 
8.6 Other problems   
 
8.6.1 Did the baby have any urine problems? .................................................... 1. Yes 2. No 8. NK URINE 
 
8.6.2 How much urine did s/he pass?  
1. Too much 2. Too little 3. No urine at all  8. NK 9. NA 
URINEP 
 
8.6.3. Was there any change to the amount of urine s/he passed daily?................ 1. Yes 2. No 8. NK URINECHANGE 
8.6.4. For how long did this urine change last? 
[00 = less than 1 day; 88= not known; 99 = NA, no urine change]......…… 
  URINEL 
 
8.6.5. Did the baby pass no urine at all?................................................................ 1. Yes 2 No 8. NK NOURINE 
 
8.6.6. During the final illness did s/he ever pass blood in the urine?.................... 1. Yes 2 No 8. NK BLOODURINE 
 
 
8.6.7. Did the child have sunken eyes at any time during the final illness?............ 1. Yes 2. No 8. NK SUNK 
 
8.6.8. For how long did the sunken eyes last? 
00 = less than 1 day; 88= not known; 99 = NA, no sunken eyes]................. 
  SUNKL 
 
 
8.6.9. Did s/he have bleeding from the nose, mouth or anus? 1. Yes 2. No 
 
8. NK BLEED 
 
8.6.10. During the illness that led to death, did he/she have malaria? .................. 1. Yes 2. No 8. NK IMALARIA 
 
 
9. INFORMATION ABOUT CARESEEKING  
 
 
COMPLETE THIS SECTION FOR NEONATAL AND POSTNEONATAL DEATHS ONLY. 
FOR STILLBIRTHS PUT A DOUBLE LINE THROUGH THIS SECTION AND GO TO SECTION 10. 
 
9.1. Was care sought outside the home while NAME had this illness/injury?......... 1. Yes 2. No 8. NK CARESEE 
 
9.2. Was care sought from a doctor, nurse, clinic or hospital for this 
illness/injury?...................................................................................................  
1. Yes 2. No 8. NK APPCARE 
 
9.3. Was a traditional healer consulted for this illness/injury? ………………… 1. Yes 2. No 8. NK OTHCARE 
 
9.4. Was a religious leader consulted for this illness/injury?.................................. 1. Yes 2. No 8. NK RELICARE 
 
9.5. Was a community-based practitioner consulted for this illness/injury?.......... 1. Yes 2. No 8. NK COMMCARE 
 
9.6. Was a private physician or nurse consulted for this illness/injury?................. 1. Yes 2. No 8. NK PPHYCARE 
 
9.7. Trained birth attendant?........................................................................ 1. Yes 2. No 8. NK CSK_TBA 
9.8. Homeopath?................................................................................................  1. Yes 2. No 8. NK CARESK_HMPT
H 
9.9. Did you seek care at a pharmacy for this illness/injury?................................. 1. Yes 2. No 8. NK PHARMCARE 
 
9.10. Did you seek care from a drug seller, store or market for this illness/injury?  1. Yes 2. No 8. NK DRUGCARE 
 
9.11. Did you seek care from a relative or friend for this illness/injury? 1. Yes 2. No 8. NK RELFRCARE 
 
9.12. Did you seek care from any clinic, health post or hospital for this illness? . 1. Yes 2. No 8. NK FACCARE 
 
9.12.1. How many times? .......................................................................................................   FACCARENO 
 
9.12.2. PLEASE PROVIDE FACILITY CODE1 [99=NA].................................................   CODECARE1 
 
9.12.3 PLEASE PROVIDE FACILITY CODE2 [99=NA].................................................   CODECARE2 
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9.12.4 PLEASE PROVIDE FACILITY CODE3 [99=NA]..................................................   CODECARE3 
 
9.12.2. PLEASE PROVIDE FACILITY CODE4 [99=NA].................................................   CODECARE4 
 
9.12.3 PLEASE PROVIDE FACILITY CODE5 [99=NA].................................................   CODECARE5 
 
9.12.4 PLEASE PROVIDE FACILITY CODE6 [99=NA]..................................................   CODECARE6 
 
9.13. Did you seek care from any other source for this illness/injury? 
         If yes, specify:_____________________________________________ 
1. Yes 2. No 8. NK OTHERCARE 
 
 
9.14. How many days after the illness was care sought? ........................................   DCARS 
 
9.15. In the final days did you travel with NAME to a hospital or health facility?.. 1. Yes 2 No 
 
8. NK TRAVELHOSP 
 
9.16. What mode of transport did you use to go to the 
hospital?.............................................................. 
1. Walking 
/ Foot 
2. 
Bicycle 
3. 
Motorbike 
4. Car  
 3. Taxi 4. Bus /  
Tro-Tro 
5. Other, SPECIFY: TRANSP 
 
 
9.17. Where or from whom did you first seek care  
[USE FACILITY CODE LIST; 88=NK; 99=NA]............................................................... 
  CARESEEK1 
 
9.18 Where or from whom did you seek care for the second time? 
[USE FACILITY CODE LIST; 88=NK; 99=NA]............................................................... 
  CARESEEK2 
 
9.19. Where or from whom did you seek care for the third time? 
[USE FACILITY CODE LIST; 88=NK; 99=NA]............................................................... 
  CARESEEK3 
 
9.20. Was NAME admitted to sleep at least one night in a hospital, health centre  
       or other health institution during their final illness/injury?.............................. 
1. Yes 2. No 
 
8. NK PLACEADM 
9.21Where was NAME admitted? 
[USE FACILITY CODE LIST; 99 = not admitted]............................................................. 
  IHOSP 
 
9.22. Where did NAME die? 
1. Clinic/hospital 2. Private maternity home 3. At home PLACEDIED 
 
4. On route to clinic/hospital 5. Other:  
 
 
9.23. IF THE ANSWER TO 8.18. IS 1 OR 2, STATE WHERE.  
[USE FACILITY CODE LIST; NA=99]...............................................................…..…… 
  ADDPLDIED 
 
9.24. If the baby was discharged from hospital, what was 
their condition on discharge?..................................... 
1. Well 2. Somewhat unwell 3. Very unwell DISCHILL 
 
9.25. Did a health care worker tell you the cause of death?................. 1. Yes 2. No 8. NK 9. NA HWCOD 
 
 
9.26. What did the health worker say? 
 
 
 
 
HWSAY 
 
9.27. Were there any problems during admission to the hospital or health 
facility?....................................................................................................................  
1. Yes 2 No 
 
8. NK ADMPROB 
9.28. Were there any problems with the way [NAME] was treated in the hospital 
or health facility?....................................................................................................  
1. Yes 2 No 
 
8. NK TREATPROB 
9.29. Were there any problems getting medications or diagnostic tests in the 
hospital or health facility?.......................................................................................  
1. Yes 2 No 
 
8. NK MEDPROB 
9.30. Does it take more than 2 hours to get to the nearest hospital or health 
facility from [Name’s household]?.........................................................................  
1. Yes 2 No 
 
8. NK DISTFAC 
9.31. the final illness were there any doubts about whether medical care was 
needed?....................................................................................................................  
1. Yes 2 No 
 
8. NK DOUBTS 
9.32. Was traditional medicine used?..................................................................... 1. Yes 2 No 
 
8. NK TRADITIONME
D 
9.33. At the time of death, did you use a telephone or cellphone to call for help?. 1. Yes 2 No 8. NK CALLHELP 
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9.34. Over the course of [NAME’s] illness, did the total costs of care and 
treatment prohibit other household payments?....................................................... 
1. Yes 2 No 
 
8. NK PROHIBCOST 
 
 
10: TREATMENT AND RECORDS  
 
COMPLETE THIS SECTION FOR NEONATAL AND POSTNEONATAL DEATHS ONLY. 
FOR STILLBIRTHS PUT A DOUBLE LINE THROUGH THIS SECTION AND GO TO SECTION 11. 
 
10.1. Medicines 
 
10.1.1. Did NAME receive any medical therapy during their illness?..................... 1. Yes 2. No 8. NK DRUGS 
 
IF NO THEN PUT A DOUBLE LINE THROUGH THIS SECTION AND GO TO SECTION 10.2 
 
Did NAME receive any of the following? 
10.1.2. Antibiotics …………………………………………….........………… 1. Yes 2. No 8. NK IANTIB 
 
10.1.3. Aspirin………………………………………………………........…… 1. Yes 2. No 8. NK IASPIRIN 
 
10.1.4. Anti-malarial……...………………………………………............…… 1. Yes 2. No 8. NK IANTIMAL 
 
10.1.5.  If possible, please specify the  
           antimalarial drug received…............. 
1. Chloroquine 2. Fansidar 3. Quinine ANTIMT 
 4. Artesonate 
 
5. Amodiaquine 8. NK  
 6. Artesonate-Amodiaquine 
 
9. NA  
 7. Other, specify:  
 
10.1.6. Other known oral medicine.................................................................... 1. Yes 2. No 8. NK ORALMK 
 
10.1.7. Other unknown oral medicine................................................................ 1. Yes 2. No 8. NK ORALMUK 
 
10.1.8. Antibiotic injection................................................................................ 1. Yes 2. No 8. NK ABINJ 
 
10.1.9. Other injection...................................................................................... 1. Yes 2. No 8. NK OTHINJ 
 
10.1.10. ORS...................................................................................................... 1. Yes 2. No 8. NK ORS 
 
10.1.11. IV drip........................................................................................................  1. Yes 2. No 8. NK IVDRIP 
 
10.1.12 Blood transfusion....................................................................... 1. Yes 2. No 8. NK BLOODTRANS 
 
10.1.13 Treatment / food through tube passed through nose........................ 1. Yes 2. No 8. NK NGT 
 
10.1.14 Other, SPECIFY:____________________________________ 1. Yes 2. No 8. NK OTHMED 
 
 
10.2. Surgery 
 
10.2.1. Did s/he have any operation for the illness?.............................................. 1. Yes 2. No 8. NK OPER 
 
10.2.2. How long before death did s/he have the operation? 
[00 = less than 1 day; 88 = not known; 99 = NA, no operation]................ 
  OPERL 
 
10.2.3 On what part of the body was the operation? 
1. Abdomen 2. Chest 3. Head  4. Other, specify:  8. NK 9. NA OPERP 
 
10.2.3. Did s/he have any other operation before death?....................................... 1. Yes 2. No 8. NK SURGB4DEATHV 
 
10.3 Immunisations  
 
10.3.1. Did the baby have a BCG immunisation? (BCG) [DEMONSTRATE 
WHERE THE IMMUNISATION IS INJECTED INTO TOP OF ARM]....... 
1. Yes  2. No  8. NK BCG 
 
10.3.2. Did the baby have a measles immunisation at 6-12 months of age? 
[DEMONSTRATE WHERE THE IMMUNISATION IS INJECTED INTO THE 
ARM]...................................................................................................................... 
1. Yes  2. No  8. NK MEASIMM 
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10.3.3. To your knowledge, did the baby receive all the vaccinations that they 
were due before they died?..................................................................................... 
1. Yes  2. No  8. NK VACC 
 
10.4 Health records 
 
10.4.1. Are there health records available? ........................................……………... 
 
1. Yes 2 No 
 
8. NK IRECORD 
 
10.4.2. Can I transcribe the health records? ............................................ 1. Yes 2 No 
 
9. NA/ No health 
records 
ITRANSC 
 
10.4.3What type of health records does the respondent have? 
Child health record / weighing card................................................................ 1. Yes 2. No 8. NK HTYPE1 
 
Mother’s ANC card.........................................................................................  1. Yes 2. No 8. NK HYTPE2 
 
Burial permit....................................................................................................  1. Yes 2. No 8. NK HYTPE3 
 
Hospital prescription........................................................................................  1. Yes 2. No 8. NK HYTPE4 
 
Treatment card..................................................................................................  1. Yes 2. No 8. NK HYTPE5 
 
Postmortem result.............................................................................................  1. Yes 2. No 8. NK HYTPE6 
 
Hospital discharge card ………………………………………………........... 1. Yes 2. No 8. NK HYTPE7 
 
Laboratory results …………………………………………………………… 1. Yes 2. No 8. NK HYTPE8 
 
Other documents, SPECIFY: _____________________________________ 1. Yes 2. No 8. NK HYTPE9 
 
 
IF THERE ARE NO HEALTH RECORDS PUT A DOUBLE LINE THROUGH THIS SECTION AND 
SECTION 10.5 AND GO TO SECTION 10.6 
 
10.4.4. TRANSCRIBE ALL THE ENTRIES WITHIN THE 12 MONTHS BEFORE THE CHILD DIED IF 
RESPONDENT ALLOWS YOU TO SEE THE RECORDS. INCLUDE ALL DATES. 
 
MAKE SURE YOU INCLUDE ALL IMMUNISATIONS. WRITE THE DATE OF THE LAST MEDICAL 
NOTE IN SECTION 10.4.5.  
___________________________________________________________________________________________
___________________________________________________________________________________________
___________________________________________________________________________________________
___________________________________________________________________________________________
___________________________________________________________________________________________
___________________________________________________________________________________________ 
 
IENTRY 
10.4.5. RECORD THE DATE OF THE LAST 
MEDICAL NOTE [090909 = no note].................... 
        IMEDNOTE 
 
10.5. Infant weight 
 
10.5.1. RECORD THE TWO MOST RECENT WEIGHTS OF THE INFANT IN KILOGRAMS 
 
No date = 080808, No weight = 88.88 
 
DO NOT INCLUDE BIRTHWEIGHT. BIRTHWEIGHT SHOULD BE INCLUDED IN SECTION 5.  
THE EARLIER ONE SHOULD BE DATE 1 AND THE LATER ONE SHOULD BE DATE 2 E.G. DATE 1 = 
10/01/03, DATE 2 = 10/02/03. 
 
Date 1          DATE1 
 
Weight 1   .    WEIGHT1 
 
Date 2          DATE2 
 
Weight 2   .    WEIGHT2 
 
 
10.6. Death certificate  
 
10.6.1. Was a death certificate issued? ................................................................. 1. Yes 2 No 8. NK DEATHC 
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ASK TO SEE THE DEATH CERTIFICATE AND RECORD WHETHER YOU ARE ABLE TO SEE IT. 
 
10.6.2. ABLE TO SEE DEATH CERTIFICATE? ...........………………… 
 
1. Yes 2. No 9. NA no 
certificate 
VIEWDC 
 
DRAW A LINE THROUGH THIS SECTION IF NO CERTIFICATE 
 
10.6.3. RECORD THE IMMEDIATE CAUSE OF DEATH FROM THE CERTIFICATE 
 IMMCOD 
 
 
10.6.4.RECORD THE FIRST UNDERLYING CAUSE OF DEATH FROM THE CERTIFICATE 
 UNDCOD1 
 
 
10.6.5. RECORD THE SECOND UNDERLYING CAUSE OF DEATH FROM THE CERTIFICATE 
 UNDCOD2 
 
 
10.6.6. RECORD THE THIRD UNDERLYING CAUSE OF DEATH FROM THE CERTIFICATE 
 UNDCOD3 
 
 
10.6.7. RECORD THE CONTRIBUTING CAUSE(S) OF DEATH FROM THE CERTIFICATE 
 CONTCOD 
 
 
 
11. ALCOHOL AND TOBACCO USE 
 
11.1. Did NAMES mother ever drink alcohol?……....…………………………. 
 
1. Yes 2. No 8 NK ALCOHOL 
11.2. Did his/her mother ever smoke tobacco (cigarette, cigar, pipe etc.)?.......... 
 
1. Yes 2. No 8 NK TOBACCCO 
 
12. HIV/AIDS AND TUBERCULOSIS 
 
SAY “THE FINAL QUESTIONS ABOUT THE BABY’S DEATH ARE ABOUT HIV/AIDS AND TB” 
 
12.1. Has the child’s mother ever been tested for “HIV/AIDS”?.......................... 1. Yes 2. No 8. NK HIVTEST 
 
12.2. Was the “HIV/AIDS” test ever positive? [9= NA /  no test]..… 1. Yes 2. No 8. NK 9. NA HIVPOS 
 
12.3. Has the child’s mother ever been told she had “AIDS” by a health        
worker?......................................................................................................... ............
.................................................... 
1. Yes 2. No 8. NK HIVHW 
12.4. Has anyone in the family been diagnosed as having tuberculosis?  1. Yes 2. No 8. NK FAMTB 
 
12.5. Did they live in the same house as this infant?  1. Yes 2. No 8. NK 9. NA HOUSETB 
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13. INTERVIEWER COMMENTS AND OBSERVATIONS 
Please write any additional comments or observations that you may have in this space.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
END OF INFANT VPM FORM. THANK RESPONDENT(S) AND CHECK YOUR FORM. 
 
 
 
 
 
 
 
 
 
